WO2023250513A1 - 13-membered macrolide compounds for treating diseases mediated by abnormal protein translation - Google Patents
13-membered macrolide compounds for treating diseases mediated by abnormal protein translation Download PDFInfo
- Publication number
- WO2023250513A1 WO2023250513A1 PCT/US2023/069034 US2023069034W WO2023250513A1 WO 2023250513 A1 WO2023250513 A1 WO 2023250513A1 US 2023069034 W US2023069034 W US 2023069034W WO 2023250513 A1 WO2023250513 A1 WO 2023250513A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkylene
- alkyl
- compound
- optionally substituted
- heteroaryl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 434
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 53
- 201000010099 disease Diseases 0.000 title claims abstract description 38
- 239000003120 macrolide antibiotic agent Substances 0.000 title abstract description 13
- 230000014616 translation Effects 0.000 title description 28
- 230000002159 abnormal effect Effects 0.000 title description 6
- 230000001404 mediated effect Effects 0.000 title description 4
- 238000000034 method Methods 0.000 claims abstract description 171
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 40
- 108020004485 Nonsense Codon Proteins 0.000 claims abstract description 34
- 230000035772 mutation Effects 0.000 claims abstract description 29
- 208000026350 Inborn Genetic disease Diseases 0.000 claims abstract description 25
- 208000016361 genetic disease Diseases 0.000 claims abstract description 25
- 230000002062 proliferating effect Effects 0.000 claims abstract description 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 189
- -1 heteroalkenyl Chemical group 0.000 claims description 158
- 125000000217 alkyl group Chemical group 0.000 claims description 111
- 150000003839 salts Chemical class 0.000 claims description 85
- 125000005843 halogen group Chemical group 0.000 claims description 70
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 68
- 125000001072 heteroaryl group Chemical group 0.000 claims description 65
- 125000005275 alkylenearyl group Chemical group 0.000 claims description 63
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 62
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 60
- 229910052739 hydrogen Inorganic materials 0.000 claims description 58
- 125000005218 alkyleneheteroaryl group Chemical group 0.000 claims description 46
- 125000003118 aryl group Chemical group 0.000 claims description 45
- 125000000623 heterocyclic group Chemical group 0.000 claims description 40
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 40
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 35
- 125000003342 alkenyl group Chemical group 0.000 claims description 33
- 239000003795 chemical substances by application Substances 0.000 claims description 32
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 32
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 29
- 125000004429 atom Chemical group 0.000 claims description 28
- 125000003545 alkoxy group Chemical group 0.000 claims description 26
- 125000004432 carbon atom Chemical group C* 0.000 claims description 22
- 125000001424 substituent group Chemical group 0.000 claims description 19
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 18
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims description 16
- 208000035475 disorder Diseases 0.000 claims description 15
- 125000005842 heteroatom Chemical group 0.000 claims description 15
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 15
- 239000004305 biphenyl Substances 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 125000004043 oxo group Chemical group O=* 0.000 claims description 14
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 14
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 13
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 13
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 13
- 125000006239 protecting group Chemical group 0.000 claims description 13
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 11
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 11
- 125000002947 alkylene group Chemical group 0.000 claims description 10
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 10
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 6
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 3
- 230000008878 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 229940126575 aminoglycoside Drugs 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 49
- 201000011510 cancer Diseases 0.000 abstract description 25
- 230000037434 nonsense mutation Effects 0.000 abstract description 11
- 230000008569 process Effects 0.000 abstract description 11
- 229940041033 macrolides Drugs 0.000 abstract description 9
- 150000004675 formic acid derivatives Chemical class 0.000 description 161
- 239000000203 mixture Substances 0.000 description 145
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 134
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 125
- 238000005481 NMR spectroscopy Methods 0.000 description 108
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 81
- 239000011541 reaction mixture Substances 0.000 description 63
- 235000002639 sodium chloride Nutrition 0.000 description 49
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 45
- 239000000243 solution Substances 0.000 description 42
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 36
- 239000004480 active ingredient Substances 0.000 description 33
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 27
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 26
- 238000006243 chemical reaction Methods 0.000 description 25
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- 239000003814 drug Substances 0.000 description 23
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 21
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 20
- 239000003755 preservative agent Substances 0.000 description 19
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 235000019439 ethyl acetate Nutrition 0.000 description 18
- 238000009472 formulation Methods 0.000 description 18
- JYSWKHQKHYBRIH-UHFFFAOYSA-N octadecane-8,10-dione Chemical compound CCCCCCCCC(=O)CC(=O)CCCCCCC JYSWKHQKHYBRIH-UHFFFAOYSA-N 0.000 description 18
- 239000000843 powder Substances 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 239000001257 hydrogen Substances 0.000 description 17
- 239000011734 sodium Substances 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 238000004128 high performance liquid chromatography Methods 0.000 description 16
- 239000000725 suspension Substances 0.000 description 16
- 229920002472 Starch Polymers 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 14
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 14
- 235000019441 ethanol Nutrition 0.000 description 14
- 239000000543 intermediate Substances 0.000 description 14
- 235000019698 starch Nutrition 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 13
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 13
- 239000002552 dosage form Substances 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 229910052757 nitrogen Inorganic materials 0.000 description 13
- 229920001223 polyethylene glycol Polymers 0.000 description 13
- 235000000346 sugar Nutrition 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 235000019253 formic acid Nutrition 0.000 description 12
- 239000010410 layer Substances 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 239000002245 particle Substances 0.000 description 12
- 239000003380 propellant Substances 0.000 description 12
- 238000000746 purification Methods 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 229940032147 starch Drugs 0.000 description 12
- 239000008107 starch Substances 0.000 description 12
- 238000013519 translation Methods 0.000 description 12
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 11
- 238000010511 deprotection reaction Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 239000003826 tablet Substances 0.000 description 11
- 125000004149 thio group Chemical group *S* 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 125000002252 acyl group Chemical group 0.000 description 10
- 239000002775 capsule Substances 0.000 description 10
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- 125000001153 fluoro group Chemical group F* 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 208000011580 syndromic disease Diseases 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 9
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 description 9
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000008101 lactose Substances 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- 229910052938 sodium sulfate Inorganic materials 0.000 description 9
- 235000011152 sodium sulphate Nutrition 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 229910052717 sulfur Inorganic materials 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 8
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 8
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 8
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 8
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 8
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 8
- 201000003883 Cystic fibrosis Diseases 0.000 description 8
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- 125000004442 acylamino group Chemical group 0.000 description 8
- 239000000443 aerosol Substances 0.000 description 8
- 125000003282 alkyl amino group Chemical group 0.000 description 8
- 125000004414 alkyl thio group Chemical group 0.000 description 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 8
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 8
- 239000013058 crude material Substances 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 8
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 8
- 239000003995 emulsifying agent Substances 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- JIQNWFBLYKVZFY-UHFFFAOYSA-N methoxycyclohexatriene Chemical compound COC1=C[C]=CC=C1 JIQNWFBLYKVZFY-UHFFFAOYSA-N 0.000 description 8
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 8
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- 108010010803 Gelatin Proteins 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 7
- 235000010443 alginic acid Nutrition 0.000 description 7
- 229920000615 alginic acid Polymers 0.000 description 7
- 235000011114 ammonium hydroxide Nutrition 0.000 description 7
- 230000033115 angiogenesis Effects 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 239000002270 dispersing agent Substances 0.000 description 7
- 238000010828 elution Methods 0.000 description 7
- 239000008273 gelatin Substances 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- 235000011852 gelatine desserts Nutrition 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- XHFGWHUWQXTGAT-UHFFFAOYSA-N n-methylpropan-2-amine Chemical compound CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 6
- 239000007832 Na2SO4 Substances 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 125000002393 azetidinyl group Chemical group 0.000 description 6
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 125000004452 carbocyclyl group Chemical group 0.000 description 6
- 150000001721 carbon Chemical group 0.000 description 6
- 125000000068 chlorophenyl group Chemical group 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000008298 dragée Substances 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 150000004677 hydrates Chemical class 0.000 description 6
- 239000003701 inert diluent Substances 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 6
- 239000000314 lubricant Substances 0.000 description 6
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 6
- 125000002757 morpholinyl group Chemical group 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000006187 pill Substances 0.000 description 6
- 125000003386 piperidinyl group Chemical group 0.000 description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 208000002320 spinal muscular atrophy Diseases 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 125000005017 substituted alkenyl group Chemical group 0.000 description 6
- 125000004426 substituted alkynyl group Chemical group 0.000 description 6
- 125000003107 substituted aryl group Chemical group 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 239000001993 wax Substances 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 5
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 5
- 206010011777 Cystinosis Diseases 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 5
- 206010041067 Small cell lung cancer Diseases 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 5
- WEVYAHXRMPXWCK-FIBGUPNXSA-N acetonitrile-d3 Chemical compound [2H]C([2H])([2H])C#N WEVYAHXRMPXWCK-FIBGUPNXSA-N 0.000 description 5
- 239000000783 alginic acid Substances 0.000 description 5
- 229960001126 alginic acid Drugs 0.000 description 5
- 150000004781 alginic acids Chemical class 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 125000003710 aryl alkyl group Chemical group 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000006172 buffering agent Substances 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 5
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 5
- 229940105329 carboxymethylcellulose Drugs 0.000 description 5
- 238000002648 combination therapy Methods 0.000 description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 5
- LIWAQLJGPBVORC-UHFFFAOYSA-N ethylmethylamine Chemical compound CCNC LIWAQLJGPBVORC-UHFFFAOYSA-N 0.000 description 5
- 239000000945 filler Substances 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 5
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 230000002028 premature Effects 0.000 description 5
- 125000004076 pyridyl group Chemical group 0.000 description 5
- 125000006413 ring segment Chemical group 0.000 description 5
- 208000000587 small cell lung carcinoma Diseases 0.000 description 5
- 239000007909 solid dosage form Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 4
- WMPDAIZRQDCGFH-UHFFFAOYSA-N 3-methoxybenzaldehyde Chemical compound COC1=CC=CC(C=O)=C1 WMPDAIZRQDCGFH-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 4
- 206010060999 Benign neoplasm Diseases 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 208000031220 Hemophilia Diseases 0.000 description 4
- 208000009292 Hemophilia A Diseases 0.000 description 4
- 208000017604 Hodgkin disease Diseases 0.000 description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 4
- 208000028781 Mucopolysaccharidosis type 1 Diseases 0.000 description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 208000006289 Rett Syndrome Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 235000010419 agar Nutrition 0.000 description 4
- 150000001336 alkenes Chemical class 0.000 description 4
- 125000005036 alkoxyphenyl group Chemical group 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 235000010290 biphenyl Nutrition 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 description 4
- 229960003563 calcium carbonate Drugs 0.000 description 4
- 235000010216 calcium carbonate Nutrition 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 4
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 125000005059 halophenyl group Chemical group 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 4
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 4
- 206010028537 myelofibrosis Diseases 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 229960000572 olaparib Drugs 0.000 description 4
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 description 4
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- DTUQWGWMVIHBKE-UHFFFAOYSA-N phenylacetaldehyde Chemical compound O=CCC1=CC=CC=C1 DTUQWGWMVIHBKE-UHFFFAOYSA-N 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 229940083542 sodium Drugs 0.000 description 4
- 235000015424 sodium Nutrition 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- MDOJTZQKHMAPBK-UHFFFAOYSA-N 4-iodo-3-nitrobenzamide Chemical compound NC(=O)C1=CC=C(I)C([N+]([O-])=O)=C1 MDOJTZQKHMAPBK-UHFFFAOYSA-N 0.000 description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 3
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 3
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 108010092160 Dactinomycin Proteins 0.000 description 3
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 208000015178 Hurler syndrome Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 3
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 description 3
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- LIMFPAAAIVQRRD-BCGVJQADSA-N N-[2-[(3S,4R)-3-fluoro-4-methoxypiperidin-1-yl]pyrimidin-4-yl]-8-[(2R,3S)-2-methyl-3-(methylsulfonylmethyl)azetidin-1-yl]-5-propan-2-ylisoquinolin-3-amine Chemical compound F[C@H]1CN(CC[C@H]1OC)C1=NC=CC(=N1)NC=1N=CC2=C(C=CC(=C2C=1)C(C)C)N1[C@@H]([C@H](C1)CS(=O)(=O)C)C LIMFPAAAIVQRRD-BCGVJQADSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 208000035977 Rare disease Diseases 0.000 description 3
- 208000037340 Rare genetic disease Diseases 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 208000014769 Usher Syndromes Diseases 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 229940023476 agar Drugs 0.000 description 3
- 125000003158 alcohol group Chemical group 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000000440 bentonite Substances 0.000 description 3
- 229910000278 bentonite Inorganic materials 0.000 description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- 208000005980 beta thalassemia Diseases 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 230000005587 bubbling Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229960005069 calcium Drugs 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- HWGQMRYQVZSGDQ-HZPDHXFCSA-N chembl3137320 Chemical compound CN1N=CN=C1[C@H]([C@H](N1)C=2C=CC(F)=CC=2)C2=NNC(=O)C3=C2C1=CC(F)=C3 HWGQMRYQVZSGDQ-HZPDHXFCSA-N 0.000 description 3
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 3
- 229960004630 chlorambucil Drugs 0.000 description 3
- 229960004106 citric acid Drugs 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 235000019868 cocoa butter Nutrition 0.000 description 3
- 229940110456 cocoa butter Drugs 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229940099112 cornstarch Drugs 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- IGSKHXTUVXSOMB-UHFFFAOYSA-N cyclopropylmethanamine Chemical compound NCC1CC1 IGSKHXTUVXSOMB-UHFFFAOYSA-N 0.000 description 3
- 230000030498 cytoplasmic translation Effects 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 3
- 229960003668 docetaxel Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 208000025750 heavy chain disease Diseases 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000000138 intercalating agent Substances 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 229960001156 mitoxantrone Drugs 0.000 description 3
- 201000006938 muscular dystrophy Diseases 0.000 description 3
- 201000005962 mycosis fungoides Diseases 0.000 description 3
- 208000011392 nephropathic cystinosis Diseases 0.000 description 3
- 239000000346 nonvolatile oil Substances 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 235000011007 phosphoric acid Nutrition 0.000 description 3
- 239000008389 polyethoxylated castor oil Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 229960003975 potassium Drugs 0.000 description 3
- 235000007686 potassium Nutrition 0.000 description 3
- 208000003476 primary myelofibrosis Diseases 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
- HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 235000010413 sodium alginate Nutrition 0.000 description 3
- 239000000661 sodium alginate Substances 0.000 description 3
- 229940005550 sodium alginate Drugs 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 150000003512 tertiary amines Chemical class 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 125000000169 tricyclic heterocycle group Chemical group 0.000 description 3
- 229950011257 veliparib Drugs 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- JXGVXCZADZNAMJ-LLVKDONJSA-N (2r)-1-phenylmethoxycarbonylpyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@H]1CCCN1C(=O)OCC1=CC=CC=C1 JXGVXCZADZNAMJ-LLVKDONJSA-N 0.000 description 2
- FHOAKXBXYSJBGX-RXMQYKEDSA-N (2r)-3-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](CO)C(O)=O FHOAKXBXYSJBGX-RXMQYKEDSA-N 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 description 2
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 2
- BFPMCZWKUSUMKE-UHFFFAOYSA-N 1-cyclopropyl-n-methylmethanamine Chemical compound CNCC1CC1 BFPMCZWKUSUMKE-UHFFFAOYSA-N 0.000 description 2
- FMDGXCSMDZMDHZ-UHFFFAOYSA-N 1-isocyanato-4-methoxybenzene Chemical compound COC1=CC=C(N=C=O)C=C1 FMDGXCSMDZMDHZ-UHFFFAOYSA-N 0.000 description 2
- AHIVQGOUBLVTCB-AWEZNQCLSA-N 2-[2-fluoro-4-[(2s)-pyrrolidin-2-yl]phenyl]-1h-benzimidazole-4-carboxamide Chemical compound N=1C=2C(C(=O)N)=CC=CC=2NC=1C(C(=C1)F)=CC=C1[C@@H]1CCCN1 AHIVQGOUBLVTCB-AWEZNQCLSA-N 0.000 description 2
- MJUHIAWSJRKXSH-UHFFFAOYSA-N 2-pyridin-3-ylacetaldehyde Chemical compound O=CCC1=CC=CN=C1 MJUHIAWSJRKXSH-UHFFFAOYSA-N 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 2
- SRWILAKSARHZPR-UHFFFAOYSA-N 3-chlorobenzaldehyde Chemical compound ClC1=CC=CC(C=O)=C1 SRWILAKSARHZPR-UHFFFAOYSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- DTJVECUKADWGMO-UHFFFAOYSA-N 4-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(S(Cl)(=O)=O)C=C1 DTJVECUKADWGMO-UHFFFAOYSA-N 0.000 description 2
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 2
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 description 2
- ISDBWOPVZKNQDW-UHFFFAOYSA-N 4-phenylbenzaldehyde Chemical compound C1=CC(C=O)=CC=C1C1=CC=CC=C1 ISDBWOPVZKNQDW-UHFFFAOYSA-N 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- GYLDXIAOMVERTK-UHFFFAOYSA-N 5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine Chemical compound C12=C(N)N=CN=C2N(C(C)C)N=C1C1=CC=C(OC(N)=N2)C2=C1 GYLDXIAOMVERTK-UHFFFAOYSA-N 0.000 description 2
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 2
- UPALIKSFLSVKIS-UHFFFAOYSA-N 5-amino-2-[2-(dimethylamino)ethyl]benzo[de]isoquinoline-1,3-dione Chemical compound NC1=CC(C(N(CCN(C)C)C2=O)=O)=C3C2=CC=CC3=C1 UPALIKSFLSVKIS-UHFFFAOYSA-N 0.000 description 2
- IJRKLHTZAIFUTB-UHFFFAOYSA-N 5-nitro-2-(2-phenylethylamino)benzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1NCCC1=CC=CC=C1 IJRKLHTZAIFUTB-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 201000003076 Angiosarcoma Diseases 0.000 description 2
- 206010073360 Appendix cancer Diseases 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- 235000010777 Arachis hypogaea Nutrition 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 206010003658 Atrial Fibrillation Diseases 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- 206010004265 Benign familial pemphigus Diseases 0.000 description 2
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- 201000004085 CLL/SLL Diseases 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 206010007275 Carcinoid tumour Diseases 0.000 description 2
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Chemical group OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 201000007547 Dravet syndrome Diseases 0.000 description 2
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 2
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 2
- 208000037574 Familial benign chronic pemphigus Diseases 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- 208000032000 Glycogen storage disease due to muscle glycogen phosphorylase deficiency Diseases 0.000 description 2
- 206010018462 Glycogen storage disease type V Diseases 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 208000027655 Hailey-Hailey disease Diseases 0.000 description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 description 2
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 2
- 206010070999 Intraductal papillary mucinous neoplasm Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 206010023347 Keratoacanthoma Diseases 0.000 description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 2
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 description 2
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 240000003183 Manihot esculenta Species 0.000 description 2
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 2
- 208000036572 Myoclonic epilepsy Diseases 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- 201000005118 Nephrogenic diabetes insipidus Diseases 0.000 description 2
- 208000009905 Neurofibromatoses Diseases 0.000 description 2
- 208000033755 Neutrophilic Chronic Leukemia Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 240000007817 Olea europaea Species 0.000 description 2
- 239000012661 PARP inhibitor Substances 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 2
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 2
- 208000031839 Peripheral nerve sheath tumour malignant Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010057846 Primitive neuroectodermal tumour Diseases 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 235000004443 Ricinus communis Nutrition 0.000 description 2
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 2
- 208000017733 acquired polycythemia vera Diseases 0.000 description 2
- 229930183665 actinomycin Natural products 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 229950010817 alvocidib Drugs 0.000 description 2
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001414 amino alcohols Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229960004701 amonafide Drugs 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 2
- 230000002280 anti-androgenic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000000051 antiandrogen Substances 0.000 description 2
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 2
- 208000021780 appendiceal neoplasm Diseases 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 2
- MJSHDCCLFGOEIK-UHFFFAOYSA-N benzyl (2,5-dioxopyrrolidin-1-yl) carbonate Chemical compound O=C1CCC(=O)N1OC(=O)OCC1=CC=CC=C1 MJSHDCCLFGOEIK-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 229960000997 bicalutamide Drugs 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 2
- 229950003628 buparlisib Drugs 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- 229940097647 casodex Drugs 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 229960002798 cetrimide Drugs 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 229960004926 chlorobutanol Drugs 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 208000023738 chronic lymphocytic leukemia/small lymphocytic lymphoma Diseases 0.000 description 2
- 201000010903 chronic neutrophilic leukemia Diseases 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 229960005061 crizotinib Drugs 0.000 description 2
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 2
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- KZZKOVLJUKWSKX-UHFFFAOYSA-N cyclobutanamine Chemical compound NC1CCC1 KZZKOVLJUKWSKX-UHFFFAOYSA-N 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 125000005070 decynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 2
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
- 229940038472 dicalcium phosphate Drugs 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- SMVRDGHCVNAOIN-UHFFFAOYSA-L disodium;1-dodecoxydodecane;sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O.CCCCCCCCCCCCOCCCCCCCCCCCC SMVRDGHCVNAOIN-UHFFFAOYSA-L 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- CTSPAMFJBXKSOY-UHFFFAOYSA-N ellipticine Chemical compound N1=CC=C2C(C)=C(NC=3C4=CC=CC=3)C4=C(C)C2=C1 CTSPAMFJBXKSOY-UHFFFAOYSA-N 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 229950011487 enocitabine Drugs 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000008995 epigenetic change Effects 0.000 description 2
- 229930013356 epothilone Natural products 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 229960005167 everolimus Drugs 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 201000007386 factor VII deficiency Diseases 0.000 description 2
- 201000007830 familial atrial fibrillation Diseases 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 229960000390 fludarabine Drugs 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 229950006191 gluconic acid Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 201000004534 glycogen storage disease V Diseases 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000003979 granulating agent Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 201000009277 hairy cell leukemia Diseases 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 2
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 229940102213 injectable suspension Drugs 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 229940084651 iressa Drugs 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- YDNLNVZZTACNJX-UHFFFAOYSA-N isocyanatomethylbenzene Chemical compound O=C=NCC1=CC=CC=C1 YDNLNVZZTACNJX-UHFFFAOYSA-N 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- SXPXHJKHWVCCRO-UHFFFAOYSA-N isoquinoline-6-carbaldehyde Chemical compound C1=NC=CC2=CC(C=O)=CC=C21 SXPXHJKHWVCCRO-UHFFFAOYSA-N 0.000 description 2
- QEAGQILEKLFCEK-UHFFFAOYSA-N isoquinoline-7-carbaldehyde Chemical compound C1=CN=CC2=CC(C=O)=CC=C21 QEAGQILEKLFCEK-UHFFFAOYSA-N 0.000 description 2
- PURKAOJPTOLRMP-UHFFFAOYSA-N ivacaftor Chemical compound C1=C(O)C(C(C)(C)C)=CC(C(C)(C)C)=C1NC(=O)C1=CNC2=CC=CC=C2C1=O PURKAOJPTOLRMP-UHFFFAOYSA-N 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229950008814 momelotinib Drugs 0.000 description 2
- ZVHNDZWQTBEVRY-UHFFFAOYSA-N momelotinib Chemical compound C1=CC(C(NCC#N)=O)=CC=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCOCC2)=N1 ZVHNDZWQTBEVRY-UHFFFAOYSA-N 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical group OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- LPOIGVZLNWEGJG-UHFFFAOYSA-N n-benzyl-5-(4-methylpiperazin-1-yl)-2-nitroaniline Chemical compound C1CN(C)CCN1C1=CC=C([N+]([O-])=O)C(NCC=2C=CC=CC=2)=C1 LPOIGVZLNWEGJG-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- VEBLEROFGPOMPB-UHFFFAOYSA-N n-methylcyclopropanamine Chemical compound CNC1CC1 VEBLEROFGPOMPB-UHFFFAOYSA-N 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 201000004931 neurofibromatosis Diseases 0.000 description 2
- 208000029974 neurofibrosarcoma Diseases 0.000 description 2
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 description 2
- 229950011068 niraparib Drugs 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 235000014571 nuts Nutrition 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 210000002220 organoid Anatomy 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Chemical group OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 229960003742 phenol Drugs 0.000 description 2
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 229940067107 phenylethyl alcohol Drugs 0.000 description 2
- OAHKWDDSKCRNFE-UHFFFAOYSA-N phenylmethanesulfonyl chloride Chemical compound ClS(=O)(=O)CC1=CC=CC=C1 OAHKWDDSKCRNFE-UHFFFAOYSA-N 0.000 description 2
- 229920001993 poloxamer 188 Polymers 0.000 description 2
- 208000030761 polycystic kidney disease Diseases 0.000 description 2
- 208000037244 polycythemia vera Diseases 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 2
- 229940043349 potassium metabisulfite Drugs 0.000 description 2
- 235000010263 potassium metabisulphite Nutrition 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 201000007271 pre-malignant neoplasm Diseases 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 description 2
- CDRNYKLYADJTMN-UHFFFAOYSA-N pyridine-3-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CN=C1 CDRNYKLYADJTMN-UHFFFAOYSA-N 0.000 description 2
- BGUWFUQJCDRPTL-UHFFFAOYSA-N pyridine-4-carbaldehyde Chemical compound O=CC1=CC=NC=C1 BGUWFUQJCDRPTL-UHFFFAOYSA-N 0.000 description 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
- 229960004622 raloxifene Drugs 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 2
- 229950004707 rucaparib Drugs 0.000 description 2
- 229960000215 ruxolitinib Drugs 0.000 description 2
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 229950009216 sapanisertib Drugs 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 150000004760 silicates Chemical class 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 229940001607 sodium bisulfite Drugs 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 235000011083 sodium citrates Nutrition 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 2
- 229940001584 sodium metabisulfite Drugs 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 235000011078 sorbitan tristearate Nutrition 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000008117 stearic acid Chemical group 0.000 description 2
- PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Chemical compound C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229950004550 talazoparib Drugs 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 2
- 229940063683 taxotere Drugs 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 229960001196 thiotepa Drugs 0.000 description 2
- 229960003087 tioguanine Drugs 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 229960000281 trometamol Drugs 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- 229960001055 uracil mustard Drugs 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 230000004862 vasculogenesis Effects 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- AADVCYNFEREWOS-UHFFFAOYSA-N (+)-DDM Natural products C=CC=CC(C)C(OC(N)=O)C(C)C(O)C(C)CC(C)=CC(C)C(O)C(C)C=CC(O)CC1OC(=O)C(C)C(O)C1C AADVCYNFEREWOS-UHFFFAOYSA-N 0.000 description 1
- XSSYCIGJYCVRRK-RQJHMYQMSA-N (-)-carbovir Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1C[C@H](CO)C=C1 XSSYCIGJYCVRRK-RQJHMYQMSA-N 0.000 description 1
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- RWRDJVNMSZYMDV-SIUYXFDKSA-L (223)RaCl2 Chemical compound Cl[223Ra]Cl RWRDJVNMSZYMDV-SIUYXFDKSA-L 0.000 description 1
- STUWGJZDJHPWGZ-GFCCVEGCSA-N (2R)-1-N-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide Chemical compound S1C(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C(C)N=C1NC(=O)N1CCC[C@@H]1C(N)=O STUWGJZDJHPWGZ-GFCCVEGCSA-N 0.000 description 1
- DENYZIUJOTUUNY-MRXNPFEDSA-N (2R)-14-fluoro-2-methyl-6,9,10,19-tetrazapentacyclo[14.2.1.02,6.08,18.012,17]nonadeca-1(18),8,12(17),13,15-pentaen-11-one Chemical compound FC=1C=C2C=3C=4C(CN5[C@@](C4NC3C1)(CCC5)C)=NNC2=O DENYZIUJOTUUNY-MRXNPFEDSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- QVHJQCGUWFKTSE-RXMQYKEDSA-N (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound OC(=O)[C@@H](C)NC(=O)OC(C)(C)C QVHJQCGUWFKTSE-RXMQYKEDSA-N 0.000 description 1
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- MHDPPLULTMGBSI-UUOKFMHZSA-N (2r,3r,4s,5r)-2-(6-amino-8-chloropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound ClC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O MHDPPLULTMGBSI-UUOKFMHZSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- JXGVXCZADZNAMJ-NSHDSACASA-N (2s)-1-phenylmethoxycarbonylpyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)OCC1=CC=CC=C1 JXGVXCZADZNAMJ-NSHDSACASA-N 0.000 description 1
- QVHJQCGUWFKTSE-YFKPBYRVSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)OC(C)(C)C QVHJQCGUWFKTSE-YFKPBYRVSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- FLWWDYNPWOSLEO-HQVZTVAUSA-N (2s)-2-[[4-[1-(2-amino-4-oxo-1h-pteridin-6-yl)ethyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1C(C)N(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FLWWDYNPWOSLEO-HQVZTVAUSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- CGMTUJFWROPELF-YPAAEMCBSA-N (3E,5S)-5-[(2S)-butan-2-yl]-3-(1-hydroxyethylidene)pyrrolidine-2,4-dione Chemical compound CC[C@H](C)[C@@H]1NC(=O)\C(=C(/C)O)C1=O CGMTUJFWROPELF-YPAAEMCBSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 1
- OIIOPWHTJZYKIL-PMACEKPBSA-N (5S)-5-[[[5-[2-chloro-3-[2-chloro-3-[6-methoxy-5-[[[(2S)-5-oxopyrrolidin-2-yl]methylamino]methyl]pyrazin-2-yl]phenyl]phenyl]-3-methoxypyrazin-2-yl]methylamino]methyl]pyrrolidin-2-one Chemical compound C1(=C(N=C(C2=C(C(C3=CC=CC(=C3Cl)C3=NC(OC)=C(N=C3)CNC[C@H]3NC(=O)CC3)=CC=C2)Cl)C=N1)OC)CNC[C@H]1NC(=O)CC1 OIIOPWHTJZYKIL-PMACEKPBSA-N 0.000 description 1
- ZCGNOLQNACZJCN-VMMOASCLSA-N (5ar,8ar,9r)-5-[[(2r,4ar,6r,7r,8r,8as)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one;n,3-bis(2-chloroethyl)-2-oxo-1,3,2$ Chemical compound [CH3-].[CH3-].[Pt+2].OC(=O)C1(C(O)=O)CCC1.ClCCNP1(=O)OCCCN1CCCl.COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3C(O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 ZCGNOLQNACZJCN-VMMOASCLSA-N 0.000 description 1
- XRBSKUSTLXISAB-XVVDYKMHSA-N (5r,6r,7r,8r)-8-hydroxy-7-(hydroxymethyl)-5-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxole-6-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H](CO)[C@@H]2C(O)=O)=C1 XRBSKUSTLXISAB-XVVDYKMHSA-N 0.000 description 1
- VUEGYUOUAAVYAS-JGGQBBKZSA-N (6ar,9s,10ar)-9-(dimethylsulfamoylamino)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CNC3=C1 VUEGYUOUAAVYAS-JGGQBBKZSA-N 0.000 description 1
- XRBSKUSTLXISAB-UHFFFAOYSA-N (7R,7'R,8R,8'R)-form-Podophyllic acid Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C(CO)C2C(O)=O)=C1 XRBSKUSTLXISAB-UHFFFAOYSA-N 0.000 description 1
- AESVUZLWRXEGEX-DKCAWCKPSA-N (7S,9R)-7-[(2S,4R,5R,6R)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione iron(3+) Chemical compound [Fe+3].COc1cccc2C(=O)c3c(O)c4C[C@@](O)(C[C@H](O[C@@H]5C[C@@H](N)[C@@H](O)[C@@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO AESVUZLWRXEGEX-DKCAWCKPSA-N 0.000 description 1
- JXVAMODRWBNUSF-KZQKBALLSA-N (7s,9r,10r)-7-[(2r,4s,5s,6s)-5-[[(2s,4as,5as,7s,9s,9ar,10ar)-2,9-dimethyl-3-oxo-4,4a,5a,6,7,9,9a,10a-octahydrodipyrano[4,2-a:4',3'-e][1,4]dioxin-7-yl]oxy]-4-(dimethylamino)-6-methyloxan-2-yl]oxy-10-[(2s,4s,5s,6s)-4-(dimethylamino)-5-hydroxy-6-methyloxan-2 Chemical compound O([C@@H]1C2=C(O)C=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C2[C@@H](O[C@@H]2O[C@@H](C)[C@@H](O[C@@H]3O[C@@H](C)[C@H]4O[C@@H]5O[C@@H](C)C(=O)C[C@@H]5O[C@H]4C3)[C@H](C2)N(C)C)C[C@]1(O)CC)[C@H]1C[C@H](N(C)C)[C@H](O)[C@H](C)O1 JXVAMODRWBNUSF-KZQKBALLSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- DTOUUUZOYKYHEP-UHFFFAOYSA-N 1,3-bis(2-ethylhexyl)-5-methyl-1,3-diazinan-5-amine Chemical compound CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1 DTOUUUZOYKYHEP-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- ILWJAOPQHOZXAN-UHFFFAOYSA-N 1,3-dithianyl Chemical group [CH]1SCCCS1 ILWJAOPQHOZXAN-UHFFFAOYSA-N 0.000 description 1
- FLOJNXXFMHCMMR-UHFFFAOYSA-N 1,3-dithiolanyl Chemical group [CH]1SCCS1 FLOJNXXFMHCMMR-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- QXOGPTXQGKQSJT-UHFFFAOYSA-N 1-amino-4-[4-(3,4-dimethylphenyl)sulfanylanilino]-9,10-dioxoanthracene-2-sulfonic acid Chemical compound Cc1ccc(Sc2ccc(Nc3cc(c(N)c4C(=O)c5ccccc5C(=O)c34)S(O)(=O)=O)cc2)cc1C QXOGPTXQGKQSJT-UHFFFAOYSA-N 0.000 description 1
- IUKIFVIMIKWDQO-UHFFFAOYSA-N 1-aminoheptane-2,3,4,5,6-pentol Chemical compound CC(O)C(O)C(O)C(O)C(O)CN IUKIFVIMIKWDQO-UHFFFAOYSA-N 0.000 description 1
- HHIRBXHEYVDUAM-UHFFFAOYSA-N 1-chloro-3-isocyanatobenzene Chemical compound ClC1=CC=CC(N=C=O)=C1 HHIRBXHEYVDUAM-UHFFFAOYSA-N 0.000 description 1
- ADAKRBAJFHTIEW-UHFFFAOYSA-N 1-chloro-4-isocyanatobenzene Chemical compound ClC1=CC=C(N=C=O)C=C1 ADAKRBAJFHTIEW-UHFFFAOYSA-N 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- CQZXDIHVSPZIGF-UHFFFAOYSA-N 1-methylimidazole-4-carbaldehyde Chemical compound CN1C=NC(C=O)=C1 CQZXDIHVSPZIGF-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- CTLOSZHDGZLOQE-UHFFFAOYSA-N 14-methoxy-9-[(4-methylpiperazin-1-yl)methyl]-9,19-diazapentacyclo[10.7.0.02,6.07,11.013,18]nonadeca-1(12),2(6),7(11),13(18),14,16-hexaene-8,10-dione Chemical compound O=C1C2=C3C=4C(OC)=CC=CC=4NC3=C3CCCC3=C2C(=O)N1CN1CCN(C)CC1 CTLOSZHDGZLOQE-UHFFFAOYSA-N 0.000 description 1
- BTOTXLJHDSNXMW-POYBYMJQSA-N 2,3-dideoxyuridine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(=O)NC(=O)C=C1 BTOTXLJHDSNXMW-POYBYMJQSA-N 0.000 description 1
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- BOMZMNZEXMAQQW-UHFFFAOYSA-N 2,5,11-trimethyl-6h-pyrido[4,3-b]carbazol-2-ium-9-ol;acetate Chemical compound CC([O-])=O.C[N+]1=CC=C2C(C)=C(NC=3C4=CC(O)=CC=3)C4=C(C)C2=C1 BOMZMNZEXMAQQW-UHFFFAOYSA-N 0.000 description 1
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
- VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 1
- QEBYEVQKHRUYPE-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(1-methylpyrazol-3-yl)methyl]-4-[[methyl(pyridin-3-ylmethyl)amino]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CN(C)N=C1CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1CN(C)CC1=CC=CN=C1 QEBYEVQKHRUYPE-UHFFFAOYSA-N 0.000 description 1
- WGIMXKDCVCTHGW-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOCCO WGIMXKDCVCTHGW-UHFFFAOYSA-N 0.000 description 1
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- YQNRVGJCPCNMKT-LFVJCYFKSA-N 2-[(e)-[[2-(4-benzylpiperazin-1-ium-1-yl)acetyl]hydrazinylidene]methyl]-6-prop-2-enylphenolate Chemical compound [O-]C1=C(CC=C)C=CC=C1\C=N\NC(=O)C[NH+]1CCN(CC=2C=CC=CC=2)CC1 YQNRVGJCPCNMKT-LFVJCYFKSA-N 0.000 description 1
- XXVLKDRPHSFIIB-UHFFFAOYSA-N 2-[2-(dimethylamino)ethyl]-5-nitrobenzo[de]isoquinoline-1,3-dione Chemical compound [O-][N+](=O)C1=CC(C(N(CCN(C)C)C2=O)=O)=C3C2=CC=CC3=C1 XXVLKDRPHSFIIB-UHFFFAOYSA-N 0.000 description 1
- QUNOQBDEVTWCTA-UHFFFAOYSA-N 2-[2-[3-[2-(1,3-dioxobenzo[de]isoquinolin-2-yl)ethylamino]propylamino]ethyl]benzo[de]isoquinoline-1,3-dione Chemical compound C1=CC(C(=O)N(CCNCCCNCCN2C(C=3C=CC=C4C=CC=C(C=34)C2=O)=O)C2=O)=C3C2=CC=CC3=C1 QUNOQBDEVTWCTA-UHFFFAOYSA-N 0.000 description 1
- KGERZPVQIRYWRK-GDLZYMKVSA-N 2-[3-(3,5-dimethyltriazol-4-yl)-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indol-7-yl]propan-2-ol Chemical compound CC=1N=NN(C=1C1=CC=2N(C=3C=C(C=CC=3C=2N=C1)C(C)(C)O)[C@H](C1=CC=CC=C1)C1CCOCC1)C KGERZPVQIRYWRK-GDLZYMKVSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- PBUUPFTVAPUWDE-UGZDLDLSSA-N 2-[[(2S,4S)-2-[bis(2-chloroethyl)amino]-2-oxo-1,3,2lambda5-oxazaphosphinan-4-yl]sulfanyl]ethanesulfonic acid Chemical compound OS(=O)(=O)CCS[C@H]1CCO[P@](=O)(N(CCCl)CCCl)N1 PBUUPFTVAPUWDE-UGZDLDLSSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- PAYROHWFGZADBR-UHFFFAOYSA-N 2-[[4-amino-5-(5-iodo-4-methoxy-2-propan-2-ylphenoxy)pyrimidin-2-yl]amino]propane-1,3-diol Chemical compound C1=C(I)C(OC)=CC(C(C)C)=C1OC1=CN=C(NC(CO)CO)N=C1N PAYROHWFGZADBR-UHFFFAOYSA-N 0.000 description 1
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- FDAYLTPAFBGXAB-UHFFFAOYSA-N 2-chloro-n,n-bis(2-chloroethyl)ethanamine Chemical compound ClCCN(CCCl)CCCl FDAYLTPAFBGXAB-UHFFFAOYSA-N 0.000 description 1
- VNBAOSVONFJBKP-UHFFFAOYSA-N 2-chloro-n,n-bis(2-chloroethyl)propan-1-amine;hydrochloride Chemical compound Cl.CC(Cl)CN(CCCl)CCCl VNBAOSVONFJBKP-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical group C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- VMZCDNSFRSVYKQ-UHFFFAOYSA-N 2-phenylacetyl chloride Chemical compound ClC(=O)CC1=CC=CC=C1 VMZCDNSFRSVYKQ-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- YLVFMHCTUFZMFC-UHFFFAOYSA-N 2-pyridin-3-ylacetyl chloride Chemical compound ClC(=O)CC1=CC=CN=C1 YLVFMHCTUFZMFC-UHFFFAOYSA-N 0.000 description 1
- AZTCLKFBAGFZRR-UHFFFAOYSA-N 2-pyridin-4-ylacetaldehyde Chemical compound O=CCC1=CC=NC=C1 AZTCLKFBAGFZRR-UHFFFAOYSA-N 0.000 description 1
- 125000001627 3 membered heterocyclic group Chemical group 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 1
- XLZYKTYMLBOINK-UHFFFAOYSA-N 3-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)C=2C=CC(O)=CC=2)=C1 XLZYKTYMLBOINK-UHFFFAOYSA-N 0.000 description 1
- PWMYMKOUNYTVQN-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-n,n-dimethylpropan-1-amine Chemical compound C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 PWMYMKOUNYTVQN-UHFFFAOYSA-N 0.000 description 1
- UBLAMKHIFZBBSS-UHFFFAOYSA-N 3-Methylbutyl pentanoate Chemical compound CCCCC(=O)OCCC(C)C UBLAMKHIFZBBSS-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- GSCPDZHWVNUUFI-UHFFFAOYSA-N 3-aminobenzamide Chemical compound NC(=O)C1=CC=CC(N)=C1 GSCPDZHWVNUUFI-UHFFFAOYSA-N 0.000 description 1
- HGWUUOXXAIISDB-UHFFFAOYSA-N 3-azabicyclo[3.1.0]hexane Chemical compound C1NCC2CC21 HGWUUOXXAIISDB-UHFFFAOYSA-N 0.000 description 1
- NEOIOGUWEUTYIH-UHFFFAOYSA-N 3-azabicyclo[3.2.0]heptane Chemical compound C1NCC2CCC21 NEOIOGUWEUTYIH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OINWZUJVEXUHCC-UHFFFAOYSA-N 3-chlorobenzenesulfonyl chloride Chemical compound ClC1=CC=CC(S(Cl)(=O)=O)=C1 OINWZUJVEXUHCC-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- RUQIUASLAXJZIE-UHFFFAOYSA-N 3-methoxybenzoyl chloride Chemical compound COC1=CC=CC(C(Cl)=O)=C1 RUQIUASLAXJZIE-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 1
- KFKSIUOALVIACE-UHFFFAOYSA-N 3-phenylbenzaldehyde Chemical compound O=CC1=CC=CC(C=2C=CC=CC=2)=C1 KFKSIUOALVIACE-UHFFFAOYSA-N 0.000 description 1
- 125000001963 4 membered heterocyclic group Chemical group 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 1
- TVTXCJFHQKSQQM-LJQIRTBHSA-N 4-[[(2r,3s,4r,5s)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-2-carbonyl]amino]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1NC(=O)[C@H]1[C@H](C=2C(=C(Cl)C=CC=2)F)[C@@](C#N)(C=2C(=CC(Cl)=CC=2)F)[C@H](CC(C)(C)C)N1 TVTXCJFHQKSQQM-LJQIRTBHSA-N 0.000 description 1
- HYNBNUYQTQIHJK-UHFFFAOYSA-N 4-[[4-fluoro-3-(4-methoxypiperidine-1-carbonyl)phenyl]methyl]-2h-phthalazin-1-one Chemical compound C1CC(OC)CCN1C(=O)C1=CC(CC=2C3=CC=CC=C3C(=O)NN=2)=CC=C1F HYNBNUYQTQIHJK-UHFFFAOYSA-N 0.000 description 1
- JFIWEPHGRUDAJN-DYUFWOLASA-N 4-amino-1-[(2r,3r,4s,5r)-4-ethynyl-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@](O)(C#C)[C@@H](CO)O1 JFIWEPHGRUDAJN-DYUFWOLASA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- MZFQJBMXUXJUHF-UHFFFAOYSA-N 4-azabicyclo[4.1.0]heptane Chemical compound C1CNCC2CC21 MZFQJBMXUXJUHF-UHFFFAOYSA-N 0.000 description 1
- GSDQYSSLIKJJOG-UHFFFAOYSA-N 4-chloro-2-(3-chloroanilino)benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC1=CC=CC(Cl)=C1 GSDQYSSLIKJJOG-UHFFFAOYSA-N 0.000 description 1
- OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
- ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 4-chlorobenzenesulfonyl chloride Chemical compound ClC1=CC=C(S(Cl)(=O)=O)C=C1 ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 0.000 description 1
- XRHGYUZYPHTUJZ-UHFFFAOYSA-N 4-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-N 0.000 description 1
- RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 description 1
- DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- JJWMRRNGWSITSQ-UHFFFAOYSA-N 5-phenacyloxy-2h-isoquinolin-1-one Chemical compound C=1C=CC(C(NC=C2)=O)=C2C=1OCC(=O)C1=CC=CC=C1 JJWMRRNGWSITSQ-UHFFFAOYSA-N 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 1
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 1
- GNMUEVRJHCWKTO-FQEVSTJZSA-N 6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)- Chemical compound C([C@@H]1N=C(C2=C(N3C(C)=NN=C31)SC(=C2C)C)C=1C=CC(Cl)=CC=1)C(=O)NC1=CC=C(O)C=C1 GNMUEVRJHCWKTO-FQEVSTJZSA-N 0.000 description 1
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 description 1
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 1
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- XASOHFCUIQARJT-UHFFFAOYSA-N 8-methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one Chemical compound C(N1C(=O)C2=C(OC)C=C(C=3N4C(=NC=3)C=C(C=C4)OCCN3CCOCC3)C=C2CC1)C(F)(F)F XASOHFCUIQARJT-UHFFFAOYSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010000591 Acrochordon Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 description 1
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 1
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 description 1
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- ULXXDDBFHOBEHA-ONEGZZNKSA-N Afatinib Chemical compound N1=CN=C2C=C(OC3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-ONEGZZNKSA-N 0.000 description 1
- 240000006054 Agastache cana Species 0.000 description 1
- ZGCSNRKSJLVANE-UHFFFAOYSA-N Aglycone-Rebeccamycin Natural products N1C2=C3NC4=C(Cl)C=CC=C4C3=C(C(=O)NC3=O)C3=C2C2=C1C(Cl)=CC=C2 ZGCSNRKSJLVANE-UHFFFAOYSA-N 0.000 description 1
- 235000006667 Aleurites moluccana Nutrition 0.000 description 1
- 244000136475 Aleurites moluccana Species 0.000 description 1
- 208000012791 Alpha-heavy chain disease Diseases 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N Alternaria alternata Crofton-weed toxin Natural products CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000000058 Anaplasia Diseases 0.000 description 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
- 102000008076 Angiogenic Proteins Human genes 0.000 description 1
- 108010074415 Angiogenic Proteins Proteins 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- MXPOCMVWFLDDLZ-NSCUHMNNSA-N Apaziquone Chemical compound CN1C(\C=C\CO)=C(CO)C(C2=O)=C1C(=O)C=C2N1CC1 MXPOCMVWFLDDLZ-NSCUHMNNSA-N 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 229930091051 Arenine Natural products 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 235000006264 Asimina triloba Nutrition 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 description 1
- 229940126199 BMS-986158 Drugs 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 229930185605 Bisphenol Natural products 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 235000007689 Borago officinalis Nutrition 0.000 description 1
- 240000004355 Borago officinalis Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 1
- 244000188595 Brassica sinapistrum Species 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- BGGALFIXXQOTPY-NRFANRHFSA-N C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC Chemical compound C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC BGGALFIXXQOTPY-NRFANRHFSA-N 0.000 description 1
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- VZSAMEOETVNDQH-UHFFFAOYSA-N CC1(OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C)C Chemical compound CC1(OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C)C VZSAMEOETVNDQH-UHFFFAOYSA-N 0.000 description 1
- VSEIDZLLWQQJGK-CHOZPQDDSA-N CCC1=C(C)C2=N\C\1=C/C1=C(C)C(C(O)=O)=C(N1)\C(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C1/N=C(/C=C3\N/C(=C\2)C(C=C)=C3C)[C@@H](C)[C@@H]1CCC(O)=O Chemical compound CCC1=C(C)C2=N\C\1=C/C1=C(C)C(C(O)=O)=C(N1)\C(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C1/N=C(/C=C3\N/C(=C\2)C(C=C)=C3C)[C@@H](C)[C@@H]1CCC(O)=O VSEIDZLLWQQJGK-CHOZPQDDSA-N 0.000 description 1
- UHNRLQRZRNKOKU-UHFFFAOYSA-N CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O Chemical compound CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O UHNRLQRZRNKOKU-UHFFFAOYSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- SCJNYBYSTCRPAO-LXBQGUBHSA-N CN(C)C\C=C\C(=O)NC1=CC=C(N=C1)C(=O)N[C@@]1(C)CCC[C@H](C1)NC1=NC(C2=CNC3=CC=CC=C23)=C(Cl)C=N1 Chemical compound CN(C)C\C=C\C(=O)NC1=CC=C(N=C1)C(=O)N[C@@]1(C)CCC[C@H](C1)NC1=NC(C2=CNC3=CC=CC=C23)=C(Cl)C=N1 SCJNYBYSTCRPAO-LXBQGUBHSA-N 0.000 description 1
- 229960005529 CRLX101 Drugs 0.000 description 1
- AUJXLBOHYWTPFV-BLWRDSOESA-N CS[C@H]1SC[C@H]2N(C)C(=O)[C@@H](C)NC(=O)[C@H](COC(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H]1N(C)C(=O)[C@@H](C)NC(=O)[C@H](COC(=O)[C@@H](C(C)C)N(C)C2=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1 Chemical compound CS[C@H]1SC[C@H]2N(C)C(=O)[C@@H](C)NC(=O)[C@H](COC(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H]1N(C)C(=O)[C@@H](C)NC(=O)[C@H](COC(=O)[C@@H](C(C)C)N(C)C2=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1 AUJXLBOHYWTPFV-BLWRDSOESA-N 0.000 description 1
- XGPBJCHFROADCK-UHFFFAOYSA-N CX-5461 Chemical compound C1CN(C)CCCN1C1=CC=C2C(=O)C(C(=O)NCC=3N=CC(C)=NC=3)=C3SC4=CC=CC=C4N3C2=N1 XGPBJCHFROADCK-UHFFFAOYSA-N 0.000 description 1
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 1
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000005747 Carum carvi Nutrition 0.000 description 1
- 240000000467 Carum carvi Species 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- PONPPNYZKHNPKZ-RYBWXQSLSA-N Chartreusin Chemical compound O[C@@H]1[C@@H](OC)[C@@H](O)[C@@H](C)O[C@@H]1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](C)O[C@H]1OC1=CC=CC2=C(O)C(C(O3)=O)=C4C5=C3C=CC(C)=C5C(=O)OC4=C12 PONPPNYZKHNPKZ-RYBWXQSLSA-N 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- XCDXSSFOJZZGQC-UHFFFAOYSA-N Chlornaphazine Chemical compound C1=CC=CC2=CC(N(CCCl)CCCl)=CC=C21 XCDXSSFOJZZGQC-UHFFFAOYSA-N 0.000 description 1
- MKQWTWSXVILIKJ-LXGUWJNJSA-N Chlorozotocin Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC(=O)N(N=O)CCCl MKQWTWSXVILIKJ-LXGUWJNJSA-N 0.000 description 1
- 201000005262 Chondroma Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 241000132536 Cirsium Species 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 101000983970 Conus catus Alpha-conotoxin CIB Proteins 0.000 description 1
- 235000010919 Copernicia prunifera Nutrition 0.000 description 1
- 244000180278 Copernicia prunifera Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 240000009226 Corylus americana Species 0.000 description 1
- 235000001543 Corylus americana Nutrition 0.000 description 1
- 235000007466 Corylus avellana Nutrition 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- AADVCYNFEREWOS-OBRABYBLSA-N Discodermolide Chemical compound C=C\C=C/[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C/[C@H](C)[C@@H](O)[C@@H](C)\C=C/[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C AADVCYNFEREWOS-OBRABYBLSA-N 0.000 description 1
- 241000271571 Dromaius novaehollandiae Species 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- NVTRPRFAWJGJAJ-UHFFFAOYSA-L EDTA monocalcium salt Chemical compound [Ca+2].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O NVTRPRFAWJGJAJ-UHFFFAOYSA-L 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- 108010009858 Echinomycin Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 229930185938 Elsamicin Natural products 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000002460 Enteropathy-Associated T-Cell Lymphoma Diseases 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- OBMLHUPNRURLOK-XGRAFVIBSA-N Epitiostanol Chemical compound C1[C@@H]2S[C@@H]2C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 OBMLHUPNRURLOK-XGRAFVIBSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 229930189413 Esperamicin Natural products 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- ZIXGXMMUKPLXBB-UHFFFAOYSA-N Guatambuinine Natural products N1C2=CC=CC=C2C2=C1C(C)=C1C=CN=C(C)C1=C2 ZIXGXMMUKPLXBB-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 240000000950 Hippophae rhamnoides Species 0.000 description 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 1
- 101000838335 Homo sapiens Dual specificity protein phosphatase 2 Proteins 0.000 description 1
- 101001080401 Homo sapiens Proteasome assembly chaperone 1 Proteins 0.000 description 1
- 241000384508 Hoplostethus atlanticus Species 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 235000010650 Hyssopus officinalis Nutrition 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 208000007866 Immunoproliferative Small Intestinal Disease Diseases 0.000 description 1
- 201000003803 Inflammatory myofibroblastic tumor Diseases 0.000 description 1
- 206010067917 Inflammatory myofibroblastic tumour Diseases 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
- DNVXATUJJDPFDM-KRWDZBQOSA-N JQ1 Chemical compound N([C@@H](CC(=O)OC(C)(C)C)C1=NN=C(N1C=1SC(C)=C(C)C=11)C)=C1C1=CC=C(Cl)C=C1 DNVXATUJJDPFDM-KRWDZBQOSA-N 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KJQFBVYMGADDTQ-CVSPRKDYSA-N L-buthionine-(S,R)-sulfoximine Chemical compound CCCCS(=N)(=O)CC[C@H](N)C(O)=O KJQFBVYMGADDTQ-CVSPRKDYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 1
- 239000002137 L01XE24 - Ponatinib Substances 0.000 description 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 1
- UCEQXRCJXIVODC-PMACEKPBSA-N LSM-1131 Chemical compound C1CCC2=CC=CC3=C2N1C=C3[C@@H]1C(=O)NC(=O)[C@H]1C1=CNC2=CC=CC=C12 UCEQXRCJXIVODC-PMACEKPBSA-N 0.000 description 1
- UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 description 1
- JLERVPBPJHKRBJ-UHFFFAOYSA-N LY 117018 Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCC3)=CC=2)C2=CC=C(O)C=C2S1 JLERVPBPJHKRBJ-UHFFFAOYSA-N 0.000 description 1
- PONPPNYZKHNPKZ-UHFFFAOYSA-N Lambdamycin Natural products OC1C(OC)C(O)C(C)OC1OC1C(O)C(O)C(C)OC1OC1=CC=CC2=C(O)C(C(O3)=O)=C4C5=C3C=CC(C)=C5C(=O)OC4=C12 PONPPNYZKHNPKZ-UHFFFAOYSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
- 241000218652 Larix Species 0.000 description 1
- 235000005590 Larix decidua Nutrition 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 244000165082 Lavanda vera Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 241000408747 Lepomis gibbosus Species 0.000 description 1
- 240000003553 Leptospermum scoparium Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 241001072282 Limnanthes Species 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 235000012854 Litsea cubeba Nutrition 0.000 description 1
- 240000002262 Litsea cubeba Species 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 240000000982 Malva neglecta Species 0.000 description 1
- 235000000060 Malva neglecta Nutrition 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- VJRAUFKOOPNFIQ-UHFFFAOYSA-N Marcellomycin Natural products C12=C(O)C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C=C2C(C(=O)OC)C(CC)(O)CC1OC(OC1C)CC(N(C)C)C1OC(OC1C)CC(O)C1OC1CC(O)C(O)C(C)O1 VJRAUFKOOPNFIQ-UHFFFAOYSA-N 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- IVDYZAAPOLNZKG-KWHRADDSSA-N Mepitiostane Chemical compound O([C@@H]1[C@]2(CC[C@@H]3[C@@]4(C)C[C@H]5S[C@H]5C[C@@H]4CC[C@H]3[C@@H]2CC1)C)C1(OC)CCCC1 IVDYZAAPOLNZKG-KWHRADDSSA-N 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 244000179970 Monarda didyma Species 0.000 description 1
- 235000010672 Monarda didyma Nutrition 0.000 description 1
- 208000010190 Monoclonal Gammopathy of Undetermined Significance Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000012799 Mu-heavy chain disease Diseases 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Chemical group OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000002231 Muscle Neoplasms Diseases 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- 244000270834 Myristica fragrans Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- AVYVHIKSFXVDBG-UHFFFAOYSA-N N-benzyl-N-hydroxy-2,2-dimethylbutanamide Chemical compound C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O AVYVHIKSFXVDBG-UHFFFAOYSA-N 0.000 description 1
- POFVJRKJJBFPII-UHFFFAOYSA-N N-cyclopentyl-5-[2-[[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-5-fluoropyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C1(CCCC1)NC=1SC(=C(N=1)C)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCN(CC1)CC POFVJRKJJBFPII-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- JOOXLOJCABQBSG-UHFFFAOYSA-N N-tert-butyl-3-[[5-methyl-2-[4-[2-(1-pyrrolidinyl)ethoxy]anilino]-4-pyrimidinyl]amino]benzenesulfonamide Chemical compound N1=C(NC=2C=C(C=CC=2)S(=O)(=O)NC(C)(C)C)C(C)=CN=C1NC(C=C1)=CC=C1OCCN1CCCC1 JOOXLOJCABQBSG-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- CXQHYVUVSFXTMY-UHFFFAOYSA-N N1'-[3-fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Chemical compound C1=CN=C2C=C(OCCCN3CCOCC3)C(OC)=CC2=C1OC(C(=C1)F)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 CXQHYVUVSFXTMY-UHFFFAOYSA-N 0.000 description 1
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 1
- JEYWNNAZDLFBFF-UHFFFAOYSA-N Nafoxidine Chemical compound C1CC2=CC(OC)=CC=C2C(C=2C=CC(OCCN3CCCC3)=CC=2)=C1C1=CC=CC=C1 JEYWNNAZDLFBFF-UHFFFAOYSA-N 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- SYNHCENRCUAUNM-UHFFFAOYSA-N Nitrogen mustard N-oxide hydrochloride Chemical compound Cl.ClCC[N+]([O-])(C)CCCl SYNHCENRCUAUNM-UHFFFAOYSA-N 0.000 description 1
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 description 1
- KGTDRFCXGRULNK-UHFFFAOYSA-N Nogalamycin Natural products COC1C(OC)(C)C(OC)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=C4C5(C)OC(C(C(C5O)N(C)C)O)OC4=C3C3=O)=C3C=C2C(C(=O)OC)C(C)(O)C1 KGTDRFCXGRULNK-UHFFFAOYSA-N 0.000 description 1
- 241000219925 Oenothera Species 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 229930187135 Olivomycin Natural products 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 235000014643 Orbignya martiana Nutrition 0.000 description 1
- 244000021150 Orbignya martiana Species 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229960005552 PAC-1 Drugs 0.000 description 1
- RURAZZMDMNRXMI-UHFFFAOYSA-N PJ34 hydrochloride Chemical compound Cl.C1=CC=C2C3=CC(NC(=O)CN(C)C)=CC=C3NC(=O)C2=C1 RURAZZMDMNRXMI-UHFFFAOYSA-N 0.000 description 1
- 208000017459 Paget disease of the penis Diseases 0.000 description 1
- 208000025610 Paget disease of the vulva Diseases 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 235000008753 Papaver somniferum Nutrition 0.000 description 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 1
- 206010036524 Precursor B-lymphoblastic lymphomas Diseases 0.000 description 1
- 208000032758 Precursor T-lymphoblastic lymphoma/leukaemia Diseases 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- 102100027583 Proteasome assembly chaperone 1 Human genes 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 1
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
- QEHOIJJIZXRMAN-UHFFFAOYSA-N Rebeccamycin Natural products OC1C(O)C(OC)C(CO)OC1N1C2=C3NC4=C(Cl)C=CC=C4C3=C3C(=O)NC(=O)C3=C2C2=CC=CC(Cl)=C21 QEHOIJJIZXRMAN-UHFFFAOYSA-N 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 229930182475 S-glycoside Natural products 0.000 description 1
- SUYXJDLXGFPMCQ-INIZCTEOSA-N SJ000287331 Natural products CC1=c2cnccc2=C(C)C2=Nc3ccccc3[C@H]12 SUYXJDLXGFPMCQ-INIZCTEOSA-N 0.000 description 1
- LOGJQOUIVKBFGH-UHFFFAOYSA-N SU6656 Chemical compound C1CCCC(N2)=C1C=C2C=C1C(=O)NC2=CC=C(S(=O)(=O)N(C)C)C=C21 LOGJQOUIVKBFGH-UHFFFAOYSA-N 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 240000000513 Santalum album Species 0.000 description 1
- 235000008632 Santalum album Nutrition 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000006938 Schwannomatosis Diseases 0.000 description 1
- 206010048810 Sebaceous hyperplasia Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000040738 Sesamum orientale Species 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 208000021388 Sezary disease Diseases 0.000 description 1
- 244000044822 Simmondsia californica Species 0.000 description 1
- 235000004433 Simmondsia californica Nutrition 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- 229920000519 Sizofiran Polymers 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000010502 Subcutaneous panniculitis-like T-cell lymphoma Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 201000008736 Systemic mastocytosis Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 description 1
- LGGHDPFKSSRQNS-UHFFFAOYSA-N Tariquidar Chemical compound C1=CC=CC2=CC(C(=O)NC3=CC(OC)=C(OC)C=C3C(=O)NC3=CC=C(C=C3)CCN3CCC=4C=C(C(=CC=4C3)OC)OC)=CN=C21 LGGHDPFKSSRQNS-UHFFFAOYSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- WFWLQNSHRPWKFK-UHFFFAOYSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1C1OCCC1 WFWLQNSHRPWKFK-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- CGMTUJFWROPELF-UHFFFAOYSA-N Tenuazonic acid Natural products CCC(C)C1NC(=O)C(=C(C)/O)C1=O CGMTUJFWROPELF-UHFFFAOYSA-N 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- WPMWEFXCIYCJSA-UHFFFAOYSA-N Tetraethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCO WPMWEFXCIYCJSA-UHFFFAOYSA-N 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 239000004012 Tofacitinib Substances 0.000 description 1
- IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
- UMILHIMHKXVDGH-UHFFFAOYSA-N Triethylene glycol diglycidyl ether Chemical compound C1OC1COCCOCCOCCOCC1CO1 UMILHIMHKXVDGH-UHFFFAOYSA-N 0.000 description 1
- 190014017283 Triplatin tetranitrate Chemical compound 0.000 description 1
- DFBIRQPKNDILPW-CIVMWXNOSA-N Triptolide Chemical compound O=C1OCC([C@@H]2C3)=C1CC[C@]2(C)[C@]12O[C@H]1[C@@H]1O[C@]1(C(C)C)[C@@H](O)[C@]21[C@H]3O1 DFBIRQPKNDILPW-CIVMWXNOSA-N 0.000 description 1
- FYAMXEPQQLNQDM-UHFFFAOYSA-N Tris(1-aziridinyl)phosphine oxide Chemical compound C1CN1P(N1CC1)(=O)N1CC1 FYAMXEPQQLNQDM-UHFFFAOYSA-N 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 235000007769 Vetiveria zizanioides Nutrition 0.000 description 1
- 244000284012 Vetiveria zizanioides Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- ZYVSOIYQKUDENJ-ASUJBHBQSA-N [(2R,3R,4R,6R)-6-[[(6S,7S)-6-[(2S,4R,5R,6R)-4-[(2R,4R,5R,6R)-4-[(2S,4S,5S,6S)-5-acetyloxy-4-hydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-7-[(3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-4,10-dihydroxy-3-methyl-5-oxo-7,8-dihydro-6H-anthracen-2-yl]oxy]-4-[(2R,4R,5R,6R)-4-hydroxy-5-methoxy-6-methyloxan-2-yl]oxy-2-methyloxan-3-yl] acetate Chemical class COC([C@@H]1Cc2cc3cc(O[C@@H]4C[C@@H](O[C@@H]5C[C@@H](O)[C@@H](OC)[C@@H](C)O5)[C@H](OC(C)=O)[C@@H](C)O4)c(C)c(O)c3c(O)c2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@@H](OC(C)=O)[C@H](C)O3)[C@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1)C(=O)[C@@H](O)[C@@H](C)O ZYVSOIYQKUDENJ-ASUJBHBQSA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- FKAWLXNLHHIHLA-YCBIHMBMSA-N [(2r,3r,5r,7r,8s,9s)-2-[(1s,3s,4s,5r,6r,7e,9e,11e,13z)-14-cyano-3,5-dihydroxy-1-methoxy-4,6,8,9,13-pentamethyltetradeca-7,9,11,13-tetraenyl]-9-[(e)-3-[2-[(2s)-4-[[(2s,3s,4s)-4-(dimethylamino)-2,3-dihydroxy-5-methoxypentanoyl]amino]butan-2-yl]-1,3-oxazol-4 Chemical compound O1C([C@@H](C)CCNC(=O)[C@@H](O)[C@@H](O)[C@H](COC)N(C)C)=NC(\C=C\C[C@H]2[C@H]([C@H](O)C[C@]3(O2)C([C@@H](OP(O)(O)=O)[C@@H]([C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)\C=C(/C)\C(\C)=C\C=C\C(\C)=C/C#N)OC)O3)(C)C)C)=C1 FKAWLXNLHHIHLA-YCBIHMBMSA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- SPJCRMJCFSJKDE-ZWBUGVOYSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 2-[4-[bis(2-chloroethyl)amino]phenyl]acetate Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)C(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 SPJCRMJCFSJKDE-ZWBUGVOYSA-N 0.000 description 1
- IFJUINDAXYAPTO-UUBSBJJBSA-N [(8r,9s,13s,14s,17s)-17-[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]acetyl]oxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4OC(=O)COC(=O)CCCC=1C=CC(=CC=1)N(CCCl)CCCl)C)CC2=CC=3OC(=O)C1=CC=CC=C1 IFJUINDAXYAPTO-UUBSBJJBSA-N 0.000 description 1
- XMYKNCNAZKMVQN-NYYWCZLTSA-N [(e)-(3-aminopyridin-2-yl)methylideneamino]thiourea Chemical compound NC(=S)N\N=C\C1=NC=CC=C1N XMYKNCNAZKMVQN-NYYWCZLTSA-N 0.000 description 1
- IHGLINDYFMDHJG-UHFFFAOYSA-N [2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanone Chemical compound C1=CC(OC)=CC=C1C(CCC1=CC=CC=C11)=C1C(=O)C(C=C1)=CC=C1OCCN1CCCC1 IHGLINDYFMDHJG-UHFFFAOYSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XGKPLOKHSA-N [2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XGKPLOKHSA-N 0.000 description 1
- XZSRRNFBEIOBDA-CFNBKWCHSA-N [2-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-oxoethyl] 2,2-diethoxyacetate Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)C(OCC)OCC)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 XZSRRNFBEIOBDA-CFNBKWCHSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 229950005186 abagovomab Drugs 0.000 description 1
- 229950001573 abemaciclib Drugs 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- ZOZKYEHVNDEUCO-XUTVFYLZSA-N aceglatone Chemical compound O1C(=O)[C@H](OC(C)=O)[C@@H]2OC(=O)[C@@H](OC(=O)C)[C@@H]21 ZOZKYEHVNDEUCO-XUTVFYLZSA-N 0.000 description 1
- 229950002684 aceglatone Drugs 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 229940125665 acridine carboxamide Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229950009084 adecatumumab Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- QBYJBZPUGVGKQQ-SJJAEHHWSA-N aldrin Chemical compound C1[C@H]2C=C[C@@H]1[C@H]1[C@@](C3(Cl)Cl)(Cl)C(Cl)=C(Cl)[C@@]3(Cl)[C@H]12 QBYJBZPUGVGKQQ-SJJAEHHWSA-N 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical group 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000003418 alkyl amino alkoxy group Chemical group 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 125000005282 allenyl group Chemical group 0.000 description 1
- 230000008850 allosteric inhibition Effects 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 208000025751 alpha chain disease Diseases 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229960001040 ammonium chloride Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- BBDAGFIXKZCXAH-CCXZUQQUSA-N ancitabine Chemical compound N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 BBDAGFIXKZCXAH-CCXZUQQUSA-N 0.000 description 1
- 229950000242 ancitabine Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- MXMOTZIXVICDSD-UHFFFAOYSA-N anisoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1 MXMOTZIXVICDSD-UHFFFAOYSA-N 0.000 description 1
- 239000000420 anogeissus latifolia wall. gum Substances 0.000 description 1
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical compound C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229960005505 anti-CD22 immunotoxin Drugs 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000002622 anti-tumorigenesis Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000013059 antihormonal agent Substances 0.000 description 1
- 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 229950002465 apaziquone Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 150000008209 arabinosides Chemical class 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 229940078010 arimidex Drugs 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 125000005101 aryl methoxy carbonyl group Chemical group 0.000 description 1
- 125000005002 aryl methyl group Chemical group 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 229950003462 atiprimod Drugs 0.000 description 1
- SERHTTSLBVGRBY-UHFFFAOYSA-N atiprimod Chemical compound C1CC(CCC)(CCC)CCC11CN(CCCN(CC)CC)CC1 SERHTTSLBVGRBY-UHFFFAOYSA-N 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 229940126313 avutometinib Drugs 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- 229950011321 azaserine Drugs 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- VAOUCKNGGFVROV-UHFFFAOYSA-N azetidin-2-ol Chemical compound OC1CCN1 VAOUCKNGGFVROV-UHFFFAOYSA-N 0.000 description 1
- GMWFCJXSQQHBPI-UHFFFAOYSA-N azetidin-3-ol Chemical compound OC1CNC1 GMWFCJXSQQHBPI-UHFFFAOYSA-N 0.000 description 1
- 150000001541 aziridines Chemical class 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000001053 badasse Nutrition 0.000 description 1
- 229950000971 baricitinib Drugs 0.000 description 1
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- LNHWXBUNXOXMRL-VWLOTQADSA-N belotecan Chemical compound C1=CC=C2C(CCNC(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 LNHWXBUNXOXMRL-VWLOTQADSA-N 0.000 description 1
- 229950011276 belotecan Drugs 0.000 description 1
- 229960002707 bendamustine Drugs 0.000 description 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000005513 benzoazaindolyl group Chemical group 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229950000080 birabresib Drugs 0.000 description 1
- 229950005124 biricodar Drugs 0.000 description 1
- CGVWPQOFHSAKRR-NDEPHWFRSA-N biricodar Chemical compound COC1=C(OC)C(OC)=CC(C(=O)C(=O)N2[C@@H](CCCC2)C(=O)OC(CCCC=2C=NC=CC=2)CCCC=2C=NC=CC=2)=C1 CGVWPQOFHSAKRR-NDEPHWFRSA-N 0.000 description 1
- 229950008548 bisantrene Drugs 0.000 description 1
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
- 229960003736 bosutinib Drugs 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 201000000135 breast papillary carcinoma Diseases 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 201000005200 bronchus cancer Diseases 0.000 description 1
- 229960003168 bronopol Drugs 0.000 description 1
- 229950004271 brostallicin Drugs 0.000 description 1
- RXOVOXFAAGIKDQ-UHFFFAOYSA-N brostallicin Chemical compound C1=C(C(=O)NCCN=C(N)N)N(C)C=C1NC(=O)C1=CC(NC(=O)C=2N(C=C(NC(=O)C=3N(C=C(NC(=O)C(Br)=C)C=3)C)C=2)C)=CN1C RXOVOXFAAGIKDQ-UHFFFAOYSA-N 0.000 description 1
- 229960005520 bryostatin Drugs 0.000 description 1
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
- MUIWQCKLQMOUAT-AKUNNTHJSA-N bryostatin 20 Natural products COC(=O)C=C1C[C@@]2(C)C[C@]3(O)O[C@](C)(C[C@@H](O)CC(=O)O[C@](C)(C[C@@]4(C)O[C@](O)(CC5=CC(=O)O[C@]45C)C(C)(C)C=C[C@@](C)(C1)O2)[C@@H](C)O)C[C@H](OC(=O)C(C)(C)C)C3(C)C MUIWQCKLQMOUAT-AKUNNTHJSA-N 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960001292 cabozantinib Drugs 0.000 description 1
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 1
- 108700002839 cactinomycin Proteins 0.000 description 1
- 229950009908 cactinomycin Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229960004256 calcium citrate Drugs 0.000 description 1
- 229960002283 calcium glubionate Drugs 0.000 description 1
- 229940078512 calcium gluceptate Drugs 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- 229940095618 calcium glycerophosphate Drugs 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 229940078480 calcium levulinate Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- FATUQANACHZLRT-XBQZYUPDSA-L calcium;(2r,3r,4s,5r,6r)-2,3,4,5,6,7-hexahydroxyheptanoate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C([O-])=O FATUQANACHZLRT-XBQZYUPDSA-L 0.000 description 1
- OKRXSXDSNLJCRS-NLOQLBMISA-L calcium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;(2r,3r,4r,5r)-2,3,5,6-tetrahydroxy-4-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanoate;hydrate Chemical compound O.[Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.[O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O OKRXSXDSNLJCRS-NLOQLBMISA-L 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
- 229930195731 calicheamicin Natural products 0.000 description 1
- IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
- 229950009823 calusterone Drugs 0.000 description 1
- 229930182747 calyculin Natural products 0.000 description 1
- 229940088954 camptosar Drugs 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960002115 carboquone Drugs 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 229940096529 carboxypolymethylene Drugs 0.000 description 1
- XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
- 229930188550 carminomycin Natural products 0.000 description 1
- XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 229950001725 carubicin Drugs 0.000 description 1
- 108010047060 carzinophilin Proteins 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- YMNCVRSYJBNGLD-KURKYZTESA-N cephalotaxine Chemical compound C([C@@]12C=C([C@H]([C@H]2C2=C3)O)OC)CCN1CCC2=CC1=C3OCO1 YMNCVRSYJBNGLD-KURKYZTESA-N 0.000 description 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960000800 cetrimonium bromide Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- MXJSQPACGKUSQB-UHFFFAOYSA-N chartreusin Natural products COC1C(O)C(C)OC(OC2C(O)C(O)C(C)OC2Oc3cccc4c(O)c5C(=O)Oc6ccc(C)c7C(=O)Cc(c5c67)c34)C1O MXJSQPACGKUSQB-UHFFFAOYSA-N 0.000 description 1
- IHOVFYSQUDPMCN-DBEBIPAYSA-N chembl444172 Chemical compound C([C@H](COC=1C2=CC=CN=C2C=CC=1)O)N(CC1)CCN1[C@@H]1C2=CC=CC=C2[C@H]2C(F)(F)[C@H]2C2=CC=CC=C12 IHOVFYSQUDPMCN-DBEBIPAYSA-N 0.000 description 1
- ROWSTIYZUWEOMM-UHFFFAOYSA-N chembl488755 Chemical compound C12=CC=CC=C2C(=O)C2=C1C1=CC=C(O)C=C1N=C2NCCN(C)C ROWSTIYZUWEOMM-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000010575 cherry hemangioma Diseases 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229950008249 chlornaphazine Drugs 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- 229960005443 chloroxylenol Drugs 0.000 description 1
- 229960001480 chlorozotocin Drugs 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960002271 cobimetinib Drugs 0.000 description 1
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 description 1
- 235000019516 cod Nutrition 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 239000008294 cold cream Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 229940126179 compound 72 Drugs 0.000 description 1
- 201000010918 connective tissue cancer Diseases 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 229940013361 cresol Drugs 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- 229960005052 demecolcine Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229950003913 detorubicin Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- WVYXNIXAMZOZFK-UHFFFAOYSA-N diaziquone Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 1
- 229950002389 diaziquone Drugs 0.000 description 1
- 229940111685 dibasic potassium phosphate Drugs 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- CGMRCMMOCQYHAD-UHFFFAOYSA-J dicalcium hydroxide phosphate Chemical compound [OH-].[Ca++].[Ca++].[O-]P([O-])([O-])=O CGMRCMMOCQYHAD-UHFFFAOYSA-J 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- NLORYLAYLIXTID-ISLYRVAYSA-N diethylstilbestrol diphosphate Chemical compound C=1C=C(OP(O)(O)=O)C=CC=1C(/CC)=C(\CC)C1=CC=C(OP(O)(O)=O)C=C1 NLORYLAYLIXTID-ISLYRVAYSA-N 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- WSDISUOETYTPRL-UHFFFAOYSA-N dmdm hydantoin Chemical compound CC1(C)N(CO)C(=O)N(CO)C1=O WSDISUOETYTPRL-UHFFFAOYSA-N 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- 125000005066 dodecenyl group Chemical group C(=CCCCCCCCCCC)* 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical group CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
- 229950004683 drostanolone propionate Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 229950004438 elinafide Drugs 0.000 description 1
- 229950000549 elliptinium acetate Drugs 0.000 description 1
- HPVDVZANUAGIRR-ZAVMYBFASA-N elsamicin Chemical compound O[C@@H]1[C@@](C)(O)[C@@H](O)[C@@H](C)O[C@H]1OC1=CC=CC2=C(O)C(C(O3)=O)=C4C5=C3C=CC(C)=C5C(=O)OC4=C12 HPVDVZANUAGIRR-ZAVMYBFASA-N 0.000 description 1
- MGQRRMONVLMKJL-KWJIQSIXSA-N elsamitrucin Chemical compound O1[C@H](C)[C@H](O)[C@H](OC)[C@@H](N)[C@H]1O[C@@H]1[C@](O)(C)[C@@H](O)[C@@H](C)O[C@H]1OC1=CC=CC2=C(O)C(C(O3)=O)=C4C5=C3C=CC(C)=C5C(=O)OC4=C12 MGQRRMONVLMKJL-KWJIQSIXSA-N 0.000 description 1
- 229950002339 elsamitrucin Drugs 0.000 description 1
- 201000011025 embryonal testis carcinoma Diseases 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229950002973 epitiostanol Drugs 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- 150000003883 epothilone derivatives Chemical class 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- 229960003649 eribulin Drugs 0.000 description 1
- UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 208000028653 esophageal adenocarcinoma Diseases 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- ITSGNOIFAJAQHJ-BMFNZSJVSA-N esorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 ITSGNOIFAJAQHJ-BMFNZSJVSA-N 0.000 description 1
- 229950002017 esorubicin Drugs 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- KFOZNPPBKHYHQD-UHFFFAOYSA-N ethenesulfonyl chloride Chemical compound ClS(=O)(=O)C=C KFOZNPPBKHYHQD-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- QSRLNKCNOLVZIR-KRWDZBQOSA-N ethyl (2s)-2-[[2-[4-[bis(2-chloroethyl)amino]phenyl]acetyl]amino]-4-methylsulfanylbutanoate Chemical compound CCOC(=O)[C@H](CCSC)NC(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 QSRLNKCNOLVZIR-KRWDZBQOSA-N 0.000 description 1
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229960005237 etoglucid Drugs 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- ZVYVPGLRVWUPMP-FYSMJZIKSA-N exatecan Chemical compound C1C[C@H](N)C2=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC3=CC(F)=C(C)C1=C32 ZVYVPGLRVWUPMP-FYSMJZIKSA-N 0.000 description 1
- 229950009429 exatecan Drugs 0.000 description 1
- 229950000484 exisulind Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 229940043168 fareston Drugs 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- QXNWVJOHUAQHLM-AZUAARDMSA-N ferruginol Chemical compound CC([C@@H]1CC2)(C)CCC[C@]1(C)C1=C2C=C(C(C)C)C(O)=C1 QXNWVJOHUAQHLM-AZUAARDMSA-N 0.000 description 1
- HOJWCCXHGGCJQV-YLJYHZDGSA-N ferruginol Natural products CC(C)c1ccc2c(CC[C@@H]3C(C)(C)CCC[C@]23C)c1O HOJWCCXHGGCJQV-YLJYHZDGSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229950008692 foretinib Drugs 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 229950011423 forodesine Drugs 0.000 description 1
- 229960000297 fosfestrol Drugs 0.000 description 1
- GKDRMWXFWHEQQT-UHFFFAOYSA-N fostamatinib Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C(NC=3N=C4N(COP(O)(O)=O)C(=O)C(C)(C)OC4=CC=3)C(F)=CN=2)=C1 GKDRMWXFWHEQQT-UHFFFAOYSA-N 0.000 description 1
- 229950005309 fostamatinib Drugs 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 229940044658 gallium nitrate Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 201000003115 germ cell cancer Diseases 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000000174 gluconic acid Chemical group 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Chemical group 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000000348 glycosyl donor Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 229940087559 grape seed Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical class COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000019314 gum ghatti Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 125000006588 heterocycloalkylene group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 229960004867 hexetidine Drugs 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 229940088013 hycamtin Drugs 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 229940015872 ibandronate Drugs 0.000 description 1
- 229960001507 ibrutinib Drugs 0.000 description 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- 229950003978 imexon Drugs 0.000 description 1
- BIXBBIPTYBJTRY-UHFFFAOYSA-N imexon Chemical compound NC1=NC(=O)N2CC12 BIXBBIPTYBJTRY-UHFFFAOYSA-N 0.000 description 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
- UVNXNSUKKOLFBM-UHFFFAOYSA-N imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=CSC2=NC=CN21 UVNXNSUKKOLFBM-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 229940113174 imidurea Drugs 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- IWKXDMQDITUYRK-KUBHLMPHSA-N immucillin H Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)N[C@H]1C1=CNC2=C1N=CNC2=O IWKXDMQDITUYRK-KUBHLMPHSA-N 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 1
- 229950008097 improsulfan Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- VVVPGLRKXQSQSZ-UHFFFAOYSA-N indolo[3,2-c]carbazole Chemical compound C1=CC=CC2=NC3=C4C5=CC=CC=C5N=C4C=CC3=C21 VVVPGLRKXQSQSZ-UHFFFAOYSA-N 0.000 description 1
- 229960005544 indolocarbazole Drugs 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229950002133 iniparib Drugs 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229950005254 irofulven Drugs 0.000 description 1
- NICJCIQSJJKZAH-AWEZNQCLSA-N irofulven Chemical compound O=C([C@@]1(O)C)C2=CC(C)=C(CO)C2=C(C)C21CC2 NICJCIQSJJKZAH-AWEZNQCLSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000005969 isothiazolinyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000003971 isoxazolinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- QRWUHWVLCGLLOK-UHFFFAOYSA-N ist 622 Chemical compound C=1C2=C(C=3C4=5)OC(=O)C4=C(C)C=CC=5OC(=O)C=3C(OC(=O)CCOCC)=C2C=CC=1OC1OC(C)C2OC(C=3C=CC=CC=3)OC2C1OC1OC(C)C(O)C(OC)C1O QRWUHWVLCGLLOK-UHFFFAOYSA-N 0.000 description 1
- 229960004508 ivacaftor Drugs 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 229940090046 jet injector Drugs 0.000 description 1
- 229940005405 kalydeco Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229950010652 laniquidar Drugs 0.000 description 1
- TULGGJGJQXESOO-UHFFFAOYSA-N laniquidar Chemical compound C12=CC=CC=C2CCN2C(C(=O)OC)=CN=C2C1=C1CCN(CCC=2C=CC(OCC=3N=C4C=CC=CC4=CC=3)=CC=2)CC1 TULGGJGJQXESOO-UHFFFAOYSA-N 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 229950005692 larotaxel Drugs 0.000 description 1
- SEFGUGYLLVNFIJ-QDRLFVHASA-N larotaxel dihydrate Chemical compound O.O.O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@@]23[C@H]1[C@@]1(CO[C@@H]1C[C@@H]2C3)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 SEFGUGYLLVNFIJ-QDRLFVHASA-N 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 244000056931 lavandin Species 0.000 description 1
- 235000009606 lavandin Nutrition 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 206010024217 lentigo Diseases 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 229960003784 lenvatinib Drugs 0.000 description 1
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 1
- 229950001845 lestaurtinib Drugs 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229960003538 lonidamine Drugs 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- FBQPGGIHOFZRGH-UHFFFAOYSA-N lucanthone Chemical compound S1C2=CC=CC=C2C(=O)C2=C1C(C)=CC=C2NCCN(CC)CC FBQPGGIHOFZRGH-UHFFFAOYSA-N 0.000 description 1
- 229950005239 lucanthone Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- RVFGKBWWUQOIOU-NDEPHWFRSA-N lurtotecan Chemical compound O=C([C@]1(O)CC)OCC(C(N2CC3=4)=O)=C1C=C2C3=NC1=CC=2OCCOC=2C=C1C=4CN1CCN(C)CC1 RVFGKBWWUQOIOU-NDEPHWFRSA-N 0.000 description 1
- 229950002654 lurtotecan Drugs 0.000 description 1
- 208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- HAVFFEMDLROBGI-UHFFFAOYSA-N m8926c7ilx Chemical compound C1CC(O)CCN1CC1=CC=C(OC=2C3=C(C(NN=C33)=O)C=CC=2)C3=C1 HAVFFEMDLROBGI-UHFFFAOYSA-N 0.000 description 1
- 230000016089 mRNA destabilization Effects 0.000 description 1
- 238000006841 macrolactonization reaction Methods 0.000 description 1
- 229950000547 mafosfamide Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 229960000816 magnesium hydroxide Drugs 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- MQXVYODZCMMZEM-ZYUZMQFOSA-N mannomustine Chemical compound ClCCNC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CNCCCl MQXVYODZCMMZEM-ZYUZMQFOSA-N 0.000 description 1
- 229950008612 mannomustine Drugs 0.000 description 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
- 208000021937 marginal zone lymphoma Diseases 0.000 description 1
- 229950002736 marizomib Drugs 0.000 description 1
- 208000008585 mastocytosis Diseases 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 208000030163 medullary breast carcinoma Diseases 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 229950009246 mepitiostane Drugs 0.000 description 1
- 210000001704 mesoblast Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- VJRAUFKOOPNFIQ-TVEKBUMESA-N methyl (1r,2r,4s)-4-[(2r,4s,5s,6s)-5-[(2s,4s,5s,6s)-5-[(2s,4s,5s,6s)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-(dimethylamino)-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7,10-tetrahydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylat Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1 VJRAUFKOOPNFIQ-TVEKBUMESA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 231100000782 microtubule inhibitor Toxicity 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 229960003539 mitoguazone Drugs 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- 229950001745 mitonafide Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- QXYYYPFGTSJXNS-UHFFFAOYSA-N mitozolomide Chemical compound N1=NN(CCCl)C(=O)N2C1=C(C(=O)N)N=C2 QXYYYPFGTSJXNS-UHFFFAOYSA-N 0.000 description 1
- 229950005967 mitozolomide Drugs 0.000 description 1
- 229950002915 mivebresib Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 229940111688 monobasic potassium phosphate Drugs 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 1
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- FOYWNSCCNCUEPU-UHFFFAOYSA-N mopidamol Chemical compound C12=NC(N(CCO)CCO)=NC=C2N=C(N(CCO)CCO)N=C1N1CCCCC1 FOYWNSCCNCUEPU-UHFFFAOYSA-N 0.000 description 1
- 229950010718 mopidamol Drugs 0.000 description 1
- 208000026114 mu chain disease Diseases 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229940124303 multikinase inhibitor Drugs 0.000 description 1
- 201000002077 muscle cancer Diseases 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
- QKYWADPCTHTJHQ-UHFFFAOYSA-N n,2-dimethylpropan-1-amine Chemical compound CNCC(C)C QKYWADPCTHTJHQ-UHFFFAOYSA-N 0.000 description 1
- ZQGJEUVBUVKZKS-UHFFFAOYSA-N n,2-dimethylpropan-2-amine Chemical compound CNC(C)(C)C ZQGJEUVBUVKZKS-UHFFFAOYSA-N 0.000 description 1
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 1
- YCJZWBZJSYLMPB-UHFFFAOYSA-N n-(2-chloropyrimidin-4-yl)-2,5-dimethyl-1-phenylimidazole-4-carboxamide Chemical compound CC=1N(C=2C=CC=CC=2)C(C)=NC=1C(=O)NC1=CC=NC(Cl)=N1 YCJZWBZJSYLMPB-UHFFFAOYSA-N 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
- BXYDVWIAGDJBEC-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-12-oxo-12h-benzo[g]pyrido[2,1-b]quinazoline-4-carboxamide Chemical compound C1=CC=C2C=C(C(N3C=CC=C(C3=N3)C(=O)NCCN(C)C)=O)C3=CC2=C1 BXYDVWIAGDJBEC-UHFFFAOYSA-N 0.000 description 1
- XBGNERSKEKDZDS-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]acridine-4-carboxamide Chemical compound C1=CC=C2N=C3C(C(=O)NCCN(C)C)=CC=CC3=CC2=C1 XBGNERSKEKDZDS-UHFFFAOYSA-N 0.000 description 1
- RDONXGFGWSSFMY-UHFFFAOYSA-N n-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(NS(=O)(=O)CC)=CC=C1OC1=CC=C(F)C=C1F RDONXGFGWSSFMY-UHFFFAOYSA-N 0.000 description 1
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 description 1
- RIJLVEAXPNLDTC-UHFFFAOYSA-N n-[5-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound C1CC1C(=O)NC(=NN12)N=C1C=CC=C2C(C=C1)=CC=C1CN1CCS(=O)(=O)CC1 RIJLVEAXPNLDTC-UHFFFAOYSA-N 0.000 description 1
- YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- RIVIDPPYRINTTH-UHFFFAOYSA-N n-ethylpropan-2-amine Chemical compound CCNC(C)C RIVIDPPYRINTTH-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229950002366 nafoxidine Drugs 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 229940086322 navelbine Drugs 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 201000009494 neurilemmomatosis Diseases 0.000 description 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- YMVWGSQGCWCDGW-UHFFFAOYSA-N nitracrine Chemical compound C1=CC([N+]([O-])=O)=C2C(NCCCN(C)C)=C(C=CC=C3)C3=NC2=C1 YMVWGSQGCWCDGW-UHFFFAOYSA-N 0.000 description 1
- 229950008607 nitracrine Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- KGTDRFCXGRULNK-JYOBTZKQSA-N nogalamycin Chemical compound CO[C@@H]1[C@@](OC)(C)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=C4[C@@]5(C)O[C@H]([C@H]([C@@H]([C@H]5O)N(C)C)O)OC4=C3C3=O)=C3C=C2[C@@H](C(=O)OC)[C@@](C)(O)C1 KGTDRFCXGRULNK-JYOBTZKQSA-N 0.000 description 1
- 229950009266 nogalamycin Drugs 0.000 description 1
- 229940085033 nolvadex Drugs 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005071 nonynyl group Chemical group C(#CCCCCCCC)* 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000001702 nutmeg Substances 0.000 description 1
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- JPMIIZHYYWMHDT-UHFFFAOYSA-N octhilinone Chemical compound CCCCCCCCN1SC=CC1=O JPMIIZHYYWMHDT-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- CZDBNBLGZNWKMC-MWQNXGTOSA-N olivomycin Chemical class O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1)O[C@H]1O[C@@H](C)[C@H](O)[C@@H](OC2O[C@@H](C)[C@H](O)[C@@H](O)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@H](O)[C@H](OC)[C@H](C)O1 CZDBNBLGZNWKMC-MWQNXGTOSA-N 0.000 description 1
- 229940005619 omacetaxine Drugs 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 229950011093 onapristone Drugs 0.000 description 1
- 229950000846 onartuzumab Drugs 0.000 description 1
- 201000002740 oral squamous cell carcinoma Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 229950001094 ortataxel Drugs 0.000 description 1
- BWKDAMBGCPRVPI-ZQRPHVBESA-N ortataxel Chemical compound O([C@@H]1[C@]23OC(=O)O[C@H]2[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]2(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]21)OC(C)=O)C3(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC(C)C)C(=O)C1=CC=CC=C1 BWKDAMBGCPRVPI-ZQRPHVBESA-N 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 208000013371 ovarian adenocarcinoma Diseases 0.000 description 1
- 201000011029 ovarian embryonal carcinoma Diseases 0.000 description 1
- 201000006588 ovary adenocarcinoma Diseases 0.000 description 1
- 125000005963 oxadiazolidinyl group Chemical group 0.000 description 1
- 125000005882 oxadiazolinyl group Chemical group 0.000 description 1
- MOOYVEVEDVVKGD-UHFFFAOYSA-N oxaldehydic acid;hydrate Chemical compound O.OC(=O)C=O MOOYVEVEDVVKGD-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000005968 oxazolinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229950011410 pacritinib Drugs 0.000 description 1
- HWXVIOGONBBTBY-ONEGZZNKSA-N pacritinib Chemical compound C=1C=C(C=2)NC(N=3)=NC=CC=3C(C=3)=CC=CC=3COC\C=C\COCC=2C=1OCCN1CCCC1 HWXVIOGONBBTBY-ONEGZZNKSA-N 0.000 description 1
- 229960004390 palbociclib Drugs 0.000 description 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 208000012111 paraneoplastic syndrome Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960003407 pegaptanib Drugs 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- 229950003180 peplomycin Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 229940100595 phenylacetaldehyde Drugs 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
- 229950001100 piposulfan Drugs 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229960004403 pixantrone Drugs 0.000 description 1
- PEZPMAYDXJQYRV-UHFFFAOYSA-N pixantrone Chemical compound O=C1C2=CN=CC=C2C(=O)C2=C1C(NCCN)=CC=C2NCCN PEZPMAYDXJQYRV-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000117 poly(dioxanone) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229960001131 ponatinib Drugs 0.000 description 1
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229960004109 potassium acetate Drugs 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 235000010235 potassium benzoate Nutrition 0.000 description 1
- 239000004300 potassium benzoate Substances 0.000 description 1
- 229940103091 potassium benzoate Drugs 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000004224 potassium gluconate Substances 0.000 description 1
- 235000013926 potassium gluconate Nutrition 0.000 description 1
- 229960003189 potassium gluconate Drugs 0.000 description 1
- 229940096992 potassium oleate Drugs 0.000 description 1
- 229940093916 potassium phosphate Drugs 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- BHZRJJOHZFYXTO-UHFFFAOYSA-L potassium sulfite Chemical compound [K+].[K+].[O-]S([O-])=O BHZRJJOHZFYXTO-UHFFFAOYSA-L 0.000 description 1
- 235000019252 potassium sulphite Nutrition 0.000 description 1
- MLICVSDCCDDWMD-KVVVOXFISA-M potassium;(z)-octadec-9-enoate Chemical compound [K+].CCCCCCCC\C=C/CCCCCCCC([O-])=O MLICVSDCCDDWMD-KVVVOXFISA-M 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 201000006037 primary mediastinal B-cell lymphoma Diseases 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- WOLQREOUPKZMEX-UHFFFAOYSA-N pteroyltriglutamic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C=C1 WOLQREOUPKZMEX-UHFFFAOYSA-N 0.000 description 1
- 235000020236 pumpkin seed Nutrition 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- ATBIAJXSKNPHEI-UHFFFAOYSA-N pyridine-3-carbonyl chloride Chemical compound ClC(=O)C1=CC=CN=C1 ATBIAJXSKNPHEI-UHFFFAOYSA-N 0.000 description 1
- RVQZKNOMKUSGCI-UHFFFAOYSA-N pyridine-4-carbonyl chloride Chemical compound ClC(=O)C1=CC=NC=C1 RVQZKNOMKUSGCI-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- AUJXLBOHYWTPFV-UHFFFAOYSA-N quinomycin A Natural products CN1C(=O)C(C)NC(=O)C(NC(=O)C=2N=C3C=CC=CC3=NC=2)COC(=O)C(C(C)C)N(C)C(=O)C2N(C)C(=O)C(C)NC(=O)C(NC(=O)C=3N=C4C=CC=CC4=NC=3)COC(=O)C(C(C)C)N(C)C(=O)C1CSC2SC AUJXLBOHYWTPFV-UHFFFAOYSA-N 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229940092814 radium (223ra) dichloride Drugs 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 229960002185 ranimustine Drugs 0.000 description 1
- BMKDZUISNHGIBY-UHFFFAOYSA-N razoxane Chemical compound C1C(=O)NC(=O)CN1C(C)CN1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-UHFFFAOYSA-N 0.000 description 1
- 229960000460 razoxane Drugs 0.000 description 1
- 229960005567 rebeccamycin Drugs 0.000 description 1
- INSACQSBHKIWNS-QZQSLCQPSA-N rebeccamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](OC)[C@@H](CO)O[C@H]1N1C2=C3N=C4[C](Cl)C=CC=C4C3=C3C(=O)NC(=O)C3=C2C2=CC=CC(Cl)=C21 INSACQSBHKIWNS-QZQSLCQPSA-N 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 1
- 229950010550 resiquimod Drugs 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 229950003687 ribociclib Drugs 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229950004892 rodorubicin Drugs 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- 229950009213 rubitecan Drugs 0.000 description 1
- YBCAZPLXEGKKFM-UHFFFAOYSA-K ruthenium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Ru+3] YBCAZPLXEGKKFM-UHFFFAOYSA-K 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- NGWSFRIPKNWYAO-SHTIJGAHSA-N salinosporamide A Chemical compound C([C@@H]1[C@H](O)[C@]23C(=O)O[C@]2([C@H](C(=O)N3)CCCl)C)CCC=C1 NGWSFRIPKNWYAO-SHTIJGAHSA-N 0.000 description 1
- NGWSFRIPKNWYAO-UHFFFAOYSA-N salinosporamide A Natural products N1C(=O)C(CCCl)C2(C)OC(=O)C21C(O)C1CCCC=C1 NGWSFRIPKNWYAO-UHFFFAOYSA-N 0.000 description 1
- LBGFKUUHOPIEMA-PEARBKPGSA-N sapacitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](C#N)[C@H](O)[C@@H](CO)O1 LBGFKUUHOPIEMA-PEARBKPGSA-N 0.000 description 1
- 229950006896 sapacitabine Drugs 0.000 description 1
- 229950009919 saracatinib Drugs 0.000 description 1
- OUKYUETWWIPKQR-UHFFFAOYSA-N saracatinib Chemical compound C1CN(C)CCN1CCOC1=CC(OC2CCOCC2)=C(C(NC=2C(=CC=C3OCOC3=2)Cl)=NC=N2)C2=C1 OUKYUETWWIPKQR-UHFFFAOYSA-N 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 208000014956 scrotum Paget disease Diseases 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 201000003385 seborrheic keratosis Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
- 229950010746 selumetinib Drugs 0.000 description 1
- 201000005574 senile angioma Diseases 0.000 description 1
- BLGWHBSBBJNKJO-UHFFFAOYSA-N serabelisib Chemical compound C=1C=C2OC(N)=NC2=CC=1C(=CN12)C=CC1=NC=C2C(=O)N1CCOCC1 BLGWHBSBBJNKJO-UHFFFAOYSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- AGBSXNCBIWWLHD-FQEVSTJZSA-N siremadlin Chemical compound COC1=NC(OC)=NC=C1C(N1C(C)C)=NC2=C1[C@H](C=1C=CC(Cl)=CC=1)N(C=1C(N(C)C=C(Cl)C=1)=O)C2=O AGBSXNCBIWWLHD-FQEVSTJZSA-N 0.000 description 1
- 229950001403 sizofiran Drugs 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000000195 skin tag Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
- 235000010334 sodium propionate Nutrition 0.000 description 1
- 239000004324 sodium propionate Substances 0.000 description 1
- 229960003212 sodium propionate Drugs 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 229950006315 spirogermanium Drugs 0.000 description 1
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- INIBXSLTWQVIHS-ASACRTLUSA-O stanford v protocol Chemical compound ClCCN(C)CCCl.O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3C(O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)C(O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C INIBXSLTWQVIHS-ASACRTLUSA-O 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- MVGSNCBCUWPVDA-MFOYZWKCSA-N sulindac sulfone Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)(=O)=O)C=C1 MVGSNCBCUWPVDA-MFOYZWKCSA-N 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 229960005566 swainsonine Drugs 0.000 description 1
- FXUAIOOAOAVCGD-FKSUSPILSA-N swainsonine Chemical compound C1CC[C@H](O)[C@H]2[C@H](O)[C@H](O)CN21 FXUAIOOAOAVCGD-FKSUSPILSA-N 0.000 description 1
- FXUAIOOAOAVCGD-UHFFFAOYSA-N swainsonine Natural products C1CCC(O)C2C(O)C(O)CN21 FXUAIOOAOAVCGD-UHFFFAOYSA-N 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229950010924 talaporfin Drugs 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 1
- 229950007866 tanespimycin Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229950005890 tariquidar Drugs 0.000 description 1
- 229940061353 temodar Drugs 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- MCGDVVXFTUKWNU-UHFFFAOYSA-N tert-butyl 3-(aminomethyl)-3-hydroxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)(CN)C1 MCGDVVXFTUKWNU-UHFFFAOYSA-N 0.000 description 1
- RQCNHUCCQJMSRG-UHFFFAOYSA-N tert-butyl piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1 RQCNHUCCQJMSRG-UHFFFAOYSA-N 0.000 description 1
- SWQDRYKDDGFPLL-UHFFFAOYSA-N tert-butyl prop-2-enyl carbonate Chemical compound CC(C)(C)OC(=O)OCC=C SWQDRYKDDGFPLL-UHFFFAOYSA-N 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- MODVSQKJJIBWPZ-VLLPJHQWSA-N tesetaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3CC[C@@]2(C)[C@H]2[C@@H](C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C(=CC=CN=4)F)C[C@]1(O)C3(C)C)O[C@H](O2)CN(C)C)C(=O)C1=CC=CC=C1 MODVSQKJJIBWPZ-VLLPJHQWSA-N 0.000 description 1
- 229950009016 tesetaxel Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 206010062123 testicular embryonal carcinoma Diseases 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- 125000001935 tetracenyl group Chemical group C1(=CC=CC2=CC3=CC4=CC=CC=C4C=C3C=C12)* 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000005304 thiadiazolidinyl group Chemical group 0.000 description 1
- 125000005305 thiadiazolinyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 150000003569 thioglycosides Chemical class 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- YFTWHEBLORWGNI-UHFFFAOYSA-N tiamiprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC(N)=NC2=C1NC=N2 YFTWHEBLORWGNI-UHFFFAOYSA-N 0.000 description 1
- 229950011457 tiamiprine Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229950005976 tivantinib Drugs 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229940035307 toposar Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960004066 trametinib Drugs 0.000 description 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
- 229950001353 tretamine Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 229960005526 triapine Drugs 0.000 description 1
- PXSOHRWMIRDKMP-UHFFFAOYSA-N triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 description 1
- 229960004560 triaziquone Drugs 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229960001670 trilostane Drugs 0.000 description 1
- KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- 229950000212 trioxifene Drugs 0.000 description 1
- 229950002860 triplatin tetranitrate Drugs 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- YKUJZZHGTWVWHA-UHFFFAOYSA-N triptolide Natural products COC12CC3OC3(C(C)C)C(O)C14OC4CC5C6=C(CCC25C)C(=O)OC6 YKUJZZHGTWVWHA-UHFFFAOYSA-N 0.000 description 1
- 229960005066 trisodium edetate Drugs 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229960000875 trofosfamide Drugs 0.000 description 1
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
- 229950010147 troxacitabine Drugs 0.000 description 1
- RXRGZNYSEHTMHC-BQBZGAKWSA-N troxacitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)OC1 RXRGZNYSEHTMHC-BQBZGAKWSA-N 0.000 description 1
- HDZZVAMISRMYHH-LITAXDCLSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O HDZZVAMISRMYHH-LITAXDCLSA-N 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229950008737 vadimezan Drugs 0.000 description 1
- XGOYIMQSIKSOBS-UHFFFAOYSA-N vadimezan Chemical compound C1=CC=C2C(=O)C3=CC=C(C)C(C)=C3OC2=C1CC(O)=O XGOYIMQSIKSOBS-UHFFFAOYSA-N 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- 229940099039 velcade Drugs 0.000 description 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
- 239000010679 vetiver oil Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- NMDYYWFGPIMTKO-HBVLKOHWSA-N vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 description 1
- 229960000922 vinflunine Drugs 0.000 description 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 208000028010 vulval Paget disease Diseases 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 239000008170 walnut oil Substances 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940053867 xeloda Drugs 0.000 description 1
- UGBMEXLBFDAOGL-INIZCTEOSA-N zd6126 Chemical compound C1C[C@H](NC(C)=O)C2=CC(OP(O)(O)=O)=CC=C2C2=C1C=C(OC)C(OC)=C2OC UGBMEXLBFDAOGL-INIZCTEOSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
- 229950005752 zosuquidar Drugs 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
Definitions
- cystic fibrosis CF
- muscular dystrophy Duchenne (DMD), Becker (BMD), congenital
- spinal muscular atrophy SMA
- FIGS. 6.1A-D and S1A and SIB shows that a representative RMA compound of the invention as disclosed herein is selectively active in a sensitive CRC cell line.
- FIGS. 6.2A-D and S2A-S2D show that the representative RMA compound of the invention inhibits protein translation in a sensitive CRC cell line.
- FIGS. 6.3A-B and S3A and S3B show that the representative compound of the invention alters cell cycle in a sensitive CRC cell line.
- FIGS. 6.4A-D show that CMS2 cell lines display high sensitivity to the representative compound of the invention.
- FIG.7.1 summarizes the approach we employed in identifying RMAs.
- FIGS. 7.2A and B summarize clinical subtypes in solid and hematological cancers that are highly sensitive to the second representative RMA of the invention.
- FIG.7.3 indicates that forty five percent of small cell lung cancer cell lines are highly sensitive to the second representative RMA compound of the invention.
- FIGS. 7.4A-C indicate that the sensitivity small cell lung cancer cell lines is associated with high expression of ribogenesis, protein translation, and MYC pathway genes.
- FIGS. 7.5A-C indicate that the anti-proliferative effect of RMAs is driven by selective inhibition of new protein synthesis
- FIGS. 7.6A-B show that proteins with higher positively charged regions are more sensitive to translation inhibition by RMAs.
- FIGS. 7.7 indicates that decreased proteins show a large impact on ribogenesis and protein translation machinery.
- FIG.7.8 indicates that the second representative compound of the invention induces apoptosis in sensitive cells.
- FIG.7.9 shows that the second representative compound of the invention selectively inhibits SCLC -patient derived organoids (PDOs).
- FIG.7.10 shows that the second representative compound of the invention demonstrates combination synergy with DNA targeting chemotherapeutics known to inhibit tRNA synthesis.
- FIG.7.11 summarizes the multiple levels of selectivity of allosteric inhibition by the RMAs of the invention.
- Articles such as “a,” “an,” and “the” may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context.
- the invention includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process.
- the invention includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process.
- the terms “a,” “an,” and “the” as used herein not only include aspects with one member, but also include aspects with more than one member.
- “about X” is intended to teach and provide written description support for a claim limitation of, e.g., “0.98X.”
- “about X” indicates from (X-l) to (X+l).
- “about X” as used herein specifically indicates at least the values X, X-l, and X+l.
- the “R” group may reside on either the 5-membered or the 6-membered ring of the fused or bridged ring system.
- acyl as used herein includes an alkanoyl, aroyl, heterocycloyl, or heteroaroyl group as defined herein.
- acyl groups include, but are not limited to, acetyl, benzoyl, and ni cotinoyl.
- alkanoyl as used herein includes an alkyl-C(O)- group wherein the alkyl group is as defined herein. Examples of alkanoyl groups include, but are not limited to, acetyl and propanoyl.
- agent includes a compound or mixture of compounds that, when added to a composition, tend to produce a particular effect on the composition’s properties.
- a composition comprising a thickening agent is likely to be more viscous than an otherwise identical comparative composition that lacks the thickening agent.
- alkenyl as used herein includes a straight or branched chain hydrocarbon containing at least one carbon-carbon double bond.
- the chain may contain an indicated number of carbon atoms.
- C1-C12 alkenyl indicates that the group may have from 1 to 12 (inclusive) carbon atoms and at least one carbon-carbon double bond.
- the indicated number of carbon atoms is 1, then the Ci alkenyl is double bonded to a carbon (i.e., a carbon equivalent to an oxo group).
- the chain includes 1 to 12, about 2 to 15, about 2 to 12, about 2 to 8, or about 2 to 6 carbon atoms.
- An amino group can be a primary amino group (NH2), or a secondary or tertiary amine, wherein the alkyl groups in the secondary ofr tertiary amine can be the same or different, and can be optionally substituted.
- alkenyl group can be unsubstituted or optionally substituted.
- one or more hydrogen atoms of the alkenyl group e.g., from 1 to 4, from 1 to 2, or 1
- the alkenyl group is unsubstituted or not optionally substituted.
- alkyl as used herein includes an aliphatic hydrocarbon chain that may be straight chain or branched.
- the chain may contain an indicated number of carbon atoms: For example, C1-C10 indicates that the group may have from 1 to 10 (inclusive) carbon atoms in it. If not otherwise indicated, an alkyl group contains from 1 to about 20 carbon atoms. In some aspects, alkyl groups have 1 to about 10 carbon atoms. In some aspects, alkyl groups (“lower alkyl”) have 1 to 8, 1 to 6, or 1 to 3 carbon atoms in the chain.
- Examples may include, but are not limited to, methyl, ethyl, propyl, isopropyl (iPr), 1 -butyl, 2 -butyl, isobutyl (iBu), Ze/7-butyl, pentyl, 2-m ethylbutyl, 1,1 -dimethylpropyl, hexyl, heptyl, octyl, nonyl, decyl, docecyl, cyclopentyl, or cyclohexyl.
- An alkyl group can be unsubstituted or optionally substituted.
- one or more hydrogen atoms of the alkyl group e.g., from 1 to 4, from 1 to 2, or 1 may be replaced with a moiety independently selected from the group consisting of fluoro, hydroxy, alkoxy, amino, alkylamino, acylamino, thio, and alkylthio.
- the alkyl group is unsubstituted or not optionally substituted.
- Alkylene as used herein includes an alkyl group that is substituted at two points.
- An example is methylene (-CH2-), propylene (-CH2CH2CH2-), and the like.
- alkoxy as used herein includes a straight or branched chain saturated or unsaturated hydrocarbon containing at least one oxygen atom in an ether group (e.g., EtO-).
- the chain may contain an indicated number of carbon atoms.
- C1-C12 alkoxy indicates that the group may have from 1 to 12 (inclusive) carbon atoms and at least one oxygen atom.
- Examples of a C1-C12 alkoxy group include, but are not limited to, methoxy, ethoxy, isopropoxy, butoxy, n-pentoxy, isopentoxy, neopentoxy, and hexoxy.
- An alkoxy group can be unsubstituted or optionally substituted.
- one or more hydrogen atoms of the alkoxy group e.g., from 1 to 4, from 1 to 2, or 1 may be replaced with a moiety independently selected from the group consisting of fluoro, hydroxy, alkoxy, amino, alkylamino, acylamino, thio, and alkylthio, with the proviso that no hydrogen atom alpha to the ether oxygen is replaced by a hydroxy, amino, or thio group.
- the alkoxy group is unsubstituted or not optionally substituted.
- An alkynyl group can be unsubstituted or optionally substituted.
- one or more hydrogen atoms of the alkynyl group e.g., from 1 to 4, from 1 to 2, or 1 may be replaced with a moiety independently selected from the group consisting of fluoro, hydroxy, alkoxy, amino, alkylamino, acylamino, thio, and alkylthio, with the proviso that no sp- hybridized hydrogen atom substituent is replaced by a hydroxy, amino, or thio group.
- the alkynyl group is unsubstituted or not optionally substituted.
- aryl as used herein includes cyclic aromatic carbon ring systems containing from 6 to 18 carbons. Examples of an aryl group include, but are not limited to, phenyl, naphthyl, anthracenyl, tetracenyl, biphenyl and phenanthrenyl.
- An aryl group can be unsubstituted or optionally substituted.
- one or more hydrogen atoms of the aryl group e.g., from 1 to 5, from 1 to 2, or 1 may be replaced with a moiety independently selected from the group consisting of alkyl, cyano, acyl, halo, hydroxy, alkoxy, amino, alkylamino, acylamino, thio, and alkylthio.
- the alkoxy group is unsubstituted or not optionally substituted.
- arylalkyl or “aralkyl” as used herein includes an alkyl group as defined herein where at least one hydrogen substituent has been replaced with an aryl group as defined herein. Examples include, but are not limited to, benzyl, 1 -phenyl ethyl, 4-methylbenzyl, and 1,1,- dimethyl- 1 -phenylmethyl .
- a substituted cycloalkyl group can incorporate an exo- or endocyclic alkene (e.g., cyclohex-2-en-l- yl).
- a cycloalkyl group is unsubstituted or not optionally substituted.
- geometric substitution includes two or more substituents that are directly attached to the same atom.
- An example is 3,3-dimethyl substitution on a cyclohexyl or spirocyclohexyl ring.
- halo or “halogen” includes fluoro, chloro, bromo, and iodo.
- heteroarylene or “heterocycloarylene” as used herein includes a heteroaryl group that is substituted at two points.
- heteroaroyl as used herein includes a heteroaryl -C(O)- group wherein heteroaryl is as defined herein.
- Heteroaroyl groups include, but are not limited to, thiophenoyl, nicotinoyl, pyrrol-2-ylcarbonyl, and pyridinoyl.
- heterocycloalkyl may be used interchangeably herein, and as used herein includes a heterocyclyl-C(O)- group wherein heterocyclyl is as defined herein. Examples include, but are not limited to, N-m ethyl prolinoyl and tetrahydrofuranoyl.
- heterocyclyl (heterocyclo; heterocyclic; heterocycloalkyl) includes a non-aromatic saturated ring of about 3 to about 8 Ring Dtoms (e.g., 5 to about 10 Ring Dtoms, or 3 to about 6 Ring atoms), in which one or more of the atoms in the ring system is an element or elements other than carbon, e.g., nitrogen, oxygen or sulfur.
- a heterocyclyl group optionally comprises at least one sp 2 -hybridized atom (e.g., a ring incorporating an carbonyl, endocyclic olefin, or exocyclic olefin).
- a nitrogen or sulfur atom of the heterocyclyl is optionally oxidized to the corresponding N-oxide, S-oxide or S, S-di oxide.
- the monocyclic heterocycle means a three-, four-, five-, six-, seven-, or eight-membered ring containing at least one heteroatom independently selected from the group consisting of O, N, and S.
- the three- or four-membered ring contains zero or one double bond, and one heteroatom selected from the group consisting of O, N, and S.
- the five-membered ring contains zero or one double bond and one, two or three heteroatoms selected from the group consisting of O, N and S.
- monocyclic heterocycles include, but are not limited to, azetidinyl, azepanyl, aziridinyl, diazepanyl, 1,3-dioxanyl, 1,3-dioxolanyl, 1,3- dithiolanyl, 1,3-dithianyl, imidazolinyl, imidazolidinyl, isothiazolinyl, isothiazolidinyl, isoxazolinyl, isoxazolidinyl, morpholinyl, oxadiazolinyl, oxadiazolidinyl, oxazolinyl, oxazolidinyl, piperazinyl, piperidinyl, pyranyl, pyrazolinyl, pyrazolidinyl, pyridazin-3(2H)-onyl, pyridin-2(lH)-onyl, pyrrolinyl, pyrroliny
- heterocycloalkylene as used herein includes a heterocyclyl (heterocyclo; heterocyclic) group that is substituted at two points.
- heterocyclyl also includes multicyclic rings such as a bicyclic heterocycle, or a tricyclic heterocycle which may be in a fused, bridged, or spiro orientation.
- the bicyclic heterocycle is a monocyclic heterocycle fused to a phenyl group, or a monocyclic heterocycle fused to a monocyclic cycloalkyl, or a monocyclic heterocycle fused to a monocyclic cycloalkenyl, or a monocyclic heterocycle fused to a monocyclic heterocycle, or a bridged monocyclic heterocycle ring system in which two non-adjacent atoms of the Ring Dre linked by an alkylene bridge of 1, 2, 3, or 4 carbon atoms, or an alkenylene bridge of two, three, or four carbon atoms.
- bicyclic heterocycles include, but are not limited to, 3- azabicyclo[3.1.0]hexane, 3-azabicyclo[4.1.0]heptane, 3-azabicyclo[3.2.0]heptane, (3aR,6aS)- hexahydro-lH-2Z,2-cyclopenta[c]pyrrole, (3aR,7aS)-octahydro-2X2-isoindole.
- Tricyclic heterocycles are exemplified by a bicyclic heterocycle fused to a phenyl group, or a bicyclic heterocycle fused to a monocyclic cycloalkyl, or a bicyclic heterocycle fused to a monocyclic cycloalkenyl, or a bicyclic heterocycle fused to a monocyclic heterocycle, or a bicyclic heterocycle in which two non-adjacent atoms of the bicyclic Ring Dre linked by an alkylene bridge of 1, 2, 3, or 4 carbon atoms, or an alkenylene bridge of two, three, or four carbon atoms.
- a heterocycyl group can be unsubstituted or optionally substituted.
- one or more hydrogen atoms of the group e.g., from 1 to 4, from 1 to 2, or 1 may be replaced with a moiety independently selected from the group consisting of fluoro, hydroxy, alkoxy, amino, alkylamino, acylamino, thio, and alkylthio.
- a substituted heterocycyl group can incorporate an exo- or endocyclic alkene (e.g., cyclohex-2-en-l-yl).
- the heterocycyl group is unsubstituted or not optionally substituted.
- the monocyclic, bicyclic, and tricyclic heterocycles are connected to the parent molecular moiety through any carbon atom or any nitrogen atom contained within the rings, and can be unsubstituted or substituted.
- hydrophilic moiety or “hydrophilic group” includes a moiety or a functional group that has a strong affinity to water. Examples may include, but are not limited to, a charged moiety, such as a cationic moiety or an anionic moiety, or a polar uncharged moiety, such as an alkoxy group or an amine group.
- hydroxyalkyl includes an alkyl group where at least one hydrogen substituent has been replaced with an alcohol (-OH) group.
- the hydroxyalkyl group has one alcohol group.
- the hydroxyalkyl group has one or two alcohol groups, each on a different carbon atom.
- the hydroxyalkyl group has 1, 2, 3, 4, 5, or 6 alcohol groups. Examples may include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, and 1 -hydroxy ethyl.
- the groups may be the same or different.
- R a and R b are independently selected from the group consisting of alkyl, fluoro, amino, and hydroxyalkyl
- a molecule with two R a groups and two R b groups could have all groups be an alkyl group (e.g., four different alkyl groups).
- the first R a could be alkyl
- the second R a could be fluoro
- the first R b could be hydroxyalkyl
- the second R b could be amino (or any other substituents taken from the group).
- both R a and the first R b could be fluoro
- the second R b could be alkyl (i.e., some pairs of substituent groups may be the same, while other pairs may be different).
- “Protecting Group” means “amino protecting group,” which is a protecting group that is suitable for preventing undesired reactions at an amino nitrogen.
- Representative amino-protecting groups include, but are not limited to, formyl; acyl groups, for example alkanoyl groups, such as acetyl; alkoxycarbonyl groups, such as tert-butoxycarbonyl (Boc); arylmethoxycarbonyl groups, such as benzyloxycarbonyl (Cbz) and 9-fluorenylmethoxycarbonyl (Fmoc); arylmethyl groups, such as benzyl (Bn), trityl (Tr), and l,l-di-(4'-methoxyphenyl)methyl; silyl groups, such as trimethylsilyl (TMS) and tert-butyldimethylsilyl (TBDMS); and the like.
- oxygen protecting groups include, but are not limited to silyl groups, such as TMS and TMDMS; esters, such as formate, acetate, and benzoate (Bz); ethers such as methoxymethyl (MOM), tetrahydropyranyl (THP), and benzyl (Bn).
- silyl groups such as TMS and TMDMS
- esters such as formate, acetate, and benzoate (Bz)
- ethers such as methoxymethyl (MOM), tetrahydropyranyl (THP), and benzyl (Bn).
- Oxo Protecting Group means a protecting group for an aldehyde or ketone.
- Non- limiting examples of “oxo Protecting Groups” include acetals, 1-3 -di oxalanes, mixed ketals and thioketals.
- Yield for each of the reactions described herein is expressed as a percentage of the theoretical yield.
- Subject and “patient” are used interchangeably.
- a “subject” or “patient” for the purposes of the present invention includes humans and other animals, particularly mammals, and other organisms. Thus the methods are applicable to both human therapy and veterinary applications.
- the patient is a mammal, and in a more specific embodiment the patient is human.
- a “pharmaceutically acceptable salt” of a compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. It is understood that the pharmaceutically acceptable salts are non-toxic. Additional information on suitable pharmaceutically acceptable salts can be found in Remington ’s Pharmaceutical Sciences, 17 th ed., Mack Publishing Company, Easton, PA, 1985, which is incorporated herein by reference or S. M. Berge, et al., “Pharmaceutical Salts,” J. Pharm. Sci., 1977;66: 1-19 both of which are incorporated herein by reference.
- Examples of pharmaceutically acceptable acid addition salts include those formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; as well as organic acids such as acetic acid, trifluoroacetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, 3-(4-hydroxybenzoyl)benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid,
- Examples of a pharmaceutically acceptable base addition salts include those formed when an acidic proton present in the parent compound is replaced by a metal ion, such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Specific salts are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins.
- organic bases include isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, tromethamine, A-methylglucamine, polyamine resins, and the like.
- Exemplary organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine.
- Platinum(s),” and “platin-containing agent(s)” include, for example, cisplatin, carboplatin, and oxaliplatin.
- a prophylactic effect includes delaying or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof.
- “Therapeutically effective amount” is an amount of a compound of the invention, that when administered to a patient, ameliorates a symptom of the disease.
- the amount of a compound of the invention which constitutes a “therapeutically effective amount” will vary depending on the compound, the disease state and its severity, the age of the patient to be treated, and the like. The therapeutically effective amount can be determined routinely by one of ordinary skill in the art having regard to their knowledge and to this disclosure.
- co-administration encompass administration of two or more agents to an animal, including humans, so that both agents and/or their metabolites are present in the subject at the same time.
- Co-administration includes simultaneous administration in separate compositions, administration at different times in separate compositions, or administration in a composition in which both agents are present.
- genetic disease means a genetic disorder, genetic disease, genetic condition or genetic syndrome.
- Preventing” or “prevention” of a disease, disorder, or syndrome includes inhibiting the disease from occurring in a human, i.e. causing the clinical symptoms of the disease, disorder, or syndrome not to develop in an animal that may be exposed to or predisposed to the disease, disorder, or syndrome but does not yet experience or display symptoms of the disease, disorder, or syndrome.
- Treating” or “treatment” of a disease, disorder, or syndrome includes (i) inhibiting the disease, disorder, or syndrome, i.e., arresting its development; and (ii) relieving the disease, disorder, or syndrome, i.e., causing regression of the disease, disorder, or syndrome.
- adjustments for systemic versus localized delivery, age, body weight, general health, sex, diet, time of administration, drug interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by one of ordinary skill in the art.
- proliferative disease refers to a disease that occurs due to abnormal growth or extension by the multiplication of cells (Walker, Cambridge Dictionary of Biology; Cambridge University Press: Cambridge, UK, 1990).
- a proliferative disease may be associated with: 1) the pathological proliferation of normally quiescent cells; 2) the pathological migration of cells from their normal location (e.g., metastasis of neoplastic cells); 3) the pathological expression of proteolytic enzymes such as the matrix metalloproteinases (e.g., collagenases, gelatinases, and elastases); or 4) the pathological angiogenesis as in proliferative retinopathy and tumor metastasis.
- Exemplary proliferative diseases include cancers (i.e., "malignant neoplasms"), benign neoplasms, angiogenesis, inflammatory diseases, and autoimmune diseases.
- angiogenesis refers to the physiological process through which new blood vessels form from pre-existing vessels.
- Angiogenesis is distinct from vasculogenesis, which is the de novo formation of endothelial cells from mesoderm cell precursors. The first vessels in a developing embryo form through vasculogenesis, after which angiogenesis is responsible for most blood vessel growth during normal or abnormal development.
- Angiogenesis is a vital process in growth and development, as well as in wound healing and in the formation of granulation tissue.
- angiogenesis is also a fundamental step in the transition of tumors from a benign state to a malignant one, leading to the use of angiogenesis inhibitors in the treatment of cancer.
- Angiogenesis may be chemically stimulated by angiogenic proteins, such as growth factors (e.g., VEGF).
- neoplasm and “tumor” are used herein interchangeably and refer to an abnormal mass of tissue wherein the growth of the mass surpasses and is not coordinated with the growth of a normal tissue.
- a neoplasm or tumor may be "benign” or “malignant,” depending on the following characteristics: degree of cellular differentiation (including morphology and functionality), rate of growth, local invasion, and metastasis.
- a "benign neoplasm” is generally well differentiated, has characteristically slower growth than a malignant neoplasm, and remains localized to the site of origin.
- a benign neoplasm does not have the capacity to infiltrate, invade, or metastasize to distant sites.
- Exemplary benign neoplasms include, but are not limited to, lipoma, chondroma, adenomas, acrochordon, senile angiomas, seborrheic keratoses, lentigos, and sebaceous hyperplasias.
- certain "benign" tumors may later give rise to malignant neoplasms, which may result from additional genetic changes in a subpopulation of the tumor's neoplastic cells, and these tumors are referred to as "pre-malignant neoplasms.”
- An exemplary pre-malignant neoplasm is a teratoma.
- a malignant neoplasm is generally poorly differentiated (anaplasia) and has characteristically rapid growth accompanied by progressive infiltration, invasion, and destruction of the surrounding tissue. Furthermore, a malignant neoplasm generally has the capacity to metastasize to distant sites.
- the term “metastasis,” “metastatic,” or “metastasize” refers to the spread or migration of cancerous cells from a primary or original tumor to one organ or tissue and is typically identifiable by the presence of a "secondary tumor” or “secondary cell mass” of the tissue type of the primary or original tumor and not of that of the organ or tissue in which the secondary (metastatic) tumor is located.
- a prostate cancer that has migrated to bone is said to be metastasized prostate cancer and includes cancerous prostate cancer cells growing in bone tissue.
- cancer refers to a malignant neoplasm (Stedman's Medical Dictionary, 25th ed.; Hensyl ed.; Williams & Wilkins: Philadelphia, 1990).
- exemplary cancers include, but are not limited to, acoustic neuroma; adenocarcinoma; adrenal gland cancer; anal cancer; angiosarcoma (e.g., lymphangiosarcoma, lymphangioendotheliosarcoma, hemangiosarcoma); appendix cancer; benign monoclonal gammopathy; biliary cancer (e.g., cholangiocarcinoma); bladder cancer; breast cancer (e.g., adenocarcinoma of the breast, papillary carcinoma of the breast, mammary cancer, medullary carcinoma of the breast); brain cancer (e.g., meningioma, glioblastomas, glioma (e.g.
- liver cancer e.g., hepatocellular cancer (HCC), malignant hepatoma
- lung cancer e.g., bronchogenic carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), adenocarcinoma of the lung
- leiomyosarcoma LMS
- mastocytosis e.g., systemic mastocytosis
- muscle cancer myelodysplastic syndrome (MDS); mesothelioma; myeloproliferative disorder (MPD) (e.g., polycythemia vera (PV), essential thrombocytosis (ET), agnogenic myeloid metaplasia (AMM) a.k.a.
- myelofibrosis MF
- chronic idiopathic myelofibrosis chronic myelocytic leukemia (CML), chronic neutrophilic leukemia (CNL), hypereosinophilic syndrome (HES)
- neuroblastoma e.g., neurofibromatosis (NF) type 1 or type 2, schwannomatosis
- neuroendocrine cancer e.g., gastroenteropancreatic neuroendoctrine tumor (GEP-NET), carcinoid tumor
- osteosarcoma e.g., bone cancer
- ovarian cancer e.g., cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma
- papillary adenocarcinoma pancreatic cancer
- pancreatic cancer e.g., pancreatic andenocarcinoma, intraductal papillary mucinous neoplasm (IPMN), Islet cell tumors
- Rare diseases caused by nonsense mutations are mutations where a stop codon (UAA, UAG or UGA) replaces an amino acid-coding codon, leading to premature termination of translation and eventually to truncated inactive proteins.
- the Human Gene Mutation Database reports the occurrence of thousands of disease-causing mutations, approximately 12% of which are single point (nonsense) mutations that result in a premature termination codon. (Krawczak M, et al., Hum Mutat. 2000, 15, 45-51.; Mort, et al., M. Hum. Mutat. 2008, 29, 1037-47).
- Nonsense mutations that result in truncated proteins have been demonstrated to account for many forms of genetic disease including cancer, hemophilia, Tay-Sachs, lysosomal storage disorders or mucopolysaccharidoses such as Hurler Syndrome, Duchenne muscular dystrophy, ataxia telangiectasia, Rett syndrome, various inherited retinopathies, and cystic fibrosis.
- R.2a is selected from the group consisting of H, halo, optionally substituted C1-10 alkyl, optionally substituted C1-10 alkoxy, and optionally substituted C1-10 alkenyl, wherein C1-10 alkyl, C1-10 alkoxy, and C1-10 alkenyl are optionally substituted with one or more groups selected from the group consisting of halo, aryl, amino, alkyl, heteroalkyl, heteroalkenyl, heterocycloalkyl, and heteroaryl; and
- R.2b is selected from the group consisting of halo, optionally substituted C1-10 alkyl, optionally substituted C1-10 alkoxy, and optionally substituted C1-10 alkenyl, wherein C1-10 alkyl, C1-10 alkoxy, and C1-10 alkenyl are optionally substituted with one or more groups selected from the group consisting of halo, aryl, amino, alkyl, heteroalkyl, heteroalkenyl, heterocycloalkyl, and heteroaryl;
- R.4a and R4b are each independently selected from the group consisting of -H, and optionally substituted C1-10 alkyl, wherein C1-10 alkyl, is optionally substituted with one or more groups selected from the group consisting of halo, aryl, amino, alkyl, heteroalkyl, heteroalkenyl, heterocycloalkyl, and heteroaryl;
- Rs is selected from the group consisting of H, an oxygen protecting group, and , ” indicates the point of attachment;
- Reb is -H, optionally substituted C1-10 alkyl, optionally substituted C1-10 hydroxyalkyl, and optionally substituted allyl, wherein C1-10 alkyl, C1-10 hydroxyalkyl, and allyl are optionally substituted with one or more groups selected from the group consisting of halo, aryl, amino, alkyl, heteroalkyl, heteroalkenyl, heterocycloalkyl, and heteroaryl;
- Rsa and Rsb are each independently selected from the group consisting of -H and optionally substituted C1-10 alkyl, wherein C1-10 alkyl, is optionally substituted with one or more groups selected from the group consisting of halo, aryl, amino, alkyl, heteroalkyl, heteroalkenyl, heterocycloalkyl, and heteroaryl;
- the compound of formula I is a compound of formula IA:
- the compound of formula I is a compound of formula ID:
- Reb is selected from the group consisting of -H, optionally substituted Ci-C io alkyl, optionally substituted Ci-Cio hydroxyalkyl, and optionally substituted allyl.
- the compound of formula I is a compound of formula IF:
- the compound of formula I is a compound of formula IG:
- one of R2a and R2b is methyl and the other is halo.
- one of R2a and R2b is methyl and the other of R2a and R2b is selected from the group consisting of optionally substituted C1-10 alkyl, optionally substituted C1-10 alkoxy, and optionally substituted C1-10 alkenyl, wherein optionally substituted C1-10 alkyl, optionally substituted C1-10 alkoxy, and optionally substituted C1-10 alkenyl are optionally substituted with one or more selected from the group consisting of halo, aryl, and heteroaryl.
- Rioa and Riob are taken together to form wherein Q is a 3-, 4-, 5-, or 6- membered cycloalkyl or heterocyclic ring, wherein each “ ” indicates a point of attachment and Rua and Rub are each independently selected from the group consisting of H, halo, and optionally substituted C1-10 alkyl; or Riia and Rm> are taken together to form wherein Q is a 3-, 4-, 5-, or 6- membered cycloalkyl or heterocyclic ring, wherein each ” indicates a point of attachment and Rioa and Rwb are each independently selected from the group consisting of H, halo, and optionally substituted C1-10 alkyl
- R q is H.
- R q is -C1-6 alkylene-aryl. In one embodiment, R q is — C1-3 alkylene- aryl. In one embodiment, R q is -C1.2 alkylene-aryl. In one embodiment, Rq is -CTL-aryl. In one embodiment, R q is -C1-6 alkyl ene-heteroaryl. In one embodiment, R q is -CHz-heteroaryl. In one embodiment, R q is -CH2-phenyl. In one embodiment, Rq is -CH2-phenyl wherein phenyl is optionally substituted. In one embodiment, optionally substituted phenyl is alkoxyphenyl or halophenyl.
- R q is -SO 2 -C1-6 alkyl. In one embodiment, R q is -SO2-C1-3 alkyl. In one embodiment, R q is -SO 2 -Ci- 2 alkyl. In one embodiment, R q is -SO 2 -Me.
- NRx’Rx is NH 2 , N(H)Me, NMe 2 , N(Me)Et, NEt 2 , N(H)isopropyl, N(Me)isopropyl, N(H)cyclopropyl, N(Me)cyclopropyl, N(H)cyclobutyl, N(Me)cyclobutyl, N(H)CH 2 cyclopropyl, N(Me)isopropyl, orN(Me)t-butyl.
- R9a is selected from the group consisting of -H and optionally substituted C1-10 alkyl
- R’ and R” are each independently optionally substituted alkyl
- B is wherein Q is a 3-, 4-, 5-, or 6-membered cycloalkyl or heterocyclic ring, wherein each “ « ⁇ w ” indicates a point of attachment and A is CR’R”, wherein R’ and R” are each independently optionally substituted alkyl.
- Rq a is -H or C1.4 alkyl. In one embodiment, Rq a is -H or methyl.
- A is and Q is a 3-, 4-, 5-, or 6-membered optionally substituted cycloalkyl or a 3-, 4-, 5-, or 6-membered optionally substituted heterocycloalkyl and B is CR’R”, wherein R’ and R” are H, wherein each “ ” indicates a point of attachment.
- B is and Q is a 3-, 4-, 5-, or 6-membered optionally substituted cycloalkyl or is a 3-, 4-, 5-, or 6-membered optionally substituted heterocycloalkyl and A is CR’R”, wherein R’ and R” are H, wherein each ” indicates a point of attachment.
- either A or B is , wherein Q is a 3-, 4-, 5-, or 6- membered cycloalkyl or 3-, 4-, 5-, or 6-membered heterocyclic ring, and the other of A and B is - CH2-, and Rq is as defined for formula I compounds.
- the compound of C-l, or a pharmaceutically acceptable salt thereof is a compound of formula C-2 or C-3, or a pharmaceutically acceptable salt thereof:
- the compound, or a pharmaceutically acceptable salt thereof is a compound of formula C-2a or C-3a, or a pharmaceutically acceptable salt thereof:
- the compound, or a pharmaceutically acceptable salt thereof is a compound of formula C-2b or C-3b, or a pharmaceutically acceptable salt thereof:
- the compound of formula C-l, C-2, C-3, C-2a, C-3a, C-2b, and C-3b, or a pharmaceutically acceptable salt thereof is a compound of formula C-4, C-5, C-6, or C-7, C- 8, C-9, C-10, or C-l 1, or a pharmaceutically acceptable salt thereof:
- Rt is -C1-6 alkylene-aryl. In one embodiment, Rtis -C1.3 alkylene- aryl. In one embodiment, Rt is -C1-2 alkylene-aryl. In one embodiment, R t is -Cfb-aryl. In one embodiment, Rt is -C1-6 alkylene-heteroaryl. In one embodiment, Rt is -CH2-heteroaryl. In one embodiment, Rt is -CTL-phenyl. In one embodiment, Rt is -CH2-phenyl wherein phenyl is optionally substituted, hi one embodiment, optionally substituted phenyl is alkoxyphenyl or halophenyl.
- optionally substituted phenyl is 2-, 3-, or 4-methoxy phenyl or 2-, 3-, or 4-chlorophenyl. In one embodiment, optionally substituted phenyl is biphenyl. In one embodiment, Rt is CH2-heteroaryl, wherein heteroaryl is optionally substituted. In one embodiment, Rt is -CH2-pyridyl, wherein pyridyl can be 2-, 3-, or 4-pyridyl. In one embodiment, Rt is -CH2-imidazolyl. In one embodiment, Rt is -CTL-quinolinyl, or -CH2-isoquinolinyl.
- Rt is -CfbCHz-aryl. In one embodiment, Rt is -CfbCHt-phenyl wherein phenyl is optionally substituted. In one embodiment, optionally substituted phenyl is alkoxyphenyl or halophenyl. In one embodiment, optionally substituted phenyl is 2-, 3-, or 4- methoxy phenyl or 2-, 3-, or 4-chlorophenyl. In one embodiment, Rt is -CHiCHi-heteroaryl, wherein heteroaryl is optionally substituted. In one embodiment, Rt is -CfbCfb-pyridyl. In one embodiment, Rt is -CTbCTh-imidazolyl. In one embodiment, Rt is -CHzCfh-quinolinyl, or - CHzCTH-soquinolinyl.
- Rt is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, or t-butyl.
- optionally substituted phenyl is chlorophenyl or methoxyphenyl.
- optionally substituted phenyl is 2-, 3-, or 4-methoxy phenyl or 2-, 3-, or 4- chlorophenyl.
- heteroaryl is quinolinyl or isoquinolinyl, either of which is optionally substituted.
- NR X R X is NH 2 , N(H)Me, NMe 2 , N(Me)Et, N(Me)isopropyl, NEt 2 , azetidinyl, azetidinyl-OH, pyrrolidinyl, piperidinyl, morpholinyl, piperizinyl, N(H)-isopropyl, N(Me)isopropyl, N(H)cyclopropyl, N(Me)cyclopropyl, N(H)cyclobutyl, N(Me)cyclobutyl, N(H)CH 2 cyclopropyl, N(Me)CH 2 cyclopropyl, N(Me)isopropyl, N(Me)-tbutyl, N(H)CH 2 CH 2 -alkoxy,
- Rt is -SO 2 -C1-6 alkylene-NRx’Rx”. In one embodiment, Rt is -SO 2 -Ci-3 alkyl ene-NRx’Rx”. In one embodiment, Rt is -SO 2 -Ci- 2 alkyl ene-NR x Rx”. In one embodiment, Rt is -SO 2 -CH 2 NRx’Rx”. In one embodiment, Rt is -SO 2 -CH 2 CH 2 NR x Rx”.
- the invention includes a pharmaceutical composition comprising a compound described herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
- the invention includes a kit comprising a compound described herein, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, and instructions for administering to a subject in need thereof.
- the compound is selected from Table A, or a pharmaceutically acceptable salt thereof.
- R 3 , R 4a , R 4b , R 5 , R 6a , R 6b , R 8a , and R 8b are as defined herein;
- G 4 is of the formula: each instance of R 15 is independently silyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R 15 groups are joined to form an optionally substituted heterocyclyl or heteroaryl ring; and each instance of R 16a is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
- the uncyclized eastern half intermediate is a compound of formula P-2: or salt thereof, wherein:
- PG is a protecting group
- G 4 is of formula: each instance of R 15 is independently silyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R 15 groups are joined to form an optionally substituted heterocyclyl or heteroaryl ring; and each instance of R 16a is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
- compounds of the present disclosure are prepared by coupling a compound of Formula Pl (the eastern half) wherein R s is a sugar residue , wherein PG is a protecting group and “ ⁇ « «” indicates a point of attachment, and a compound of Formula P-4 (the western half) to provide an uncyclized compound precursor of Formula P-5 as depicted in the following Scheme.
- Late-stage installment of the R.2b group can be achieved via treatment of a compound of Formula P-6 prepared as provide above with a base and a suitable electrophile group (e.g., halogenating agent or R2-LG, wherein LG is a leaving group) as depicted in the following Scheme.
- a suitable electrophile group e.g., halogenating agent or R2-LG, wherein LG is a leaving group
- LG is a leaving group; , ” indicates a point of attachment; each instance of R 15 is independently silyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R 15 groups are joined to form an optionally substituted heterocyclyl or heteroaryl ring; and each instance of R 16a is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
- R s is the sugar moiety .
- the sugar moiety is typically attached to the compound framework during synthesis of the eastern half, but may also be attached at other stages of the preparation.
- the sugar moiety may be attached by a chemical or enzymatic glycosylation reaction between the hydroxyl group at the C5 position and a glycosyl donor.
- the sugar moiety is attached to the compound framework as a thioglycoside.
- substituents of the sugar moiety are modified after the glycosylation of the compound or compound precursor (c.g., eastern half).
- what is provided herein is a method for inhibiting protein translation in a cell, comprising treating the cell with a therapeutically effective amount of a compound of Formula I.
- the cell is a cancer cell.
- what is provided herein is a method for treating a disease caused by abnormal protein translation in a patient in need of such treatment, comprising treating the patient with a therapeutically effective amount of a compound of Formula I.
- the patient is a human or animal.
- the disease is cancer.
- the cancer is selected from the cancers provided herein.
- a method for treating cancer comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of Formula I.
- CF cystic fibrosis
- DMD muscular dystrophy
- BMD Becker
- SMA spinal muscular atrophy
- a & B hemophilia
- Usher syndrome Retinitis pigmentosa, X-linked retinitis pigmentosa
- mucopolysaccharidosis nephropathic cystinosis, Rett syndrome, cancer, Beta-thalassemia, and obesity.
- a method of increasing the expression level of a gene having a premature termination codon mutation comprising translating the gene into a protein in the presence of a compound or composition as disclosed herein in any of the respective embodiments and any combination thereof.
- a compound or composition as disclosed herein for use in increasing the expression level of a gene having a premature termination codon mutation is a compound or composition as disclosed herein for use in increasing the expression level of a gene having a premature termination codon mutation.
- the premature termination codon mutation has an RNA code selected from the group consisting of UGA, UAG and UAA.
- the present invention provides pharmaceutical compositions comprising a compound of the present invention and a pharmaceutically acceptable excipient.
- the compound of the present invention is provided in an effective amount in the pharmaceutical composition.
- the effective amount is a therapeutically effective amount.
- the effective amount is a prophylactically effective amount.
- compositions agents include any and all solvents, diluents, or other liquid vehicles, dispersions, suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
- General considerations in formulation and/or manufacture of pharmaceutical compositions agents can be found, for example, in Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980), and Remington: The Science and Practice of Pharmacy, 21st Edition (Lippincott Williams & Wilkins, 2005).
- compositions described herein can be prepared by any method known in the art of pharmacology. In general, such preparatory methods include the steps of bringing the compound of the present invention (the “active ingredient”) into association with a carrier and/or one or more other accessory ingredients, and then, if necessary and/or desirable, shaping and/or packaging the product into a desired single- or multi-dose unit.
- compositions can be prepared, packaged, and/or sold in bulk, as a single unit dose, and/or as a plurality of single unit doses.
- a “unit dose” is discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient.
- the amount of the active ingredient is generally equal to the dosage of the active ingredient which would be administered to a subject and/or a convenient fraction of such a dosage such as, for example, one-half or one-third of such a dosage.
- Relative amounts of the active ingredient, the pharmaceutically acceptable excipient, and/or any additional ingredients in a pharmaceutical composition of the invention will vary, depending upon the identity, size, and/or condition of the subject treated and further depending upon the route by which the composition is to be administered.
- the composition may comprise between 0.1% and 100% (w/w) active ingredient.
- compositions include inert diluents, dispersing and/or granulating agents, surface active agents and/or emulsifiers, disintegrating agents, binding agents, preservatives, buffering agents, lubricating agents, and/or oils. Excipients such as cocoa butter and suppository waxes, coloring agents, coating agents, sweetening, flavoring, and perfuming agents may also be present in the composition.
- Exemplary diluents include calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, cornstarch, powdered sugar, and mixtures thereof.
- Exemplary granulating and/or dispersing agents include potato starch, corn starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose and wood products, natural sponge, cation-exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked poly(vinyl-pyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate (Veegum), sodium lauryl sulfate, quaternary ammonium compounds, and mixtures thereof.
- crospovidone cross-linked poly(vinyl-pyrrolidone)
- sodium carboxymethyl starch sodium starch glycolate
- Exemplary surface active agents and/or emulsifiers include natural emulsifiers (e.g. acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin), colloidal clays (e.g. bentonite [aluminum silicate] and Veegum [magnesium aluminum silicate]), long chain amino acid derivatives, high molecular weight alcohols (e.g.
- stearyl alcohol cethyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g. carboxy polymethylene, polyacrylic acid, acrylic acid polymer, and carboxyvinyl polymer), carrageenan, cellulosic derivatives (e.g. carboxymethylcellulose sodium, powdered cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methyl cellulose), sorbitan fatty acid esters (e.g.
- Cremophor polyoxyethylene ethers, (e.g. polyoxyethylene lauryl ether [Brij 30]), poly(vinyl-pyrrolidone), diethylene glycol monolaurate, triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, Pluronic F 68, Pol oxamer 188, cetrimonium bromide, cethylpyridinium chloride, benzalkonium chloride, docusate sodium, and/or mixtures thereof.
- polyoxyethylene ethers e.g. polyoxyethylene lauryl ether [Brij 30]
- poly(vinyl-pyrrolidone) diethylene glycol monolaurate
- triethanolamine oleate sodium oleate
- potassium oleate ethyl oleate
- oleic acid ethyl la
- Exemplary binding agents include starch (e.g. cornstarch and starch paste), gelatin, sugars (e.g. sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol, etc.), natural and synthetic gums (e.g.
- acacia sodium alginate, extract of Irish moss, panwar gum, ghatti gum, mucilage of isapol husks, carboxymethylcellulose, methylcellulose, ethyl cellulose, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, cellulose acetate, poly(vinyl-pyrrolidone), magnesium aluminum silicate (Veegum), and larch arabogalactan), alginates, polyethylene oxide, polyethylene glycol, inorganic calcium salts, silicic acid, polymethacrylates, waxes, water, alcohol, and/or mixtures thereof.
- Exemplary preservatives include antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, alcohol preservatives, acidic preservatives, and other preservatives.
- Exemplary chelating agents include ethylenediaminetetraacetic acid (EDTA) and salts and hydrates thereof (e.g., sodium edetate, disodium edetate, trisodium edetate, calcium disodium edetate, dipotassium edetate, and the like), citric acid and salts and hydrates thereof (e.g., citric acid monohydrate), fumaric acid and salts and hydrates thereof: malic acid and salts and hydrates thereof: phosphoric acid and salts and hydrates thereof: and tartaric acid and salts and hydrates thereof.
- EDTA ethylenediaminetetraacetic acid
- salts and hydrates thereof e.g., sodium edetate, disodium edetate, trisodium edetate, calcium disodium edetate, dipotassium edetate, and the like
- citric acid and salts and hydrates thereof e.g., citric acid mono
- antimicrobial preservatives include benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cethylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and thimerosal.
- Exemplary antifungal preservatives include butyl paraben, methyl paraben, ethyl paraben, propyl paraben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and sorbic acid.
- Exemplary alcohol preservatives include ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate, and phenylethyl alcohol.
- Exemplary acidic preservatives include vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid, and phytic acid.
- preservatives include tocopherol, tocopherol acetate, deteroxime mesylate, cetrimide, butylated hydroxyanisol (BHA), butylated hydroxytoluened (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, Glydant Plus, Phenonip, methylparaben, Germall 115, Germaben II, NeoIone, Kathon, and Euxyl.
- the preservative is an anti-oxidant.
- the preservative is a chelating agent.
- Exemplary buffering agents include citrate buffer solutions, acetate buffer solutions, phosphate buffer solutions, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glubionate, calcium gluceptate, calcium gluconate, D-gluconic acid, calcium glycerophosphate, calcium lactate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixtures, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, dibasic sodium phosphate, monobasic sodium phosphate, sodium phosphate mixtures, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline
- Exemplary lubricating agents include magnesium stearate, calcium stearate, stearic acid, silica, talc, malt, glyceryl behanate, hydrogenated vegetable oils, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium lauryl sulfate, and mixtures thereof.
- Exemplary natural oils include almond, apricot kernel, avocado, babassu, bergamot, black current seed, borage, cade, camomile, canola, caraway, carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee, com, cotton seed, emu, eucalyptus, evening primrose, fish, flaxseed, geraniol, gourd, grape seed, hazel nut, hyssop, isopropyl myristate, jojoba, kukui nut, lavandin, lavender, lemon, litsea cubeba, macademia nut, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange, orange roughy, palm, palm kernel, peach kernel, peanut, poppy seed, pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood, sasquana, savoury,
- Liquid dosage forms for oral and parenteral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
- the liquid dosage forms may comprise inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (e.g., cottonseed, groundnut, com, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
- inert diluents commonly used in the art such as, for example, water or other solvents,
- Injectable preparations for example, sterile injectable aqueous or oleaginous suspensions can be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparation can be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3 -butanediol.
- acceptable vehicles and solvents that can be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil can be employed including synthetic mono- or diglycerides.
- fatty acids such as oleic acid are used in the preparation of injectables.
- the injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
- a sterile injectable composition e.g., a sterile injectable aqueous or oleaginous suspension
- a sterile injectable preparation can be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as Tween 80) and suspending agents.
- the sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3 -butanediol.
- suitable vehicles and solvents that can be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium (e.g., synthetic mono- or di glycerides).
- Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically- acceptable oils, such as olive oil or castor oil, especially in their polyoxy ethylated versions.
- These oil solutions or suspensions can also contain a long-chain alcohol diluent or dispersant, or carboxymethyl cellulose or similar dispersing agents.
- Other commonly used surfactants such as Tweens or Spans or other similar emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms can also be used for the purposes of formulation.
- compositions for rectal or vaginal administration are typically suppositories which can be prepared by mixing the conjugates of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active ingredient.
- suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active ingredient.
- Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
- the active ingredient is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cethyl alcohol and
- the dosage form may comprise buffering agents.
- Solid compositions of a similar type can be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
- the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally comprise opacifying agents and can be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
- embedding compositions which can be used include polymeric substances and waxes.
- Solid compositions of a similar type can be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
- compositions which can be used orally, include push-fit capsules made of gelatin as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
- the push-fit capsules may contain the active ingredients in admixture with filler such as lactose, binders such as starches, lubricants such as talc or magnesium stearate and, optionally, stabilizers.
- the compounds presented herein may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
- stabilizers may be added. All formulations for oral administration should be in dosages suitable for the chosen route of administration.
- Dragee cores are provided with suitable coatings.
- suitable coatings may be used which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures.
- Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active aminoglycoside compounds doses.
- the active ingredient can be in micro-encapsulated form with one or more excipients as noted above.
- the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art.
- the active ingredient can be admixed with at least one inert diluent such as sucrose, lactose or starch.
- Such dosage forms may comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose.
- Dosage forms for topical and/or transdermal administration of a compound of this invention may include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants and/or patches.
- the active ingredient is admixed under sterile conditions with a pharmaceutically acceptable carrier and/or any needed preservatives and/or buffers as can be required.
- the present invention contemplates the use of transdermal patches, which often have the added advantage of providing controlled delivery of an active ingredient to the body.
- Such dosage forms can be prepared, for example, by dissolving and/or dispensing the active ingredient in the proper medium.
- the rate can be controlled by either providing a rate controlling membrane and/or by dispersing the active ingredient in a polymer matrix and/or gel.
- Suitable devices for use in delivering intradermal pharmaceutical compositions described herein include short needle devices such as those described in U.S. Pat. Nos. 4,886,499;
- Intradermal compositions can be administered by devices which limit the effective penetration length of a needle into the skin, such as those described in PCT publication WO 99/34850 and functional equivalents thereof. Jet injection devices which deliver liquid vaccines to the dermis via a liquid jet injector and/or via a needle which pierces the stratum comeum and produces a jet which reaches the dermis are suitable. Jet injection devices are described, for example, in U.S. Pat. Nos. 5,480,381; 5,599,302; 5,334,144; 5,993,412; 5,649,912; 5,569,189; 5,704,911; 5,383,851;
- a pharmaceutical composition of the invention can be prepared, packaged, and/or sold in a formulation suitable for pulmonary administration via the buccal cavity.
- Such a formulation may comprise dry particles which comprise the active ingredient and which have a diameter in the range from about 0.5 to about 7 nanometers or from about 1 to about 6 nanometers.
- Such compositions are conveniently in the form of dry powders for administration using a device comprising a dry powder reservoir to which a stream of propellant can be directed to disperse the powder and/or using a self-propelling solvent/powder dispensing container such as a device comprising the active ingredient dissolved and/or suspended in a low-boiling propellant in a sealed container.
- Such powders comprise particles wherein at least 98% of the particles by weight have a diameter greater than 0.5 nanometers and at least 95% of the particles by number have a diameter less than 7 nanometers.
- Low boiling propellants generally include liquid propellants having a boiling point of below 65 °F at atmospheric pressure.
- the propellant may constitute 50 to 99.9% (w/w) of the composition, and the active ingredient may constitute 0.1 to 20% (w/w) of the composition.
- the propellant may further comprise additional ingredients such as a liquid non-ionic and/or solid anionic surfactant and/or a solid diluent (which may have a particle size of the same order as particles comprising the active ingredient).
- Formulations described herein as being useful for pulmonary delivery are useful for intranasal delivery of a pharmaceutical composition of the invention.
- Another formulation suitable for intranasal administration is a coarse powder comprising the active ingredient and having an average particle from about 0.2 to 500 micrometers. Such a formulation is administered by rapid inhalation through the nasal passage from a container of the powder held close to the nares.
- formulations for buccal administration may comprise a powder and/or an aerosolized and/or atomized solution and/or suspension comprising the active ingredient.
- Such powdered, aerosolized, and/or aerosolized formulations when dispersed, may have an average particle and/or droplet size in the range from about 0.1 to about 200 nanometers, and may further comprise one or more of the additional ingredients described herein.
- compositions are principally directed to pharmaceutical compositions which are suitable for administration to humans, it will be understood by the skilled artisan that such compositions are generally suitable for administration to animals of all sorts. Modification of pharmaceutical compositions suitable for administration to humans in order to render the compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and/or perform such modification with ordinary experimentation.
- the compounds presented herein are conveniently delivered in the form of an aerosol spray presentation (which typically includes powdered, liquefied and/or gaseous carriers) from a pressurized pack or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, tri chlorofluoromethane, dichloro-tetrafluoroethane or carbon dioxide.
- a suitable propellant e.g., dichlorodifluoromethane, tri chlorofluoromethane, dichloro-tetrafluoroethane or carbon dioxide.
- the dosage unit may be determined by providing a valve to deliver a metered amount.
- compositions for topical administration may include the compositions formulated for a medicated application such as an ointment, paste, cream, or powder.
- Ointments include all oleaginous, adsorption, emulsion, and water-soluble based compositions for topical application, while creams and lotions are those compositions that include an emulsion base only.
- Topically administered medications may contain a penetration enhancer to facilitate adsorption of the active ingredients through the skin. Suitable penetration enhancers include glycerin, alcohols, alkyl methyl sulfoxides, pyrrolidones and luarocapram.
- compositions for topical application include polyethylene glycol, lanolin, cold cream and petrolatum as well as any other suitable absorption, emulsion or water-soluble ointment base.
- Topical preparations may also include emulsifiers, gelling agents, and antimicrobial preservatives as necessary to preserve the composition and provide for a homogenous mixture.
- Transdermal administration of the compositions may also comprise the use of a "patch.”
- the patch may supply one or more compositions at a predetermined rate and in a continuous manner over a fixed period of time.
- the compositions may be delivered by eye drops, intranasal sprays, inhalation, and/or other aerosol delivery vehicles.
- Methods for delivering compositions directly to the lungs via nasal aerosol sprays has been described in U.S. Pat. Nos. 5,756,353 and 5,804,212 (each specifically incorporated herein by reference in their entirety).
- the delivery of drugs using intranasal microparticle resins (Takenaga et al., 1998) and lysophosphatidyl-glycerol compounds (U.S. Pat. No. 5,725,871, specifically incorporated herein by reference in its entirety) are also well-known in the pharmaceutical arts and could be employed to deliver the compositions described herein.
- compositions disclosed herein may be delivered via an aerosol.
- aerosol refers to a colloidal system of finely divided solid or liquid particles dispersed in a liquefied or pressurized gas propellant.
- the typical aerosol for inhalation consists of a suspension of active ingredients in liquid propellant or a mixture of liquid propellant and a suitable solvent.
- Suitable propellants include hydrocarbons and hydrocarbon ethers.
- Suitable containers will vary according to the pressure requirements of the propellant.
- Administration of the aerosol will vary according to subject's age, weight and the severity and response of the symptoms.
- compositions presented herein may be formulated for parenteral administration, e.g., by bolus injection or continuous infusion.
- Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multidose containers with optionally, an added preservative.
- the compositions may be suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- the exact amount of a compound required to achieve an effective amount will vary from subject to subject, depending, for example, on species, age, and general condition of a subject, severity of the side effects or disorder, identity of the particular compound(s), mode of administration, and the like.
- the desired dosage can be delivered three times a day, two times a day, once a day, every other day, every third day, every week, every two weeks, every three weeks, or every four weeks.
- the desired dosage can be delivered using multiple administrations (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or more administrations).
- dose ranges as described herein provide guidance for the administration of provided pharmaceutical compositions to an adult.
- the amount to be administered to, for example, a child or an adolescent can be determined by a medical practitioner or person skilled in the art and can be lower or the same as that administered to an adult.
- a compound or composition, as described herein can be administered in combination with one or more additional therapeutically active agents.
- the compounds or compositions can be administered in combination with additional therapeutically active agents that improve their bioavailability, reduce and/or modify their metabolism, inhibit their excretion, and/or modify their distribution within the body.
- the therapy employed may achieve a desired effect for the same disorder, and/or it may achieve different effects.
- the compound or composition can be administered concurrently with, prior to, or subsequent to, one or more additional therapeutically active agents.
- each agent will be administered at a dose and/or on a time schedule determined for that agent.
- the additional therapeutically active agent utilized in this combination can be administered together in a single composition or administered separately in different compositions.
- the particular combination to employ in a regimen will take into account compatibility of the inventive compound with the additional therapeutically active agent and/or the desired therapeutic effect to be achieved.
- additional therapeutically active agents utilized in combination be utilized at levels that do not exceed the levels at which they are utilized individually. In some embodiments, the levels utilized in combination will be lower than those utilized individually.
- kits e.g., pharmaceutical packs
- the kits provided may comprise an inventive pharmaceutical composition or compound and a container (e.g., a vial, ampule, bottle, syringe, and/or dispenser package, or other suitable container).
- a container e.g., a vial, ampule, bottle, syringe, and/or dispenser package, or other suitable container.
- provided kits may optionally further include a second container comprising a pharmaceutical excipient for dilution or suspension of an inventive pharmaceutical composition or compound.
- the inventive pharmaceutical composition or compound provided in the container and the second container are combined to form one-unit dosage form.
- Combination therapy can be effective with drugs that work by different mechanisms, thereby decreasing the likelihood that resistant cancer cells will develop.
- each drug can be used at its optimal dose, without intolerable side effects.
- a compound of Formula I as disclosed herein and a second medicament can be combined for therapeutic benefit, for instance, for treating a proliferative disease or disorder such as cancer.
- the second medicament can have a different mechanism. Alternatively, it can use the same mechanism as the compound as disclosed herein for therapeutic benefit.
- the combination can act via a synergistic effect.
- Combination therapies can also include additional (e.g. a third, fourth, fifth, etc.) medicaments.
- chemotherapeutics are presently known in the art and can be used in combination with the compounds of the invention.
- the chemotherapeutic is selected from the group consisting of DNA intercalating agents, topoisomerase inhibitors, microtubule inhibitors, multi-kinase inhibitors, PARP inhibitor, transcription and translation inhibitors, as well as mitotic inhibitors, alkylating agents, anti-metabolites, growth factor inhibitors, cell cycle inhibitors, enzymes, biological response modifiers, anti-hormones, angiogenesis inhibitors, and anti-androgens.
- Therapeutic agents that can be combined with a compound of the invention are found in Goodman and Gilman's "The Pharmacological Basis of Therapeutics" Tenth Edition edited by Hardman, Limbird and Gilman or the Physician's Desk Reference, both of which are incorporated herein by reference in their entirety.
- Non-limiting examples of intercalating agents include, methotrexate, actinomycin, mitoxantrone, adriamycin, doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin.
- topoisomerase inhibitors include irinotecan (CAMPTOSAR), topotecan (HYCAMTIN), etoposide (ETOPOPHOS, VEPESSID, TOPOSAR), teniposide (VUMON), ellipticine, TAS-103, mitonafide, amonafide, chartreusin, elsamicin, IST-622, ditercalinimum, elinafide, and echinomycin.
- Non-limiting examples of microtubule-disruptor agents include ecteinascidins.
- Non-limiting examples of microtubule-stabilizing agents include pacitaxel, docetaxel, and epothilones A-F; 4-(3-(l-(cyclopropanecarbonyl)piperazine-4-carbonyl)-4-fluorobenzyl)phtha- lazin-l(2H)- one (olaparib, AZD2281, Ku-0059436), 2-[(2R)-2-methylpyrrolidin-2-yl]-lH-benzimidazole-4- carboxamide (Veliparib, ABT-888), (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(l-methyl-lH-l,2,4- triazol-5-yl)-8,- 9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(
- transcription and translation inhibitors include alpha-amatinin, CX-5461, TAS-106, BMH-21, metatrestin, JQ-1, birabresib, mivebresib, triptolide, 8-Cl-Ado, 8- NEh-Ado, fludarabine, alvocidib, abemaciclib, palbociclib, ribociclib, rapamycin, everolimus, Torinl, PP242, MLN0128, Rapalink-lsilvestrol, omacetaxine, RG-7388, HDM-201, INCB057643, SY-1365, and BMS-986158.
- a compound of formula I can be combined with one or more compounds selected from the following compounds to treat cancer: Gleevec® (Imatinib Mesylate), Velcade®. (bortezomib), Casodex (bicalutamide), Iressa®. (gefitinib), and Adriamycin as well as a host of chemotherapeutic agents.
- Non-limiting examples of chemotherapeutic agents include alkylating agents such as thiotepa and cyclosphosphamide (CYTOXAN®); alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphaoramide and trimethylolomelamine; nitrogen mustards such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine,
- paclitaxel TAXOL®., Bristol-Myers Squibb Oncology, Princeton, N.J.
- TXOTERE® Rhone-Poulenc Rorer, Antony, France
- retinoic acid esperamicins
- capecitabine ecitabine
- pharmaceutically acceptable salts, acids or derivatives of any of the above TAXOL®., Bristol-Myers Squibb Oncology, Princeton, N.J.
- chemotherapeutic cell conditioners are anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as anti-estrogens including for example tamoxifen, (Nolvadex®), raloxifene, aromatase inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen, trioxifene, keoxifene, LY 117018, onapristone, and toremifene (Fareston); and anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine;
- the compounds or pharmaceutical composition of the present invention can be used in combination with commonly prescribed anti-cancer drugs such as Herceptin®, Avastin®, Erbitux®, Rituxan®, Taxol®, Arimidex.RTM., Taxotere®, ABVD, AVICINE, Abagovomab, Acridine carboxamide, Adecatumumab, 17-N-Allylamino-17- demethoxygeldanamycin, Alpharadin, Alvocidib, 3-Aminopyridine-2-carboxaldehyde thiosemicarbazone, Amonafide, Anthracenedione, Anti-CD22 immunotoxins, Antineoplastic, Antitumorigenic herbs, Apaziquone, Atiprimod, Azathioprine, Belotecan, Bendamustine, BIBW 2992, Biricodar, Brostallicin, Bryostatin, Buthionine sulfoximine, CBV (chem
- the compounds of Formula I can be used in combination with the agents disclosed herein or other suitable agents, depending on the condition being treated. Hence, in some embodiments the one or more compounds of the invention will be co-administered with other agents as described above.
- the compounds described herein are administered with the second agent simultaneously or separately.
- This administration in combination can include simultaneous administration of the two agents in the same dosage form, simultaneous administration in separate dosage forms, and separate administration. That is, a compound described herein and any of the agents described above can be formulated together in the same dosage form and administered simultaneously. Alternatively, a compound of the invention and any of the agents described above can be simultaneously administered, wherein both the agents are present in separate formulations.
- a compound of the present invention can be administered just followed by and any of the agents described above, or vice versa.
- a compound of the invention and any of the agents described above are administered a few minutes apart, or a few hours apart, or a few days apart.
- SI-5-11-1 (17 6 mg, 0.221 mmol) was dissolved in methanol (1 mL), and the mixture was heated at 60 °C (external temperature) for 7 hours (h). The reaction was allowed to cool to rt and was concentrated. The residue was purified by HPLC (Atlantis T3 column, 5-50% MeCN-water-0.1% HCO2H) to give SI-6-11-2 (6.87 mg).
- S3-1-I1-1-1 (30 mg, 0.039 mmol) was dissolved in DCM (1 mL) and triethylamine (0.016 mL, 0.116 mmol), and acetic anhydride (0.011 mL, 0.116 mmol) was added. After 45 min, the reaction mixture was quenched with NaHCOs (sat., aq. solution) and was extracted with DCM (2 times). The combined extracts were concentrated. The crude material was dissolved in methanol (1 mL), and the reaction mixture was heated to 60 °C external temperature. After 3 h, the reaction was allowed to cool to rt and was concentrated.
- S3-1-I1-1-2 (63 5 mg, 0.081 mmol) was dissolved in DCM (0.4 mL) and A,A-diisopropylethylamine (0.0563 mL, 0.324 mmol), and 1 -hydroxybenzotriazole (14.1 mg, 0.105 mmol), Cbz-L-Proline (24.2 mg, 0.0971 mmol), and XA-di isopropyl carbodi imide (0.0149 mL, 0.0971 mmol) were added.
- S2-2-I5-1 (87 mg, O i l mmol) was dissolved in MeCN (3 mL) and HC1 (4M in dioxane, 0.27 mL, 1.1 mmol) was added at rt and the reaction mixture was allowed to stirred at rt for 10 min. The reaction mixture was concentrated and the crude mixture of S3-1-I5-1-2 and S3-l-I5b-l-2 (83 mg, 95% yield) was used in the next step without further purification.
- S3-1-I5-1-2 MS (ESI+) mlz'. 229.5 [M + 3H] 3+ , 343.7 [M + 2H] 2+ , 686.4 [M + H] + .
- S3-l-I5b-l-2 MS (ESI+) mlz ⁇ 241.5 [M + 3H] 3+ , 361.7 [M + 2H] 2+ , 722.4 [M + H] + .
- SI-4-11 (1.126 g, 1.43 mmol) was dissolved in A.
- additional di-tert-butyl dicarbonate (0.491 mL, 2.14 mmol) and 4- dimethylaminopyridine (17.4 mg, 0.143 mmol) were added.
- the reaction mixture was diluted with EtOAc and was washed with NaHCCh (sat, aq, 1 time), water (3 times), and brine (1 time).
- reaction mixture was allowed to cool to rt and excess solvent and reagent removed under vacuum.
- the crude material was dissolved in methanol (1 mL), and the reaction mixture was heated to 60 °C external temperature.
- hydrochloric acid (0.005 mL) and Pd/C (5 wt%, 7.22 mg, 0.0034 mmol) was added.
- a balloon of hydrogen was bubbling through the reaction mixture. After 30 min, it was fdtered through Celite® with ethyl acetate, and the fdtrate was concentrated in vacuo.
- the crude S7-1-I1 (8 mg, 0.010 mmol) was dissolved in THF (1 mL) and dimethylamine (2M in THF, 0.016 mL, 0.031 mmol) was added at rt. The reaction mixture was allowed to stirred rt for 2 h. LC/MS shows full conversion. The reaction was quenched by adding saturated NaHCCh (2 mL) and the aqueous layer was extracted with methylene chloride three times (2 mL). The combined organic layers were dried over MgSCL, filtered and concentrated. The residue was used in the next step without further purification.
- Compound A was prepared according to the methods of SI-2-11 from II and replacing Sl-
- RMAs Ribosome Modulating Agents
- CRC colorectal
- SCLC small cell lung cancer
- DMEM medium Invitrogen, catalog number: 11995- 040
- FBS fetal bovine serum
- RPMI-1640 Invitrogen, catalog number: 11875-093
- FBS fetal bovine serum
- Plates were prepared from 60mM DMSO compound stocks with intermediate doses in medium using an automated liquid handler, to achieve the following conditions: 60uM as top concentration, 4 doses, 3-fold dilutions all at 0.1% final volume/volume of DMSO/well. 2ul of diluted compounds, from plates where doses were prepared, were added to 40ul of medium with cells already attached. Staurosporine was used as a reference compound at a starting concentration of 2uM, 7 doses, and 3 -fold dilutions for every plate with test compounds.
- CellTiterGlo Luminescence kit (Coming, catalog number: G7573) was used to measure ATP levels as a readout for cell viability.
- CellTiterGlo reagents were equilibrated at room temperature prior to use. Plates seeded with cells were also equilibrated at room temperature for approximately 30 minutes. 25ul of CellTiterGlo reagent/well were added to cells. Plates were gently mixed for 10 minutes at room temperature and protected from light. Luminescence was recorded with an EnVision plate reader and measurements were performed with 0.1s iterations.
- FRT cells expressing CFTR P-globin fusion proteins are cultured in Coon’s F- 12 Medium supplemented with 5% fetal bovine serum and 100 units/mL penicillin-streptomycin. Cells are kept in a humidified, 5% CO2 atmosphere at 37°C. Cells are transfected with 0.5 pg/mL of the described construct, and 48 hours later, the levels of luciferase are measured with the luciferase assay lit (Promega, USA), according to the manufacturer’s instructions.
- a NanoLuc luciferase reporter plasmid was developed to target the identification of both readthrough and NMD modulators by using the addition of a nonsense mutation (W134X) in the Nanoluc region to test for readthrough as well as upstream of a P-globin intron to test for NMD attenuation.
- the G418 used in experiments was commercial G418-sulfate (Gibco, # 10131-027). Following normalization, the differences in luciferase activities reflect the frequency of stop codon readthrough.
- Panel 1 Readthrough was observed when cells were treated with various amounts of Compound 40 alone or in combination with 100 uM G418.
- Panel 2 Readthrough was observed when cells were treated with various amounts Compound 40 alone or in combination with 100 uM G418 alone or in combination with 50 uM G418.
- FRT cells expressing CFTR P-globin fusion proteins are cultured at 37°C and 5% CO2 in BioChrom Coon’s F-12 Medium (Cedar Lane Labs, #F0855) with 5% fetal bovine serum (Gibco, #26140-079), 1% penicillin-streptomycin (Gibco, #15140-122), L-glutamine (Gibco, #25030) and 200 pg/mL Zeocin (Life Technology, #R25005).
- Cells are removed from -80 °C freezers, thawed, and pelleted at 1000 rpm for 5 min at room temperature. The cells are resuspended in FRT growth media. A multidrop reagent dispenser (Thermo Fisher Scientific, #22-387-053) is used to plate cells (25,000 cells/well, 50 pL/well) into 384-well assay plates (Coming, #3570BC). The plates are centrifuged at 500 rpm for 2 min at room temperature and incubated for 48 h at 37°C and 5% CO2. before compound administration of 5 pL/well, to yield a final assay volume of 55 pL/well. The cells are incubated for 48 h at 37°C and 5% CO2.
- the medium is aspirated and replaced with 16 pL of Opti-MEM medium (Life Technology, #11058), without FBS, buffered with HEPES (Gibco, #15630-080). 4 pL of Nano-Gio Live Cell Reagent (Promega, #N2013) is added and luminescence was read using an integration time of 0.1-2 seconds.
- test compounds in inducing readthrough of Collagen VII protein was assessed in 4 different RDEB derived patient cells using two different cell types (fibroblasts and keratinocytes).
- RDEB patient fibroblasts have a hypermotility phenotype relative to fibroblasts derived from normal subjects. This cellular phenotype is thought to be linked to the inability of RDEB fibroblasts to attach to the growth substrate due to a lack of Collagen VII (Chen et al., Nature genetics vol. 32,4 (2002): 670-5; Cogan et al., 2014). We therefore test the effect of test compounds in reducing/ rescuing the hypermotility phenotype by induction of Collagen VII nonsense mutation readthrough.
- fibroblast migration assay As follows: Colloidal gold salts were immobilized on coverslips and covered with type I collagen (15 mg/ml). Fibroblast cultures were suspended, plated on the coverslips, and allowed to migrate for 16-20 hours. The cells were fixed in 0.1% formaldehyde in phosphate-buffered saline and examined under dark field optics. 15-20 non- overlapping fields in each experimental condition were analyzed with NIH Image 1.6 and the percentage area of each field consumed by cell migration tracks was determined (termed Migration Index, MI).
- MI Migration Index
- test compounds were assessed after 48 hours of treatment. Compounds were ranked by considering the MI of compound treated fibroblasts relative to untreated and NHF cells. In this assay untreated cells are most motile, (with little/ no readthrough; marked as +) while NHFs are least motile. Compounds that induce a high level of readthrough have a similar motility level (and therefore MI) to NHFs (marked as +++).
- ELX-02 was used as a positive control and a CFTR activity standard for readthrough ranking.
- IEQ measurements custom software was used to measure transepithelial voltage (VT) and conductance (GT) with a 24-channel current clamp circuit and electrode manifold (TECC24; EP Design BVBA, Bertem, Belgium) coupled to a cartesian robot.
- VT transepithelial voltage
- GT conductance
- TECC24 24-channel current clamp circuit and electrode manifold
- Electrodes were washed between each plate read cycle. Baseline reads were measured for approximately 20 minutes. After this period for each epithelium, 25 pL of 100 pM benzamil (10 pM final concentration) was added apically to block ENaC currents, and readings were taken for an additional 20 minutes. After this period, forskolin (10 pM final concentration) and the potentiator VX-770 (100 nM final concentration) were added apically (27.8 pL of combined 100 pM forskolin, 1 pM VX-770 stock).
- ApcMin mice C57BL/6J-ApcMin/J)JAX, Jackson laboratory, Bar Harbor ME harboring the L850X mutation are randomized and dosed with either test agent or vehicle control starting at 10 weeks of age. The mice are dosed daily for a period of 8 weeks at which time the mice are sacrificed, and small intestine, large intestine and spleen are harvested. Spleen weights are measured and recorded. Photographs of the whole small intestine and partial large intestine (approximately 300-400mm) are captured. The middle section of each small intestine is fixed in 10% neutral buffered formalin (NBF, RT) for 24-36h and transferred to ethanol. Subsequently, all samples are processed to FFPE blocks for histology analysis.
- NNF neutral buffered formalin
- HEK293 human embryonic kidney cells used as counter-screen.
- SW1417 and SW948 are colorectal cancer derived cell lines. All cell lines grown as recommended by ATCC.
- p21 protein expression was assessed via Western Blot assay. Protein lysates from treated cells were loaded on 4-12% acrylamide gels. Anti-p21 antibody was used to detect protein on gel. 4 Image studio 5.2 software was used to acquire images and quantitate intensities from both protein translation detection assays. GraphPad Prism 9 software was used to calculate tumor volume, IC50 (uM), and relative protein expression. Spotfire (TIBCO) 12.0.0.223 was used to plot bar graph for organoid response.
- FIG.l provides a chart showing that compounds selective for cancerous cells were present in the library.
- FIG.2 indicates that aryl and lipophilic compounds were found to be more potent.
- AHA In-cell Metabolic labeling Assay: Cells were seeded at a density of 30xl0 4 cells in a 96-well black clear-bottom plates (Sigma) in triplicate for 48 hours. Cells were treated with DMSO and specified concentrations of test compounds for 24 hours, and 50ug/mL of CHX (Sigma) for 2 hours prior to incubation in methionine free (-Met) media. Cells were washed once with warm -Met media and incubated in -Met media with treatments for 30 minutes. 50uM of AHA (L- Azidohomoalanine) reagent was added to the -Met media for each condition and incubated for 1 hour.
- AHA L- Azidohomoalanine
- FIGS. 3A and 3B provide an SAR examination of the series.
- FIGS. 4A and 4B indicate that Compound 9 inhibited protein translation in the CRC cell lines that were tested.
- Organoid Culture Fourteen colorectal cancer-derived (CMS2) organoids and 1 normal organoid from the Hubrecht Organoid Technology (HUB) were thawed, expanded, and screened following HUB’s guidelines and using established formulated media. For cell viability screening assay, organoids were passaged and seeded at high density. After one day of expansion, organoids were harvested by adding Dispase at a final concentration of 1 mg/mL to the culture medium and incubating at 37°C to digest Matrigel (MG)/Basement Membrane Extract (BME). Then, organoids were collected and size-selected between 40 and 100pm using cell strainers.
- CMS2 colorectal cancer-derived organoids and 1 normal organoid from the Hubrecht Organoid Technology
- organoids were dispensed/well in a total volume of 40pL of organoid culture medium (with 5% extracellular matrix) in triplicates for all test conditions in ultra-low attachment (ULA) 384-well plates.
- Two plates were simultaneously seeded from the same organoid suspension, one for CellTiter-Glo measurement directly after plating (“Day 0”) and one to be measured 7 days after incubation with 9 doses in 3 -fold dilutions of compound 9 with 60uM as top concentration with normalization to 0.3% vehicle in all test wells.
- Day 0 CellTiter-Glo measurement directly after plating
- 9 doses in 3 -fold dilutions of compound 9 with 60uM as top concentration with normalization to 0.3% vehicle in all test wells.
- All compounds were dispensed on the “Day 7” assay plate using the Tecan D300.
- FIGS. 5A and 5B show that Compound 9 (as provided in the figure) selectively inhibited CRC organoids and causes tumor growth inhibition.
- RMAs Ribosome Modulating Agents
- Ribosomes in cancer cells accumulate numerous patient-specific structural and functional modifications with disease progression. These changes facilitate tumor progression by modifying protein translation.
- prior ribosome inhibitors have had limited success in the clinic because they target universally conserved catalytic steps and lack selectivity for cancer cells.
- RMAs Ribosome Modulating Agents
- an RMA compound of the invention as disclosed herein shows for the first time two levels of selectivity: 1) selective translation inhibition of a subset of proteins enriched for components of the ribosome and protein translation machinery that are upregulated by MYC; and 2) selective inhibition of proliferation of a subset of colorectal cancer (CRC) cell lines.
- CRC colorectal cancer
- the RMA compound of the invention represents a new class of allosteric ribosome inhibitors that display cancer selectivity through specific ribosome inhibition in the CMS2 subtype of CRC potentially targeting MYC- driven addiction to high protein translation.
- this study demonstrates that ribosome heterogeneity in cancer can be exploited to develop selective ribogenesis inhibitors.
- the CRC CMS2 subtype with a high unmet need for therapeutics, shows vulnerability to our novel selective ribosome mdulator. The mechanism suggests that other cancer subtypes with high MYC activation could also be targeted.
- ribosome abundance, composition, stoichiometry, and function can vary significantly between developmental states, tissues, cell types and even at different subcellular locations in the same cell (1,2).
- Tissue- or disease-specific expression of Ribosomal Protein Genes (RPGs), rRNA variants, as well as differential chemical modification of rRNA bases contribute to ribosome heterogeneity.
- RPGs Ribosomal Protein Genes
- rRNA variants as well as differential chemical modification of rRNA bases contribute to ribosome heterogeneity.
- This ribosome heterogeneity can alter the structure, processivity, and transcript selectivity of ribosomes and provides one mechanism for selectively regulating protein expression in response to various stimuli or cell states (1,2).
- RMAs Ribosome Modulating Agents
- Mitoxantrone (Selleckchem S2485), Doxorubicin (Selleckchem S1208) or Actinomycin-D (Sigma Aldrich SBR00013) were dosed in a 10-point three-fold dilution series. DMSO’s limit for all treatments was 0.2%. Treatment timepoints for COLO320DM (48 hours) and for SW1417, SW403 and SW948 (144 hours) were selected to span at least two cell doublings. ATP levels were measured as readout for cell viability using CellTiter-Glo 2.0 reagent (Promega G9243) for all timepoints, including day 0 (untreated cells). Luminescence reading was performed using Cytation5 Multi- Mode plate reader (Agilent).
- DMEM for SILAC was supplemented with dialyzed Fetal Bovine Serum (FBS) (Gibco).
- the light media was supplemented with L-Lysine-2HC1 for SILAC (Thermo) and L- Arginine-HCl for SILAC (Gibco).
- the heavy media was supplemented with L-Lysine-2HC1, 13 C6, 15 N2 for SILAC (Thermo) and L-Arginine-HCl, 13 C6, 15 N4 for SILAC (Thermo).
- SW1417 cells were seeded at a density of 2xl0 6 cells per 60mm dish in light media (+Light Arg/Lys) for 24 hours.
- Cells were treated with DMSO and the compound of the invention (20uM) for 1 hour in DMEM for SILAC with dialyzed FBS (-Arg/Lys), followed by a wash with warm heavy media (+Heavy Arg/Lys). Cells in both conditions were incubated in +Heavy Arg/Lys media for a total of 6 and 24 hours. Subsequently, cells were scrapped off, collected in a 1.5mL tube, and centrifuged at 500g for 5 minutes. Cell pellets were washed twice with PBS, centrifuged at 500g for 5 minutes, and stored at - 20C until ready to be processed for Mass Spectrometry.
- Cell pellets were lysed in 5% SDS, 50 mM tri ethylammonium bicarbonate (TEAB) pH 8.5, and protein concentration was determined using the BCA protein assay. Samples were reduced in 10 mM dithiothreitol for 30 min at 37°C followed by alkylation in 20 mM iodoacetamide for 20 min at room temperature. Samples were acidified and digested on an S- TrapTM spin column (Profiti) by addition of trypsin at 1 :20 for 3 h at 47°C. Peptides were eluted in 50 mM TEAB pH 8.0, 0.2% formic acid and 50% acetonitrile, respectively.
- TEAB tri ethylammonium bicarbonate
- SW1417 cells were plated at a density of O. lxlO 6 cells/well in a 12-well plate, and COLO320DM cells were plated at a density of IxlO 6 cells/well in a 6-well plate. After 24 hours, cells were treated with DMSO or the compound of the invention at various concentrations for 48 hours. Following treatment, cell pellets were washed twice with IX PBS, and then fixed with Fixation buffer (BioLegend) for 15 minutes at room temperature. The pellets were then washed with Staining buffer (BioLegend) and then permeabilized with IX Click-iTTM permeabilization and wash reagent (ThermoFisher) for 15 minutes at room temperature. The cells were then stained with DNA-specific dye FxCycleTM Violet Stain (Invitrogen) for 30 minutes and analyzed using the BD FACSCelestaTM Cell Analyzer (flow cytometer).
- FxCycleTM Violet Stain Invitrogen
Abstract
Provided are 13-membered macrolides that can be used to treat proliferative diseases such as cancer as well as genetic diseases that are associated with a premature termination codon mutation or other nonsense mutations. The compounds can induce and/or promote readthrough of the premature termination codon mutation. Also provided are pharmaceutical compositions containing the compounds, methods of using the compounds and processes for making the compounds.
Description
13-Membered Macrolide Compounds for Treating Diseases Mediated by Abnormal Protein Translation
Background
[0001] Macrolides are macrocyclic lactones that contain 12 to 16 ring atoms. The macrolide class of compounds was first discovered in 1952, when scientists isolated erythromycin from soil.
Since then, macrolides have triggered the attention of medicinal chemists and pharmaceutical scientists alike, as targets for synthesis as well as for use as treatments for bacterial infections in humans and animals. In the last 70+ years, synthetic derivatives of erythromycin as well as other natural and man-made macrolides have been a mainstay of the antibacterial pharmacopeia.
Today, macrolides continue to capture the interest of pharmaceutical research and development scientists because of their antibacterial activity, as well as their other potentially beneficial attributes. A small number of macrolides have been found to exert a surprising and an “almost bewildering number of biological effects on a variety of mammalian cells,” ranging from the modulation of inflammatory/immunomodulatory responses, the inhibition of mucus secretion, apparent abilities to block or retard aging as well as enhancing barrier integrity of epithelial cells (Knicker et. al, Pharmacological Reviews October 2021, 73 (4) 1404-1433). This activity has been observed in select 14-, 15-, and 16 membered macrolides including erythromicin, azithromicin, and clarithromicin.
[0002] What is not known more generally is the effect of macrolides on abnormalities in protein translation such as observed in proliferative diseases including cancer as well as in rare genetic diseases (especially those rare diseases caused by nonsense mutations). As noted recently by Song and coworkers, (Song, P., Yang, F., Jin, H. el al The regulation of protein translation and its implications for cancer. Sig Transduct Target Ther 6, 68 (2021). https://doi.org/10.1038/s41392- 020-00444-9). Cancer has been recognized as a disease resulting from the accumulation for multiple genetic and epigenetic changes. Genetic mutations mainly alter the functions of corresponding proteins, while epigenetic changes will change the expression of potential oncogenes and tumor suppressor genes. Although the regulation and function of these alterations have been substantially explored, the relevance of protein translation or the production of nascent proteins from mRNAs to the initiation and progression of human cancers has remained largely overlooked. In the cancer context, protein translation could be affected by various factors including translation initiation factors, RNA-binding proteins, and noncoding RNAs.
[0003] Similarly, some diseases such as cystic fibrosis (CF), muscular dystrophy (Duchenne (DMD), Becker (BMD), congenital), spinal muscular atrophy (SMA), ataxia-telangiectasia, mucopolysaccharidosis type 1 (MPS1) (Hurler syndrome), hemophilia (A & B), Usher syndrome (Retinitis pigmentosa, X-linked retinitis pigmentosa), Tay-Sachs, factor VII deficiency, familial atrial fibrillation, Hailey-Hailey disease, McArdle disease, mucopolysaccharidosis, nephropathic cystinosis, polycystic kidney disease, Rett syndrome, cystinosis, severe epidermolysis bullosa, dravet syndrome, X-linked nephrogenic diabetes insipidus (XNDI), dancer, beta-thalassemia, and obesity have been found to be caused by nonsense mutations in genes, leading to premature translation termination and mRNA destabilization mediated by the nonsense mediated mRNA decay. Treatment of these diseases will require suppression of premature translation termination by inducing readthrough (or nonsense suppression) at the premature termination codon.
[0004] Thus, there is continuing interest and a need to identify macrolides with diverse beneficial properties for treating diseases in humans and animals, particularly for diseases characterized by abnormalities in protein translation such as proliferative diseases including cancer as well as rare genetic diseases (especially those rare diseases caused by nonsense mutations).
Summary
[0005] These and other needs are met by the present invention which is directed to 13-membered macrolide compounds that can be used to treat proliferative diseases and disorders such as cancer as well as rare genetic diseases, including genetic diseases associated with a premature termination codon mutation or other nonsense and/or frameshift mutations. The compounds have an antiproliferative effect by selective inhibition of protein translation and can also induce and/or promote readthrough of the premature termination codon.
[0006] In one aspect, what is provided is a compound of formula I:
R.2a is selected from the group consisting of H, halo, optionally substituted C1-10 alkyl, optionally substituted C1-10 alkoxy, and optionally substituted C1-10 alkenyl, wherein C1-10 alkyl, C1-10 alkoxy, and C1-10 alkenyl are optionally substituted with one or more groups selected from the group consisting of halo, aryl, amino, alkyl, heteroalkyl, heteroalkenyl, heterocycloalkyl, and heteroaryl; and
R.2b is selected from the group consisting of halo, optionally substituted C1-10 alkyl, optionally substituted C1-10 alkoxy, and optionally substituted C1-10 alkenyl, wherein C1-10 alkyl, C1-10 alkoxy, and C1-10 alkenyl are optionally substituted with one or more groups selected from the group consisting of halo, aryl, amino, alkyl, heteroalkyl, heteroalkenyl, heterocycloalkyl, and heteroaryl;
R.4a and R4b are each independently selected from the group consisting of -H, and optionally substituted C1-10 alkyl, wherein C1-10 alkyl, is optionally substituted with one or more groups selected from the group consisting of halo, aryl, amino, alkyl, heteroalkyl, heteroalkenyl, heterocycloalkyl, and heteroaryl;
Rs is selected from the group consisting of H, an oxygen protecting group, and
, ” indicates the point of attachment;
Rea is optionally substituted C1-10 alkyl, wherein C1-10 alkyl, is optionally substituted with one or more groups selected from the group consisting of halo, aryl, amino, alkyl, heteroalkyl, heteroalkenyl, heterocycloalkyl, and heteroaryl;
Reb is -H, optionally substituted C1-10 alkyl, optionally substituted C1-10 hydroxyalkyl, and optionally substituted allyl, wherein C1-10 alkyl, C1-10 hydroxyalkyl, and allyl are optionally substituted with one or more groups selected from the group consisting of halo, aryl, amino, alkyl, heteroalkyl, heteroalkenyl, heterocycloalkyl, and heteroaryl;
Rsa and R> are each independently selected from the group consisting of -H and optionally substituted C1-10 alkyl, wherein C1-10 alkyl, is optionally substituted with one or more groups selected from the group consisting of halo, aryl, amino, alkyl, heteroalkyl, heteroalkenyl, heterocycloalkyl, and heteroaryl;
R9a is selected from the group consisting of -H, -C(=N)-NH2, -C(=O)-C1-6 alkyl , -C(=O)- C1-6 alkylene-NR9a’R9a”, C1-10 alkyl and C1-10 alkenyl, wherein C1-10 alkyl and C1-10 alkenyl are optionally substituted with 1, 2, or 3 groups independently selected from the group consisting of amino, heterocycloalkyl, halo, hydroxy, alkoxy, aryl, heteroaryl, and heteroaryl ene-heteroaryl, wherein aryl, heteroaryl, and heteroaryl ene-heteroaryl, are optionally substituted with halo, alkoxy, and -NH2; wherein R9a’ and R9a” are selected from the group consisting of H, C1-6 alkyl, cycloalkyl, C1.4 alkylene-cycloalkyl, or R9a’ and R9a” together with the atom to which there are attached from a 3-, 4-, 5-, or 6-membered ring optionally containing an additional heteroatom selected from 0, S, SO, SO2, NH, and N-C1.4 alkyl;
Rioa and Riob are taken together with the carbon atom to which they are attached to form (Rq)o-2— (TV
K , wherein Q is a 3-, 4-, 5-, or 6-membered cycloalkyl or heterocyclic ring, wherein “ -w ” indicates points of attachment and Rna and Rub are each independently selected from the group consisting of H, halo, and optionally substituted C1-10 alkyl; or
Riia and Rub are taken together with the carbon atom to which they are attached to form
, wherein Q is a 3-, 4-, 5-, or 6-membered cycloalkyl or heterocyclic ring, wherein “ ” indicates points of attachment and Rioa and Riob are each independently selected from the group consisting of H, halo, and optionally substituted C1-10 alkyl;
Rq at each occurrence is independently selected from the group consisting of H, halo, - NRx’Rx”, C1-6 alkyl, C1-6 haloalkyl, OH, C1-6 alkoxy, -C(=O)-C1-6 alkyl, -C(=O)O-C1-6 alkylene- aryl, -C(=O)-C1-6 alkylene-C1-6 alkyl, -C(=O)-C1-6 alkyl ene-OC1-6 alkyl, -C(=O)-C1-6 alkylene- aryl, -C(=O)O-C1-6 alkylene-heteroaryl, -C(=O)-C1-6 alkylene-heteroaryl, -C1-6 alkylene- cycloalkyl, -C1-6 alkylene-aryl, -C1-6 alkylene-heterocycloalkyl, -C1-6 alkylene-heteroaryl, -C1-6 alkylene-C(=O)-NRx’Rx”, -C(=O)-C1-6 alkylene-cycloalkyl, -C(=O)-C1-6 alkylene- heterocycloalkyl, -C(=O)-C1-6 alkylene-NRx’Rx”, -C(=0)-CHCH20H-alkylene-NRxRx”, -SO2-C1.6 alkyl, -SO2-C1.6 alkylene-NRx’Rx”, -NRZC(=0)-C1-6 alkyl, -NRZC(=0)0-C1-6 alkylene-aryl, - NRZC(=O)-C1-6 alkylene-aryl, -NRZC(=0)0-C1-6 alkylene-heteroaryl, -NRZC(=0)-C1-6 alkylene- heteroaryl, -C1-6 alkylene-cycloalkyl, -C1-6 alkylene-heterocycloalkyl, -C1-6 alkylene-aryl, -C1-6 alkylene-heteroaryl, -NRX””C(=0)-C1-6 alkylene-cycloalkyl, -NRX” C(=O)-C1-6 alkylene- heterocycloalkyl, -NRZC(=0)-C1-6 alkylene-NRx’Rx”, -NRzC(=0)-CHCH20H-alkylene-NRx’Rx”, - NRx ” ’ SO2-C1.6 alkyl, -NRx””SO2-C1-6 alkylene-NRx’Rx”, -C(=O)-heterocycloalkyl, -C(=O)-C1-6 alkylene-heterocycloalkyl, -C1-6 alkyl ene-NRzC(=0)-C1-6 alkyl, -C(=O)-C1-6 alkylene- NRx””cycloalkyl, -C(=O)-C1-6 alkylene-NRx””-Ci.6 alkylene-cycloalkyl, -NRX””-C(=0)-C1-6 alkylene-heterocycloalkyl, -C(=O)-C1-6 alkylene-NRx””-C1-6 alkylene-cycloalkyl, -C(=O)-C1-6 alkylene-NRx””-C1-6 alkylene- C1-6 alkoxy, -C1-6 alkylene-NRX””-C(=O)-C1-6 alkylene-NRx’Rx”, - NRx””-C(=0)-C1-6alkylene -NRX ” ”-C1-6 alkylene-NRx’Rx”, -C(=O)-cycloalkyl, -C(=O)-aryl, - C(=O)-heterocycloalkyl, C(=O)-heteroaryl, -C1-6 alkylene-arylene-aryl, -C(=O)-cycloalkyl, - C(=O)-heterocycloalkyl, -C(=O)-NRzaryl, -C(=0)NRZ-C1-6 alkylene-aryl, -SO2-C1.6 alkyl, -SO2- aryl, -SO2-heteroaryl, -SO2-C1.6 alkylene-NRx’Rx”, and -SO2- C1-6 alkylene-aryl; or or two Rq together with the atom to which they are attached form oxo, or an oxo protecting group, or a 3, 4, 5, or 6-membered cycloalkyl or heterocycle optionally substituted with one or more substituents selected from the group consisting of OH, halo, C1-6 alkyl, Ci/> haloalkyl, C1-6 alkylene-NH2, C1-6 alkyl ene-NH(C1-6 alkyl), C1-6 alkyl ene-N(C1-6 alkyl)2, C1-6 alkylene-NH- C(=O)-C1-6 alkyl, Ci-6 alkylene-N(Ci-6 alkyl)-C(=O)-Ci-6 alkyl, Ci-6 alkylene-NH-C(=O)-Ci-6 alkylene-NH2, C1-6 alkylene-NH-C(=O)-C1-6 alkylene-NH(C1-6 alkyl), -C(=O)-C1-6 alkyl, -C(=O)- C1-6 alkylene-N(C1-6 alkyl)2, and C1-6 alkylene-NH-C(=O)-C1-6 alkylene-N(C1-6 alkyl)z;
RX’ and RX” are each independently selected from the group consisting of H, C1-6 alkyl, cycloalkyl, C1-6 alkylene-cycloalkyl, C1-6 alkylene-heterocycloalkyl, C1-6 alkylene-aryl, C1-6 alkylene-heteroaryl, C1-6 alkylene-N-RzRX’” C1-6 alkylene-OH, C1-6 alkylene-O-C1-6 alkyl,
cycloalkyl, heterocycloalkyl, or Rx’ and Rx” are joined together with the atom to which they are attached to form a 3-, 4-, 5-, 6-, or 7-membered ring optionally containing an additional heteroatom selected from 0, S, SO, SO2, N-Rx ’, wherein said ring is further optionally substituted with halo, OH, C1-6 alkyl, -O-C1-6 alkyl; wherein RX”’ is H, C1-6 alkyl, -C(=0)-C1-6 alkyl, -C(=0)0-C1-6 alkylene-aryl, -C(=0)-C1-6 alkyl ene-aryl, -C(=0)0-C1-6 alkylene-heteroaryl, -C(=0)-C1-6 alkylene-heteroaryl, -C1-6 alkylene- aryl, -C1-6 alkylene-heteroaryl, -C(=0)-C1-6 alkylene-cycloalkyl, -C(=0)-C1-6 alkylene- heterocycloalkyl; each Rx ’ and Rz is independently H or C1-6 alkyl; or are joined together with the atom to which they are attached form a 3, 4, 5, or 6-membered cycloalkyl or heterocycle optionally substituted with one or more substituents selected from the group consisting of OH, halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(C1-6 alkyl), C1-6 alkylene-N(C1-6 alkyl)2, C1-6 alkyl ene-NH-C(=0)-C i-6 alkyl, C1-6 alkylene-N(C1-6 alkyl)-C(=0)-C1-6 alkyl, C1-6 alkyl ene-NH-C(=0)-C i-6 alkylene-NH2, C1-6 alkylene-NH-C(=0)-C1-6 alkyl ene-NH(C1-6 alkyl), - C(=0)-C1-6 alkyl, -C(=0)-C1-6 alkylene-N(C1-6 alkyl)2, and C1-6 alkylene-NH-C(=0)-C1-6 alkyl ene-N(C i-6 alkyl^; and wherein unless otherwise specified, each occurrence of alkylene, alkyl, alkenyl, alkoxy, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl is independently and optionally substituted with halo, OH, C1-6 alkyl, alkoxy, or oxo.
[0007] Pharmaceutical compositions comprising the compounds are also described herein, as are of using the compounds of formula I to treat genetic diseases and also in the manufacture of a medicaments to treat such genetic diseases. Also provided are processes for making compounds of formula I.
Brief Description of the Figures
[0008] FIG.l provides a chart showing that compounds selective for cancerous cells were present in the library.
[0009] FIG.2 indicates that aryl and lipophilic compounds were found to be more potent. [0010] FIGS. 3A and 3B provide an SAR examination of some of the compounds in the series. [0011] FIGS. 4A and 4B indicate that Compound 9 (as provided in the figure) affected protein translation in the CRC cell lines that were tested.
[0012] FIGS. 5A and 5B shows that Compound 9 selectively inhibited CRC organoids and was efficacious in vivo.
[0013] FIGS. 6.1A-D and S1A and SIB shows that a representative RMA compound of the invention as disclosed herein is selectively active in a sensitive CRC cell line.
[0014] FIGS. 6.2A-D and S2A-S2D show that the representative RMA compound of the invention inhibits protein translation in a sensitive CRC cell line.
[0015] FIGS. 6.3A-B and S3A and S3B show that the representative compound of the invention alters cell cycle in a sensitive CRC cell line.
[0016] FIGS. 6.4A-D show that CMS2 cell lines display high sensitivity to the representative compound of the invention.
[0017] FIGS. 6.5A-E show that the representative compound of the invention is synergistic with DNA intercalating agents in selected CRC cell lines.
[0018] FIG.7.1 summarizes the approach we employed in identifying RMAs.
[0019] FIGS. 7.2A and B summarize clinical subtypes in solid and hematological cancers that are highly sensitive to the second representative RMA of the invention.
[0020] FIG.7.3 indicates that forty five percent of small cell lung cancer cell lines are highly sensitive to the second representative RMA compound of the invention.
[0021] FIGS. 7.4A-C, indicate that the sensitivity small cell lung cancer cell lines is associated with high expression of ribogenesis, protein translation, and MYC pathway genes.
[0022] FIGS. 7.5A-C indicate that the anti-proliferative effect of RMAs is driven by selective inhibition of new protein synthesis
[0023] FIGS. 7.6A-B show that proteins with higher positively charged regions are more sensitive to translation inhibition by RMAs.
[0024] FIGS. 7.7 indicates that decreased proteins show a large impact on ribogenesis and protein translation machinery.
[0025] FIG.7.8 indicates that the second representative compound of the invention induces apoptosis in sensitive cells.
[0026] FIG.7.9 shows that the second representative compound of the invention selectively inhibits SCLC -patient derived organoids (PDOs).
[0027] FIG.7.10 shows that the second representative compound of the invention demonstrates combination synergy with DNA targeting chemotherapeutics known to inhibit tRNA synthesis.
[0028] FIG.7.11 summarizes the multiple levels of selectivity of allosteric inhibition by the RMAs of the invention.
Detailed Description
Definitions
[0029] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety, including U.S. Pat. Publ. No. 2013/0090326, In case of conflict, the present specification, including these definitions, will control.
[0030] Articles such as “a,” “an,” and “the” may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. The invention includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The invention includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process. Thus, the terms “a,” “an,” and “the” as used herein not only include aspects with one member, but also include aspects with more than one member.
[0031] The term “about” as used herein means “approximately” and is used to modify a numerical value indicates a defined range around that value. If “X” were the value, “about X” would generally indicate a value from 0.95X to 1.05X. Any reference to “about X” specifically indicates at least the values X, 0.95X, 0.96X, 0.97X, 0.98X, 0.99X, 1.01X, 1.02X, 1.03X, 1.04X, and 1.05X. Thus, “about X” is intended to teach and provide written description support for a claim limitation of, e.g., “0.98X.” When the quantity “X” only includes whole-integer values (e.g., “X carbons”), “about X” indicates from (X-l) to (X+l). In this case, “about X” as used
herein specifically indicates at least the values X, X-l, and X+l.
[0032] When “about” is applied to the beginning of a numerical range, it applies to both ends of the range. Thus, “from about 5 to 20%” is equivalent to “from about 5% to about 20% ” When “about” is applied to the first value of a set of values, it applies to all values in that set. Thus, “about 7, 9, or 11%” is equivalent to “about 7%, about 9%, or about 11% .”
[0034] The symbol means a single bond, “=” means a double bond, “=” means a triple bond, “ means a single or double bond. The symbol “*/vw” refers to a group on a double-bond as occupying either position on the terminus of a double bond to which the symbol is attached; that is, the geometry, E- or Z-, of the double bond is ambiguous. When a group is depicted removed from its parent Formula, the “ ~ ” symbol will be used at the end of the bond which was theoretically cleaved in order to separate the group from its parent structural Formula.
[0035] When chemical structures are depicted or described, unless explicitly stated otherwise, all carbons are assumed to have hydrogen substitution to conform to a valence of four. For example, in the structure on the left-hand side of the schematic below there are nine hydrogens implied. The nine hydrogens are depicted in the right-hand structure. Sometimes a particular atom in a structure is described in textual Formula as having a hydrogen or hydrogens as substitution (expressly defined hydrogen), for example, -CH2CH2-. It is understood by one of ordinary skill in the art that the aforementioned descriptive techniques are common in the chemical arts to provide brevity and simplicity to description of otherwise complex structures.
[0036] If a group “R” is depicted as “floating” on a ring system, as for example in the following Formula.
then, unless otherwise defined, a substituent “R” may reside on any atom of the ring system, assuming replacement of a depicted, implied, or expressly defined hydrogen from one of the Ring atoms, so long as a stable structure is formed.
[0037] If a group “R” is depicted as floating on a fused or bridged ring system, as for example in the following Formulas:
then, unless otherwise defined, a substituent “R” may reside on any atom of the fused or bridged ring system, assuming replacement of a depicted hydrogen (for example the -NH- in the Formula above), implied hydrogen (for example as in the Formula above, where the hydrogens are not shown but understood to be present), or expressly defined hydrogen (for example where in the Formula above, “Z” equals =CH-) from one of the Ring atoms, so long as a stable structure is formed. In the example depicted, the “R” group may reside on either the 5-membered or the 6-membered ring of the fused or bridged ring system.
[0038] When a group “R” is depicted as existing on a ring system containing saturated carbons, as for example in the following Formula
where, in this example, “y” can be more than one, assuming each replaces a currently depicted, implied, or expressly defined hydrogen on the ring; then, unless otherwise defined, where the resulting structure is stable, two “R’s” may reside on the same carbon. In one example, two R’s on the same carbon, including that carbon, may form a ring, thus creating a spirocyclic ring structure with the depicted Ring Ds for example in the following Formula
[0039] The term “acyl” as used herein includes an alkanoyl, aroyl, heterocycloyl, or heteroaroyl group as defined herein. Examples of acyl groups include, but are not limited to, acetyl, benzoyl, and ni cotinoyl.
[0040] The term “alkanoyl” as used herein includes an alkyl-C(O)- group wherein the alkyl group is as defined herein. Examples of alkanoyl groups include, but are not limited to, acetyl and propanoyl.
[0041] The term “agent” as used herein includes a compound or mixture of compounds that, when added to a composition, tend to produce a particular effect on the composition’s properties. For example, a composition comprising a thickening agent is likely to be more viscous than an otherwise identical comparative composition that lacks the thickening agent.
[0042] The term “alkenyl” as used herein includes a straight or branched chain hydrocarbon containing at least one carbon-carbon double bond. The chain may contain an indicated number of carbon atoms. For example, “C1-C12 alkenyl” indicates that the group may have from 1 to 12 (inclusive) carbon atoms and at least one carbon-carbon double bond. When the indicated number of carbon atoms is 1, then the Ci alkenyl is double bonded to a carbon (i.e., a carbon equivalent to an oxo group). In certain aspects, the chain includes 1 to 12, about 2 to 15, about 2 to 12, about 2 to 8, or about 2 to 6 carbon atoms. An alkenyl group can be preferably one stereoisomer (i.e., cis- or, alternatively, trans-). Examples of an alkenyl group may include, but are not limited to, ethenyl (i.e., vinyl), allyl, propenyl, butenyl, crotyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, dodecenyl, cyclopentenyl, cyclohexenyl, 2-isopentenyl, allenyl, butadienyl, pentadienyl, 3-(l,4-pentadienyl), and hexadienyl.
[0043] An amino group can be a primary amino group (NH2), or a secondary or tertiary amine, wherein the alkyl groups in the secondary ofr tertiary amine can be the same or different, and can be optionally substituted.
[0044] An alkenyl group can be unsubstituted or optionally substituted. When optionally substituted, one or more hydrogen atoms of the alkenyl group (e.g., from 1 to 4, from 1 to 2, or 1) may be replaced with a moiety independently selected from the group consisting of fluoro, hydroxy, alkoxy, amino, alkylamino, acylamino, thio, and alkylthio, with the proviso that no hydrogen atom substituent on the carbon-carbon double bond is replaced by a hydroxy, amino, or thio group. In some aspects, the alkenyl group is unsubstituted or not optionally substituted. [0045] “Alkenylene” as used herein includes an alkenyl group that is substituted at two points. An example is but-2-enylene (-CH2CH=CHCH2-) and the like.
[0046] The term “alkyl” as used herein includes an aliphatic hydrocarbon chain that may be straight chain or branched. The chain may contain an indicated number of carbon atoms: For
example, C1-C10 indicates that the group may have from 1 to 10 (inclusive) carbon atoms in it. If not otherwise indicated, an alkyl group contains from 1 to about 20 carbon atoms. In some aspects, alkyl groups have 1 to about 10 carbon atoms. In some aspects, alkyl groups (“lower alkyl”) have 1 to 8, 1 to 6, or 1 to 3 carbon atoms in the chain. Examples may include, but are not limited to, methyl, ethyl, propyl, isopropyl (iPr), 1 -butyl, 2 -butyl, isobutyl (iBu), Ze/7-butyl, pentyl, 2-m ethylbutyl, 1,1 -dimethylpropyl, hexyl, heptyl, octyl, nonyl, decyl, docecyl, cyclopentyl, or cyclohexyl.
[0047] An alkyl group can be unsubstituted or optionally substituted. When optionally substituted, one or more hydrogen atoms of the alkyl group (e.g., from 1 to 4, from 1 to 2, or 1) may be replaced with a moiety independently selected from the group consisting of fluoro, hydroxy, alkoxy, amino, alkylamino, acylamino, thio, and alkylthio. In some aspects, the alkyl group is unsubstituted or not optionally substituted.
[0048] “Alkylene” as used herein includes an alkyl group that is substituted at two points. An example is methylene (-CH2-), propylene (-CH2CH2CH2-), and the like.
[0049] The term “alkoxy” as used herein includes a straight or branched chain saturated or unsaturated hydrocarbon containing at least one oxygen atom in an ether group (e.g., EtO-). The chain may contain an indicated number of carbon atoms. For example, “C1-C12 alkoxy” indicates that the group may have from 1 to 12 (inclusive) carbon atoms and at least one oxygen atom. Examples of a C1-C12 alkoxy group include, but are not limited to, methoxy, ethoxy, isopropoxy, butoxy, n-pentoxy, isopentoxy, neopentoxy, and hexoxy.
[0050] An alkoxy group can be unsubstituted or optionally substituted. When optionally substituted, one or more hydrogen atoms of the alkoxy group (e.g., from 1 to 4, from 1 to 2, or 1) may be replaced with a moiety independently selected from the group consisting of fluoro, hydroxy, alkoxy, amino, alkylamino, acylamino, thio, and alkylthio, with the proviso that no hydrogen atom alpha to the ether oxygen is replaced by a hydroxy, amino, or thio group. In some aspects, the alkoxy group is unsubstituted or not optionally substituted.
[0051] The term “alkynyl” as used herein includes a straight, branched, or cyclic hydrocarbon containing at least one carbon-carbon triple bond. Examples may include, but are not limited to, ethynyl, propargyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl, or decynyl.
[0052] “Alkynylene” as used herein includes an alkynyl group that is substituted at two points.
An example is 2-butynylene (-CH2CCCH2-) and the like.
[0053] An alkynyl group can be unsubstituted or optionally substituted. When optionally substituted, one or more hydrogen atoms of the alkynyl group (e.g., from 1 to 4, from 1 to 2, or 1) may be replaced with a moiety independently selected from the group consisting of fluoro, hydroxy, alkoxy, amino, alkylamino, acylamino, thio, and alkylthio, with the proviso that no sp- hybridized hydrogen atom substituent is replaced by a hydroxy, amino, or thio group. In some aspects, the alkynyl group is unsubstituted or not optionally substituted.
[0054] The term “aryl” as used herein includes cyclic aromatic carbon ring systems containing from 6 to 18 carbons. Examples of an aryl group include, but are not limited to, phenyl, naphthyl, anthracenyl, tetracenyl, biphenyl and phenanthrenyl.
[0055] An aryl group can be unsubstituted or optionally substituted. When optionally substituted, one or more hydrogen atoms of the aryl group (e.g., from 1 to 5, from 1 to 2, or 1) may be replaced with a moiety independently selected from the group consisting of alkyl, cyano, acyl, halo, hydroxy, alkoxy, amino, alkylamino, acylamino, thio, and alkylthio. In some aspects, the alkoxy group is unsubstituted or not optionally substituted.
[0056] The term “arylalkyl” or “aralkyl” as used herein includes an alkyl group as defined herein where at least one hydrogen substituent has been replaced with an aryl group as defined herein. Examples include, but are not limited to, benzyl, 1 -phenyl ethyl, 4-methylbenzyl, and 1,1,- dimethyl- 1 -phenylmethyl .
[0057] An arylalkyl or aralkyl group can be unsubstituted or optionally substituted as per its component groups. For example, but without limitation, the aryl group of an arylalkyl group can be substituted, such as in 4-methylbenzyl. In some aspects, the group is unsubstituted or not optionally substituted, especially if including a defined substituent, such as a hydroxyalkyl or alkylaminoalkoxy group.
[0058] The term “cycloalkyl” as used herein includes non-aromatic saturated monocyclic or multi cyclic ring system that may contain an indicated number of carbon atoms. For example, C3- C12 indicates that the group may have from 3 to 12 (inclusive) carbon atoms in it. If not otherwise indicated, a cycloalkyl group includes about 3 to about 20 carbon atoms. In some aspects, cyclo alkyl groups have 3 to about 12 carbon atoms in the group. In some aspects, cycloalkyl groups have 3 to about 7 carbon atoms in the group. Examples may include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 4,4-dimethylcyclohexyl, and cycloheptyl.
[0059] A cycloalkyl group can be unsubstituted or optionally substituted. When optionally substituted, one or more hydrogen atoms of the cycloalkyl group (e.g., from 1 to 4, from 1 to 2, or 1) may be replaced with a moiety independently selected from the group consisting of fluoro, hydroxy, alkoxy, amino, alkylamino, acylamino, thio, and alkylthio. In some aspects, a substituted cycloalkyl group can incorporate an exo- or endocyclic alkene (e.g., cyclohex-2-en-l- yl). In some aspects, a cycloalkyl group is unsubstituted or not optionally substituted.
[0060] As used herein, “fluoroalkyl” includes an alkyl group wherein the alkyl group includes one or more fluoro- substituents. Examples include, but are not limited to, trifluoromethyl.
[0061] As used herein, “geminal” substitution includes two or more substituents that are directly attached to the same atom. An example is 3,3-dimethyl substitution on a cyclohexyl or spirocyclohexyl ring.
[0062] As used herein, “halo” or “halogen” includes fluoro, chloro, bromo, and iodo.
[0063] The term “heteroaryl” or “heterocycloaryl” includes mono and bicyclic aromatic groups of about 4 to about 14 Ring atoms (e.g., 4 to 10 or 5 to 10 atoms) containing at least one heteroatom. Heteroatom as used in the term heteroaryl refers to oxygen, sulfur and nitrogen. A nitrogen atom of a heteroaryl is optionally oxidized to the corresponding N-oxide. Examples include, but are not limited to, pyrazinyl, furanyl, thienyl, pyridyl, pyrimidinyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, pyrazolyl, furazanyl, pyrrolyl, pyrazolyl, triazolyl, 1,2,4-thiadiazolyl, pyrazinyl, pyridazinyl, quinoxalinyl, phthalazinyl, imidazo[l,2-a]pyridine, imidazo[2,l-b]thiazolyl, benzofurazanyl, indolyl, azaindolyl, benzimidazolyl, benzothienyl, quinolinyl, imidazolyl, thi enopyridyl, quinazolinyl, thienopyrimidyl, pyrrol opyridyl, imidazopyridyl, isoquinolinyl, benzoazaindolyl, 1,2,4-triazinyl, and benzothiazolyl.
[0064] The term “heteroarylene” or “heterocycloarylene” as used herein includes a heteroaryl group that is substituted at two points.
[0065] An heteroaryl group can be unsubstituted or optionally substituted. When optionally substituted, one or more hydrogen atoms of the heteroaryl group (e.g., from 1 to 5, from 1 to 2, or 1) may be replaced with a moiety independently selected from the group consisting of alkyl, cyano, acyl, halo, hydroxy, alkoxy, amino, alkylamino, acylamino, thio, and alkylthio. In some aspects, the heteroaryl group is unsubstituted or not optionally substituted.
[0066] The term “heteroaroyl” as used herein includes a heteroaryl -C(O)- group wherein heteroaryl is as defined herein. Heteroaroyl groups include, but are not limited to, thiophenoyl,
nicotinoyl, pyrrol-2-ylcarbonyl, and pyridinoyl.
[0067] The term “heterocycloalkyl” may be used interchangeably herein, and as used herein includes a heterocyclyl-C(O)- group wherein heterocyclyl is as defined herein. Examples include, but are not limited to, N-m ethyl prolinoyl and tetrahydrofuranoyl.
[0068] As used herein, “heterocyclyl” (heterocyclo; heterocyclic; heterocycloalkyl) includes a non-aromatic saturated ring of about 3 to about 8 Ring Dtoms (e.g., 5 to about 10 Ring Dtoms, or 3 to about 6 Ring atoms), in which one or more of the atoms in the ring system is an element or elements other than carbon, e.g., nitrogen, oxygen or sulfur. A heterocyclyl group optionally comprises at least one sp2-hybridized atom (e.g., a ring incorporating an carbonyl, endocyclic olefin, or exocyclic olefin). In some embodiments, a nitrogen or sulfur atom of the heterocyclyl is optionally oxidized to the corresponding N-oxide, S-oxide or S, S-di oxide. The monocyclic heterocycle means a three-, four-, five-, six-, seven-, or eight-membered ring containing at least one heteroatom independently selected from the group consisting of O, N, and S. The three- or four-membered ring contains zero or one double bond, and one heteroatom selected from the group consisting of O, N, and S. The five-membered ring contains zero or one double bond and one, two or three heteroatoms selected from the group consisting of O, N and S. The six- membered ring contains zero, one or two double bonds and one, two, or three heteroatoms selected from the group consisting of 0, N, and S. The seven- and eight-membered rings contains zero, one, two, or three double bonds and one, two, or three heteroatoms selected from the group consisting of 0, N, and S. Representative examples of monocyclic heterocycles include, but are not limited to, azetidinyl, azepanyl, aziridinyl, diazepanyl, 1,3-dioxanyl, 1,3-dioxolanyl, 1,3- dithiolanyl, 1,3-dithianyl, imidazolinyl, imidazolidinyl, isothiazolinyl, isothiazolidinyl, isoxazolinyl, isoxazolidinyl, morpholinyl, oxadiazolinyl, oxadiazolidinyl, oxazolinyl, oxazolidinyl, piperazinyl, piperidinyl, pyranyl, pyrazolinyl, pyrazolidinyl, pyridazin-3(2H)-onyl, pyridin-2(lH)-onyl, pyrrolinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydrothienyl, thiadiazolinyl, thiadiazolidinyl, thiazolinyl, thiazolidinyl, thiomorpholinyl, 1,1-dioxidothiomorpholinyl (thiomorpholine sulfone), thiopyranyl, and trithianyl.
[0069] The term “heterocycloalkylene” as used herein includes a heterocyclyl (heterocyclo; heterocyclic) group that is substituted at two points.
[0070] The term “heterocyclyl” also includes multicyclic rings such as a bicyclic heterocycle, or a
tricyclic heterocycle which may be in a fused, bridged, or spiro orientation. The bicyclic heterocycle is a monocyclic heterocycle fused to a phenyl group, or a monocyclic heterocycle fused to a monocyclic cycloalkyl, or a monocyclic heterocycle fused to a monocyclic cycloalkenyl, or a monocyclic heterocycle fused to a monocyclic heterocycle, or a bridged monocyclic heterocycle ring system in which two non-adjacent atoms of the Ring Dre linked by an alkylene bridge of 1, 2, 3, or 4 carbon atoms, or an alkenylene bridge of two, three, or four carbon atoms. Representative examples of bicyclic heterocycles include, but are not limited to, 3- azabicyclo[3.1.0]hexane, 3-azabicyclo[4.1.0]heptane, 3-azabicyclo[3.2.0]heptane, (3aR,6aS)- hexahydro-lH-2Z,2-cyclopenta[c]pyrrole, (3aR,7aS)-octahydro-2X2-isoindole.
[0071] Tricyclic heterocycles are exemplified by a bicyclic heterocycle fused to a phenyl group, or a bicyclic heterocycle fused to a monocyclic cycloalkyl, or a bicyclic heterocycle fused to a monocyclic cycloalkenyl, or a bicyclic heterocycle fused to a monocyclic heterocycle, or a bicyclic heterocycle in which two non-adjacent atoms of the bicyclic Ring Dre linked by an alkylene bridge of 1, 2, 3, or 4 carbon atoms, or an alkenylene bridge of two, three, or four carbon atoms.
[0072] A heterocycyl group can be unsubstituted or optionally substituted. When optionally substituted, one or more hydrogen atoms of the group (e.g., from 1 to 4, from 1 to 2, or 1) may be replaced with a moiety independently selected from the group consisting of fluoro, hydroxy, alkoxy, amino, alkylamino, acylamino, thio, and alkylthio. In some aspects, a substituted heterocycyl group can incorporate an exo- or endocyclic alkene (e.g., cyclohex-2-en-l-yl). In some aspects, the heterocycyl group is unsubstituted or not optionally substituted.
[0073] The monocyclic, bicyclic, and tricyclic heterocycles are connected to the parent molecular moiety through any carbon atom or any nitrogen atom contained within the rings, and can be unsubstituted or substituted.
[0074] As used herein, the term “hydrophilic moiety” or “hydrophilic group” includes a moiety or a functional group that has a strong affinity to water. Examples may include, but are not limited to, a charged moiety, such as a cationic moiety or an anionic moiety, or a polar uncharged moiety, such as an alkoxy group or an amine group.
[0075] As used herein, the term “hydroxyalkyl” includes an alkyl group where at least one hydrogen substituent has been replaced with an alcohol (-OH) group. In certain aspects, the hydroxyalkyl group has one alcohol group. In certain aspects, the hydroxyalkyl group has one or
two alcohol groups, each on a different carbon atom. In certain aspects, the hydroxyalkyl group has 1, 2, 3, 4, 5, or 6 alcohol groups. Examples may include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, and 1 -hydroxy ethyl.
[0076] When any two substituent groups or any two instances of the same substituent group are “independently selected” from a list of alternatives, the groups may be the same or different. For example, if Ra and Rb are independently selected from the group consisting of alkyl, fluoro, amino, and hydroxyalkyl, then a molecule with two Ra groups and two Rb groups could have all groups be an alkyl group (e.g., four different alkyl groups). Alternatively, the first Ra could be alkyl, the second Ra could be fluoro, the first Rb could be hydroxyalkyl, and the second Rb could be amino (or any other substituents taken from the group). Alternatively, both Ra and the first Rb could be fluoro, while the second Rb could be alkyl (i.e., some pairs of substituent groups may be the same, while other pairs may be different).
[0077] “Oxo” means -C(=O)-
[0078] “Protecting Group” means “amino protecting group,” which is a protecting group that is suitable for preventing undesired reactions at an amino nitrogen. Representative amino-protecting groups include, but are not limited to, formyl; acyl groups, for example alkanoyl groups, such as acetyl; alkoxycarbonyl groups, such as tert-butoxycarbonyl (Boc); arylmethoxycarbonyl groups, such as benzyloxycarbonyl (Cbz) and 9-fluorenylmethoxycarbonyl (Fmoc); arylmethyl groups, such as benzyl (Bn), trityl (Tr), and l,l-di-(4'-methoxyphenyl)methyl; silyl groups, such as trimethylsilyl (TMS) and tert-butyldimethylsilyl (TBDMS); and the like. Representative oxygen protecting groups include, but are not limited to silyl groups, such as TMS and TMDMS; esters, such as formate, acetate, and benzoate (Bz); ethers such as methoxymethyl (MOM), tetrahydropyranyl (THP), and benzyl (Bn).
[0079] “ Oxo Protecting Group” means a protecting group for an aldehyde or ketone. Non- limiting examples of “oxo Protecting Groups” include acetals, 1-3 -di oxalanes, mixed ketals and thioketals.
[0080] “Yield” for each of the reactions described herein is expressed as a percentage of the theoretical yield.
[0081] “Subject and “patient” are used interchangeably. A “subject” or “patient” for the purposes of the present invention includes humans and other animals, particularly mammals, and other organisms. Thus the methods are applicable to both human therapy and veterinary applications. In
a specific embodiment the patient is a mammal, and in a more specific embodiment the patient is human.
[0082] A “pharmaceutically acceptable salt” of a compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. It is understood that the pharmaceutically acceptable salts are non-toxic. Additional information on suitable pharmaceutically acceptable salts can be found in Remington ’s Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, 1985, which is incorporated herein by reference or S. M. Berge, et al., “Pharmaceutical Salts,” J. Pharm. Sci., 1977;66: 1-19 both of which are incorporated herein by reference.
[0083] Examples of pharmaceutically acceptable acid addition salts include those formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; as well as organic acids such as acetic acid, trifluoroacetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, 3-(4-hydroxybenzoyl)benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, glucoheptonic acid, 4, 4’-methylenebis-(3-hydroxy-2-ene-l -carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, p- toluenesulfonic acid, and salicylic acid and the like.
[0084] Examples of a pharmaceutically acceptable base addition salts include those formed when an acidic proton present in the parent compound is replaced by a metal ion, such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Specific salts are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins. Examples of organic bases include isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine,
glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, tromethamine, A-methylglucamine, polyamine resins, and the like. Exemplary organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine. “Platin(s),” and “platin-containing agent(s)” include, for example, cisplatin, carboplatin, and oxaliplatin.
[0085] A “therapeutic effect,” as that term is used herein, encompasses a therapeutic benefit and/or a prophylactic benefit as described above. A prophylactic effect includes delaying or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof.
[0086] “Therapeutically effective amount” is an amount of a compound of the invention, that when administered to a patient, ameliorates a symptom of the disease. The amount of a compound of the invention which constitutes a “therapeutically effective amount” will vary depending on the compound, the disease state and its severity, the age of the patient to be treated, and the like. The therapeutically effective amount can be determined routinely by one of ordinary skill in the art having regard to their knowledge and to this disclosure.
[0087] The term "co-administration," "administered in combination with," and their grammatical equivalents, as used herein, encompass administration of two or more agents to an animal, including humans, so that both agents and/or their metabolites are present in the subject at the same time. Co-administration includes simultaneous administration in separate compositions, administration at different times in separate compositions, or administration in a composition in which both agents are present.
[0088] The phrase “genetic disease”, as used herein, means a genetic disorder, genetic disease, genetic condition or genetic syndrome.
[0089] “Preventing” or “prevention” of a disease, disorder, or syndrome includes inhibiting the disease from occurring in a human, i.e. causing the clinical symptoms of the disease, disorder, or syndrome not to develop in an animal that may be exposed to or predisposed to the disease, disorder, or syndrome but does not yet experience or display symptoms of the disease, disorder, or syndrome.
[0090] “Treating” or “treatment” of a disease, disorder, or syndrome, as used herein, includes (i) inhibiting the disease, disorder, or syndrome, i.e., arresting its development; and (ii) relieving the
disease, disorder, or syndrome, i.e., causing regression of the disease, disorder, or syndrome. As is known in the art, adjustments for systemic versus localized delivery, age, body weight, general health, sex, diet, time of administration, drug interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by one of ordinary skill in the art.
[0091] As used herein, “proliferative disease” refers to a disease that occurs due to abnormal growth or extension by the multiplication of cells (Walker, Cambridge Dictionary of Biology; Cambridge University Press: Cambridge, UK, 1990). A proliferative disease may be associated with: 1) the pathological proliferation of normally quiescent cells; 2) the pathological migration of cells from their normal location (e.g., metastasis of neoplastic cells); 3) the pathological expression of proteolytic enzymes such as the matrix metalloproteinases (e.g., collagenases, gelatinases, and elastases); or 4) the pathological angiogenesis as in proliferative retinopathy and tumor metastasis. Exemplary proliferative diseases include cancers (i.e., "malignant neoplasms"), benign neoplasms, angiogenesis, inflammatory diseases, and autoimmune diseases.
[0092] As used herein, “angiogenesis” refers to the physiological process through which new blood vessels form from pre-existing vessels. Angiogenesis is distinct from vasculogenesis, which is the de novo formation of endothelial cells from mesoderm cell precursors. The first vessels in a developing embryo form through vasculogenesis, after which angiogenesis is responsible for most blood vessel growth during normal or abnormal development. Angiogenesis is a vital process in growth and development, as well as in wound healing and in the formation of granulation tissue. However, angiogenesis is also a fundamental step in the transition of tumors from a benign state to a malignant one, leading to the use of angiogenesis inhibitors in the treatment of cancer. Angiogenesis may be chemically stimulated by angiogenic proteins, such as growth factors (e.g., VEGF).
[0093] The terms “neoplasm” and “tumor” are used herein interchangeably and refer to an abnormal mass of tissue wherein the growth of the mass surpasses and is not coordinated with the growth of a normal tissue. A neoplasm or tumor may be "benign" or "malignant," depending on the following characteristics: degree of cellular differentiation (including morphology and functionality), rate of growth, local invasion, and metastasis. A "benign neoplasm" is generally well differentiated, has characteristically slower growth than a malignant neoplasm, and remains localized to the site of origin. In addition, a benign neoplasm does not have the capacity to
infiltrate, invade, or metastasize to distant sites. Exemplary benign neoplasms include, but are not limited to, lipoma, chondroma, adenomas, acrochordon, senile angiomas, seborrheic keratoses, lentigos, and sebaceous hyperplasias. In some cases, certain "benign" tumors may later give rise to malignant neoplasms, which may result from additional genetic changes in a subpopulation of the tumor's neoplastic cells, and these tumors are referred to as "pre-malignant neoplasms." An exemplary pre-malignant neoplasm is a teratoma. In contrast, a "malignant neoplasm" is generally poorly differentiated (anaplasia) and has characteristically rapid growth accompanied by progressive infiltration, invasion, and destruction of the surrounding tissue. Furthermore, a malignant neoplasm generally has the capacity to metastasize to distant sites. The term "metastasis," "metastatic," or "metastasize" refers to the spread or migration of cancerous cells from a primary or original tumor to one organ or tissue and is typically identifiable by the presence of a "secondary tumor" or "secondary cell mass" of the tissue type of the primary or original tumor and not of that of the organ or tissue in which the secondary (metastatic) tumor is located. For example, a prostate cancer that has migrated to bone is said to be metastasized prostate cancer and includes cancerous prostate cancer cells growing in bone tissue.
[0094] As used herein, the term “cancer” refers to a malignant neoplasm (Stedman's Medical Dictionary, 25th ed.; Hensyl ed.; Williams & Wilkins: Philadelphia, 1990). Exemplary cancers include, but are not limited to, acoustic neuroma; adenocarcinoma; adrenal gland cancer; anal cancer; angiosarcoma (e.g., lymphangiosarcoma, lymphangioendotheliosarcoma, hemangiosarcoma); appendix cancer; benign monoclonal gammopathy; biliary cancer (e.g., cholangiocarcinoma); bladder cancer; breast cancer (e.g., adenocarcinoma of the breast, papillary carcinoma of the breast, mammary cancer, medullary carcinoma of the breast); brain cancer (e.g., meningioma, glioblastomas, glioma (e.g., astrocytoma, oligodendroglioma), medulloblastoma); bronchus cancer; carcinoid tumor; cervical cancer (e.g., cervical adenocarcinoma); choriocarcinoma; chordoma; craniopharyngioma; colorectal cancer (e.g., colon cancer, rectal cancer, colorectal adenocarcinoma); connective tissue cancer; epithelial carcinoma; ependymoma; endotheliosarcoma (e.g., Kaposi's sarcoma, multiple idiopathic hemorrhagic sarcoma); endometrial cancer (e.g., uterine cancer, uterine sarcoma); esophageal cancer (e.g., adenocarcinoma of the esophagus, Barrett's adenocarinoma); Ewing's sarcoma; ocular cancer (e.g., intraocular melanoma, retinoblastoma); familiar hypereosinophilia; gall bladder cancer; gastric cancer (e.g., stomach adenocarcinoma); gastrointestinal stromal tumor (GIST); germ cell
cancer; head and neck cancer (e.g., head and neck squamous cell carcinoma, oral cancer (e.g., oral squamous cell carcinoma), throat cancer (e.g., laryngeal cancer, pharyngeal cancer, nasopharyngeal cancer, oropharyngeal cancer)); hematopoietic cancers (e.g., leukemia such as acute lymphocytic leukemia (ALL) (e.g., B-cell ALL, T-cell ALL), acute myelocytic leukemia (AML) (e.g., B-cell AML, T-cell AML), chronic myelocytic leukemia (CML) (e.g., B-cell CML, T-cell CML), and chronic lymphocytic leukemia (CLL) (e.g., B-cell CLL, T-cell CLL)); lymphoma such as Hodgkin lymphoma (HL) (e.g., B-cell HL, T-cell HL) and non-Hodgkin lymphoma (NHL) (e.g., B-cell NHL such as diffuse large cell lymphoma (DLCL) (e.g., diffuse large B-cell lymphoma), follicular lymphoma, chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL), marginal zone B-cell lymphomas (e.g., mucosa-associated lymphoid tissue (MALT) lymphomas, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma), primary mediastinal B-cell lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma (i.e., Waldenstrom's macroglobulinemia), hairy cell leukemia (HCL), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma and primary central nervous system (CNS) lymphoma; and T-cell NHL such as precursor T- lymphoblastic lymphoma/leukemia, peripheral T-cell lymphoma (PTCL) (e.g., cutaneous T-cell lymphoma (CTCL) (e.g., mycosis fungiodes, Sezary syndrome), angioimmunoblastic T-cell lymphoma, extranodal natural killer T-cell lymphoma, enteropathy type T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, and anaplastic large cell lymphoma); a mixture of one or more leukemia/lymphoma as described above; and multiple myeloma (MM)), heavy chain disease (e.g., alpha chain disease, gamma chain disease, mu chain disease); hemangioblastoma; hypopharynx cancer; inflammatory myofibroblastic tumors; immunocytic amyloidosis; kidney cancer (e.g., nephroblastoma a.k.a. Wilms' tumor, renal cell carcinoma); liver cancer (e.g., hepatocellular cancer (HCC), malignant hepatoma); lung cancer (e.g., bronchogenic carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), adenocarcinoma of the lung); leiomyosarcoma (LMS); mastocytosis (e.g., systemic mastocytosis); muscle cancer; myelodysplastic syndrome (MDS); mesothelioma; myeloproliferative disorder (MPD) (e.g., polycythemia vera (PV), essential thrombocytosis (ET), agnogenic myeloid metaplasia (AMM) a.k.a. myelofibrosis (MF), chronic idiopathic myelofibrosis, chronic myelocytic leukemia (CML), chronic neutrophilic leukemia (CNL), hypereosinophilic syndrome (HES)); neuroblastoma; neurofibroma (e.g., neurofibromatosis (NF) type 1 or type 2, schwannomatosis); neuroendocrine
cancer (e.g., gastroenteropancreatic neuroendoctrine tumor (GEP-NET), carcinoid tumor); osteosarcoma (e.g., bone cancer); ovarian cancer (e.g., cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma); papillary adenocarcinoma; pancreatic cancer (e.g., pancreatic andenocarcinoma, intraductal papillary mucinous neoplasm (IPMN), Islet cell tumors); penile cancer (e.g., Paget's disease of the penis and scrotum); pinealoma; primitive neuroectodermal tumor (PNT); plasma cell neoplasia; paraneoplastic syndromes; intraepithelial neoplasms; prostate cancer (e.g., prostate adenocarcinoma); rectal cancer; rhabdomyosarcoma; salivary gland cancer; skin cancer (e.g., squamous cell carcinoma (SCC), keratoacanthoma (KA), melanoma, basal cell carcinoma (BCC)); small bowel cancer (e.g., appendix cancer); soft tissue sarcoma (e.g., malignant fibrous histiocytoma (MFH), liposarcoma, malignant peripheral nerve sheath tumor (MPNST), chondrosarcoma, fibrosarcoma, myxosarcoma); sebaceous gland carcinoma; small intestine cancer; sweat gland carcinoma; synovioma; testicular cancer (e.g., seminoma, testicular embryonal carcinoma); thyroid cancer (e.g., papillary carcinoma of the thyroid, papillary thyroid carcinoma (PTC), medullary thyroid cancer); urethral cancer; vaginal cancer; and vulvar cancer (e.g., Paget's disease of the vulva).
[0095] Rare diseases caused by nonsense mutations are mutations where a stop codon (UAA, UAG or UGA) replaces an amino acid-coding codon, leading to premature termination of translation and eventually to truncated inactive proteins. The Human Gene Mutation Database reports the occurrence of thousands of disease-causing mutations, approximately 12% of which are single point (nonsense) mutations that result in a premature termination codon. (Krawczak M, et al., Hum Mutat. 2000, 15, 45-51.; Mort, et al., M. Hum. Mutat. 2008, 29, 1037-47). Nonsense mutations that result in truncated proteins have been demonstrated to account for many forms of genetic disease including cancer, hemophilia, Tay-Sachs, lysosomal storage disorders or mucopolysaccharidoses such as Hurler Syndrome, Duchenne muscular dystrophy, ataxia telangiectasia, Rett syndrome, various inherited retinopathies, and cystic fibrosis.
[0096] CFTR modulator types as used herein are drugs or compounds that target the underlying defect in the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Three types of modulators are potentiators, correctors, and amplifiers, [accessed on May 23, 2019, Cystic fibrosis F oundati on https ://www. cff org/Research/Developing-New-Treatments/CFTR-Modulator- Types/]. Potentiators, such as the drug ivacaftor (Kalydeco®), work on residual function and splice mutations where an insufficient amount of normal CFTR protein is present by holding the
gate open so chloride can flow through. Correctors help the CFTR protein with two copies of the F508del mutation to form the right 3-D shape so that it is able to move - or traffic - to the cell surface. Amplifiers increase the amount of CFTR protein that the cell makes. Many CFTR mutations produce insufficient CFTR protein. If the cell made more CFTR protein, potentiators and correctors would be able to allow even more chloride to flow across the cell membrane.
Selected Embodiments
I or a pharmaceutically acceptable salt thereof, wherein:
R.2a is selected from the group consisting of H, halo, optionally substituted C1-10 alkyl, optionally substituted C1-10 alkoxy, and optionally substituted C1-10 alkenyl, wherein C1-10 alkyl, C1-10 alkoxy, and C1-10 alkenyl are optionally substituted with one or more groups selected from the group consisting of halo, aryl, amino, alkyl, heteroalkyl, heteroalkenyl, heterocycloalkyl, and heteroaryl; and
R.2b is selected from the group consisting of halo, optionally substituted C1-10 alkyl, optionally substituted C1-10 alkoxy, and optionally substituted C1-10 alkenyl, wherein C1-10 alkyl, C1-10 alkoxy, and C1-10 alkenyl are optionally substituted with one or more groups selected from the group consisting of halo, aryl, amino, alkyl, heteroalkyl, heteroalkenyl, heterocycloalkyl, and heteroaryl;
R.4a and R4b are each independently selected from the group consisting of -H, and
optionally substituted C1-10 alkyl, wherein C1-10 alkyl, is optionally substituted with one or more groups selected from the group consisting of halo, aryl, amino, alkyl, heteroalkyl, heteroalkenyl, heterocycloalkyl, and heteroaryl;
Rs is selected from the group consisting of H, an oxygen protecting group, and
, ” indicates the point of attachment;
Rea is optionally substituted C1-10 alkyl, wherein C1-10 alkyl, is optionally substituted with one or more groups selected from the group consisting of halo, aryl, amino, alkyl, heteroalkyl, heteroalkenyl, heterocycloalkyl, and heteroaryl;
Reb is -H, optionally substituted C1-10 alkyl, optionally substituted C1-10 hydroxyalkyl, and optionally substituted allyl, wherein C1-10 alkyl, C1-10 hydroxyalkyl, and allyl are optionally substituted with one or more groups selected from the group consisting of halo, aryl, amino, alkyl, heteroalkyl, heteroalkenyl, heterocycloalkyl, and heteroaryl;
Rsa and Rsb are each independently selected from the group consisting of -H and optionally substituted C1-10 alkyl, wherein C1-10 alkyl, is optionally substituted with one or more groups selected from the group consisting of halo, aryl, amino, alkyl, heteroalkyl, heteroalkenyl, heterocycloalkyl, and heteroaryl;
R9a is selected from the group consisting of -H, -C(=N)-NH2, -C(=O)-C1-6 alkyl , -C(=O)- C1-6 alkylene-NR9a’R9a”, C1-10 alkyl and C1-10 alkenyl, wherein C1-10 alkyl and C1-10 alkenyl are optionally substituted with 1, 2, or 3 groups independently selected from the group consisting of amino, heterocycloalkyl, halo, hydroxy, alkoxy, aryl, heteroaryl, and heteroaryl ene-heteroaryl, wherein aryl, heteroaryl, and heteroaryl ene-heteroaryl, are optionally substituted with halo, alkoxy, and -NHz; wherein R.9a' and R9a” are selected from the group consisting of H, C1-6 alkyl, cycloalkyl, Ci-4 alkylene-cycloalkyl, or R9a’ and R9a” together with the atom to which there are attached from a 3-, 4-, 5-, or 6-membered ring optionally containing an additional heteroatom selected from 0, S, SO, SO2, NH, and N-C1.4 alkyl;
Rioa and Riob are taken together with the carbon atom to which they are attached to form
, wherein Q is a 3-, 4-, 5-, or 6-membered cycloalkyl or heterocyclic ring,
wherein each •nnn' ” indicates a point of attachment and Rna and Rub are each independently selected from the group consisting of H, halo, and optionally substituted C1-10 alkyl; or
Riia and Rm> are taken together with the carbon atom to which they are attached to form
, wherein Q is a 3-, 4-, 5-, or 6-membered cycloalkyl or heterocyclic ring, wherein each “ ” indicates a point of attachment and Rwa and Rwb are each independently selected from the group consisting of H, halo, and optionally substituted C1-10 alkyl;
Rq at each occurrence is independently selected from the group consisting of H, halo, - NRx’Rx”, C1-6 alkyl, C1-6 haloalkyl, OH, C1-6 alkoxy, -C(=O)-C1-6 alkyl, -C(=O)O-C1-6 alkylene- aryl, -C(=O)-C1-6 alkylene-C1-6 alkyl, -C(=O)-C1-6 alkyl ene-OC1-6 alkyl, -C(=O)-C1-6 alkylene- aryl, -C(=O)O-C1-6 alkylene-heteroaryl, -C(=O)-C1-6 alkylene-heteroaryl, -C1-6 alkylene- cycloalkyl, -C1-6 alkylene-aryl, -C1-6 alkylene-heterocycloalkyl, -C1-6 alkylene-heteroaryl, -C1-6 alkylene-C(=O)-NRx’Rx”, -C(=O)-C1-6 alkylene-cycloalkyl, -C(=O)-C1-6 alkylene- heterocycloalkyl, -C(=O)-C1-6 alkylene-NRx’Rx”, -C(=0)-CHCH20H-alkylene-NRX’Rx”, -SO2-C1.6 alkyl, -SO2-C1.6 alkylene-NRx’Rx”, -NRZC(=0)-C1-6 alkyl, -NRZC(=0)0-C1-6 alkylene-aryl, - NRZC(=0)-C1-6 alkylene-aryl, -NRZC(=0)0-C1-6 alkylene-heteroaryl, -NRZC(=0)-C1-6 alkylene- heteroaryl, -C1-6 alkylene-cycloalkyl, -C1-6 alkylene-heterocycloalkyl, -C1-6 alkylene-aryl, -C1-6 alkylene-heteroaryl, -NRX ” ”C(=O)-C1-6 alkylene-cycloalkyl, -NRX ” ”C(=O)-C1-6 alkylene- heterocycloalkyl, -NRZC(=0)-C1-6 alkylene-NRx’Rx”, -NRzC(=0)-CHCH20H-alkylene-NRx’Rx”, - NRx ” ’ SO2-C1.6 alkyl, -NRX””SO2-C1-6 alkylene-NRx’Rx”, -C(=O)-heterocycloalkyl, -C(=O)-C1-6 alkylene-heterocycloalkyl, -C1-6 alkylene-NRzC(=O)-C1-6 alkyl, -C(=O)-C1-6 alkylene- NRx””Cycloalkyl, -C(=O)-C1-6 alkylene-NRx””-C1-6 alkylene-cycloalkyl, -NRX””-C(=0)-C1-6 alkylene-heterocycloalkyl, -C(=O)-C1-6 alkylene-NRx””-C1-6 alkylene-cycloalkyl, -C(=O)-C1-6 alkylene-NRx””-C1-6 alkylene- C1-6 alkoxy, -C1-6 alkylene-NRx””-C(=O)-C1-6 alkylene-NRx’Rx”, - NRx””-C(=0)-C1-6alkylene -NRX ’ ”-C1-6 alkylene-NRx’Rx”, -C(=O)-cycloalkyl, -C(=O)-aryl, - C(=O)-heterocycloalkyl, C(=O)-heteroaryl, -C1-6 alkylene-arylene-aryl, -C(=O)-cycloalkyl, - C(=O)-heterocycloalkyl, -C(=O)-NRzaryl, -C(=0)NRZ-C1-6 alkylene-aryl, -SO2-C1.6 alkyl, -SO2- aryl, -SO2-heteroaryl, -SO2-C1.6 alkylene-NRx’Rx”, and -SO2- C1-6 alkylene-aryl; or or two Rq together with the atom to which they are attached form oxo, or an oxo protecting group, or a 3, 4, 5, or 6-membered cycloalkyl or heterocycle optionally substituted with one or more substituents selected from the group consisting of OH, halo, C1-6 alkyl, Ci/> haloalkyl, C1-6
alkylene-NEb, C1-6 alkyl ene-NH(C1-6 alkyl), C1-6 alkyl ene-N(C1-6 alkyl)2, C1-6 alkylene-NH- C(=0)-C1-6 alkyl, Ci-6 alkylene-N(Ci-6 alkyl)-C(=O)-Ci-6 alkyl, Ci-6 alkylene-NH-C(=O)-Ci-6 alkylene-NHz, C1-6 alkylene-NH-C(=0)-C1-6 alkylene-NH(C1-6 alkyl), -C(=0)-C1-6 alkyl, -C(=0)- C1-6 alkylene-N(C1-6 alkyl)2, and C1-6 alkylene-NH-C(=0)-C1-6 alkylene-N(C1-6 alkyl)z;
RX’ and Rx are each independently selected from the group consisting of H, C1-6 alkyl, cycloalkyl, C1-6 alkylene-cycloalkyl, C1-6 alkylene-heterocycloalkyl, C1-6 alkylene-aryl, C1-6 alkyl ene-heteroaryl, C1-6 alkylene-N-RzRx’” C1-6 alkylene-OH, C1-6 alkylene-O-C1-6 alkyl, cycloalkyl, heterocycloalkyl, or Rx’ and Rx” are joined together with the atom to which they are attached to form a 3-, 4-, 5-, 6-, or 7-membered ring optionally containing an additional heteroatom selected from 0, S, SO, SO2, N-Rx ”, wherein said ring is further optionally substituted with halo, OH, C1-6 alkyl, -O-C1-6 alkyl; wherein Rx’” is H, C1-6 alkyl, -C(=0)-C1-6 alkyl, -C(=0)0-C1-6 alkylene-aryl, -C(=0)-C1-6 alkylene-aryl, -C(=0)0-C1-6 alkylene-heteroaryl, -C(=0)-C1-6 alkylene-heteroaryl, -C1-6 alkylene- aryl, -C1-6 alkylene-heteroaryl, -C(=0)-C1-6 alkylene-cycloalkyl, -C(=0)-C1-6 alkylene- heterocycloalkyl; each Rx”” and Rz is independently H or C1-6 alkyl; or are joined together with the atom to which they are attached form a 3, 4, 5, or 6-membered cycloalkyl or heterocycle optionally substituted with one or more substituents selected from the group consisting of OH, halo, Ci-e alkyl, C1-6 haloalkyl, C1-6 alkylene-NH2, C1-6 alkylene-NH(C1-6 alkyl), C1-6 alkylene-N(C1-6 alkyl)2, C1-6 alkyl ene-NH-C(=0)-C i-6 alkyl, C1-6 alkylene-N(C1-6 alkyl)-C(=0)-C1-6 alkyl, C1-6 alkyl ene-NH-C(=0)-C i-6 alkylene-Mh, C1-6 alkylene-NH-C(=0)-C1-6 alkyl ene-NH(C 1.6 alkyl), - C(=0)-C1-6 alkyl, -C(=0)-C1-6 alkylene-N(C1-6 alkyl)2, and C1-6 alkylene-NH-C(=0)-C1-6 alkyl ene-N(C i-6 alkyl)2; and wherein unless otherwise specified, each occurrence of alkylene, alkyl, alkenyl, alkoxy, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl is independently and optionally substituted with halo, OH, C1-6 alkyl, alkoxy, or oxo.
[0098] In one embodiment, the compound of formula I is a compound of formula IA:
IA.
[0100] In one embodiment, the compound of formula I is a compound of formula IC:
[0102] In one embodiment, Reb is selected from the group consisting of -H, optionally substituted Ci-C io alkyl, optionally substituted Ci-Cio hydroxyalkyl, and optionally substituted allyl.
[0103] In one embodiment, Reb is selected from the group consisting of methyl, hydroxymethyl hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, -CH2CHOHCH2OH, and allyl.
[0104] In one embodiment, the compound of formula I is a compound of formula IE:
[0106] In one embodiment, the compound of formula I is a compound of formula IG:
IG.
[0107] In one embodiment, one of Rza and IGb is optionally substituted C1-10 alkyl.
[0108] In one embodiment, one of R.2a and R.2b is methyl and the other of R.2a and R.2b is H, or both of R2a and R2b are methyl.
[0109] In one embodiment, one of R2a and R2b is methyl and the other is halo.
[0110] In one embodiment, one of R2a and R2b is methyl and the other is optionally substituted Ci- io alkyl.
[0111] In one embodiment, one of R2a and R2b is methyl and the other of R2a and R2b is selected from the group consisting of optionally substituted C1-10 alkyl, optionally substituted C1-10 alkoxy, and optionally substituted C1-10 alkenyl, wherein optionally substituted C1-10 alkyl, optionally substituted C1-10 alkoxy, and optionally substituted C1-10 alkenyl are optionally substituted with one or more selected from the group consisting of halo, aryl, and heteroaryl.
[0112] In one embodiment of the compound of formula I, Rya is selected from the group consisting of -H and optionally substituted C1-10 alkyl; and
Rioa and Riob are taken together to form
wherein Q is a 3-, 4-, 5-, or 6- membered cycloalkyl or heterocyclic ring, wherein each “ ” indicates a point of attachment and Rua and Rub are each independently selected from the group consisting of H, halo, and optionally substituted C1-10 alkyl; or
Riia and Rm> are taken together to form
wherein Q is a 3-, 4-, 5-, or 6- membered cycloalkyl or heterocyclic ring, wherein each
” indicates a point of attachment and Rioa and Rwb are each independently selected from the group consisting of H, halo, and optionally substituted C1-10 alkyl
[0113] In one embodiment, Rq at each occurrence is independently selected from the group consisting of H, halo, -NRxRx”, C1-6 alkyl, C1-6 haloalkyl, OH, C1-6 alkoxy, -C(=O)-C1-6 alkyl, - C(=O)O-C1-6 alkylene-phenyl, -C1-6 alkyl ene-phenyl, -C1-6 alkylene-(5-10 membered heteroaryl), -C1-6 alkylene-C(=O)-NRX’Rx’’, -C(=O)-C1-6 alkylene-(3-6 membered heterocycloalkyl), -C(=O)- C1-6 alkylene-NRx’Rx”, -SO2-C1.6 alkyl, -SO2-C1.6 alkylene-NRx’Rx”, -NRX’ ’ C(=O)-C1-6 alkylene- (3-6 membered heterocycloalkyl), -NRZC(=O)-CI.6 alkylene-NRx’Rx”, -C(=O)-(3-6 membered heterocycloalkyl), -C1-6 alkyl ene-NRzC(=O)-C1-6 alkyl, -C1-6 alkylene-NRX””-C(=O)-C1-6 alkylene-NRx’Rx”, -NRX ” ”-C(=O)-C1-6 alkylene-NRx””-C1-6 alkylene-NRx’Rx”, -C(=O)-phenyl, - C(=O)-(5-10 membered heteroaryl), -C1-6 alkylene-biphenyl, -C(=O)-(3-6 membered cycloalkyl), -C(=O)-NRz-phenyl, -C(=O)NRZ-C1-6 alkylene-phenyl, -SO2-phenyl, -SO2-(5-10 membered heteroaryl), and -SO2-C1.6 alkylene-phenyl, wherein phenyl, biphenyl, 3-6 membered cycloalkyl; 3-6 membered heterocycloalkyl, and 5-10 membered heteroaryl are optionally substituted with wherein Rx’ and Rx” are each independently selected from the group consisting of H, C1-6 alkyl, C1-6 alkylene-(3-6 membered cycloalkyl), C1-6 alkylene-(3-6 membered heterocycloalkyl), C1-6 alkylene-O-C1-6 alkyl, 3-6 membered cycloalkyl, and 3-6 membered heterocycloalkyl; each Rx ”” and Rz is independently H or C1-6 alkyl; or two Rq together with the atom to which they are attached form oxo, or an oxo protecting group, or a 5 or 6-membered heterocycle optionally substituted with one or more substituents selected from the group consisting of OH, halo, C1-6 alkyl, -C(=O)-C1-6 alkyl, and -C(=O)-C1-6 alkyl ene-N(C i-6 alkyty; wherein each occurrence of alkylene, alkyl, phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl is independently and optionally substituted with halo, OH, C1-6 alkoxy, or C1-6 alkyl.
[0114] In one embodiment, Rq at each occurrence is independently selected from the group consisting of H, -NRxRx”, C1-6 alkyl, C1-6 haloalkyl, -C(=O)-C1-6 alkyl, -C(=O)O-C1-6 alkylene- phenyl, -C1-6 alkylene-phenyl, -C1-6 alkylene-(5-10 membered heteroaryl), -C1-6 alkylene-C(=O)-
NRx’Rx”, -C(=0)-C1-6 alkylene-(3-6 membered heterocycloalkyl), -C(=O)-C1-6 alkylene-NRx’Rx”, - SO2-C1.6 alkyl, -SO2-C1.6 alkylene-NRx’Rx”, -NRX””C(=0)-C1-6 alkylene-(3-6 membered heterocycloalkyl), -NRZC(=0)-C1-6 alkyl ene-NRx’Rx”, -C(=O)-(3-6 membered heterocycloalkyl), - C1-6 alkylene-NRzC(=O)-C1-6 alkyl, -NRx -C(=O)-Ci.r, alkylene-NRX””-C1-6 alkylene-NRx’Rx”, - C(=O)-phenyl, -C(=O)-(5-10 membered heteroaryl), -C1-6 alkyl ene-biphenyl, -C(=O)-(3-6 membered cycloalkyl), -C(=O)-NRz-phenyl, -C(=0)NRZ-C1-6 alkyl ene-phenyl, -SCb-phenyl, - SC>2-(5- 10 membered heteroaryl), and -SO2-C1.6 alkyl ene-phenyl; wherein Rx’ and Rx” are each independently selected from the group consisting of H, C1-6 alkyl, C1-6 alkylene-(3-6 membered cycloalkyl), C1-6 alkyl ene-O-C1-6 alkyl, and 3-6 membered cycloalkyl; each Rx”” and Rz is independently H or C1-6 alkyl; or two Rq together with the atom to which they are attached form oxo, or a 5 or 6- membered heterocycle optionally substituted with one or more substituents selected from the group consisting of C1-6 alkyl, -C(=O)-C1-6 alkyl, and -C(=O)-C1-6 alkylene-N(C1-6 alkyl)2; wherein each occurrence of alkylene, alkyl, phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl is independently and optionally substituted with OH, C1-6 alkoxy, or C1-6 alkyl.
[0115] In one embodiment, Rq is H.
[0116] In one embodiment, Rq is -C1-6 alkylene-aryl. In one embodiment, Rq is — C1-3 alkylene- aryl. In one embodiment, Rq is -C1.2 alkylene-aryl. In one embodiment, Rq is -CTL-aryl. In one embodiment, Rq is -C1-6 alkyl ene-heteroaryl. In one embodiment, Rq is -CHz-heteroaryl. In one embodiment, Rq is -CH2-phenyl. In one embodiment, Rq is -CH2-phenyl wherein phenyl is optionally substituted. In one embodiment, optionally substituted phenyl is alkoxyphenyl or halophenyl. In one embodiment, optionally substituted phenyl is 2-, 3-, or 4-methoxy phenyl or 2-, 3-, or 4-chlorophenyl. In one embodiment, optionally substituted phenyl is biphenyl. In one embodiment, Rq is CH2 -heteroaryl, wherein heteroaryl is optionally substituted. In one embodiment, Rq is -CH2-pyridyl, wherein pyridyl can be 2-, 3-, or 4-pyridyl. In one embodiment, Rq is -CH2-imidazolyl. In one embodiment, Rq is -CTb-quinolinyl, or -CH2-isoquinolinyl.
[0117] In one embodiment, Rq is -CTLCTb-aryl. In one embodiment, Rq is -CHzCHi-phenyl wherein phenyl is optionally substituted. In one embodiment, optionally substituted phenyl is alkoxyphenyl or halophenyl. In one embodiment, optionally substituted phenyl is 2-, 3-, or 4- methoxy phenyl or 2-, 3-, or 4-chlorophenyl. In one embodiment, Rq is -CH2CH2-heteroaryl,
wherein heteroaryl is optionally substituted. In one embodiment, Rq is -CHzCHz-pyridyl. In one embodiment, Rq is -CELCEL-imidazolyl. In one embodiment, Rq is -CHiCHi-quinolinyl, or - CHzCHz-soquinolinyl.
[0118] In one embodiment, Rq is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, or t-butyl. [0119] In one embodiment, Rq is -C(=O)-CHi-6-alkylene-aryl. In one embodiment, Rq is - C(=O)-CHi-3-alkylene-aryl. In one embodiment, Rq is -C(=O)-CHi-2-alkylene-aryl. In one embodiment, Rq is -C(=O)-CH2-aryl, wherein aryl is substituted or unsubstituted. In one embodiment, Rq is -C(=O)-CH2-phenyl. In one embodiment, Rq is -C(=O)-CH2-heteroaryl wherein aryl is substituted or unsubstituted. In one embodiment, Rq is -C(=O)-CH2-imidazolyl. [0120] In one embodiment, Rq is -C(=O)-C1-6 alkyl. In one embodiment, Rq is -C(=O)-Ci-3 alkyl. In one embodiment, Rq is -C(=O)-Ci-2 alkyl. In one embodiment, Rq is -C(=O)-CH3.
[0121] In one embodiment, Rq is -C(=O)-aryl, wherein aryl is optionally substituted. In one embodiment, Rq is -C(=O)-phenyl, wherein phenyl is alkoxypheny or chlorophenyl. In one embodiment, optionally substituted phenyl is chlorophenyl or methoxyphenyl. In one embodiment, optionally substituted phenyl is 2-, 3-, or 4-methoxy phenyl or 2-, 3-, or 4- chlorophenyl.
[0122] In one embodiment, Rq is -C(=O)-cycloalkyl, wherein cycloalkyl is substituted or unsubstituted.
[0123] In one embodiment, Rq is -C(=O)-heterocycloalkyl, wherein heterocycloalkyl is substituted or unsubstituted. In one embodiment, Rq is -C(=O)-pyrrolidinyl. In one embodiment, Rq is -C(=O)-piperidinyl.
[0124] In one embodiment, Rq is -C(=O)-N(H)C1-6 alkyl. In one embodiment, Rq is -C(=O)- N(H)CI-3 alkyl. In one embodiment, Rq is -C(=O)-N(H)CI-2 alkyl. In one embodiment, Rq is - C(=O)-N(H)methyl .
[0125] In one embodiment, Rq is -C(=O)-N(C1-6 alkyl)(C1-6 alkyl), wherein C1-6 alkyl can be the same or different at each occurrence. In one embodiment, Rq is -C(=O)-N(CI-3 alkyl)(C 1.3 alkyl), wherein C1-6 alkyl can be the same or different at each occurrence. In one embodiment, Rq is - C(=O)-N(CI-2 alkyl)(Ci-2 alkyl), wherein C1-6 alkyl can be the same or different at each occurrence.
[0126] In one embodiment, Rq is -C(=O)-N(H)-aryl or -C(=O)-N(Me)-aryl, wherein aryl is optionally substituted. In one embodiment, Rq is -C(=O)-phenyl, wherein phenyl is optionally
substituted. In one embodiment, optionally substituted phenyl is chlorophenyl or methoxyphenyl. In one embodiment, optionally substituted phenyl is 2-, 3-, or 4-methoxy phenyl or 2-, 3-, or 4- chlorophenyl.
[0127] In one embodiment, Rq is -C(=O)-heteroaryl, wherein heteroaryl is optionally substituted. In one embodiment, Rq is -C(=O)-pyridyl, wherein pyridyl is optionally substituted. In one embodiment, heteroaryl is quinolinyl or isoquinolinyl, either of which is optionally substituted. . [0128] In one embodiment, Rq is -C(=O)-C1-6 alkylene-NRx’Rx”. In one embodiment, Rq is - C(=O)-Ci-3 alkylene-NRxRx”. In one embodiment, Rq is -C(=O)-Ci-2 alkylene-NRxRx”. In one embodiment, Rq is -C(=O)-CH2-NRX’RX”. In one embodiment, Rq is -C(=O)-CH(Me)-NRx Rx-. In one embodiment, Rq is -C(=O)-C(Me)2-NRx’Rx”. In one embodiment, Rq is -C(=O)CH2-NRX RX”. In one embodiment, Rq is -C(=O)-C(Me)(CH2OH)NRx Rx” In one embodiment, Rq is - C(=O)CH2CH2-NRX’RX”. In one embodiment, NRx’Rx” is NH2, N(H)Me, NMe2, N(Me)Et, N(Me)isopropyl, NEt2, azetidinyl, azetidinyl-OH, pyrrolidinyl, piperidinyl, morpholinyl, piperizinyl, N(H)-isopropyl, N(Me)isopropyl, N(H)cyclopropyl, N(Me)cyclopropyl, N(H)cyclobutyl, N(Me)cyclobutyl, N(H)CH2cyclopropyl, N(Me)CH2cyclopropyl, N(Me)isopropyl, N(Me)-tbutyl, N(H)CH2CH2-alkoxy,
[0130] In one embodiment, Rq is -SO2-C1-6 alkyl. In one embodiment, Rq is -SO2-C1-3 alkyl. In one embodiment, Rq is -SO2-Ci-2 alkyl. In one embodiment, Rq is -SO2-Me.
[0131] In one embodiment, Rq is -SO2-C1.6 alkylene-NRx’Rx”. In one embodiment, Rq is -SO2-C1.
3 alkylene-NRxRx”. In one embodiment, R<i is -SO2-Ci-2 alkylene-NRx’Rx”. In one embodiment, Rq is -SO2-CH2NRX RX”. In one embodiment, Rq is -SO2-CH2CH2NRxRx”. In one embodiment, NRx’Rx” is NH2, N(H)Me, NMe2, N(Me)Et, NEt2, N(H)isopropyl, N(Me)isopropyl, N(H)cyclopropyl, N(Me)cyclopropyl, N(H)cyclobutyl, N(Me)cyclobutyl, N(H)CH2cyclopropyl, N(Me)isopropyl, orN(Me)t-butyl.
[0132] In one embodiment, Rq is -SO2-aryl. In one embodiment, Rq is -SO2-phenyl, wherein
phenyl is optionally substituted. In one embodiment, Rq is -SCh-chlorophenyl or -SO2- methoxyphenyl. In one embodiment, Rq is -SO2-(5-10 membered heteroaryl). In one embodiment, Rq is -SO2-pyridyl. In one embodiment, Rq is -SO2-C1.6 alkylene-phenyl. In one embodiment, Rq is -SO2-CH2-phenyl.
[0133] In one embodiment, Rq is NH-C(=O)C1-6 alkylene-NRX’Rx or N(Me)-C(=O)C1-6 alkylene- NRX’RX In one embodiment, Rq is NH-C(=O)CI-3 alkylene-NRx’Rx or N(Me)-C(=O)Ci-3 alkyl ene-NRX’Rx In one embodiment, Rq is NH-C(=O)CI-2 alkyl ene-NRX’Rx or N(Me)-C(=O)Ci-2 alkylene-NRx’Rx In one embodiment, Rq is N(Me)-C(=O)C1-6 alkylene-NRx’Rx. In one embodiment, Rq is NH-C(=O)CH2-NRX’Rx. In one embodiment, Rq is N(Me)-C(=O)CH2-NRxRx. In one embodiment, NRx’Rx” is NRx’Rx”is NH2, N(H)Me, NMe2, N(Me)Et, NEt2, N(H)isopropyl, N(Me)isopropyl, N(H)cyclopropyl, N(Me)cyclopropyl, N(H)cyclobutyl, N(Me)cyclobutyl, N(H)CH2cyclopropyl, N(Me)isopropyl, N(Me)t-butyl, or N(H)CH2CH2NMe2. In one embodiment, NRxRx”is azetidinyl, azetidinyl-OH, pyrrolidinyl, piperidinyl, morpholinyl, or piperizinyl. In one embodiment, NRX’RX” is NH-C1-6 alkylene-NRX””Rz. In one embodiment, NRx Rx” is N(H)CH2CH2-NRx ” ”Rz In one embodiment, NRx’Rx” is N(H)CH2CH2-NMe2.
[0134] In one embodiment, Rq is NH-C(=O)C1-6 alkylene-heterocycloalkyl. In one embodiment, Rq is NH-C(=O)CI-3 alkylene-heterocycloalkyl. In one embodiment, Rq is NH-C(=O)CI-2 alkylene-heterocycloalkyl. In one embodiment, Rq is NH-C(=O)CH2-heterocycloalkyl. In one embodiment, Rq is NH-C(=O)CH2-pyrrolidinyl, NH-C(=O)CH2-piperidinyl, NH-C(=O)CH2- piperizinyl, or NH-C(=O)CH2-morpholinyl.
[0135] In one embodiment, Rq is N(Me)-C(=O)C1-6 alkylene-heterocycloalkyl. In one embodiment, Rq is N(Me)-C(=O)Ci-3 alkylene-heterocycloalkyl. In one embodiment, Rq is N(Me)-C(=O)Ci-2 alkylene-heterocycloalkyl. In one embodiment, Rq is NH-C(=O)CH2- heterocycloalkyl. In one embodiment, Rq is NH-C(=O)CH2-morpholinyl.
[0136] In one embodiment, Rq is C1-6 alkylene-C(=O)-NRx’Rx. In one embodiment, Rq is C1.3 alkylene-C(=O)-NRx’Rx. In one embodiment, Rq is C1.2 alkyl ene-C(=O)-NRX’Rx. In one embodiment, Rq is CH2-C(=O)-NRX RX. In one embodiment, NRX RX’’ is NRX RX’’ is NH2, NHMe, NMe2, NMe-Et, NEt2, NH-isopropyl, NMe-isopropyl, NH-cyclopropyl, NMe-cyclopropyl, NH- cyclobutyl, NMe-cyclobutyl, NHCH2 cyclopropyl, NMe-isopropyl, or NMe-t-butyl. In one embodiment, NRxRx”is azetidinyl, azetidinyl-OH, pyrrolidinyl, piperidinyl, morpholinyl, or piperizinyl. In one embodiment, NRX’RX” is NH-C1-6 alkylene-NRX””Rz. In one embodiment,
NRx Rx” is NH-CH2CH2-NR.X ” ”Rz. In one embodiment, NRx Rx” is NH-CH2CH2-NMe2.
[0137] In one embodiment, each Rq is independently selected from the group consisting of H, - CH2CI, carboxybenzyl, acetyl, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertbutyl, benzyl,
[0138] In one embodiment, of the compound of formula I, IA, IB, IC, ID, IE, IF, and IG,
selected from the group consisting of H, -CH2CI, carboxybenzyl, acetyl, methyl, ethyl, propyl,
wherein “ ” indicates a point of attachment.
[0139] In one embodiment, of the compound of formula I, IA, IB, IC, ID, IE, IF, and IG,
group consisting of H, -CH2CI, carboxybenzyl, acetyl, methyl, ethyl, propyl, isopropyl, butyl,
[0140] In one embodiment, the compound of formula I, IA, IB, IC, ID, IE, IF, and IG is a compound of formula C-l, or a pharmaceutically acceptable salt thereof:
wherein R.2a, Rib, R-t, R5, Rsa, Reb, Rsa, Rsb, and Rq have the definitions as provided for a compound of formula I, IA, IB, IC, ID, IE, IF, IG, and IH; and
R9a is selected from the group consisting of -H and optionally substituted C1-10 alkyl;
A is
wherein Q is a 3-, 4-, 5-, or 6-membered cycloalkyl or heterocyclic ring, wherein each “ ” indicates a point of attachment and B is CR’R”, wherein
R’ and R” are each independently optionally substituted alkyl; or
B is
wherein Q is a 3-, 4-, 5-, or 6-membered cycloalkyl or heterocyclic ring, wherein each “ «~w ” indicates a point of attachment and A is CR’R”, wherein R’ and R” are each independently optionally substituted alkyl.
[0141] In one embodiment, Rqa is -H or C1.4 alkyl. In one embodiment, Rqa is -H or methyl.
[0142] In one embodiment, A is
and Q is a 3-, 4-, 5-, or 6-membered optionally substituted cycloalkyl or a 3-, 4-, 5-, or 6-membered optionally substituted heterocycloalkyl and B is CR’R”, wherein R’ and R” are H, wherein each “ ” indicates a point of attachment.
[0143] In one embodiment, B is
and Q is a 3-, 4-, 5-, or 6-membered optionally substituted cycloalkyl or is a 3-, 4-, 5-, or 6-membered optionally substituted heterocycloalkyl and A is CR’R”, wherein R’ and R” are H, wherein each ” indicates a point of attachment.
[0144] In one embodiment, either A or B is
, wherein Q is a 3-, 4-, 5-, or 6- membered cycloalkyl or 3-, 4-, 5-, or 6-membered heterocyclic ring, and the other of A and B is - CH2-, and Rq is as defined for formula I compounds.
[0145] In one embodiment, the compound of C-l, or a pharmaceutically acceptable salt thereof, is a compound of formula C-2 or C-3, or a pharmaceutically acceptable salt thereof:
[0146] In one embodiment, the compound, or a pharmaceutically acceptable salt thereof, is a compound of formula C-2a or C-3a, or a pharmaceutically acceptable salt thereof:
C-3a
[0147] In one embodiment, the compound, or a pharmaceutically acceptable salt thereof, is a compound of formula C-2b or C-3b, or a pharmaceutically acceptable salt thereof:
[0148] In one embodiment, the compound of formula C-l, C-2, C-3, C-2a, C-3a, C-2b, and C-3b, or a pharmaceutically acceptable salt thereof, is a compound of formula C-4, C-5, C-6, or C-7, C- 8, C-9, C-10, or C-l 1, or a pharmaceutically acceptable salt thereof:
[0149] In one embodiment, the compound of formula C-l, or a pharmaceutically acceptable salt thereof, is a compound of formula C-12, C-l 3, C-14, C15, C-16, C-17, C-18, or C-19, or a pharmaceutically acceptable salt thereof:
C-19 wherein Rna and Rub are as defined for R’ and R”; each Rt is independently selected from the group consisting of H, halo, -NRx Rx”, C1-6 alkyl, C1-6 haloalkyl, OH, C1-6 alkoxy, -C(=O)-C1-6 alkyl, -C(=O)O-C1-6 alkylene-aryl, -C(=O)-Ci- 6 alkylene-aryl, -C(=O)O-C1-6 alkylene-heteroaryl, -C(=O)-C1-6 alkylene-heteroaryl, -C1-6 alkylene-aryl, -C1-6 alkylene-heteroaryl, -C1-6 alkylene-C(=O)-NRx’Rx”, -C(=O)-C1-6 alkylene- cycloalkyl, -C(=O)-C1-6 alkyl ene-heterocycloalkyl, -C(=O)-C1-6 alkylene-NRX’RX”, -C(=O)- CHCH2OH-alkylene-NRX’RX”, -SO2-C1.6 alkyl, -SO2-C1.6 alkylene-NRx’Rx”, -NRZC(=O)-CI.6 alkyl, -NRZC(=0)0-C1-6 alkylene-aryl, -NRZC(=0)-C1-6 alkylene-aryl, -NRZC(=0)0-C1-6 alkylene-heteroaryl, -NRZC(=0)-C1-6 alkylene-heteroaryl, -C1-6 alkylene-aryl, -C1-6 alkylene- heteroaryl, -NRX””C(=0)-C1-6 alkylene-cycloalkyl, -NRX””C(=0)-C1-6 alkylene-heterocycloalkyl, -NRZC(=O)-CI-6 alkylene-NRx’Rx”, -NRzC(=O)-CHCH2OH-alkylene-NRx Rx”, -NRX””SO2-C1-6 alkyl, -NRX””SO2-C1-6 alkylene-NRx’Rx”, -C(=O)-heterocycloalkyl, -C(=O)-C1-6 alkylene- heterocycloalkyl, -C1-6 alkyl ene-NRzC(=O)-C 1-6 alkyl, -C(=O)-C1-6 alkylene-NRx””cycloalkyl, - C(=O)-C1-6 alkylene-NRX””-C1-6 alkylene-cycloalkyl, -NRX””-C(=0)-C1-6 alkylene- heterocycloalkyl, -C(=O)-C1-6 alkylene-NRx” ”-C1-6 alkylene-cycloalkyl, -C(=O)-C1-6 alkylene- NRX””-C1-6 alkylene- C1-6 alkoxy, -C1-6 alkylene-NRX” ”-C(=O)-C1-6 alkylene-NRx’Rx”, -NRX ” ”- C(=O)-C1-6 alkylene -NRX””-C1-6 alkylene-NRx’Rx”, -C(=O)-aryl, -C(=O)-heteroaryl, -C1-6 alkylene-arylene-aryl, -C(=O)-cycloalkyl, -C(=O)-NRzaryl, -C(=0)NRz-Ci.6 alkylene-aryl, -SO2- aryl, -SO2-heteroaryl, and -SO2- C1-6 alkylene-aryl; wherein Rx> and Rx” are each independently selected from the group consisting of H, C1-6 alkyl, C1-6 alkylene-cycloalkyl, C1-6 alkylene-heterocycloalkyl, C1-6 alkyl ene-O-C1-6 alkyl,
cycloalkyl, heterocycloalkyl, or Rx’ and Rx” are joined together with the atom to which they are attached to form a 3-, 4-, 5-, 6-, or 7-membered optionally substituted ring optionally containing an additional heteroatom selected from 0, S, SO, SO2, N-Rx ”, wherein Rx ” is H, C1-6 alkyl, - C(=0)-C1-6 alkyl, -C(=0)0-C1-6 alkylene-aryl, -C(=O)-Ci-t> alkylene-aryl, -C(=O)O-Ci.t, alkylene- heteroaryl, -C(=0)-C1-6 alkylene-heteroaryl, -C1-6 alkylene-aryl, -C1-6 alkylene-heteroaryl, - C(=0)-C1-6 alkylene-cycloalkyl, -C(=0)-C1-6 alkylene-heterocycloalkyl; and each RX”” and Rz is independently H or C1-6 alkyl, wherein each occurrence of alkylene, alkyl, phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl is independently and optionally substituted with halo, OH, C1-6 alkoxy, or C1-6 alkyl.
[0150] In one embodiment, Rt is H.
[0151] In one embodiment, Rtis -C1-6 alkylene-aryl. In one embodiment, Rtis -C1.3 alkylene- aryl. In one embodiment, Rt is -C1-2 alkylene-aryl. In one embodiment, Rt is -Cfb-aryl. In one embodiment, Rt is -C1-6 alkylene-heteroaryl. In one embodiment, Rt is -CH2-heteroaryl. In one embodiment, Rt is -CTL-phenyl. In one embodiment, Rt is -CH2-phenyl wherein phenyl is optionally substituted, hi one embodiment, optionally substituted phenyl is alkoxyphenyl or halophenyl. In one embodiment, optionally substituted phenyl is 2-, 3-, or 4-methoxy phenyl or 2-, 3-, or 4-chlorophenyl. In one embodiment, optionally substituted phenyl is biphenyl. In one embodiment, Rt is CH2-heteroaryl, wherein heteroaryl is optionally substituted. In one embodiment, Rt is -CH2-pyridyl, wherein pyridyl can be 2-, 3-, or 4-pyridyl. In one embodiment, Rt is -CH2-imidazolyl. In one embodiment, Rt is -CTL-quinolinyl, or -CH2-isoquinolinyl.
[0152] In one embodiment, Rt is -CfbCHz-aryl. In one embodiment, Rt is -CfbCHt-phenyl wherein phenyl is optionally substituted. In one embodiment, optionally substituted phenyl is alkoxyphenyl or halophenyl. In one embodiment, optionally substituted phenyl is 2-, 3-, or 4- methoxy phenyl or 2-, 3-, or 4-chlorophenyl. In one embodiment, Rt is -CHiCHi-heteroaryl, wherein heteroaryl is optionally substituted. In one embodiment, Rt is -CfbCfb-pyridyl. In one embodiment, Rt is -CTbCTh-imidazolyl. In one embodiment, Rt is -CHzCfh-quinolinyl, or - CHzCTH-soquinolinyl.
[0153] In one embodiment, Rt is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, or t-butyl. [0154] In one embodiment, Rt is -C(=O)-CH2-aryl, wherein aryl is substituted or unsubstituted. In one embodiment, Rt is -C(=O)-CH2-phenyl. In one embodiment, Rt is -C(=O)-CH2-heteroaryl
wherein aryl is substituted or unsubstituted. In one embodiment, Rt is -C(=O)-CH2-imidazolyl.
[0155] In one embodiment, Rt is -C(=O)-C1-6 alkyl. In one embodiment, Rt is -C(=O)-C1-6 methyl.
[0156] In one embodiment, Rt is -C(=O)-aryl, wherein aryl is optionally substituted. In one embodiment, Rt is -C(=O)-phenyl, wherein phenyl is alkoxypheny or chlorophenyl. In one embodiment, optionally substituted phenyl is chlorophenyl or methoxyphenyl. In one embodiment, optionally substituted phenyl is 2-, 3-, or 4-methoxy phenyl or 2-, 3-, or 4- chlorophenyl.
[0157] In one embodiment, Rt is -C(=O)-cycloalkyl, wherein cycloalkyl is substituted or unsubstituted.
[0158] In one embodiment, Rt is -C(=O)-heterocycloalkyl, wherein heterocycloalkyl is substituted or unsubstituted. In one embodiment, Rt is -C(=O)-pyrrolidinyl. In one embodiment, Rt is -C(=O)-piperidinyl.
[0159] In one embodiment, Rt is -C(=O)-N(H)C1-6 alkyl. In one embodiment, Rt is -C(=O)- N(H)CI-3 alkyl. In one embodiment, Rt is -C(=O)-N(H)CI-2 alkyl. In one embodiment, Rt is - C(=O)-NHCH3.
[0160] In one embodiment, Rt is -C(=O)-N(C1-6 alkyl)(C1-6 alkyl), wherein C1-6 alkyl at each occurrence can be the same or different. In one embodiment, Rt is -C(=O)-N(Me)Ci-3 alkyl. [0161] In one embodiment, Rt is -C(=O)-N(H)-aryl or -C(=O)-N(Me)-aryl, wherein aryl is optionally substituted. In one embodiment, Rt is -C(=O)-phenyl, wherein phenyl is optionally substituted. In one embodiment, optionally substituted phenyl is chlorophenyl or methoxyphenyl. In one embodiment, optionally substituted phenyl is 2-, 3-, or 4-methoxy phenyl or 2-, 3-, or 4- chlorophenyl.
[0162] In one embodiment, Rt is -C(=O)-heteroaryl, wherein heteroaryl is optionally substituted. In one embodiment, Rt is -C(=O)-pyridyl, wherein pyridyl is optionally substituted. In one embodiment, heteroaryl is quinolinyl or isoquinolinyl, either of which is optionally substituted. . [0163] In one embodiment, Rt is -C(=O)-C1-6 alkylene-NRx’Rx”. In one embodiment, Rt is - C(=O)-Ci-3 alkylene-NRx’Rx”. In one embodiment, Rt is -C(=O)-Ci-2 alkylene-NRx’Rx”. In one embodiment, Rt is -C(=O)-CH2-NRx Rx”. In one embodiment, Rt is -C(=O)-CH(Me)-NRX’Rx’. In one embodiment, Rt is -C(=O)-C(Me)2-NRx’Rx’’ In one embodiment, Rt is -C(=O)CH2-NRx Rx”. In one embodiment, Rt is -C(=O)-C(Me)(CH2OH)NRx Rx’. In one embodiment, Rt is -
C(=O)CH2CH2-NRX’RX”. In one embodiment, NRX RX” is NH2, N(H)Me, NMe2, N(Me)Et, N(Me)isopropyl, NEt2, azetidinyl, azetidinyl-OH, pyrrolidinyl, piperidinyl, morpholinyl, piperizinyl, N(H)-isopropyl, N(Me)isopropyl, N(H)cyclopropyl, N(Me)cyclopropyl, N(H)cyclobutyl, N(Me)cyclobutyl, N(H)CH2cyclopropyl, N(Me)CH2cyclopropyl, N(Me)isopropyl, N(Me)-tbutyl, N(H)CH2CH2-alkoxy,
[0164] In one embodiment, Rt is -SO2-C1-6 alkyl. In one embodiment, Rt is -SO2-Ci-3 alkyl. In one embodiment, Rt is -SO2-Ci-2 alkyl. In one embodiment, Rt is -SO2-Me.
[0165] In one embodiment, Rt is -SO2-C1-6 alkylene-NRx’Rx”. In one embodiment, Rt is -SO2-Ci-3 alkyl ene-NRx’Rx”. In one embodiment, Rt is -SO2-Ci-2 alkyl ene-NRxRx”. In one embodiment, Rt is -SO2-CH2NRx’Rx”. In one embodiment, Rt is -SO2-CH2CH2NRxRx”. In one embodiment, NRx’Rx” is NH2, N(H)Me, NMe2, N(Me)Et, NEt2, N(H)isopropyl, N(Me)isopropyl, N(H)cyclopropyl, N(Me)cyclopropyl, N(H)cyclobutyl, N(Me)cyclobutyl, N(H)CH2cyclopropyl, N(Me)isopropyl, orN(Me)t-butyl.
[0166] In one embodiment, Rt is -SO2-aryl. In one embodiment, Rt is -SO2-phenyl, wherein phenyl is optionally substituted. In one embodiment, Rt is -SO2-chlorophenyl or -SO2- methoxyphenyl. In one embodiment, Rt is -SO2-(5-10 membered heteroaryl). In one embodiment, Rt is -SO2-pyridyl. In one embodiment, Rt is -SO2-C1-6 alkyl ene-phenyl. In one embodiment, Rt is -SO2-CH2-phenyl.
[0167] In one embodiment, Rt is Ci-e alkylene-C(=O)-NRX’Rx. In one embodiment, Rt is C1.3 alkylene-C(=O)-NRx Rx. In one embodiment, Rt is Ci-2 alkylene-C(=O)-NRx’Rx. In one embodiment, Rt is CH2-C(=O)-NRx Rx. In one embodiment, NRxRx” is NRx’Rx” is NH2, NHMe, NMe2, NMe-Et, NEt2, NH-isopropyl, NMe-isopropyl, NH-cyclopropyl, NMe-cyclopropyl, NH- cyclobutyl, NMe-cyclobutyl, NHCH2 cyclopropyl, NMe-isopropyl, or NMe-t-butyl. In one embodiment, NRxRx”is azetidinyl, azetidinyl-OH, pyrrolidinyl, piperidinyl, morpholinyl, or piperizinyl. In one embodiment, NRx’Rx” is NH-C1-6 alkylene-NRx””Rz. In one embodiment, NRx Rx” is NH-CH2CH2-NRX ” ”RZ. In one embodiment, NRx Rx” is NH-CH2CH2-NMe2.
[0168] In one embodiment, Rt is selected from the group consisting of H, carboxybenzyl, acetyl,
[0169] In one embodiment, the compound of the invention or a pharmaceutically acceptable salt thereof is selected from Table A.
[0170] In one embodiment, the compound of the invention or a pharmaceutically acceptable salt thereof is selected from Table B.
[0171] In one aspect, the invention includes a pharmaceutical composition comprising a compound described herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
[0172] In one aspect, the invention includes a kit comprising a compound described herein, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, and instructions for administering to a subject in need thereof.
[0173] In one embodiment, the compound is selected from Table A, or a pharmaceutically acceptable salt thereof.
Processes for Preparing Compounds
[0174] Compounds disclosed herein can be prepared as described in the following paragraphs.
[0175] Compounds are prepared via two intermediates. The eastern half intermediate is a compound of formula P-1:
P l, or salt thereof. In the compound of formula P-1, R3, R4a, R4b, R5, R6a, R6b, R8a, and R8b are as defined herein; and
G4 is of the formula:
each instance of R15 is independently silyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R15 groups are joined to form an optionally substituted heterocyclyl or heteroaryl ring; and each instance of R16a is independently hydrogen, optionally substituted alkyl, optionally
substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
[0176] The uncyclized eastern half intermediate is a compound of formula P-2:
or salt thereof, wherein:
PG is a protecting group;
R.4a, Rrb, Rs, Rsa, Reb, Rsa, and Rsb are as defined herein;
G4 is of formula:
each instance of R15 is independently silyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R15 groups are joined to form an optionally substituted heterocyclyl or heteroaryl ring; and each instance of R16a is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
[0177] In some embodiments, -OPG is -OBz.
[0178] What is also disclosed is a compound of Formula P-3:
Coupling and Macrolactonization
[0179] In certain embodiments, compounds of the present disclosure are prepared by coupling a compound of Formula Pl (the eastern half) wherein Rs is a sugar residue
, wherein PG is a protecting group and “■<««” indicates a point of attachment, and a compound of Formula P-4 (the western half) to provide an uncyclized compound precursor of Formula P-5 as depicted in the following Scheme.
[0180] Formula P-5 is cyclized to give, after deprotection of the sugar residue a compound of Formula I as depicted in the following scheme.
[0181] Alternatively, the compound precursor of Formula P-5 wherein Rga is hydrogen is cyclized to provide a compound of Formula I, which can undergo reductive amination to provide a compound of Formula I wherein R.9a is other than H, as shown in the following Scheme.
[0182] Late-stage installment of the R.2b group can be achieved via treatment of a compound of Formula P-6 prepared as provide above with a base and a suitable electrophile group (e.g., halogenating agent or R2-LG, wherein LG is a leaving group) as depicted in the following Scheme. In this process, the sugar residue in P-6 is protected and Rga is H or alkyl.
OR5 = H
[0183] For all intermediates, the variables are as defined herein for a compound of Formula I.
[0184] Other variables depicted for intermediates and precursors are defined as follows: LG is a leaving group;
, ” indicates a point of attachment; each instance of R15 is independently silyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R15 groups are joined to form an optionally substituted heterocyclyl or heteroaryl ring; and
each instance of R16a is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
[0185] As noted above, Rs is the sugar moiety
. The sugar moiety is typically attached to the compound framework during synthesis of the eastern half, but may also be attached at other stages of the preparation. The sugar moiety may be attached by a chemical or enzymatic glycosylation reaction between the hydroxyl group at the C5 position and a glycosyl donor. In certain embodiments, the sugar moiety is attached to the compound framework as a thioglycoside. In certain embodiments, substituents of the sugar moiety are modified after the glycosylation of the compound or compound precursor (c.g., eastern half).
Methods
[0186] In one aspect, what is provided herein is a method for inhibiting protein translation in a cell, comprising treating the cell with a therapeutically effective amount of a compound of Formula I. In one embodiment, the cell is a cancer cell.
[0187] In one aspect, what is provided herein is a method for treating a disease caused by abnormal protein translation in a patient in need of such treatment, comprising treating the patient with a therapeutically effective amount of a compound of Formula I. In these and other aspects and embodiments, the patient is a human or animal. In one embodiment, the disease is cancer. In one embodiment, the cancer is selected from the cancers provided herein.
[0188] In one embodiment, the disease is caused by a premature codon termination. In one embodiment, the disease caused by a premature codon termination is selected from the diseases disclosed herein.
[0189] In one aspect, what is provided herein is a method for inhibiting protein translation in a patient who has cancer, comprising treating the patient with a therapeutically effective amount of a compound of Formula I.
[0190] In one aspect, what is provided herein is a method for treating cancer, comprising administering to a subject in need of such treatment a therapeutically effective amount of a
compound of Formula I.
[0191] In one aspect, what is provided herein is a method for treating a genetic disorder, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of Formula I. What is also provided is a method of treating a genetic disorder characterized by a premature termination codon mutation, comprising administering to a subject in need thereof a therapeutically effective amount of to a subject in need of such treatment a therapeutically effective amount of a compound of Formula I.
[0192] A genetic disorder characterized by a premature termination codon mutation can be treated by inducing and/or promoting readthrough of the mutation in the complete but otherwise defective transcript (mRNA). That is, a genetic disorder characterized by a premature termination codon mutation can be treated by inducing and/or promoting suppression of the nonsense mutation (the premature termination codon mutation). Thus, as disclosed herein, a genetic disorder that can be treated according to the method disclosed and claimed herein is one that is responds to readthrough-inducing and/or promoting compounds.
[0193] Methods for identifying genetic disorders characterized by a premature termination codon mutation are available to the skilled practitioner, and may involve full or partial genome elucidation, genetic biomarker detection, phenotype classification and hereditary information analysis. These methods often result in pairs of mutant/wild type (WT) sequences. Pairs of WT sequences can be employed to identify whether the genetic disease is characterized by a premature termination codon mutation. Similarly, the ability to determine the ability of a compound or composition to induce or promote readthrough can also is also known in the art. [0194] To that end, a plasmid comprising two reporter genes interrupted by a sequence of the mutated gene (the genetic disease-causing gene) is transected into a protein expression platform, either in full cells or in a cell-free systems, and the ratio between the expression level of the two genes in the presence of a tested compound is measured, typically in series of concentrations and duplications, and compared to the gene expression level ratio of the wild-type and/or to the expression level ratio measured in a control sample not containing the tested compound.
[0195] It is noted that the experimental model for readthrough activity (namely the nucleotide sequence of gene containing the premature stop-codon mutation) is a byproduct of the process of identifying a genetic disorder as associated with a premature stop-codon mutation and/or a protein truncation phenotype, and further noted that with the great advances in genomic data acquisition,
this process is now well within the capability of the skilled practitioner.
[0196] Methodologies for testing readthrough of a premature termination codon mutation are known. Experimental methods are provided herein that are designed to gauge the ability of compounds to induce or promote read through.
[0197] A number of in vitro methodologies can be used by the skilled practitioner to test the readthrough-inducing ability of compounds provided herein, as well as their safety as potential drugs.
[0198] Non-limiting examples of genetic diseases that are associated with the presence of at least one premature termination codon mutation or other nonsense mutations include cystic fibrosis (CF), muscular dystrophy (Duchenne (DMD), Becker (BMD), congenital), spinal muscular atrophy (SMA), ataxia-telangiectasia, mucopolysaccharidosis type 1 (MPS1) (Hurler syndrome), hemophilia (A & B), Usher syndrome (Retinitis pigmentosa, X-linked retinitis pigmentosa), Tay- Sachs, factor VII deficiency, familial atrial fibrillation, Hailey-Hailey disease, McArdle disease, mucopolysaccharidosis, nephropathic cystinosis, polycystic kidney disease, Rett syndrome, cystinosis, severe epidermolysis bullosa, dravet syndrome, X-linked nephrogenic diabetes insipidus (XNDI), dancer, beta-thalassemia, and obesity.
[0199] Additional genetic diseases that associated with the presence of at least one premature termination codon or other nonsense mutations are disclosed in, for example, “Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases,” Kim M. Keeling, K. M Bedwell, D.M., Wiley Interdisciplinary Reviews: RNA, 2011, 2(6), p. 837-852; “Cancer syndromes and therapy by stop-codon readthrough,” Bordeira-Carrico, R. et al., Trends in Molecular Medicine, 2012, 18(11), p. 667-678, and references cited therein.
[0200] In one aspect what is provided is a compound or composition as disclosed herein for use in the treatment of a genetic disease associated with a premature termination codon mutation.
[0201] In one aspect, embodiment, what is provided is a use of a compound or composition as disclosed herein in in the manufacture of a medicament for treating a genetic disease associated with a premature termination codon mutation. The genetic disease in this and other aspects and embodiments is selected from the group consisting of cystic fibrosis (CF), muscular dystrophy (Duchenne (DMD), Becker (BMD), congenital), spinal muscular atrophy (SMA), hemophilia (A & B), Usher syndrome (Retinitis pigmentosa, X-linked retinitis pigmentosa), mucopolysaccharidosis, nephropathic cystinosis, Rett syndrome, cancer, Beta-thalassemia, and
obesity.
[0202] In one aspect, what is provided is a method of increasing the expression level of a gene having a premature termination codon mutation, the method comprising translating the gene into a protein in the presence of a compound or composition as disclosed herein in any of the respective embodiments and any combination thereof. In one embodiment what is provided is a compound or composition as disclosed herein for use in increasing the expression level of a gene having a premature termination codon mutation. In a further embodiment, what is a provided is the use of a compound or composition as disclosed in the manufacture of a medicament for increasing the expression level of a gene having a premature stop-codon mutation. According to these and other aspects and embodiments, the premature termination codon mutation has an RNA code selected from the group consisting of UGA, UAG and UAA. According to these and other aspects and embodiments, the protein is translated in a cytoplasmic translation system. According to these and other aspects and embodiments, the compound or composition disclosed herein is used in a mutation suppression amount. According to these and other aspects and embodiments, an inhibition of translation IC50 of the compound or composition in a eukaryotic cytoplasmic translation system is greater that an inhibition of translation IC50 of the compound in a ribosomal translation system. According to these and other aspects and embodiments, an inhibition of translation IC50 of the compound in a eukaryotic cytoplasmic translation system is greater that an inhibition of translation IC50 of the compound in a prokaryotic translation system.
Pharmaceutical Compositions and Administration
[0203] The present invention provides pharmaceutical compositions comprising a compound of the present invention and a pharmaceutically acceptable excipient. In certain embodiments, the compound of the present invention is provided in an effective amount in the pharmaceutical composition. In certain embodiments, the effective amount is a therapeutically effective amount. In certain embodiments, the effective amount is a prophylactically effective amount.
[0204] Pharmaceutically acceptable excipients include any and all solvents, diluents, or other liquid vehicles, dispersions, suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. General considerations in formulation and/or manufacture of pharmaceutical compositions agents can be found, for example, in Remington's Pharmaceutical Sciences,
Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980), and Remington: The Science and Practice of Pharmacy, 21st Edition (Lippincott Williams & Wilkins, 2005).
[0205] Pharmaceutical compositions described herein can be prepared by any method known in the art of pharmacology. In general, such preparatory methods include the steps of bringing the compound of the present invention (the “active ingredient”) into association with a carrier and/or one or more other accessory ingredients, and then, if necessary and/or desirable, shaping and/or packaging the product into a desired single- or multi-dose unit.
[0206] Pharmaceutical compositions can be prepared, packaged, and/or sold in bulk, as a single unit dose, and/or as a plurality of single unit doses. As used herein, a “unit dose” is discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient. The amount of the active ingredient is generally equal to the dosage of the active ingredient which would be administered to a subject and/or a convenient fraction of such a dosage such as, for example, one-half or one-third of such a dosage.
[0207] Relative amounts of the active ingredient, the pharmaceutically acceptable excipient, and/or any additional ingredients in a pharmaceutical composition of the invention will vary, depending upon the identity, size, and/or condition of the subject treated and further depending upon the route by which the composition is to be administered. By way of example, the composition may comprise between 0.1% and 100% (w/w) active ingredient.
[0208] Pharmaceutically acceptable excipients used in the manufacture of provided pharmaceutical compositions include inert diluents, dispersing and/or granulating agents, surface active agents and/or emulsifiers, disintegrating agents, binding agents, preservatives, buffering agents, lubricating agents, and/or oils. Excipients such as cocoa butter and suppository waxes, coloring agents, coating agents, sweetening, flavoring, and perfuming agents may also be present in the composition.
[0209] Exemplary diluents include calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, cornstarch, powdered sugar, and mixtures thereof.
[0210] Exemplary granulating and/or dispersing agents include potato starch, corn starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose and wood products, natural sponge, cation-exchange resins, calcium carbonate, silicates,
sodium carbonate, cross-linked poly(vinyl-pyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate (Veegum), sodium lauryl sulfate, quaternary ammonium compounds, and mixtures thereof.
[0211] Exemplary surface active agents and/or emulsifiers include natural emulsifiers (e.g. acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin), colloidal clays (e.g. bentonite [aluminum silicate] and Veegum [magnesium aluminum silicate]), long chain amino acid derivatives, high molecular weight alcohols (e.g. stearyl alcohol, cethyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g. carboxy polymethylene, polyacrylic acid, acrylic acid polymer, and carboxyvinyl polymer), carrageenan, cellulosic derivatives (e.g. carboxymethylcellulose sodium, powdered cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methyl cellulose), sorbitan fatty acid esters (e.g. polyoxyethylene sorbitan monolaurate [Tween 20], polyoxyethylene sorbitan [Tween 60], polyoxyethylene sorbitan monooleate [Tween 80], sorbitan monopalmitate [Span 40], sorbitan monostearate [Span 60], sorbitan tristearate [Span 65], glyceryl monooleate, sorbitan monooleate [Span 80]), polyoxyethylene esters (e.g. polyoxyethylene monostearate [Myij 45], polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate, and Solutol), sucrose fatty acid esters, polyethylene glycol fatty acid esters (e.g. Cremophor), polyoxyethylene ethers, (e.g. polyoxyethylene lauryl ether [Brij 30]), poly(vinyl-pyrrolidone), diethylene glycol monolaurate, triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, Pluronic F 68, Pol oxamer 188, cetrimonium bromide, cethylpyridinium chloride, benzalkonium chloride, docusate sodium, and/or mixtures thereof.
[0212] Exemplary binding agents include starch (e.g. cornstarch and starch paste), gelatin, sugars (e.g. sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol, etc.), natural and synthetic gums (e.g. acacia, sodium alginate, extract of Irish moss, panwar gum, ghatti gum, mucilage of isapol husks, carboxymethylcellulose, methylcellulose, ethyl cellulose, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, microcrystalline
cellulose, cellulose acetate, poly(vinyl-pyrrolidone), magnesium aluminum silicate (Veegum), and larch arabogalactan), alginates, polyethylene oxide, polyethylene glycol, inorganic calcium salts, silicic acid, polymethacrylates, waxes, water, alcohol, and/or mixtures thereof.
[0213] Exemplary preservatives include antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, alcohol preservatives, acidic preservatives, and other preservatives.
[0214] Exemplary antioxidants include alpha tocopherol, ascorbic acid, acorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, and sodium sulfite.
[0215] Exemplary chelating agents include ethylenediaminetetraacetic acid (EDTA) and salts and hydrates thereof (e.g., sodium edetate, disodium edetate, trisodium edetate, calcium disodium edetate, dipotassium edetate, and the like), citric acid and salts and hydrates thereof (e.g., citric acid monohydrate), fumaric acid and salts and hydrates thereof: malic acid and salts and hydrates thereof: phosphoric acid and salts and hydrates thereof: and tartaric acid and salts and hydrates thereof. Exemplary antimicrobial preservatives include benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cethylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and thimerosal.
[0216] Exemplary antifungal preservatives include butyl paraben, methyl paraben, ethyl paraben, propyl paraben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and sorbic acid.
[0217] Exemplary alcohol preservatives include ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate, and phenylethyl alcohol.
[0218] Exemplary acidic preservatives include vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid, and phytic acid.
[0219] Other preservatives include tocopherol, tocopherol acetate, deteroxime mesylate, cetrimide, butylated hydroxyanisol (BHA), butylated hydroxytoluened (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, Glydant Plus, Phenonip, methylparaben,
Germall 115, Germaben II, NeoIone, Kathon, and Euxyl. In certain embodiments, the preservative is an anti-oxidant. In other embodiments, the preservative is a chelating agent.
[0220] Exemplary buffering agents include citrate buffer solutions, acetate buffer solutions, phosphate buffer solutions, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glubionate, calcium gluceptate, calcium gluconate, D-gluconic acid, calcium glycerophosphate, calcium lactate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixtures, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, dibasic sodium phosphate, monobasic sodium phosphate, sodium phosphate mixtures, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol, and mixtures thereof.
[0221] Exemplary lubricating agents include magnesium stearate, calcium stearate, stearic acid, silica, talc, malt, glyceryl behanate, hydrogenated vegetable oils, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium lauryl sulfate, and mixtures thereof.
[0222] Exemplary natural oils include almond, apricot kernel, avocado, babassu, bergamot, black current seed, borage, cade, camomile, canola, caraway, carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee, com, cotton seed, emu, eucalyptus, evening primrose, fish, flaxseed, geraniol, gourd, grape seed, hazel nut, hyssop, isopropyl myristate, jojoba, kukui nut, lavandin, lavender, lemon, litsea cubeba, macademia nut, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange, orange roughy, palm, palm kernel, peach kernel, peanut, poppy seed, pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood, sasquana, savoury, sea buckthorn, sesame, shea butter, silicone, soybean, sunflower, tea tree, thistle, tsubaki, vetiver, walnut, and wheat germ oils. Exemplary synthetic oils include, but are not limited to, butyl stearate, caprylic triglyceride, capric triglyceride, cyclomethicone, diethyl sebacate, dimethicone 360, isopropyl myristate, mineral oil, octyl dodecanol, oleyl alcohol, silicone oil, and mixtures thereof.
[0223] Liquid dosage forms for oral and parenteral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to
the active ingredients, the liquid dosage forms may comprise inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (e.g., cottonseed, groundnut, com, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents. In certain embodiments for parenteral administration, the conjugates of the invention are mixed with solubilizing agents such as Cremophor, alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins, polymers, and mixtures thereof.
[0224] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions can be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation can be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3 -butanediol. Among the acceptable vehicles and solvents that can be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables. The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
[0225] A sterile injectable composition, e.g., a sterile injectable aqueous or oleaginous suspension, can be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as Tween 80) and suspending agents. The sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3 -butanediol. Among the acceptable vehicles and solvents that can be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium (e.g., synthetic mono- or di glycerides). Fatty acids, such as oleic acid and its
glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically- acceptable oils, such as olive oil or castor oil, especially in their polyoxy ethylated versions. These oil solutions or suspensions can also contain a long-chain alcohol diluent or dispersant, or carboxymethyl cellulose or similar dispersing agents. Other commonly used surfactants such as Tweens or Spans or other similar emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms can also be used for the purposes of formulation.
[0226] In order to prolong the effect of a drug, it is often desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This can be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
[0227] Compositions for rectal or vaginal administration are typically suppositories which can be prepared by mixing the conjugates of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active ingredient.
[0228] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active ingredient is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cethyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may comprise buffering agents.
[0229] Solid compositions of a similar type can be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally comprise opacifying agents and can be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. Solid compositions of a similar type can be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
[0230] Pharmaceutical compositions, which can be used orally, include push-fit capsules made of gelatin as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules may contain the active ingredients in admixture with filler such as lactose, binders such as starches, lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the compounds presented herein may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for the chosen route of administration.
[0231] Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active aminoglycoside compounds doses.
[0232] The active ingredient can be in micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active ingredient can be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may comprise, as is normal practice, additional substances other than inert diluents,
e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may comprise buffering agents. They may optionally comprise opacifying agents and can be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner Examples of embedding compositions which can be used include polymeric substances and waxes.
[0233] Dosage forms for topical and/or transdermal administration of a compound of this invention may include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants and/or patches. Generally, the active ingredient is admixed under sterile conditions with a pharmaceutically acceptable carrier and/or any needed preservatives and/or buffers as can be required. Additionally, the present invention contemplates the use of transdermal patches, which often have the added advantage of providing controlled delivery of an active ingredient to the body. Such dosage forms can be prepared, for example, by dissolving and/or dispensing the active ingredient in the proper medium. Alternatively, or additionally, the rate can be controlled by either providing a rate controlling membrane and/or by dispersing the active ingredient in a polymer matrix and/or gel.
[0234] Suitable devices for use in delivering intradermal pharmaceutical compositions described herein include short needle devices such as those described in U.S. Pat. Nos. 4,886,499;
5,190,521; 5,328,483; 5,527,288; 4,270,537; 5,015,235; 5,141,496; and 5,417,662. Intradermal compositions can be administered by devices which limit the effective penetration length of a needle into the skin, such as those described in PCT publication WO 99/34850 and functional equivalents thereof. Jet injection devices which deliver liquid vaccines to the dermis via a liquid jet injector and/or via a needle which pierces the stratum comeum and produces a jet which reaches the dermis are suitable. Jet injection devices are described, for example, in U.S. Pat. Nos. 5,480,381; 5,599,302; 5,334,144; 5,993,412; 5,649,912; 5,569,189; 5,704,911; 5,383,851;
5,893,397; 5,466,220; 5,339,163; 5,312,335; 5,503,627; 5,064,413; 5,520,639; 4,596,556; 4,790,824; 4,941,880; 4,940,460; and PCT publications WO 97/37705 and WO 97/13537. Ballistic powder/particle delivery devices which use compressed gas to accelerate vaccine in powder form through the outer layers of the skin to the dermis are suitable. Alternatively, or additionally, conventional syringes can be used in the classical mantoux method of intradermal administration.
[0235] A pharmaceutical composition of the invention can be prepared, packaged, and/or sold in a formulation suitable for pulmonary administration via the buccal cavity. Such a formulation may comprise dry particles which comprise the active ingredient and which have a diameter in the range from about 0.5 to about 7 nanometers or from about 1 to about 6 nanometers. Such compositions are conveniently in the form of dry powders for administration using a device comprising a dry powder reservoir to which a stream of propellant can be directed to disperse the powder and/or using a self-propelling solvent/powder dispensing container such as a device comprising the active ingredient dissolved and/or suspended in a low-boiling propellant in a sealed container. Such powders comprise particles wherein at least 98% of the particles by weight have a diameter greater than 0.5 nanometers and at least 95% of the particles by number have a diameter less than 7 nanometers. Alternatively, at least 95% of the particles by weight have a diameter greater than 1 nanometer and at least 90% of the particles by number have a diameter less than 6 nanometers. Dry powder compositions may include a solid fine powder diluent such as sugar and are conveniently provided in a unit dose form.
[0236] Low boiling propellants generally include liquid propellants having a boiling point of below 65 °F at atmospheric pressure. Generally, the propellant may constitute 50 to 99.9% (w/w) of the composition, and the active ingredient may constitute 0.1 to 20% (w/w) of the composition. The propellant may further comprise additional ingredients such as a liquid non-ionic and/or solid anionic surfactant and/or a solid diluent (which may have a particle size of the same order as particles comprising the active ingredient).
[0237] Pharmaceutical compositions of the invention formulated for pulmonary delivery may provide the active ingredient in the form of droplets of a solution and/or suspension. Such formulations can be prepared, packaged, and/or sold as aqueous and/or dilute alcoholic solutions and/or suspensions, optionally sterile, comprising the active ingredient, and may conveniently be administered using any nebulization and/or atomization device. Such formulations may further comprise one or more additional ingredients including, but not limited to, a flavoring agent such as saccharin sodium, a volatile oil, a buffering agent, a surface-active agent, and/or a preservative such as methylhydroxybenzoate. The droplets provided by this route of administration may have an average diameter in the range from about 0.1 to about 200 nanometers.
[0238] Formulations described herein as being useful for pulmonary delivery are useful for intranasal delivery of a pharmaceutical composition of the invention. Another formulation
suitable for intranasal administration is a coarse powder comprising the active ingredient and having an average particle from about 0.2 to 500 micrometers. Such a formulation is administered by rapid inhalation through the nasal passage from a container of the powder held close to the nares.
[0239] Formulations for nasal administration may, for example, comprise from about as little as 0.1% (w/w) and as much as 100% (w/w) of the active ingredient, and may comprise one or more of the additional ingredients described herein. A pharmaceutical composition of the invention can be prepared, packaged, and/or sold in a formulation for buccal administration. Such formulations may, for example, be in the form of tablets and/or lozenges made using conventional methods, and may contain, for example, 0.1 to 20% (w/w) active ingredient, the balance comprising an orally dissolvable and/or degradable composition and, optionally, one or more of the additional ingredients described herein. Alternately, formulations for buccal administration may comprise a powder and/or an aerosolized and/or atomized solution and/or suspension comprising the active ingredient. Such powdered, aerosolized, and/or aerosolized formulations, when dispersed, may have an average particle and/or droplet size in the range from about 0.1 to about 200 nanometers, and may further comprise one or more of the additional ingredients described herein.
[0240] Although the descriptions of pharmaceutical compositions provided herein are principally directed to pharmaceutical compositions which are suitable for administration to humans, it will be understood by the skilled artisan that such compositions are generally suitable for administration to animals of all sorts. Modification of pharmaceutical compositions suitable for administration to humans in order to render the compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and/or perform such modification with ordinary experimentation.
[0241] Compounds provided herein are typically formulated in dosage unit form for ease of administration and uniformity of dosage. It will be understood, however, that the total daily usage of the compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular subject or organism will depend upon a variety of factors including the disease, disorder, or condition being treated and the severity of the disorder; the activity of the specific active ingredient employed; the specific composition employed; the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and rate of
excretion of the specific active ingredient employed; the duration of the treatment; drugs used in combination or coincidental with the specific active ingredient employed; and like factors well known in the medical arts.
[0242] To practice the method of this invention, the above-described compound or its pharmaceutical composition can be administered intravenously, intravitreally, intradermally, transdermally, intrathecally, intraarterially, intraperitoneally, intranasally, intravaginally, intrarectally, intraosseously, periprosthetically, topically, intramuscularly, subcutaneously, mucosally, intraosseosly, periprosthetically, in utero, orally, topically, locally, via inhalation (e.g., aerosol inhalation), by injection, by infusion, by continuous infusion, by localized perfusion bathing target cells directly, via a catheter, via a lavage, in cremes, in lipid compositions (e.g., liposomes), or by other method or any combination of the forgoing as would be known to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, 2003, incorporated herein by reference). In general, the most appropriate route of administration will depend upon a variety of factors including the nature of the agent (e.g., its stability in the environment of the gastrointestinal tract), and/or the condition of the subject (e.g., whether the subject is able to tolerate oral administration).
[0243] In certain embodiments, the pharmaceutical composition and/or additional agent is formulated to be administered via an alimentary route. Alimentary routes include all possible routes of administration in which the composition is in direct contact with the alimentary tract. Specifically, the pharmaceutical compositions disclosed herein may be administered orally, buccally, rectally, or sublingually. As such, these compositions may be formulated with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard- or soft-shell gelatin capsules, they may be compressed into tablets, or they may be incorporated directly with the food of the diet.
[0244] In further embodiments, a composition described herein may be administered via a parenteral route. As used herein, the term "parenteral" includes routes that bypass the alimentary tract. Specifically, the pharmaceutical compositions disclosed herein may be administered, for example but not limited to, intravenously, intradermally, intramuscularly, intraarterially, intrathecally, subcutaneous, or intraperitoneally
[0245] According to some embodiments, the administration is effected orally. For oral administration, the compounds presented herein can be formulated readily by combining the
compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds presented herein to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for oral ingestion by a patient. Pharmacological preparations for oral use can be made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carbomethylcellulose; and/or physiologically acceptable polymers such as polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
[0246] For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.
[0247] For administration by inhalation, the compounds presented herein are conveniently delivered in the form of an aerosol spray presentation (which typically includes powdered, liquefied and/or gaseous carriers) from a pressurized pack or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, tri chlorofluoromethane, dichloro-tetrafluoroethane or carbon dioxide. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compounds presented herein and a suitable powder base such as, but not limited to, lactose or starch.
[0248] For administration by injection, the compounds presented herein may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer with or without organic solvents such as propylene glycol, polyethylene glycol.
[0249] Pharmaceutical compositions for topical administration may include the compositions formulated for a medicated application such as an ointment, paste, cream, or powder. Ointments include all oleaginous, adsorption, emulsion, and water-soluble based compositions for topical application, while creams and lotions are those compositions that include an emulsion base only. Topically administered medications may contain a penetration enhancer to facilitate adsorption of
the active ingredients through the skin. Suitable penetration enhancers include glycerin, alcohols, alkyl methyl sulfoxides, pyrrolidones and luarocapram. Possible bases for compositions for topical application include polyethylene glycol, lanolin, cold cream and petrolatum as well as any other suitable absorption, emulsion or water-soluble ointment base. Topical preparations may also include emulsifiers, gelling agents, and antimicrobial preservatives as necessary to preserve the composition and provide for a homogenous mixture. Transdermal administration of the compositions may also comprise the use of a "patch." For example, the patch may supply one or more compositions at a predetermined rate and in a continuous manner over a fixed period of time.
[0250] In certain embodiments, the compositions may be delivered by eye drops, intranasal sprays, inhalation, and/or other aerosol delivery vehicles. Methods for delivering compositions directly to the lungs via nasal aerosol sprays has been described in U.S. Pat. Nos. 5,756,353 and 5,804,212 (each specifically incorporated herein by reference in their entirety). Likewise, the delivery of drugs using intranasal microparticle resins (Takenaga et al., 1998) and lysophosphatidyl-glycerol compounds (U.S. Pat. No. 5,725,871, specifically incorporated herein by reference in its entirety) are also well-known in the pharmaceutical arts and could be employed to deliver the compositions described herein. Likewise, transmucosal drug delivery in the form of a polytetrafluoroethylene support matrix is described in U.S. Pat. No. 5,780,045 (specifically incorporated herein by reference in its entirety), and could be employed to deliver the compositions described herein.
[0251] It is further envisioned the compositions disclosed herein may be delivered via an aerosol. The term aerosol refers to a colloidal system of finely divided solid or liquid particles dispersed in a liquefied or pressurized gas propellant. The typical aerosol for inhalation consists of a suspension of active ingredients in liquid propellant or a mixture of liquid propellant and a suitable solvent. Suitable propellants include hydrocarbons and hydrocarbon ethers. Suitable containers will vary according to the pressure requirements of the propellant. Administration of the aerosol will vary according to subject's age, weight and the severity and response of the symptoms.
[0252] For transmucosal administration, penetrants are used in the formulation. Such penetrants are generally known in the art.
[0253] The compounds presented herein may be formulated for parenteral administration, e.g., by
bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multidose containers with optionally, an added preservative. The compositions may be suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
[0254] Alternatively, the compounds presented herein may be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water, before use.
[0255] The exact amount of a compound required to achieve an effective amount will vary from subject to subject, depending, for example, on species, age, and general condition of a subject, severity of the side effects or disorder, identity of the particular compound(s), mode of administration, and the like. The desired dosage can be delivered three times a day, two times a day, once a day, every other day, every third day, every week, every two weeks, every three weeks, or every four weeks. In certain embodiments, the desired dosage can be delivered using multiple administrations (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or more administrations).
[0256] In certain embodiments, an effective amount of a compound for administration one or more times a day to a 70 kg adult human may comprise about 0.0001 mg to about 3000 mg, about 0.0001 mg to about 2000 mg, about 0.0001 mg to about 1000 mg, about 0.001 mg to about 1000 mg, about 0.01 mg to about 1000 mg, about 0.1 mg to about 1000 mg, about 1 mg to about 1000 mg, about 1 mg to about 100 mg, about 10 mg to about 1000 mg, or about 100 mg to about 1000 mg, of a compound per unit dosage form.
[0257] In certain embodiments, the compounds of the invention may be administered orally or parenterally at dosage levels sufficient to deliver from about 0.001 mg/kg to about 100 mg/kg, from about 0.01 mg/kg to about 50 mg/kg, preferably from about 0.1 mg/kg to about 40 mg/kg, preferably from about 0.5 mg/kg to about 30 mg/kg, from about 0.01 mg/kg to about 10 mg/kg, from about 0.1 mg/kg to about 10 mg/kg, and more preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
[0258] It will be appreciated that dose ranges as described herein provide guidance for the administration of provided pharmaceutical compositions to an adult. The amount to be administered to, for example, a child or an adolescent can be determined by a medical practitioner or person skilled in the art and can be lower or the same as that administered to an adult.
[0259] It will be also appreciated that a compound or composition, as described herein, can be administered in combination with one or more additional therapeutically active agents. The compounds or compositions can be administered in combination with additional therapeutically active agents that improve their bioavailability, reduce and/or modify their metabolism, inhibit their excretion, and/or modify their distribution within the body. It will also be appreciated that the therapy employed may achieve a desired effect for the same disorder, and/or it may achieve different effects.
[0260] The compound or composition can be administered concurrently with, prior to, or subsequent to, one or more additional therapeutically active agents. In general, each agent will be administered at a dose and/or on a time schedule determined for that agent. In will further be appreciated that the additional therapeutically active agent utilized in this combination can be administered together in a single composition or administered separately in different compositions. The particular combination to employ in a regimen will take into account compatibility of the inventive compound with the additional therapeutically active agent and/or the desired therapeutic effect to be achieved. In general, it is expected that additional therapeutically active agents utilized in combination be utilized at levels that do not exceed the levels at which they are utilized individually. In some embodiments, the levels utilized in combination will be lower than those utilized individually.
[0261] Also encompassed by the invention are kits (e.g., pharmaceutical packs). The kits provided may comprise an inventive pharmaceutical composition or compound and a container (e.g., a vial, ampule, bottle, syringe, and/or dispenser package, or other suitable container). In some embodiments, provided kits may optionally further include a second container comprising a pharmaceutical excipient for dilution or suspension of an inventive pharmaceutical composition or compound. In some embodiments, the inventive pharmaceutical composition or compound provided in the container and the second container are combined to form one-unit dosage form.
Combinations
[0262] Combination therapy can be effective with drugs that work by different mechanisms, thereby decreasing the likelihood that resistant cancer cells will develop. When drugs with different effects are combined, each drug can be used at its optimal dose, without intolerable side effects. A compound of Formula I as disclosed herein and a second medicament can be combined
for therapeutic benefit, for instance, for treating a proliferative disease or disorder such as cancer. The second medicament can have a different mechanism. Alternatively, it can use the same mechanism as the compound as disclosed herein for therapeutic benefit. The combination can act via a synergistic effect. Combination therapies can also include additional (e.g. a third, fourth, fifth, etc.) medicaments.
[0263] Thus, other embodiments of the invention provide methods for combination therapies in which an agent known to modulate other pathways, or other components of the same pathway, or even overlapping sets of target enzymes are used in combination with a compound of the present invention, or a pharmaceutically acceptable salt, ester, prodrug, solvate, tautomer, hydrate or derivative thereof. In one aspect, such therapy includes but is not limited to the combination of one or more compounds of the invention with chemotherapeutic agents, therapeutic antibodies, and radiation treatment, to provide a synergistic or additive therapeutic effect.
[0264] Many chemotherapeutics are presently known in the art and can be used in combination with the compounds of the invention. In some embodiments, the chemotherapeutic is selected from the group consisting of DNA intercalating agents, topoisomerase inhibitors, microtubule inhibitors, multi-kinase inhibitors, PARP inhibitor, transcription and translation inhibitors, as well as mitotic inhibitors, alkylating agents, anti-metabolites, growth factor inhibitors, cell cycle inhibitors, enzymes, biological response modifiers, anti-hormones, angiogenesis inhibitors, and anti-androgens. Therapeutic agents that can be combined with a compound of the invention are found in Goodman and Gilman's "The Pharmacological Basis of Therapeutics" Tenth Edition edited by Hardman, Limbird and Gilman or the Physician's Desk Reference, both of which are incorporated herein by reference in their entirety.
[0265] Non-limiting examples of intercalating agents include, methotrexate, actinomycin, mitoxantrone, adriamycin, doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin. [0266] Non-limiting examples of topoisomerase inhibitors include irinotecan (CAMPTOSAR), topotecan (HYCAMTIN), etoposide (ETOPOPHOS, VEPESSID, TOPOSAR), teniposide (VUMON), ellipticine, TAS-103, mitonafide, amonafide, chartreusin, elsamicin, IST-622, ditercalinimum, elinafide, and echinomycin.
[0267] Non-limiting examples of microtubule-disruptor agents include ecteinascidins. Non- limiting examples of microtubule-stabilizing agents include pacitaxel, docetaxel, and epothilones A-F; 4-(3-(l-(cyclopropanecarbonyl)piperazine-4-carbonyl)-4-fluorobenzyl)phtha- lazin-l(2H)-
one (olaparib, AZD2281, Ku-0059436), 2-[(2R)-2-methylpyrrolidin-2-yl]-lH-benzimidazole-4- carboxamide (Veliparib, ABT-888), (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(l-methyl-lH-l,2,4- triazol-5-yl)-8,- 9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one (talazoparib, BMN 673), 4- iodo-3 -nitrobenzamide (iniparib, BSI-201), 8-fluoro-5-(4-((methylamino)methyl)phenyl)-3,4- dihydro-2H-azepino[5,4,3-c- d]indol-l(6H)-onephosphoric acid (Rucaparib, AG-014699, PF- 01367338), 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,l-jk][l,4]benz- odiazepin-7(4H)-one (AG14361), 3 -aminobenzamide (INO-1001), 2-(2-fluoro-4-((S)-pyrrolidin- 2-yl)phenyl)-3H-benzo[d]imidazole-4-carboxa- mide (A-966492), N-(5,6-dihydro-6-oxo-2- phenanthridinyl)-2-acetamide hydrochloride (PJ34, PJ34 HC1), MK-4827, 3,4-dihydro-4-oxo-3,4- dihydro-4-oxo-N-[(lS)-l-phenylethyl]-2-quinazolinep- ropanamide (ME0328), 5-(2-oxo-2- phenylethoxy)-l(2H)-isoquinolinone (UPF-1069), 4-[[4-fluoro-3-[(4-methoxy-l- piperidinyl)carbonyl]phenyl]methyl]-l(2H)-ph- thalazinone (AZD 2461),
[0268] Non-limiting examples of PARP inhibitors include olaparib, niraparib, rucaparib, talazoparib, veliparib, CEP 9722, E7016, and BGB-290.
[0269] Non-limiting examples of transcription and translation inhibitors include alpha-amatinin, CX-5461, TAS-106, BMH-21, metatrestin, JQ-1, birabresib, mivebresib, triptolide, 8-Cl-Ado, 8- NEh-Ado, fludarabine, alvocidib, abemaciclib, palbociclib, ribociclib, rapamycin, everolimus, Torinl, PP242, MLN0128, Rapalink-lsilvestrol, omacetaxine, RG-7388, HDM-201, INCB057643, SY-1365, and BMS-986158.
[0270] In one embodiment, a compound of formula I can be combined with one or more compounds selected from the following compounds to treat cancer: Gleevec® (Imatinib Mesylate), Velcade®. (bortezomib), Casodex (bicalutamide), Iressa®. (gefitinib), and Adriamycin as well as a host of chemotherapeutic agents. Non-limiting examples of chemotherapeutic agents include alkylating agents such as thiotepa and cyclosphosphamide (CYTOXAN®); alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphaoramide and trimethylolomelamine; nitrogen mustards such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine,
ranimustine; antibiotics such as aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, calicheamicin, carabicin, carminomycin, carzinophilin, Casodex®, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norieucine, doxorubicin, epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5 -fluorouracil (5-FU); folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elfomithine; elliptinium acetate; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidamine; mitoguazone; mitoxantrone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK®; razoxane; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2"-trichlorotriethylamine; urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxanes, e.g. paclitaxel (TAXOL®., Bristol-Myers Squibb Oncology, Princeton, N.J.) and docetaxel (TAXOTERE®., Rhone-Poulenc Rorer, Antony, France); retinoic acid; esperamicins; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the above. Also included as suitable chemotherapeutic cell conditioners are anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as anti-estrogens including for example tamoxifen, (Nolvadex®), raloxifene, aromatase inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen, trioxifene, keoxifene, LY 117018, onapristone, and toremifene (Fareston); and anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronate; camptothecin- 11 (CPT-11); topoisomeRASe inhibitor RFS 2000; difluoromethylomithine (DMFO).
[0271] Where desired, the compounds or pharmaceutical composition of the present invention can be used in combination with commonly prescribed anti-cancer drugs such as Herceptin®, Avastin®, Erbitux®, Rituxan®, Taxol®, Arimidex.RTM., Taxotere®, ABVD, AVICINE, Abagovomab, Acridine carboxamide, Adecatumumab, 17-N-Allylamino-17- demethoxygeldanamycin, Alpharadin, Alvocidib, 3-Aminopyridine-2-carboxaldehyde thiosemicarbazone, Amonafide, Anthracenedione, Anti-CD22 immunotoxins, Antineoplastic, Antitumorigenic herbs, Apaziquone, Atiprimod, Azathioprine, Belotecan, Bendamustine, BIBW 2992, Biricodar, Brostallicin, Bryostatin, Buthionine sulfoximine, CBV (chemotherapy), Calyculin, cell-cycle nonspecific antineoplastic agents, Dichloroacetic acid, Discodermolide, Elsamitrucin, Enocitabine, Epothilone, Eribulin, Everolimus, Exatecan, Exisulind, Ferruginol, Forodesine, Fosfestrol, ICE chemotherapy regimen, IT-101, Imexon, Imiquimod, Indolocarbazole, Irofulven, Laniquidar, Larotaxel, Lenalidomide, Lucanthone, Lurtotecan, Mafosfamide, Mitozolomide, Nafoxidine, Nedaplatin, Olaparib, Ortataxel, PAC-1, Pawpaw, Pixantrone, Proteasome inhibitor, Rebeccamycin, Resiquimod, Rubitecan, SN-38, Salinosporamide A, Sapacitabine, Stanford V, Swainsonine, Talaporfin, Tariquidar, Tegafur- uracil, Temodar, Tesetaxel, Triplatin tetranitrate, Tris(2-chloroethyl)amine, Troxacitabine, Uramustine, Vadimezan, Vinflunine, ZD6126 or Zosuquidar; In other embodiments, agents useful in methods for combination therapy with one or more compounds of structure (I) include, but are not limited to: Erlotinib, Afatinib, Iressa, GDC0941, MLN1117, BYL719 (Alpelisib), BKM120 (Buparlisib), CYT387, GLPG0634, Baricitinib, Lestaurtinib, momelotinib, Pacritinib, Ruxolitinib, TG101348, Crizotinib, tivantinib, AMG337, cabozantinib, foretinib, onartuzumab, NVP- AEW541, Dasatinib, Ponatinib, saracatinib, bosutinib, trametinib, selumetinib, cobimetinib, PD0325901, RO5126766, Axitinib, Bevacizumab, Bostutinib, Cetuximab, Crizotinib, Fostamatinib, Gefitinib, Imatinib, Lapatinib, Lenvatinib, Ibrutinib, Nilotinib, Panitumumab, Pazopanib, Pegaptanib, Ranibizumab, Ruxolitinib, Sorafenib, Sunitinib, SU6656, Trastuzumab, Tofacitinib, Vandetanib, Vemurafenib, Irinotecan, Taxol, Docetaxel, Rapamycin or MLN0128. [0272] The compounds of Formula I can be used in combination with the agents disclosed herein or other suitable agents, depending on the condition being treated. Hence, in some embodiments the one or more compounds of the invention will be co-administered with other agents as described above. When used in combination therapy, the compounds described herein are administered with the second agent simultaneously or separately. This administration in
combination can include simultaneous administration of the two agents in the same dosage form, simultaneous administration in separate dosage forms, and separate administration. That is, a compound described herein and any of the agents described above can be formulated together in the same dosage form and administered simultaneously. Alternatively, a compound of the invention and any of the agents described above can be simultaneously administered, wherein both the agents are present in separate formulations. In one alternative, a compound of the present invention can be administered just followed by and any of the agents described above, or vice versa. In some embodiments of the separate administration protocol, a compound of the invention and any of the agents described above are administered a few minutes apart, or a few hours apart, or a few days apart.
Examples
[0273] In order that the invention described herein may be more fully understood, the following examples are set forth. The synthetic and biological examples described in this application are offered to illustrate the cwompounds, pharmaceutical compositions, and methods provided herein and are not to be construed in any way as limiting their scope.
[0274] The examples and preparations provided below further illustrate and exemplify the compounds of the present invention and methods of preparing such compounds. It is to be understood that the scope of the present invention is not limited in any way by the scope of the following examples and preparations. In the following examples, and throughout the specification and claims, molecules with a single stereocenter, unless otherwise noted, exist as a racemic mixture. Those molecules with two or more stereocenters, unless otherwise noted, exist as a racemic mixture of diastereomers. Single enantiomers/diastereomers may be obtained by methods known to those skilled in the art.
IS1-1
[0276] ter/-Butyl 3-((((benzyloxy)carbonyl)amino)methyl)-3-hydroxypyrrolidine-l- carboxylate (IS1-1). A solution of tert-butyl 3 -(aminomethyl)-3 -hydroxypyrrolidine- 1- carboxylate (0.74 g, 3.4 mmol) in DCM (11.3 mL) was cooled to 0°C. Triethylamine (0.95 mL, 6.8 mmol) followed by N-(benzyl oxycarbonyl oxy)succinimide (0.93 g, 3.74 mmol) were added and the reaction mixture was stirred at 0 °C for 30 minutes (mins). The reaction mixture was diluted with ethyl acetate and washed with saturated (sat.) NH4CI. The washed solution was dried over NaiSCU, filtered and concentrated in vacuo. The crude residue was purified by silica gel column chromatography (12 g, 0-60% EtOAc/hexane) to give IS1-1 (1.2 g, 3.4 mmol, 100%). MS (ESI+) mlz-. 373.17 [M + Na]+; 'H NMR (400 MHz, Chloroform -J) 8 7.40 - 7.31 (m, 5H), 5.34 (d, 1H), 5.11 (s, 2H), 3.48 (dd, 2H), 3.33 (d, 4H), 3.07 (d, 1H), 1.88 (s, 2H), 1.44 (s, 9H).
IS1-2
[0277] tert- Butyl 3-((((benzyloxy)carbonyl)amino)methyl)-3-hydroxy-2-oxopyrrolidine-l- carboxylate (IS1-2). To a solution of IS1-1 (1.2 g, 3.4 mmol) in ethyl acetate (15 mL) was added a solution of sodium periodate (3.27 g, 15.3 mmol) in water (15 mL). Ruthenium chloride (70.9 mg, 0.34 mmol) was added in one portion and the reaction mixture was stirred at room temperature for two hours. The reaction mixture was poured into a separating funnel, the organic layer was separated and the aqueous layer was extracted with ethyl acetate (2 times). The
combined extracts were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The crude residue was purified by silica gel column chromatography (24 g, 0-60% EtOAc/Hexane) to give IS1-2 (140 mg, 0.38 mmol, 11.2%). MS (ESI+) mix. 387.12 [M + Na]+;
'H NMR (400 MHz, Chloroform-^/) 8 7.42 - 7.26 (m, 5H), 5.53 (dd, 1H), 5.09 (d, 2H), 3.75 (ddd, 1H), 3.66 - 3.48 (m, 2H), 3.29 (dd, 1H), 2.14 (dddd, 1H), 2.00 (dd, 1H), 1.51 (s, 9H).
19
[0278] 3-( lm/7/f>m(7//)7)-3-hydroxypyrrolidin-2-one (19). A solution of IS1-2 (140 mg, 0.38 mmol) in acetonitrile (1.5 mL) was added with hydrochloric acid (0.29 mL, 4M in 1,4-dioxane, 1.15 mmol). The reaction mixture was stirred at room temperature for 30 mins, at which point ultra performance liquid chromatography (UPLC) showed complete conversion to Boc- deprotected product. The reaction mixture was diluted with dichloromethane (DCM) and washed with sat. aqueous (aq.) NaHCCh. The washed solution was dried over NazSCU, filtered and concentrated in vacuo. The crude material was dissolved in methanol and Pd/C (40.8 mg, 5wt%, 5 mol%) was added. The reaction mixture was bubbled with hydrogen for 15 mins and stirred under an atmosphere of hydrogen for 1 hour (hr). Upon completion, the mixture was filtered through Celite® with ethyl acetate and the filtrate was concentrated in vacuo to give amino alcohol 19 (40 mg, 0.31 mmol, 80.1%) as a clear oil. The crude material was used in the next step without further purification. MS (ESI+) m/z'. 131.03 [M + H]+,153.00 [M + Na]+.
[0279] Tables 1C provides a list of commercially available aminoalcohol intermediates that were used to prepare various compounds.
Scheme SI.
[0280] Benzyl 4-(((2R,4R,5R,6R)-5-(((2S,3R,4S,6R)-3-(benzoyloxy)-4-(dimethylamino)-6- methyltetrahydro-2H-pyran-2-yl)oxy)-4-methoxy-2,4-dimethyl-6-(2,2,5-trimethyl-4-oxo-4H- l,3-dioxin-6-yl)heptyl)amino)-4-(hydroxymethyl)piperidine-l-carboxylate (S1-2-I1). Benzyl
4-amino-4-(hydroxymethyl)piperidine-l-carboxylate (205 mg, 0.775 mmol) and Sl-1 (548 mg,
0.930 mmol) were dissolved in MeOH (3 mL) and Ti(0Et)4 (0.322 mL, 1.54 mmol) was added. After 30 min, a small aliquot was removed from the reaction mixture and was added to a suspension of a small amount of NaBFL in MeOH. LC/MS analysis showed complete conversion. The reaction mixture was cooled in an ice bath and NaBHi (43.8 mg, 1.16 mmol) was added. When gas evolution ceased, 30% aqueous NH4OH (6 mL) was added, and the mixture was filtered through a pad of Celite®, washing with EtOAc. The filtrate was washed with brine, was dried over Na2SO4, was filtered and was concentrated. The residue was purified on a 24 g SiO2 column, eluting with 2-10% MeOH/DCM/0.5% NH4OH, to give SI-2-11 (0.426 g, 66%). MS (ESI+) mlz-. 838.33 [M + H]+; 'H NMR (400 MHz, Chloroform-d) 5 8.12 - 8.00 (m, 2H), 7.61 - 7.52 (m, 1H), 7.44 (t, 2H), 7.40 - 7.27 (m, 5H), 5.13 (s, 2H), 5.18 - 5.04 (m, 1H), 4.69 (d, 1H), 3.90 (d, 1H), 3.68 (s, 2H), 3.56 (dd, 1H), 3.30 (s, 4H), 3.23 (s, 1H), 3.06 (s, 3H), 2.95 - 2.83 (m, 1H), 2.42 (s, 1H), 2.39 - 2.28 (m, 1H), 2.32 (s, 6H), 1.86 - 1.65 (m, 10H), 1.64-1.46 (m, 4 H), 1.45 (d, J2H), 1.41 - 1.22 (m, 8H), 0.98 (d, 3H), 0.83 (d, 3H).
[0281] BenzyZ (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-3-(benzoyloxy)-4-(dimethylamino)-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-9, 11,13, 15-tetramethyl-14, 16-dioxo-17- oxa-3,7-diazaspiro[5.12]octadecane-3-carboxylate (SI-4-11). SI-2-11 (0.426 g, 0.508 mmol) was concentrated twice from toluene. The material was dissolved in chlorobenzene (130 mL), and a stream of nitrogen was bubbled through the solution for 10 min. The mixture was heated at a bath temperature of 150 °C (approximately 130-135 °C internal temperature) overnight. The reaction was allowed to cool to room temperature (rt) and was concentrated. The residue was purified on 24 g of silica gel (elution with 0-10% MeOH-DCM gradient) to give SI-4-11 (243 mg, 61%). MS (ESI+) mlz-. 780.31 [M + H]+.
[0282] Benzyl (9R,1 lR,12R,13R)-12-(((2S,3R,4S,6R)-4-(J^/ij;Za»Hno)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-9, 11,13, 15-tetramethyl-14, 16-dioxo-17- oxa-3,7-diazaspiro[5.12]octadecane-3-carboxylate (Sl-6-Il-l)(Compound 1). SI-4-11 (41 mg, 0.043 mmol) was dissolved in methanol (2 mL), and the mixture was heated at 60 °C (external temperature) overnight. The reaction was allowed to cool to rt and was concentrated. The residue was purified by HPLC (Atlantis T3 column, 5-50% MeCN-water-0.1% HCO2H) to give S1-6-I1- 1 (9.9 mg, 28%). MS (ESI+) m/z: 676.35 [M + H]“, Formate salt, mixture of C2 epimers,
NMR (400 MHz, Methanol-d4) 8 7.33 - 7.15 (m, 5H), 5.01 (s, 2H), 4.31 (dd, 1H), 4.28 - 4.21 (m, 1H), 3.97 (d, 0.7H), 3.88 (d, 0.3H), 3.72 - 3.61 (m, 1H), 3.55-3.35 (m, 6H), 3.26 - 3.11 (m, 6H), 2.77 (s, 0.9H), 2.71 (s, 2.1H), 2.68-2.58 (m, 1H), 2.45-2.38 (m, 0.7H), 2.35-2.22 (m, 6.3H), 2.18- 2.08 (m, 1H), 1.68 (d, 1H), 1.56 - 1.41 (m, 4H), 1.26 - 1.07 (m, 12H), 0.95-0.80 (m, 3H).
[0283] Benzyl (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-3-(benzoyloxy)-4-(dimethylamino)-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15-pentamethyl-14,16-dioxo-17- oxa-3,7-diazaspiro[5.12]octadecane-3-carboxylate (SI-5-11-1). SI-4-11 (0 243 g, 0 311 mmol) was dissolved in DCM (1.55 mL) and Na(OAc)3BH (131 mg; 0.622 mmol) was added.
Formaldehyde (37 wt% solution in water, 0.175 mL, 1.55 mmol) was added. After 10 min., the reaction mixture was quenched by the addition of NaHCOs (sat., aq. solution). The layers were separated, and the aqueous layer was extracted with DCM (1 time). The combined DCM extracts were dried over ISfeSCL, were filtered, and were concentrated to give crude SI-5-11-1 (244 mg, 99%) which was used without further purification. MS (ESI+) m/z: 794.27 [M + H]+.
[0284] Benzyl (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,H,13,15-pentamethyl-14,16-dioxo-17- oxa-3,7-diazaspiro[5.12]octadecane-3-carboxylate (Sl-6-Il-2)(Compound 2). SI-5-11-1 (17 6 mg, 0.221 mmol) was dissolved in methanol (1 mL), and the mixture was heated at 60 °C (external temperature) for 7 hours (h). The reaction was allowed to cool to rt and was concentrated. The residue was purified by HPLC (Atlantis T3 column, 5-50% MeCN-water-0.1% HCO2H) to give SI-6-11-2 (6.87 mg). MS (ESI+) mlz\ 690.36 [M + H]+, Formate salt, mixture of C2 epimers, 'H NMR (400 MHz, Methanol-d4) 5 8.55 (s, 2H), 7.45 - 7.29 (m, 5H), 5.14 (d, 2H), 4.51 - 4.37 (m, 1H), 4.30-4.15 (m, 1H), 4.00-3.60 (m, 4H), 3.44 - 3.33 (m, 3H), 3.30 - 3.10 (m, 3H), 3.10-2.95 (m, 2H), 2.80-2.40 (m, 12H), 2.10-1.92 (m, 3H), 1.92-1.60 (m, 6H), 1.52-1.44 (m, 1H), 1.40 - 1.17 (m, 12H), 1.10 - 0.90 (m, 3H).
[0285] (10R,llR,12/?,14R)-ll-(((25,3/?,45,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2//-pyran-2-yl)oxy)-12-methoxy-8,70,12,14,16-pentamethyl-6-oxa-2,16- diazaspiro[4.12]heptadecane-l, 7, 9-trione (Sl-6-I9-2)(Compound 112). Prepared according to the methods of SI-6-11-2 from 19. Formate salt. (8.96 mg). MS (ESI+) mlz'. 278.79 [M + 2H]2+, 556.29
(400 MHz, Chloroform-J) 5 8.53 (s, 2H), 4.43 (dd, 1H), 4.30 (d, 1H), 3.81 - 3.62 (m, 2H), 3.57 - 3.35 (m, 4H), 3.28 - 3.21 (m, 1H), 3.19 (s, 3H), 2.99 (s, 2H), 2.87 (s, 1H), 2.77 (d, 2H), 2.73 (s, 4H), 2.64 - 2.44 (m, 2H), 2.34 - 2.13 (m, 3H), 2.05 - 1.87 (m, 2H), 1.83 (s, 1H), 1.55 - 1.45 (m, 1H), 1.42 (s, 2H), 1.36 (d, 3H), 1.32 (dd, 6H), 1.25 (d, 1H), 1.13 (d, 1H), 1.07 (d, 2H), 0.95 (d, 1H).
[0286] (llR,13R,14R,15R)-14-(((2S,3R,4S,6R)-4-(Drme//ij;/ammo)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-ll,13,15,17-tetramethyl-l,4,19-trioxa-9- azadispiro[4.2.128.25]docosane-16, 18-dione (Sl-6-I10-l)(Compound 74). Prepared according to the methods of SI-6-11-1 from 110. Formate salt. MS (ESI+) mlz'. 599.28 [M + H]+; JH NMR (400 MHz, Methanol-d4) 84.35 (dt, 1H), 4.12 - 4.01 (m, 1H), 4.01 - 3.84 (m, 4H), 3.84 - 3.68 (m, 1H), 3.64 (q, 1H), 3.56 - 3.34 (m, 3H), 3.19 (dt, 1H), 3.12 - 2.95 (m, 1H), 2.90 (dd, 1H), 2.84 (s, 1H), 2.69 - 2.35 (m, 3H), 2.27 (d, 6H), 2.18 (t, 1H), 2.06 - 1.35 (m, 13H), 1.35 - 1.08 (m, 12H), 1.09 - 0.83 (m, 4H).
[0287] (HR,13R,14R,15R)-14-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-9,ll,13,15,17-pentamethyl-l,4,19-trioxa-9- azadispiro[4.2.128.25]docosane-16, 18-dione (Sl-6-I10-2)(Compound 75). Prepared according to the methods of SI-6-11-2 from 110 and formaldehyde. Formate salt. MS (ESI+) mlz'. 613.32 [M + H]+; 'H NMR (400 MHz, Methanol-d4) 84.48 - 4.15 (m, 2H), 4.05 - 3.85 (m, 5H), 3.72 (d, 1H), 3.63 - 3.49 (m, 2H), 3.48 - 3.34 (m, 1H), 3.30 - 3.16 (m, 1H), 3.04 - 2.89 (m, 3H), 2.72 - 2.49 (m, 2H), 2.43 (s, 1H), 2.35 (d, 9H), 2.21 - 2.03 (m, 1H), 2.03 - 1.42 (m, 11H), 1.42 - 1.13 (m, 14H), 1.05 - 0.94 (m, 2H), 0.89 (d, 1H).
Scheme S2.
[0288] Benzyl (9R,1 lR,12R,13R)-12-(((2S,3R,4S,6R)-3-(benzoyloxy)-4-(dimethylamino)-6- methyltetrahydro-2H-pyran-2-yl)oxy)- 11 -methoxy-7, 9, 11, 13, 15, 15 -hexamethyl- 14, 16-dioxo- 17- oxa-3,7-diazaspiro[5.12]octadecane-3-carboxylate (S2-1-I1-1). SI-5-11-1 (382 mg, 0.481 mmol) was dissolved in 1,2-dimethoxy ethane (4.8 mL), and the reaction mixture was cooled to -78 °C in a dry ice/acetone bath. Potassium bis(trimethylsilyl)amide (1.0 M solution in THF; 0.625 mL, 0.625 mmol) was added. After 25 min, dimethyl sulfate (0.091 mL, 0.962 mmol) was added. The dry ice was removed from the acetone bath, and the reaction mixture was allowed to slowly warm to 5 °C over 50 min. The reaction was quenched by the addition of NH4C1 (sat., aq. solution) and was diluted with EtOAc. The EtOAc layer was washed with water (2 times) and brine (1 time), was dried over Na2SO4, was filtered, and was concentrated. The residue was purified on 40 g of silica gel (elution with 4-15% MeOH-DCM-0.5% NH4OH gradient) to give S2-1-I1-1 (260 mg, 67%) . MS (ESI+) m/z: 808.35 [M + H]+. 1H NMR (400 MHz, Chloroform-d) 6 8.01 - 7.91 (m, 2H), 7.49 (t, 1H), 7.37 (t, 2H), 7.35 - 7.17 (m, 5H), 5.15-5.00 (m, 3H), 4.58 (br d, 1H), 4.10-90 (m, 2H), 3.80-3.50 (m, 2H), 3.20-2.90 (m, 5H), 2.86 (s, 3H), 2.50-2.00 (m, 11H), 2.00-1.80 (m, 1H), 1.80-1.55 (m, 2 H), 1.49 - 1.32 (m, 1H), 1.31 (s, 3H), 1.29 - 1.05 (m, 12H), 1.03 - 0.860 (m,
5H), 0.85-0.66 (m, 4H).
Scheme S3.
[0289] (2S,3R,4S,6R)-4-(Dimethylamino)-2-(((9R,llR,12R,13R)-ll-methoxy-7,9,77,13,15- pentamethyl-14,16-dioxo-17-oxa-3,7-diazaspiro[5.12]octadecan-12-yl)oxy)-6- methyltetrahydro-2H-pyran-3-yl benzoate (S3-1-I1-1-1). SI-5-11-1 (224 mg, 0282 mmol) was dissolved in methanol (5.6 mL) and 1 N aqueous HC1 (0.846 mL, 0.846 mmol), and palladium on carbon (5 wt%, 60 mg, 0.028 mmol) was added. An atmosphere of H2 was introduced. After 4 h, the reaction mixture was evacuated and back-filled with N2 (3 times). The reaction mixture was filtered through Celite®, washing with MeOH, and the filtrate was concentrated. This gave the HC1 salt of S3-1-I1-1-1 (226 mg, 100%), which was used without further purification. MS (ESI+) mlz'. 660.29 [M + H]+.
[0290] (2S,3R,4S,6R)-4-(Dimethylamino)-2-(((9R,llR,12R,13R)-ll-methoxy-7,9,ll,13,15,15- hexamethyl-14,16-dioxo-17-oxa-3,7-diazaspiro[5.12]octadecan-12-yl)oxy)-6- methyltetrahydro-2H-pyran-3-yl benzoate (S3-1-I1-1-2). Prepared according to the methods of
S3-1-I1-1-1, substituting S2-2-I1-1. This gave the HC1 salt of S3-1-I1-1-2 , which was used without further purification. MS (ESI+) mlz.' 808.33 [M + H]+.
[0291] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,H,13,15-pentamethyl-17-oxa-3,7-
diazaspiro [5.12] octadecane-14, 16-dione (S3-2-Il-l-l-l)(Compound 7). S3-1-I1-1-1 (14.7 mg, 0.0191 mmol) was dissolved in methanol (1 mL), and the reaction mixture was heated to 60 °C external temperature. After 3 h, the reaction was allowed to cool to rt and was concentrated. The residue was purified by HPLC (Atlantis T3 column, 5-30% MeCN-water-0.1% HCO2H) to give S3-2-I1-1-1-1 (3.61 mg). MS (ESI+) mlz\ 556.32 [M + H]+. Formate salt, mixture of C2 epimers, 'H NMR (400 MHz, Methanol-d4) 8 8.38 (br s, 3H), 4.46 - 4.21 (m, 2H), 4.19 - 3.99 (m, 2H), 3.96 - 3.77 (m, 1H), 3.67 - 3.50 (m, 2H), 3.40 - 3.20 (m, 2H), 3.18 - 3.08 (m, 2H), 3.08 - 2.97 (m, 2H), 2.94 (s, 1H), 2.89 (s, 2H), 2.80-2.63 (m, 7H), 2.63 - 2.38 (m, 3H), 2.34 - 2.15 (m, 2H), 2.05 -1.80 (m, 3H), 1.79 - 1.52 (m, 3H), 1.49 - 1.30 (m, 3H), 1.29 - 1.09 (m, 12H), 0.95 - 0.77 (m, 3H).
[0292] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl-17-oxa-3,7- diazaspiro [5.12] octadecane-14, 16-dione (S3-2-Il-l-2-l)(Compound 44). Prepared according to the methods of S3-2-I1-1-1-1 from S3-1-I1-1-2 to provide the title compound (1.52 mg). Formate salt. MS (ESI+) m/z.' 570.33 [M + H]+. ’H NMR (400 MHz, Methanol-d4) 8 8.42 (br s, 3H), 4.69 - 4.30 (m, 5H), 4.11 - 3.99 (m, 1H), 3.67 - 3.55 (m, 1H), 3.39 - 3.29 (m, 1H), 3.18 - 3.01 (m, 4H), 2.99 - 2.80 (m, 5H), 2.65 (s, 6H), 2.53 - 2.23 (m, 3H), 2.11 - 1.95 (m, 3H), 1.94-1.84 (m, 1H), 1.82 - 1.53 (m, 3H), 1.44 (s, 3H), 1.41 -1.32 (m, 1H), 1.28 (s, 3H), 1.26 - 1.10 (m, 12H), 0.98 - 0.72 (m, 4H).
[0293] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-3,7,9,ll,13,15-hexamethyl-17-oxa-3,7-
diazaspiro [5.12] octadecane-14, 16-dione (S3-2-Il-l-l-2)(Compound 4). S3-1-I1-1-1 (30 mg, 0.039 mmol) was dissolved in DCM (1 mL) and triethylamine (0.016 mL, 0.116 mmol), and Na(OAc)3BH (24.5 mg, 0.116 mmol) was added. Formaldehyde (37 wt% aqueous solution, 0.0157 mL, 0.194 mmol) was added. After 15 min, the reaction mixture was quenched with NaHCCh (sat., aq. solution) and was extracted with DCM (3 times). The combined extracts were concentrated. The crude material was dissolved in methanol (1 mL), and the reaction mixture was heated to 60 °C external temperature. After 3 h, the reaction was allowed to cool to rt and was concentrated. The residue was purified by HPLC (Atlantis T3 column, 5-50% MeCN-water-0.1% HCO2H) to give S3-2-I1-1-1-2 (3.36 mg). MS (ESI+) m/z: 570.33 [M + H]+. Formate salt, mixture of C2 epimers, 1 H NMR (400 MHz, Methanol-d4) 8 8.34 (br s, 2H), 4.45 - 4.31 (m, 2H), 4.19 - 4.01 (m, 1H), 3.89 - 3.77 (m, 0.5H), 3.70 - 3.54 (m, 1.5H), 3.41 - 3.27 (m, 4H), 3.14 - 3.06 (m, 1H), 3.04 - 2.83 (m, 6H), 2.80 - 2.57 (m, 11H), 2.53 - 2.23 (m, 4H), 2.20 - 1.80 (m, 3H), 1.79 - 1.62 (m, 2H), 1.49 - 1.33 (m, 2H), 1.32 - 1.08 (m, 13H), 1.01 - 0.80 (m, 3H).
[0294] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Z)z7nefZty/znMz7io)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15-pentamethyl-3-((l-methyl- lH-imidazol-4-yl)methyl)-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-2-I1-1-1- 3)(Compound 5). Prepared according to the methods of S3-2-I1-1-1-2 from S3-1-I1-1-1 and 1- methyl-lH-imidazole-4-carboxaldehyde (2.33 mg). Formate salt, mixture of C2 epimers. MS (ESI+) mlz-. 650.37 [M + H]+. ^NMR (400 MHz, Methanol-d4) 8 8.44 (s, 1H), 7.46 (s, 1H), 6.93 (s, 1H), 4.60 - 4.42 (m, 0.7H), 4.42 - 4.20 (m, 1.3H), 4.20 - 4.00 (m, 1H), 3.99 - 3.77 (m, 1H), 3.61 (s, 3H), 3.55 - 3.36 (m, 3H), 3.20 - 3.05 (m, 2H), 2.99 - 2.82 (m, 4H), 2.81 - 2.55 (m, 4H), 2.54 - 2.08 (m, 12H), 2.03 - 1.90 (m, 1H), 1.85 - 1.44 (m, 5H), 1.44 - 1.05 (m, 14H), 1.04 - 0.85 (m, 2H), 0.84 - 0.66 (m, 2H).
[0295] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Z)i>M^jZaffM>io)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-3-isopropyl-ll-methoxy-7,9,ll,13,15-pentamethyl-17- oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-2-Il-l-l-4)(Compound 6). Prepared according to the methods of S3-2-I1-1-1-2 from S3-1-I1-1-1 and acetone to provide the title compound (3.87 mg). Formate salt, mixture of C2 epimers. MS (ESI+) mlr. 598.37 [M + H]+. rH NMR (400 MHz, Methanol-d4) 8 8.45 (s, 1H), 4.60 - 4.43 (m, 0.5H), 4.42 - 4.20 (m, 1.5H), 4.18
- 4.00 (m, 1H), 3.98 - 3.74 (m, 1H), 3.62 - 3.44 (m, 1H), 3.36 - 3.20 (m, 2H), 3.07 - 2.60 (m, 10H), 2.59 - 2.09 (m, 11H), 2.10 - 1.84 (m, 2H), 1.84 - 1.45 (m, 5H), 1.43 - 1.06 (m, 18H), 1.05
[0296] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-3,7,9,ll913,15,15-heptamethyl-17-oxa- 3, 7-diazaspiro[5.12]octadecane-14, 16-dione (S3-2-Il-l-2-2)(Compound 78). Prepared according to the methods of S3-2-I1-1-1-2 from S3-1-I1-1-2 and formaldehyde to provide the title compound (5.73 mg). Formate salt. MS (ESI+) mlz\ 584.38 [M + H]+. 'H NMR (400 MHz, Methanol-d4) 8 8.44 (s, 2H), 5.06 - 4.92 (m, 1H), 4.63 - 4.51 (m, 1H), 4.48 (d, 1H), 4.21 (d, 1H), 3.74 (dt, 3.4 Hz, 1H), 3.51 - 3.34 (m, 3H), 3.27 - 3.16 (m, 4H), 3.05 (s, 3H), 2.98 - 2.86 (m, 3H), 2.82 (s, 6H), 2.78 - 2.62 (m, 4H), 2.63 - 2.54 (m, 3H), 2.42 - 2.19 (m, 2H), 2.09 - 1.99 (m, 2H), 1.87 (d, 1H), 1.82 - 1,72 (m, 1H), 1.59 - 1.45 (m, 4H), 1.43 - 1.30 (m, 12H), 1.07 (br d, 3H).
[0297] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Zh>neZZryZawHno)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-3-isobutyl-ll-methoxy-7,9,ll,13,15,15-hexamethyl- 17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-2-Il-l-2-3)(Compound 79). Prepared according to the methods of S3-2-I1-1-1-2 from S3-1-I1-1-2 and isobutyraldehyde to provide the title compound (7.73 mg). Formate salt. MS (ESI+) mlz\ 626.48 [M + H]+. XH NMR (400 MHz, Methanol-d4) 5 8.40 (s, 1.5H), 5.06 - 4.92 (m, 1H), 4.58 (d, 1H), 4.48 (d, 1H), 4.21 (d, 1H), 3.79 - 3.70 (m, 1H), 3.51 - 3.38 (m, 2H), 3.37 - 3.33 (m, 1H), 3.25 - 3.10 (m, 2H), 3.06 (s, 3H), 3001 - 2.91 (m, 3H), 2.90 - 2.78 (m, 7H), 2.75 - 2.63 (m, 4H), 2.61 - 2.46 (m, 3H), 2.38 - 2.23 (m, 2H), 2.12 - 1.96 (m, 3H), 1.91 - 1.78 (m, 2H), 1.59 - 1.45 (m, 4H), 1.44 - 1.34 (m, 9H), 1.33 (d, 3H), 1.08 (d, 3H), 1.02 (dd, 6H).
[0298] (9R,llR,12R,13R)-3-Benzyl-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexaniethyl-17-oxa-3,7- diazaspiro [5.12] octadecane-14, 16-dione (S3-2-Il-l-2-4)(Compound 80). Prepared according to the methods of S3-2-I1-1-1-2 from S3-1-I1-1-2 and benzaldehyde to provide the title compound (7.46 mg). Formate salt. MS (ESI+) mlz\ 660.45 [M + H]+. XH NMR (400 MHz, Methanol-d4) 5 8.48 (s, 3H), 7.39 - 7.25 (m, 5H), 5.01 - 4.88 (m, 1H), 4.56 (d, 1H), 4.47 (d, 1H), 4.21 (d, 1H), 3.79 - 3.67 (m, 1H), 3.60 (br s, 2H), 3.50 - 3.33 (m, 3H), 3.23 - 3.09 (m, 2H), 3.04 (s, 3H), 3.02 - 2.93 (m, 2H), 2.89 (br s, 3H), 2.84 - 2.73 (m, 8H), 2.39 - 2.19 (m, 4H), 2.07 - 1.98 (m, 1H), 1.94 (d, 1H), 1.80 (t, 2H), 1.58 - 1.44 (m, 4H), 1.43 - 1.25 (m, 12 H), 1.07 (d, 3H).
[0299] (9R,llR,12R,13R)-3-([l,l'-biphenyl]-3-ylmethyl)-12-(((2S,3R,4S,6R)-4- (dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy- 7,9,H,13,15,15-hexamethyl-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-2-I1-1-2- 5)(Compound 116). Prepared according to the methods of S3-2-I1 - 1 - 1-2 from S3- 1 -Il - 1 -2 and 3- phenylbenzaldehyde. 18.1 mg Formate salt. MS (ESI+) mlz'. 736.5 [M + H]+; 'H NMR. (400 MHz, MeOD) 5 = 7.64 - 7.58 (m, 3H), 7.56 - 7.51 (m, 1H), 7.46 - 7.38 (m, 3H), 7.37 - 7.29 (m, 2H),
4.40 (d, 1H), 4.25 - 4.15 (m, 1H), 4.12 - 3.98 (m, 2H), 3.80 - 3.74 (m, 1H), 3.70 - 3.49 (m, 3H), 3.47 - 3.35 (m, 1H), 3.28 - 3.21 (m, 1H), 3.11 (s, 1H), 3.05 - 2.85 (m, 4H), 2.80 - 2.57 (m, 3H),
2.40 - 2.21 (m, 13H), 2.05 - 1.78 (m, 4H), 1.78 - 1.64 (m, 3H), 1.54 (br s, 1H), 1.49 (s, 3H), 1.46 - 1.31 (m, 4H), 1.31 - 1.17 (m, 12H), 1.16 - 1.05 (m, 1H), 1.05 - 0.77 (m, 4H).
[0300] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-3-(4-methoxybenzyl)-7,9,ll,13,15,15- hexamethyl-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-2-Il-l-2-6)(Compound
120). Prepared according to the methods of S3-2-I1 - 1 -1 -2 from S3-1-I1-1-2 and 4- methoxybenzaldehyde. 24.0 mg Formate salt. MS (ESI+) mlz'. 690.5 [M + H]+; JH NMR (400 MHz, ACETONITRILES) 8 = 8.33 (br s, 2H), 7.26 - 7.19 (m, 2H), 6.92 - 6.86 (m, 2H), 4.55 - 4.44 (m, 1H), 4.43 - 4.35 (m, 2H), 4.08 (d, 1H), 3.77 (s, 3H), 3.58 (br dd, 1H), 3.50 (s, 2H), 3.25 - 3.17 (m, 2H), 2.96 (s, 3H), 2.86 - 2.67 (m, 7H), 2.62 (br s, 6H), 2.38 (s, 9H), 2.29 - 2.17 (m, 5H), 2.15 - 1.97 (m, 5H), 1.79 (br d, 2H), 1.63 (br d, 1H), 1.53 (br s, 2H), 1.45 (s, 3H), 1.34 - 1.28 (m, 9H), 1.28 - 1.17 (m, 5H), 0.97 (br d, 3H).
[0301] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-3-(isoquinolin-7-ylmethyl)-ll-methoxy- 7,9,H,13,15,15-hexamethyl-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-2-I1-1-2- 7)(Compound 121). Prepared according to the methods of S3-2-I1 - 1 - 1-2 from S3- 1 -Il - 1 -2 and isoquinoline-7-carboxaldehyde. 12.6 mg Formate salt. MS (ESI+) mlz'. 711.5 [M + H]+; 'H NMR (400 MHz, CD3OD) δ = 9.21 (s, 1H), 8.41 (d, 1H), 8.03 (s, 1H), 7.95 - 7.91 (m, 1H), 7.86 - 7.80 (m, 2H), 4.40 (d, 1H), 4.21 (d, 1H), 4.15 - 3.95 (m, 2H), 3.76 (s, 2H), 3.67 - 3.47 (m, 2H), 3.40
(quin, 1H), 3.29 - 3.24 (m, 1H), 3.12 - 2.98 (m, 1H), 2.95 (s, 2H), 2.94 - 2.83 (m, 1H), 2.83 - 2.68 (m, 2H), 2.68 - 2.43 (m, 2H), 2.43 - 2.33 (m, 5H), 2.33 (s, 6H), 2.30 - 2.25 (m, 2H), 2.06 - 1.86
(m, 3H), 1.84 (br d, 1H), 1.77 - 1.66 (m, 3H), 1.55 (br s, 1H), 1.49 (s, 3H), 1.40 (br s, 1H), 1.37 (s,
[0302] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,H,13,15,15-hexamethyl-3-phenethyl- 17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-2-H-l-2-8)(Compound 124). Prepared according to the methods of S3-2-I1 - 1-1 -2 from S3-1-I1-1-2 and phenyl acetaldehyde. 19.2 mg Formate salt. MS (ESI+) mfr. 674.5 [M + H]+; LH NMR (400 MHz, MeOD) 8 = 7.30 - 7.23 (m, 2H), 7.23 - 7.14 (m, 3H), 4.43 - 4.37 (m, 1H), 4.20 (br d, 1H), 4.14 - 3.98 (m, 2H), 3.78 (s, 1H), 3.56 (ddd, 1H), 3.42 (quin, 1H), 3.27 (dd, 1H), 3.17 - 3.01 (m, 1H), 3.01 - 2.87 (m, 3H), 2.87 - 2.67 (m, 4H), 2.67 - 2.56 (m, 3H), 2.39 - 2.25 (m, 11H), 2.18 - 1.80 (m, 4H), 1.80 - 1.62 (m, 3H), 1.55 (br d, 1H), 1.52 - 1.35 (m, 5H), 1.33 - 1.13 (m, 11H), 0.96 - 0.79 (m, 3H).
[0303] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl-3-(pyridin-4- ylmethyl)-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-2-Il-l-2-9)(Compound 126). Prepared according to the methods of S3-2-I1 - 1 -1 -2 from S3-1-I1-1-2 and pyridine-4- carboxaldehyde. 23.1 mg Formate salt. MS (ESI+) m/z'. 661.5 [M + H]+; 1H NMR (400 MHz, ACETONITRILE-ds) 5 = 8.51 (br d, 2H), 8.27 (br s, 2H), 7.31 (br d, 2H), 4.68 - 4.56 (m, 1H), 4.51 - 4.34 (m, 2H), 4.16 - 4.09 (m, 1H), 3.63 - 3.59 (m, 1H), 3.58 (s, 2H), 3.37 - 3.12 (m, 4H), 3.11 - 3.02 (m, 2H), 2.98 (s, 4H), 2.95 - 2.74 (m, 20H), 2.73 - 2.52 (m, 11H), 2.49 (s, 6H), 2.29 (br t, 3H), 2.20 - 2.06 (m, 3H), 2.05 - 1.97 (m, 2H), 1.89 - 1.79 (m, 2H), 1.66 (br d, 2H), 1.48 - 1.15 (m, 16H), 1.02 (d, 2H).
[0304] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl-3-(pyridin-3- ylmethyl)-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-2-Il-l-2-10)(Compound 128). Prepared according to the methods of S3-2-I1 - 1 -1 -2 from S3-1-I1-1-2 and pyridine-3- carboxaldehyde. 16.0 mg Formate salt. MS (ESI+) mlz\ 661.5 [M + H]+; 'H NMR (400 MHz, ACETONITRILE-ds) 8 = 8.51 (d, 1H), 8.47 (dd, 1H), 8.29 (s, 2H), 7.72 - 7.66 (m, 1H), 7.31 (dd, 1H), 4.60 - 4.49 (m, 1H), 4.46 - 4.36 (m, 2H), 4.12 - 4.08 (m, 1H), 3.65 - 3.61 (m, 1H), 3.61 - 3.58 (m, 1H), 3.57 (s, 2H), 3.28 - 3.16 (m, 2H), 3.16 (s, 1H), 3.02 (s, 1H), 2.96 (s, 3H), 2.88 (br s, 1H), 2.84 - 2.70 (m, 6H), 2.66 (br s, 4H), 2.52 (br s, 45H), 2.47 - 2.37 (m, 18H), 2.27 (br t, 4H), 2.14 - 2.02 (m, 3H), 1.98 (br d, 1H), 1.92 - 1.72 (m, 4H), 1.70 - 1.54 (m, 3H), 1.51 (br d, 1H), 1.45 (s, 3H), 1.39 (d, 1H), 1.34 - 1.28 (m, 9H), 1.25 - 1.15 (m, 5H), 1.06 - 0.91 (m, 4H).
[0305] (9R,llR,12R,13R)-3-(4-chlorobenzyl)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3- hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl- 17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-2-Il-l-2-ll)(Compound 129).
Prepared according to the methods of S3 -2-11-1 -1 -2 from S3 - 1 -II- 1 -2 and 4-chlorobenzaldehyde. 13.5 mg Formate salt. MS (ESI+) m!z-. 694.4 [M + H]+; JH NMR (400 MHz, CD3OD) 6 = 7.32 (s, 4H), 4.40 (d, 1H), 4.18 (d, 1H), 3.98 - 3.98 (m, 1H), 3.60 - 3.46 (m, 3H), 3.40 (quin, 1H), 3.27 (dd, 1H), 3.11 (s, 1H), 2.95 (s, 3H), 2.71 - 2.57 (m, 3H), 2.33 (s, 9H), 2.30 - 2.16 (m, 4H), 1.99 - 1.79 (m, 3H), 1.79 - 1.63 (m, 3H), 1.54 - 1.44 (m, 4H), 1.37 (s, 3H), 1.34 - 1.16 (m, 10H), 0.94 - 0.81 (m, 3H).
[0306] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-3-(isoquinolin-6-ylmethyl)-ll-methoxy- 7,9,H,13,15,15-hexamethyl-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-2-I1-1-2- 12D)(Compound 130). Prepared according to the methods of S3-2-I1-1-1-2 from S3-1-I1 -1-2 and isoquinoline-6-carboxaldehyde. 21.0 mg Formate salt. MS (ESI+) mfr. 711.5 [M + H]+; 'll NMR (400 MHz, CD3OD) δ = 9.21 (s, 1H), 8.42 (d, 1H), 8.08 (d, 1H), 7.88 (s, 1H), 7.81 (d, 1H), 7.74 (dd, 1H), 4.40 (d, 1H), 4.21 (d, 1H), 4.13 - 3.96 (m, 2H), 3.76 (s, 2H), 3.55 (dqd, 1H), 3.40 (quin, 1H), 3.26 (dd, 1H), 2.95 (s, 3H), 2.72 (br dd, 2H), 2.61 (ddd, 1H), 2.40 - 2.34 (m, 4H), 2.32 (s, 6H), 2.32 - 2.23 (m, 3H), 2.03 - 1.90 (m, 2H), 1.84 (br d, 1H), 1.79 - 1.64 (m, 3H), 1.57 - 1.46 (m, 4H), 1.41 (br s, 1H), 1.37 (s, 3H), 1.31 - 1.14 (m, 11H), 0.84 (d, 3H).
[0307] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl-3-(2- (pyridin-3-yl)ethyl)-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-2-I1-1-2- 13)(Compound 134). Prepared according to the methods of S3-2-I1 -1 -1 -2 from S3- 1 -Il -1 -2 and 3 -pyridineacetaldehyde. 22.8 mg Formate salt. MS (ESI+) mfr. 675.5 [M + H]+; 'H NMR (400 MHz, CDCh) 5 = 8.43 (d, 1H), 8.38 (dd, 1H), 7.74 (td, 1H), 7.37 (ddd, 1H), 4.44 - 4.38 (m, 1H), 4.21 (d, 1H), 4.12 - 3.98 (m, 2H), 3.78 (s, 1H), 3.70 (s, 1H), 3.60 - 3.52 (m, 1H), 3.42 (quin, 1H), 3.27 (dd, 1H), 3.15 - 3.02 (m, 1H), 3.02 - 2.91 (m, 3H), 2.90 - 2.76 (m, 4H), 2.67 - 2.58 (m, 3H), 2.41 - 2.23 (m, 10H), 2.02 - 1.81 (m, 4H), 1.80 - 1.67 (m, 2H), 1.49 (s, 4H), 1.38 (s, 3H), 1.32 - 1.17 (m, 11H), 0.96 - 0.80 (m, 3H).
[0308] (9R,llR,12R,13R)-3-(3-chlorobenzyl)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3- hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl- 17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-2-Il-l-2-14)(Compound 135).
Prepared according to the methods of S3 -2-11-1 - 1 -2 from S3 - 1 -II- 1 -2 and 3 -chlorobenzaldehyde 17.3 mg Formate salt. MS (ESI+) mfr. 694.5 [M + H]+; ^ NMR (400 MHz, CD3OD) δ = 7.41 - 7.22 (m, 4H), 4.40 (d, 1H), 4.19 (d, 1H), 4.10 - 3.98 (m, 1H), 3.80 - 3.73 (m, 1H), 3.56 (td, 1H), 3.52 (s, 2H), 3.46 - 3.33 (m, 1H), 3.29 - 3.23 (m, 1H), 3.12 - 3.01 (m, 1H), 2.96 (s, 2H), 2.93 - 2.71 (m, 1H), 2.71 - 2.57 (m, 2H), 2.34 (s, 3H), 2.33 (s, 5H), 2.30 - 2.23 (m, 3H), 2.00 - 1.81 (m, 3H), 1.80 - 1.62 (m, 3H), 1.53 - 1.45 (m, 3H), 1.37 (s, 3H), 1.33 - 1.15 (m, 12H), 1.04 - 0.91 (m, 1H), 0.91 - 0.82 (m, 3H).
[0309] (9R,llR,12R,13R)-3-([l,l'-biphenyl]-4-ylmethyl)-12-(((2S,3R,4S,6R)-4- (dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy- 7,9,H,13,15,15-hexamethyl-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-2-I1-1-2- 5)(Compound 139). Prepared according to the methods of S3-2-I1 - 1 - 1-2 from S3- 1 -Il - 1 -2 and 4- phenylbenzaldehyde. 25.4 mg Formate salt. MS (ESI+) mlz'. 736.5 [M + H]+; 'H NMR (400 MHz, MeOD) 8 = 7.65 - 7.57 (m, 4H), 7.47 - 7.38 (m, 4H), 7.37 - 7.30 (m, 1H), 4.83 (s, 11H), 4.40 (br d, J = 7.3 Hz, 1H), 4.20 (br d, J = 11.7 Hz, 1H), 4.12 - 4.01 (m, 2H), 3.61 - 3.48 (m, 3H), 3.45 - 3.35 (m, 1H), 3.35 - 3.24 (m, 5H), 2.95 (s, 3H), 2.80 - 2.68 (m, 2H), 2.68 - 2.55 (m, 1H), 2.34 (br s, 4H), 2.32 (s, 6H), 2.28 (br d, J = 8.6 Hz, 2H), 1.99 - 1.80 (m, 3H), 1.74 (br d, J = 11.1 Hz, 2H), 1.68 - 1.55 (m, 1H), 1.38 (s, 3H), 1.31 - 1.19 (m, 11H), 0.85 (br d, J = 6.5 Hz, 3H).
[0310] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(DiWZ/zj;Z«mino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl-3- (methylsulfonyl)-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-3-Il-l-2-l)( (Compound 82). S3-1-I1-1-2 (21 mg, 0.027 mmol) was dissolved in DCM (1 mL). EtsN (14.8 pL, 0.107 mmol) and MsCl (4.2 pL, 0.054 mmol) were added at rt. The reaction mixture was allowed to stir at rt for 1 h. The reaction was quenched by adding saturated NaHCOs (2 mL) and the aqueous layer was extracted with DCM three times (2 mL). The combined organic layers were dried over MgSCU, filtered and concentrated. The residue was used in the next step without further purification. MS (ESI+) mlz'. 376.7 [M + 2H]2+, 752.4 [M + H]+. The material was dissolved in MeOH (0.5 mL) and heated at 60 °C for 16 h. The reaction mixture was filtered through a syringe filter with the aid of methanol and was concentrated. The residue was purified
by HPLC (MeCN- water- 0.1% HCO2H) to yield the title compound. Formate salt (2.90 mg). MS (ESI+) mlz-. 324.7 [M + 2H]2+, 648.4 [M + H]+; 'H NMR (400 MHz, Methanol-^) 5 8.56 (s, 2H), 4.60 (s, 1H), 4.48 (d, 1H), 4.19 (s, 1H), 3.76 - 3.66 (m, 1H), 3.40 (d, 1H), 3.33 (p, 15H), 3.08 (d, 4H), 2.90 (s, 3H), 2.72 (d, 1H), 2.68 (s, 4H), 2.10 (d, 2H), 1.96 (d, 2H), 1.49 - 1.29 (m, 13H), 0.98 (d, 5H).
[0311] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,H,13,15,15-hexamethyl-3-(pyridin-3- ylsidfbnyl)-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-3-Il-l-2-2)(Compound 127). Prepared according to the methods of S3-3-I1-1-2-1 from S3-1-I1-1-2 and pyridine-3- sulfonyl chloride. 21.8 mg Formate salt. MS (ESI+) mlz'. 711.4 [M + H]+; 'H NMR (400 MHz, MeOD) 5 = 8.93 (dd, 1H), 8.82 (dd, 1H), 8.21 (ddd, 1H), 7.67 (ddd, 1H), 4.42 (d, 1H), 4.09 - 4.01 (m, 2H), 3.88 (br d, 1H), 3.60 - 3.51 (m, 1H), 3.37 (quin, 1H), 3.28 (dd, 1H), 3.17 - 3.05 (m, 4H), 2.98 (s, 3H), 2.64 (ddd, 1H), 2.34 (s, 6H), 2.25 - 2.12 (m, 6H), 1.96 - 1.88 (m, 1H), 1.74 (ddd, 2H), 1.67 - 1.54 (m, 3H), 1.53 (s, 3H), 1.35 (s, 3H), 1.33 - 1.17 (m, 13H), 0.62 (br d, 3H).
[0312] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl-3- (phenylsulfonyl)-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-3-I1-1-2- 3)(Compound 131). Prepared according to the methods of S3-3-H-1-2-1 from S3- 1 -Il - 1 -2 and benzenesulfonyl chloride. 18.7 mg Formate salt. MS (ESI+) mlz'. 710.5 [M + H]+; 'H NMR (400 MHz, CD3OD) δ = 7.79 (d, 2H), 7.70 - 7.65 (m, 1H), 7.64 - 7.59 (m, 2H), 4.41 (d, 1H), 4.05 (d, 1H), 4.00 (d, 1H), 3.86 (d, 1H), 3.59 - 3.51 (m, 1H), 3.41 - 3.32 (m, 2H), 3.27 (dd, 1H), 3.14 -
2.99 (m, 4H), 2.97 (s, 3H), 2.62 (ddd, 1H), 2.33 (s, 6H), 2.24 - 2.15 (m, 5H), 2.12 (br dd, 1H), 1.93 - 1.86 (m, 1H), 1.73 (ddd, 2H), 1.66 - 1.56 (m, 2H), 1.55 - 1.48 (m, 4H), 1.39 - 1.17 (m, 15H), 0.63 (d, 3H).
[0313] (9R,llR,12R,13R)-3-((4-chlorophenyl)sulfonyl)-12-(((2S,3R,4S,6R)-4- (dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy- 7,9,ll,13,15,15-hexamethyl-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-3-I1-1-2- 4)(Compound 132). Prepared according to the methods of S3-3-I1-1-2-1 from S3- 1 -Il - 1 -2 and 3- chlorophenylsulfonyl chloride. 26.5 mg Formate salt. MS (ESI+) mlz'. 744.4 [M + H]+; rH NMR (400 MHz, CD3OD) 6 = 7.79 - 7.75 (m, 2H), 7.65 - 7.60 (m, 2H), 4.42 (d, 1H), 4.06 (d, 1H), 4.03 (d, 1H), 3.87 (d, 1H), 3.60 - 3.51 (m, 1H), 3.37 (br quin, 1H), 3.28 (dd, 1H), 3.14 - 3.01 (m, 4H),
2.98 (s, 3H), 2,62 (ddd, 1H), 2.33 (s, 6H), 2,20 (s, 4H), 1.94 - 1.86 (m, 1H), 1.74 (ddd, 2H), 1.61 (br d, 2H), 1.56 - 1.49 (m, 4H), 1.35 (s, 3H), 1.31 - 1.19 (m, 12H), 0.63 (d, 3H).
[0314] (9R,llR,12R,13R)-3-(benzylsulfonyl)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3- hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl- 17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-3-H-l-2-5)(Compound 133). Prepared according to the methods of S3-3-I1-1-2-1 from S3-1-I1-1-2 and phenylmethyl sulfonyl chloride.
29.1 mg Formate salt. MS (ESI+) mlz-. 724.5 [M + H]+; ^NMR (400 MHz, ACETONITRILE- d3) 5 = 8.33 (s, 2H), 7.45 - 7.35 (m, 5H), 4.42 (d, 1H), 4.26 (s, 2H), 4.25 - 4.17 (m, 2H), 4.05 -
3.99 (m, 1H), 3.91 - 3.72 (m, 1H), 3.71 - 3.34 (m, 16H), 3.34 - 3.23 (m, 3H), 3.16 - 2.96 (m, 3H), 2.94 (s, 3H), 2.92 - 2.87 (m, 1H), 2.61 - 2.51 (m, 1H), 2.49 (s, 6H), 2.44 (s, 3H), 2.41 - 2.18 (m, 2H), 1.92 - 1.72 (m, 4H), 1.71 - 1.61 (m, 2H), 1.54 (br d, 1H), 1.49 (s, 3H), 1.42 - 1.16 (m, 14H),
1.00 - 0.94 (m, 1H), 0.91 (d, 2H).
[0315] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-3-((4-methoxyphenyl)sulfonyl)- 7,9,ll,13,15,15-hexamethyl-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-3-I1-1-2- 6)(Compound 136). Prepared according to the methods of S3-3-I1-1-2-1 from S3- 1 -Il - 1 -2 and 4- methoxyphenyl sulfonyl chloride. 26.4 mg Formate salt. MS (ESI+) mlz'. 740.5 [M + H]+;
NMR (400 MHz, CD3OD) δ = 7.74 - 7.69 (m, 2H), 7.13 - 7.09 (m, 2H), 4.42 (d, 1H), 4.05 (d, 1H), 4.01 (d, 1H), 3.89 (s, 4H), 3.59 - 3.51 (m, 1H), 3.41 - 3.33 (m, 1H), 3.30 - 3.25 (m, 1H), 3.13 - 3.04 (m, 2H), 3.03 - 2.91 (m, 5H), 2.62 (ddd, 1H), 2.33 (s, 6H), 2.25 - 2.14 (m, 5H), 2.14 - 2.07 (m, 1H), 1.93 - 1.86 (m, 1H), 1.77 - 1.70 (m, 2H), 1.67 - 1.56 (m, 2H), 1.56 - 1.47 (m, 4H), 1.35 (s, 3H), 1.30 - 1.20 (m, 11H), 0.65 (d, 3H).
[0316] (9R,llR,12R,13R)-3-Acetyl-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15-pentamethyl-17-oxa-3,7- diazaspiro [5.12] octadecane-14, 16-dione (S3-4-I1-1-1-1) (Compound 3). S3-1-I1-1-1 (30 mg, 0.039 mmol) was dissolved in DCM (1 mL) and triethylamine (0.016 mL, 0.116 mmol), and acetic anhydride (0.011 mL, 0.116 mmol) was added. After 45 min, the reaction mixture was quenched with NaHCOs (sat., aq. solution) and was extracted with DCM (2 times). The combined extracts were concentrated. The crude material was dissolved in methanol (1 mL), and the reaction mixture was heated to 60 °C external temperature. After 3 h, the reaction was allowed to cool to rt and was concentrated. The residue was purified by HPLC (Atlantis T3 column, 5-30% MeCN-water-0.1% HCO2H) to give S3-4-I1-1-1-1 (9.81 mg). MS (ESI+) m/z: 598.35 [M + H]+.
Formate salt, mixture of C2 epimers, 'H NMR (400 MHz, Methanol-d4) 6 8.44 (br s, 1H), 4.40 - 4.30 (m, 1H), 4.28 - 4.16 (m, 1H), 4.16 - 4.05 (m, 1H), 4.03 - 3.80 (m, 2H), 3.67 - 3.42 (m, 2H), 3.42 - 3.27 (m, 2H), 3.02 - 2.74 (m, 5H), 2.56 - 2.18 (m, 10H), 2.18 - 2.06 (m, 1H), 2.05 - 1.88 (m, 5H), 1.87 - 1.53 (m, 4H), 1.36 - 1.00 (m, 16H), 0.88 - 0.68 (m, 4H).
[0317] (9R,llR,12R,13R)-3-(L-Prolyl)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl-17-oxa-3,7- diazaspiro [5.12] octadecane-14, 16-dione (S3-4-Il-l-2-l)(Compound 56). S3-1-I1-1-2 (63 5 mg, 0.081 mmol) was dissolved in DCM (0.4 mL) and A,A-diisopropylethylamine (0.0563 mL, 0.324 mmol), and 1 -hydroxybenzotriazole (14.1 mg, 0.105 mmol), Cbz-L-Proline (24.2 mg, 0.0971 mmol), and XA-di isopropyl carbodi imide (0.0149 mL, 0.0971 mmol) were added. After 26 h, the reaction mixture was concentrated under reduced pressure, and the residue was purified on 12 g of silica gel (elution with 2-10% MeOH-DCM-0.5% NH4OH gradient) to give the amide intermediate (79.4 mg, more than 100%) as a thick oil contaminated with some minor impurities. MS (ESI+) mlz\ 905.43 [M + H]“. The material was dissolved in methanol (1 mL) and 4 M HC1 in 1,4-dioxane (0.060 mL, 0.240 mmol), and palladium on carbon (5 wt%, 0.86 mg, 0.008 mmol) was added. An atmosphere of H2 was introduced. After 4 h, the reaction mixture was evacuated and back-filled with N2 (3 times). The reaction mixture was filtered through Celite®, washing with MeOH, and the filtrate was concentrated to give the crude amine intermediate (77.0 mg) . MS (ESI+) mlz'. 771.34 [M + H]“. The amine intermediate (31.1 mg, 0.040 mmol) was dissolved in methanol (1 mL) and triethylamine (0.017 mL, 0.12 mmol), and the reaction mixture was heated to 65 °C external temperature. After 4 h, the reaction was allowed to cool to rt and was concentrated. The residue was purified by HPLC (Atlantis T3 column, 5-50% MeCN-water-0.1% HCO2H) to give S3-4-I1-1-2-1 (15.1 mg). MS (ESI+) mlz-. 667.39 [M + H]+. Formate salt. 'H NMR (400 MHz, Methanol-d4) 8 8.51 (s, 2H), 5.11 - 4.95 (m, 1H), 4.81 - 4.71 (m, 1H), 4.72 - 4.52 (m, 2H), 4.48 (d, 1H), 4.22 (d, 1H), 4.06 - 3.87 (m, 1H), 3.80 - 3.67 (m, 1H), 3.52 - 3.33 (m, 6H), 3.07 (s, 3H), 3.03 - 2.94 (m, 1H), 2.89 (br s, 3H), 2.85 - 2.73 (m, 8H), 2.60 - 2.40 (m, 1H),
2.38 - 2.19 (m, 2H), 2.20 - 1.97 (m, 6H), 1.97 - 1.72 (m, 3H), 1.59 - 1.44 (m, 5H), 1.44 - 1.27 (m, 12H), 1.08 (d, 3H).
[0318] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl-3-(methyl-L- prolyl)-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-4-I1-1-2-2) (Compound 108). The amine intermediate from S3-4-I1-1-2-1 above (31.1 mg, 0.040 mmol) was dissolved in DCM (2 mL) and triethylamine (0.017 mL, 0.12 mmol). Na(OAc)sBH (25.4 mg, 0.120 mmol) followed by formaldehyde (37% aqueous solution, 0.0327 mL, 0.403 mmol) were added. After 15 min, the reaction mixture was quenched with NaHCO (sat, aq) and was extracted with DCM (2 times). The combined extracts were concentrated under reduced pressure. The crude material was dissolved in methanol (1 mL) and the reaction mixture was heated to 65 °C external temperature. After 4 h, the reaction was allowed to cool to rt and was concentrated. The residue was purified by HPLC (Atlantis T3 column, 5-50% MeCN-water-0.1% HCO2H) to give S3-4-I1-1-2-2 (12.9 mg). MS (ESI+) mlz-. 681.41 [M + H]+. Formate salt. XHNMR (400 MHz, Methanol-d4) 5 8.51 (s, 4H), 4.68 - 4.51 (m, 1H), 4.48 (d, 1H), 4.32 - 4.03 (m, 2H), 4.00 - 3.82 (m, 1H), 3.78 - 3.66 (m, 1H), 3.62 - 3.49 (m, 1H), 3.49 - 3.32 (m, 4H), 3.26 - 3.09 (m, 1H), 3.06 (s, 3H), 3.02 - 2.90 (m, 2H), 2.89 - 2.65 (m, 13H), 2.62 - 2.46 (m, 1H), 2.36 - 2.07 (m, 3H), 2.07 - 1.59 (m, 7H), 1.58 - 1.44 (m, 5H), 1.44 - 1.24 (m, 14H), 1.06 (br s, 3H).
[0319] (9R,llR,12R,13R)-3-(D-Prolyl)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl-17-oxa-3,7- diazaspiro [5.12] octadecane-14, 16-dione (S3-4-Il-l-2-3)( (Compound 59). Prepared according
to the methods of S3-4-I1-1-2-1 from Cbz-D-proline to provide the title compound (17.7 mg).
Formate salt. MS (ESI+) m/z: 667.43 [M + H]+. XHNMR (400 MHz, Methanol-d4) 1H NMR (400 MHz, Methanol-d4) 5 8.51 (s, 2H), 4.78 - 4.69 (m, 1H), 4.68 - 4.57 (m, 1H), 4.56 - 4.37 (m, 2H), 4.21 (d, 1H), 4.05 - 3.83 (m, 1H), 3.80 - 3.68 (m, 1H), 3.51 - 3.32 (m, 6H), 3.27 - 3.12 (m, 1H), 3.11 - 2.98 (m, 4H), 2.88 (br s, 3H), 2.84 - 2.69 (m, 8H), 2.59 - 2.41 (m, 1H), 2.38 - 1.96 (m, 7H), 1.96 - 1.69 (m, 3H), 1.59 - 1.43 (m, 5H), 1.43 - 1.26 (m, 13H), 1.08 (dd, 3.1 Hz, 3H).
[0320] (9R.HR.12R.13R)-12-(((2S.3R.4S.6R)-4-(/9/7m7//r/u/n/7n>)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl-3-(methyl-D- prolyl)-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-4-Il-5)( (Compound 60).
Prepared according to the methods of S3-4-I1-1-2-3 from Cbz-D-proline to provide the title compound (13.3 mg). Formate salt. MS (ESI+) mlz'. 681.41 [M + H]+. JH NMR (400 MHz, Methanol-d4) 5 8.53 (s, 3H), 5.07 - 4.94 (m, 1H), 4.68 - 4.55 (m, 1H), 4.54 - 4.32 (m, 2H), 4.21 (d, 1H), 3.98 - 3.80 (m, 1H), 3.78 - 3.68 (m, 1H), 3.66 - 3.54 (m, 1H), 3.50 - 3.32 (m, 4H), 3.22 - 2.94 (m, 6H), 2.93 - 2.65 (m, 13H), 2.64 - 2.49 (m, 1H), 2.33 - 1.66 (m, 10H), 1.60 - 1.43 (m, 5H), 1.43 - 1.25 (m, 13H), 1.07 (br s, 3H).
[0321] (9R,llR,12R,13R)-3-(Dimethyl-L-alanyl)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3- hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl- 17-oxa-3,7-diazaspiro[5.72]octadecane-14, 16-dione (S3-4-I1-1-2-5) (Compound 76). S3-1-I1-
1-2 (48 mg, 0.061 mmol) was dissolved in DCM (0.3 mL) and A,A-diisopropylethylamine (0.042 mL, 0.24 mmol), and 1 -hydroxybenzotri azole (10.7 mg, 0.080 mmol), Boc-L-alanine (13.8 mg, 0.0734 mmol), and A,A-diisopropylcarbodiimide (0.0113 mL, 0.0734 mmol) were added. After
21 h, the reaction mixture was concentrated under reduced pressure, and the residue was purified on 12 g of silica gel (elution with 2-10% MeOH-DCM-O.5% NH4OH gradient) to give the amide intermediate (27 mg, 52%) as a thick oil. The material was dissolved in 20% trifluoroacetic acid/DCM (1 mL). After 2 h, the reaction mixture was concentrated under reduced pressure. The residue was dissolved in DCM (2 mL) and Na(OAc)sBH (26.9 mg, 0.0318 mmol) followed by formaldehyde (37% aqueous solution, 0.0513 mL, 0.636 mmol) were added. After 45 min, the reaction mixture was quenched with NaHCCh (sat, aq) and was extracted with DCM (3 times). The combined extracts were dried over Na2SC>4, were filtered, and were concentrated under reduced pressure. The crude material was dissolved in methanol (2 mL), and the reaction mixture was heated to 50 °C external temperature overnight. The reaction was allowed to cool to rt and was concentrated. The residue was purified by HPLC (Atlantis T3 column, 5-50% MeCN-water- 0.1% HCO2H) to give S3-4-I1-1-2-5 (11.42 mg). MS (ESI+) m/z: 669.48 [M + H]+. Formate salt. 'H NMR (400 MHz, Methanol-d4) 8 8.52 (s, 3H), 5.09 - 4.92 (m, 1H), 4.70 - 4.51 (m, 1H), 4.48 (d, , 1H), 4.21 (d, 1H), 4.17 - 3.93 (m, 2H), 3.80 - 3.66 (m, 1H), 3.52 - 3.33 (m, 4H), 3.26 - 3.10 (m, 1H), 3.10 - 3.01 (m, 3H), 3.00 - 2.63 (m, 11H), 2.59 (s, 3H), 2.55 (s, 3H), 2.36 - 2.16 (m, 2H), 2.15 - 1.94 (m, 4H), 1.94 - 1.72 (m, 2H), 1.60 - 1.45 (m, 5H), 1.44 - 1.24 (m, 15H), 1.07 (d, 3H).
[0322] (9R,llR,12R,13R)-3-(Dimethyl-D-alanyl)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3- hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl- 17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-4-I1-7) (Compound 77). Prepared according to the methods of S3-4-I1-1-2-5 from Boc-D-alanine to provide the title compound (11.5 mg). Formate salt. MS (ESI+) m/z: 669.48 [M + H]+. XH NMR (400 MHz, Methanol-d4) 8 8.51 (s, 3H), 5.07 - 4.92 (m, 1H), 4.62 (br d, 1H), 4.55 - 4.34 (m, 2H), 4.22 (d, 1H), 4.18 - 3.95 (m, 2H), 3.81 - 3.67 (m, 1H), 3.54 - 3.33 (m, 4H), 3.25 - 3.12 (m, 1H), 3.11 - 2.94 (m, 4H), 2.88 (br s, 3H), 2.84 - 2.74 (m, 7H), 2.63 (s, 3H), 2.56 (s, 3H), 2.35 - 1.95 (m, 5H), 1.94 - 1.73 (m, 2H), 1.59 - 1.44 (m, 5H), 1.44 - 1.26 (m, 15H), 1.08 (d, 3H).
[0323] (9R,llR,12R,13R)-3-(2-Amino-2-meZZzj;Z/jropanoj;Z)-12-(((2S,3R,4S,6R)-4- (dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy- 7,9,H,13,15,15-hexamethyl-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-4-I1-1-2- 7)( (Compound 88). Prepared according to the methods of S3-4-I1-1-2-1 from a-(Boc- amino)isobutyric acid with Boc-deprotection according to the methods of S3-4-I1-1-2-5 to provide the title compound (3.49 mg). Formate salt. MS (ESI+) mlr. 655.42 [M + H]+. JH NMR (400 MHz, Methanol-d4) 8 8.47 (s, 2H), 5.11 - 4.91 (br s, 1H), 4.70 - 4.54 (br m, 1H), 4.49 (d, 1H), 4.45 - 4.24 (br m, 1H), 4.21 (d, 1H), 3.74 (dq, 1H), 3.51 - 3.33 (m, 4H), 3.29 - 3.11 (br m, 2H), 3.06 (s, 3H), 2.95 - 2.84 (br m, 3H), 2.80 (s, 6H), 2.79 - 2.71 (br m, 1 H), 2.37 - 2.19 (br m, 1H), 2.18 - 1.97 (m, 4H), 1.95 - 1.71 (m, 3H), 1.68 (d, 6H), 1.58 - 1.45 (m, 5H), 1.40 (s, 6H), 1.37 (d, 3H), 1.33 (d, 3H), 1.07 (br d, 3H).
[0324] (9R,llR,12R,13R)-3-(2-(Dimethylamino)-2-methylpropanoyl)-12-(((2S,3R,4S,6R)-4- (dimethylamino)-3-hydroxy-6-zzzeZZryZteZraZryzZro-2H-pyran-2-yl)oxy)-l 1-methoxy- 7,9,H,13,15,15-hexamethyl-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-4-I1-2-8) (Compound 89). Prepared according to the methods of S3-4-I1-1-2-5 from a-(Boc- amino)isobutyric acid to provide the title compound (6.94 mg). Formate salt. MS (ESI+) mlz\ 683.44 [M + H]+. LH NMR (400 MHz, Methanol-d4) 8 8.42 (s, 2H), 5.04 (d, 1H), 4.65 (d, 1H), 4.48 (d, 1H), 4.22 (d, 1H), 3.74 (tdd, 1H), 3.51 - 3.32 (m, 4H), 3.28 - 3.14 (m, 2H), 3.06 (s, 3H), 2.89 (br s, 4H), 2.86 - 2.76 (m, 7H), 2.38 - 2.21 (m, 7H), 2.18 - 1.94 (m, 5H), 1.84 (br d, 2H), 1.60 - 1.44 (m, 5H), 1.41 (d, 6H), 1.38 (dd, 3H), 1.33 (d, 3H), 1.28 (s, 6H), 1.09 (d, 3H).
[0325] (9R,llR,12R,13R)-3-(D-Seryl)-12-(((2S,3R,4S,6R)-4-(rfiwietAy/am/no)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl-17-oxa-3,7- diazaspiro [5.12] octadecane-14, 16-dione (S3-4-I1-1-2-9) (Compound 91). Prepared according to the methods of S3-4-I1-1-2-1 from Boc-D-Ser-OH with Boc-deprotection according to the methods of S3-4-I1-1-2-5 to provide the title compound (5.19 mg). Formate salt. MS (ESI+) mlr. 657.43 [M + H]+. LH NMR (400 MHz, Methanol-d4) 5 8.48 (s, 1H), 5.05 (br s, 1H), 4.72 - 4.51 (m, 2H), 4.48 (d, 1H), 4.46 - 4.30 (m, 1H), 4.21 (d, 1H), 4.13 - 3.95 (m, 1H), 3.92 - 3.78 (m, 2H), 3.77 - 3.65 (m, 2H), 3.52 - 3.33 (m, 4H), 3.28 - 3.12 (m, 1H), 3.06 (s, 3H), 23.00 - 2.84 (m, 3H), 2.83 - 2.70 (m, 7H), 2.40 - 1.95 (m, 5H), 1.95 - 1.71 (m, 2H), 1.59 - 1.49 (m, 5H), 1.43 - 1.24 (m, 12H), 1.07 (d, 3H).
[0326] (9R,llR,12R,13R)-3-(Dimethyl-D-seryl)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3- hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl- 17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-4-I1-1-2-10) (Compound 90).
Prepared according to the methods of S3-4-I1-1-2-5 from Boc-D-Ser-OH to provide the title compound (7.28 mg). Formate salt. MS (ESI+) mlz\ 685.41 [M + H]+. 'H NMR (400 MHz, Methanol-d4) 5 8.48 (s, 3H), 5.01 (br s, 1H), 4.69 - 4.51 (m, 2H), 4.48 (d, 1H), 4.22 (d, 1H), 4.19 - 4.07 (m, 1H), 4.04 - 3.84 (m, 3H), 3.73 (dddd, 1H), 3.52 - 3.33 (m, 4H), 3.27 - 3.13 (m, 1H), 3.06 (s, 3H), 3.04 - 2.95 (m, 1H), 2.88 (s, 3H), 2.84 - 2.75 (m, 7H), 2.69 (s, 3H), 2.58 (s, 3H), 2.36 - 2.20 (m, 1H), 2.19 - 2.09 (m, 1H), 2.09 - 1.97 (m, 3H), 1.92 - 1.75 (m, 2H), 1,59 - 1.44 (m, 5H), 1.43 - 1.28 (m, 12H), 1.08 (d, 3H).
[0327] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-3-(4-methoxybenzoyl)-7,9,ll,13,15,15- hexamethyl-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-4-Il-l-2-ll)(Compound
114). Prepared according to the methods of S3-4-I1 - 1 -2-5 from 4-methoxybenzoic acid. 25.0 mg Formate salt. MS (ESI+) m/z: 704.5 [M + H]+; LH NMR (400 MHz, CD3OD) 8 = 7.44 - 7.33 (m, 2H), 7.03 - 6.96 (m, 2H), 4.42 (d, 1H), 4.24 (d, 1H), 4.17 - 4.00 (m, 2H), 3.98 - 3.84 (m, 1H), 3.84 (s, 3H), 3.70 - 3.39 (m, 5H), 3.28 (dd, 1H), 2.96 (s, 3H), 2.68 - 2.60 (m, 1H), 2.39 (s, 3H), 2.34 (s, 7H), 2.03 - 1.71 (m, 5H), 1.70 - 1.58 (m, 1H), 1.52 (s, 3H), 1.48 - 1.33 (m, 4H), 1.33 - 1.15 (m, 11H), 0.99 - 0.80 (m, 1H).
[0328] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-3-isonicotinoyl-ll-methoxy-7,9,ll,13,15,15- hexamethyl-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-4-Il-l-2-12)(Compound 115). Prepared according to the methods of S3-4-I1 - 1 -2-5 from isonicotinic acid. 19.2 mg Formate salt. MS (ESI+) m/z: 675.4 [M + H]+; 'H NMR (400 MHz, Acetonitrile-d3) 6 = 8.63 (d, 2H), 7.29 (d, 2H), 4.37 (d, 1H), 4.19 (d, 1H), 4.04 (br d, 1H), 3.94 (d, 2H), 3.57 - 3.30 (m, 5H), 3.25 - 3.14 (m, 1H), 3.14 - 2.99 (m, 1H), 2.89 (br d, 3H), 2.48 (ddd, 1H), 2.37 (s, 3H), 2.34 - 2.20 (m, 9H), 1.92 - 1.66 (m, 6H), 1.65 - 1.49 (m, 1H), 1.48 - 1.44 (m, 3H), 1.42 - 1.36 (m, 1H), 1.33 (br d, 3H), 1.26 (br d, 1H), 1.23 (br s, 2H), 1.22 (s, 4H), 1.20 - 1.15 (m, 4H), 0.83 (br d, 3H).
[0329] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl-3-(2- phenylacetyl)-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-4-I1-1-2- 13)(Compound 117). Prepared according to the methods of S3-4-I1 -1 -2-5 from phenylacetic acid. 16.6 mg Formate salt. MS (ESI+) miz-. 688.5 [M + H]+; 'H NMR (400 MHz, MeOD) 5 = 7.36 - 7.20 (m, 5H), 4.40 (d, 1H), 4.21 - 4.09 (m, 1H), 4.09 - 3.94 (m, 2H), 3.91 - 3.83 (m, 1H), 3.83 - 3.72 (m, 2H), 3.72 - 3.44 (m, 3H), 3.44 - 3.32 (m, 3H), 3.30 - 3.23 (m, 2H), 2.95 (d, 3H), 2.66 - 2.58 (m, 1H), 2.33 (s, 6H), 2.28 - 2.24 (m, 3H), 2.20 (br d, 1H), 1.89 - 1.67 (m, 4H), 1.67 - 1.52 (m, 2H), 1.49 (d, 3H), 1.46 - 1.33 (m, 5H), 1.32 - 1.14 (m, 16H), 1.01 - 0.90 (m, 2H), 0.90 - 0.80 (m, 3H).
[0330] (9R,llR,12R,13R)-3-(4-chlorobenzoyl)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3- hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl- 17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-4-Il-l-2-14)(Compound 118).
Prepared according to the methods of S3 -4-11-1 -2-5 from 4-chlorobenzoic acid. 34.0 mg Formate salt. MS (ESI+) mfr. 708.5 [M + H]+; LH NMR (400 MHz, CD3OD) 8 = 7.49 - 7.46 (m, 2H), 7.44
- 7.39 (m, 2H), 4.42 (d, 1H), 4.23 (d, 1H), 4.09 (d, 1H), 4.05 (d, 1H), 3.91 (br s, 1H), 3.75 - 3.38 (m, 5H), 3.38 - 3.32 (m, 1H), 3.28 (dd, 1H), 2.96 (s, 3H), 2.66 - 2.59 (m, 1H), 2.39 (s, 3H), 2.34 (s, 8H), 2.09 (br s, 1H), 1.94 (br s, 1H), 1.88 - 1.70 (m, 4H), 1.60 (br s, 1H), 1.52 (br s, 3H), 1.49 - 1.40 (m, 1H), 1.40 - 1.33 (m, 3H), 1.31 - 1.20 (m, 10H), 0.88 (br d, 3H).
[0331] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-N-(4-methoxyphenyl)-7,9,ll,13,15,15- hexamethyl-14,16-dioxo-17-oxa-3,7-diazaspiro[5.12]octadecane-3-carboxamide (S3-4-I1-1-2-
15)(Compound 119). Prepared according to the methods of S3-4-I1 -1 - 1 - 1 from S3 -4-11 -1-2- land 4-methoxyphenyl isocyanate. 19.4 mg Formate salt. MS (ESI+) mlz'. 719.5 [M + H]+; rH NMR (400 MHz, CD3OD) 6 = 7.25 - 7.18 (m, 2H), 6.87 - 6.81 (m, 2H), 4.42 (d, 1H), 4.17 (dd, 2H), 4.05 (d, 1H), 3.80 - 3.68 (m, 5H), 3.61 - 3.53 (m, 1H), 3.44 (quin, 1H), 3.38 - 3.33 (m, 1H), 3.28 (dd, 1H), 3.17 - 3.02 (m, 1H), 2.97 (s, 3H), 2.63 (ddd, 1H), 2.44 - 2.36 (m, 3H), 2.34 (s, 7H), 2.02 - 1.67 (m, 6H), 1.52 (s, 4H), 1.40 (s, 3H), 1.31 - 1.21 (m, 11H), 0.89 (d, 3H).
[0332] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-3-(3-methoxybenzyl)-7,9,ll,13,15,15- hexamethyl-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-2-I1-1-2-16) (Compound
122). Prepared according to the methods of S3-2-I1 - 1 -1 -2 from 3 -methoxybenzaldehyde. 16.4 mg, formate salt. MS (ESI+) mlr. 690.4 [M + H]+; 1H NMR (400 MHz, Acetonitrile-d3) 6 8.35 (br s, 2H), 7.25 (t, 1H), 6.94 - 6.86 (m, 2H), 6.83 (dd, 1H), 4.55 - 4.48 (m, 1H), 4.44 - 4.36 (m, 2H), 4.28 - 4.16 (m, 1H), 4.09 (br d, 2H), 4.04 - 3.79 (m, 6H), 3.78 (s, 3H), 3.70 (br s, 2H), 3.66 - 3.56 (m, 3H), 3.54 (s, 2H), 3.43 (br s, 1H), 3.32 - 3.11 (m, 3H), 2.96 (s, 3H), 2.92 - 2.71 (m, 5H), 2.65 (br s, 3H), 2.60 - 2.43 (m, 3H), 2.43 - 2.36 (m, 6H), 2.26 (br t, 3H), 2.06 (br d, 3H), 1.81 (br d, 3H), 1.70 - 1.50 (m, 4H), 1.49 - 1.40 (m, 4H), 1.38 - 1.15 (m, 15H), 0.99 (br d, 3H).
[0333] (9R,llR,12R,13R)-N-benzyl-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl-14,16-dioxo- 17-oxa-3,7-diazaspiro[5.12]octadecane-3-carboxamide (S3-4-Il-l-2-17)(Compound 123).
Prepared according to the methods of S3 -4-11-1 - 1 -1 from S3 -4-11- 1 -2- 1 and benzyl isocyanate. 12.5 mg Formate salt. MS (ESI+) m!z-. 703.5 [M + H]+; JH NMR (400 MHz, CD3OD) 6 = 7.22 - 7.16 (m, 4H), 7.14 - 7.07 (m, 1H), 4.31 (d, 1H), 4.26 (s, 2H), 4.10 (d, 1H), 4.05 - 3.97 (m, 1H), 3.94 (d, 1H), 3.88 - 3.63 (m, 1H), 3.60 - 3.49 (m, 2H), 3.47 (ddd, 1H), 3.33 (quin, 1H), 3.20 - 3.09 (m, 3H), 3.07 - 2.94 (m, 1H), 2.87 (s, 3H), 2.53 (ddd, 1H), 2.27 - 2.14 (m, 11H), 1.94 - 1.60 (m, 6H), 1.55 (br d, 1H), 1.41 (s, 3H), 1.39 - 1.31 (m, 1H), 1.29 (s, 3H), 1.21 - 1.08 (m, 12H), 0.80 - 0.74 (m, 3H).
[0334] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl-3-nicotinoyl- 17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-4-Il-l-2-18)(Compound 125).
Prepared according to the methods of S3 -4-11-1 -2-5 from nicotinic acid. Formate salt. MS (ESI+) mfr. 675.5 [M + H]+; LH NMR (400 MHz, Acetonitrile d3) 5 = 8.61 (dd, 1H), 8.59 (dd, 1H), 7.75 (td, 1H), 7.39 (ddd, 1H), 4.37 (d, 1H), 4.20 (br d, 1H), 4.04 (br d, 1H), 3.94 (br d, 2H), 3.60 - 3.16 (m, 6H), 3.09 (dd, 1H), 2.90 (s, 3H), 2.49 (ddd, 1H), 2.42 (br s, 1H), 2.37 (br s, 3H), 2.30 (br s, 3H), 2.25 (s, 6H), 1.86 (br d, , 2H), 1.77 (br td, 2H), 1.69 (ddd, 1H), 1.60 - 1.51 (m, 1H), 1.46 (s, 3H), 1.40 - 1.26 (m, 5H), 1.26 - 1.15 (m, 10H), 1.13 (dd, 1H), 0.99 - 0.87 (m, 1H), 0.84 (br d, 3H).
[0335] (9R,llR,12R,13R)-3-benzoyl-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl-17-oxa-3,7- diazaspiro [5.12] octadecane-14, 16-dione (S3-4-Il-l-2-19)(Compound 137). Prepared according to the methods of S3 -4-11-1 -2-5 from benzoic acid. 26.0 mg Formate salt. MS (ESI+) mlz\ 674.5 [M + H]+; 'H NMR (400 MHz, Acetonitrile d3) 5 = 8.34 (br s, 2H), 7.53 - 7.34 (m, 5H), 4.54 - 4.10 (m, 4H), 4.06 (br d, 1H), 3.60 (dtd, 2H), 3.44 - 3.10 (m, 20H), 3.06 (br s, 1H), 3.02 - 2.83 (m, 5H), 2.75 - 2.46 (m, 11H), 1.99 - 1.96 (m, 1H), 1.91 - 1.83 (m, 2H), 1.61 (br dd, 2H), 1.47 (s, 3H), 1.45 - 1.24 (m, 11H), 1.22 (d, 3H), 0.95 (br d, 3H).
[0336] (9R,llR,12R,13R)-N-(4-chlorophenyl)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3- hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl- 14,16-dioxo-17-oxa-3,7-diazaspiro[5.12]octadecane-3-carboxamide (S3-4-I1-1-2-
20)(Compound 138). Prepared according to the methods of S3-4-I1 -1 - 1 - 1 from S3-4-I1 -1 -2- 1 and 3 -chlorophenyl isocyanate. 25.9 mg Formate salt. MS (ESI+) mlz'. 723.4 [M + H]+; 'H NMR (400 MHz, CD3OD) 8 = 7.38 - 7.33 (m, 2H), 7.27 - 7.21 (m, 2H), 4.83 (s, 11H), 4.42 (d, 1H), 4.28 - 4.08 (m, 2H), 4.05 (d, 1H), 3.80 - 3.68 (m, 2H), 3.62 - 3.51 (m, 1H), 3.49 - 3.33 (m, 3H), 3.29 - 3.16 (m, 1H), 3.12 (s, 1H), 2.97 (s, 3H), 2.63 (ddd, 1H), 2.38 (s, 3H), 2.36 - 2.27 (m, 8H), 2.03 - 1.65 (m, 6H), 1.52 (s, 3H), 1.46 - 1.33 (m, 3H), 1.31 - 1.20 (m, 11H), 0.89 (d, 3H).
[0337] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl-14,16-dioxo- N-phenyl-17-oxa-3,7-diazaspiro[5.12]octadecane-3-carboxamide (S3-4-I1-1-2-
21)(Compound 140). Prepared according to the methods of S3-4-I1 -1 - 1 - 1 from S3-4-I1 -1 -2- 1 and phenyl isocyanate. 26.4 mg Formate salt. MS (ESI+) mfr. 689.5 [M + H]+; 'H NMR (400 MHz, MeOD) 8 = 7.36 - 7.32 (m, 2H), 7.28 - 7.23 (m, 2H), 7.01 (t, 1H), 4.42 (d, 1H), 4.23 (br d, 1H), 4.16 - 4.01 (m, 2H), 3.80 - 3.70 (m, 2H), 3.57 (ddd, 1H), 3.49 - 3.32 (m, 3H), 3.29 - 3.23 (m, 1H), 3.12 (s, 1H), 2.98 (s, 3H), 2.63 (ddd, 1H), 2.41 - 2.29 (m, 11H), 2.05 - 1.65 (m, 7H), 1.52 (s, 4H), 1.40 (s, 3H), 1.35 - 1.19 (m, 13H), 1.10 - 0.92 (m, 1H), 0.89 (br d, 3H).
[0338] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-3-(JwietAy/g/ycj7)-ll-methoxy-7,9,ll,13,15- pentamethyl-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-5-Il-l-l-l)(Compound
8). S3-1-I1-1-1 (30 mg, 0.039 mmol) was dissolved in DCM (1 mL) and triethylamine (0.016 mL, 0.116 mmol), and chloroacetyl chloride (0.0046 mL, 0.058 mmol) was added. After 15 min, dimethylamine (2 M solution in tetrahydrofuran, 0.194 mL, 389 mmol) was added. After 15 min, the reaction mixture was heated to 70 °C. After 4 h, the reaction mixture was allowed to cool to rt and stir over the weekend. The reaction mixture was diluted with DCM, was washed with water (1 time), and was concentrated. The crude material was dissolved in methanol (1 mL), and the reaction mixture was heated to 60 °C external temperature. After 3 h, the reaction was allowed to cool to rt and was concentrated. The residue was purified by HPLC (Atlantis T3 column, 5-30% MeCN-water-0.1% HCOzH) to give S3-5-I1-1-1-1 (7.30 mg). MS (ESI+) mfr. 641.42 [M + H]+.
Formate salt, mixture of C2 epimers, 'H NMR (400 MHz, Methanol-d4) 6 8.45 (br s, 1H), 4.81 - 4.68 (m, 1H), 4.66 - 4.40 (m, 2H), 4.36 - 4.22 (m, 2H), 4.21 - 4.15 (m, 0.5H), 4.15 - 4.04 (m, 1H), 4.02 - 3.92 (m, 0.5H), 3.90 - 3.68 (m, 2H), 3.59 - 3.35 (m, 5H), 3.16 - 3.00 (m, 4H), 2.96 - 2.76 (m, 16H), 2.40 - 2.20 (m, 2H), 2.18 - 1.99 (m, 2H), 1.96 - 1.69 (m, 3H), 1.66 - 1.47 (m, 2H), 1.43 (br s, 3 H), 1.40 - 1.25 (m, 10H), 1.16 - 1.02 (m, 3H).
[0339] (9R,llR,12R,13R)-3-(2-(Azetidin-l-yl)acetyl)-12-(((2S,3R,4S,6R)-4-(dimethylamino)- 3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15-pentamethyl- 17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-5-I1-1-1-2) (Compound 9). Prepared according to the methods of S3-5-I1-1-1-1 from S3-1-I1-1-1 and azetidine to provide the title compound (3.77 mg). Formate salt, mixture of C2 epimers. MS (ESI+) mlz.- 653.40 [M + H]+.
NMR (400 MHz, Methanol-d4) 6 8.49 (s, 2H), 4.49 (d, 1H), 4.43 (t, 1H), 4.34 - 4,23 (m, 2H), 4.23 - 4.02 (m, 4H), 4.02 - 3.87 (m, 1H), 3.78 - 3.60 (m, 3H), 3.50 - 3.33 (m, 4H), 3.1- 2.94 (m, 4H), 2.88 - 2.59 (m, 10H), 2.49 (d, 2H), 2.25 - 2.05 (m, 3H), 2.06 - 1.98 (m, 2H), 1.93 - 1.58 (m, 5H), 1.57 - 1.43 (m, 2H), 1.43 - 1.19 (m, 12H), 1.12 - 0.95 (m, 3H).
[0340] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15-pentamethyl-3-(2- (pyrrolidin-l-yl)acetyl)-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-5-I1-1-1-3) (Compound 10). Prepared according to the methods of S3-5-I1-1-1-1 from S3-1-I1-1-1 and pyrrolidine to provide the title compound (3.24 mg). Formate salt, mixture of C2 epimers. MS
(ESI+) mlz-. 667.34 [M + H]+. 'H NMR (400 MHz, Methanol-d4) 8 8.53 (s, 2H), 4.49 (d, 1H), 4.41 (dd, 1H), 4.25 (d, 1H), 4.11 - 3.86 (m, 3H), 3.78 - 3.61 (m, 3H), 3.51 - 3.34 (m, 4H), 3.28 -
2.87 (m, 10H), 2.83 - 2.60 (m, 7H), 2.2.59 - 2.33 (m, 2H), 2.19 - 2.09 (m, 1H), 2.10 - 1.90 (m, 6H), 1.89 - 1.54 (m, 4H), 1.54 - 1.41 (m, 2H), 1.40 - 1.18 (m, 13H), 1.10 - 0.84 (m, 3H).
[0341] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15-pentamethyl-3-(2- (piperidin-l-yl)acetyl)-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-5-I1-1-1- 4)(Compound 11). Prepared according to the methods of S3-5-I1-1-1-1 from S3-1-I1-1-1 and piperidine to provide the title compound (5.25 mg). Formate salt, mixture of C2 epimers. MS (ESI+) mlz-. 681.37 [M + H]+. ^NMR (400 MHz, Methanol-d4) 5 8.53 (s, 2H), 4.49 (d, 1H), 4.42 (t, 1H), 4.26 (d, 1H), 3.76 - 3.51 (m, 4H), 3.51 - 3.34 (m, 4H), 3.09 - 2.95 (m, 4H), 2.90 - 2.41 (m, 15H), 2.19 - 1.93 (m, 4H), 1.92 - 1.63 (m, 8H), 1.63 - 1.42 (m, 5H), 1.42 - 1.19 (m, 13H), 1.09 - 0.87 (m, 3H).
[0342] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,H,13,15-pentamethyl-3-(2- morpholinoacetyl)-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-5-I1-1-1-5) (Compound 12). Prepared according to the methods of S3-5-I1-1-1-1 from S3-1-I1-1-1 and morpholine to provide the title compound (7.08 mg). Formate salt, mixture of C2 epimers. MS (ESI+) mlz-. 683.35 [M + H]+. ^NMR (400 MHz, Methanol-d4) 5 8.54 (s, 1H), 4.48 (d, 1H), 4.40 (d, 0.5H), 4.26 (d, 1H), 4.17 (d, 0.5H), 4.02 - 3.92 (m, 0.5H), 3.84 - 3.79 (m, 0.5H), 3.77 - 3.60 (m, 6H), 3.49 - 3.35 (m, 4H), 3.29 - 3.13 (m, 3H), 3.12 - 2.95 (m, 4H), 2.83 - 2.59 (m, 9H), 2.57 - 2.41 (m, 5H), 2.17 - 2.05 (m, 1H), 2.06 - 1.90 (m, 3H), 1.89 - 1.53 (m, 4H), 1.52 - 1.40
(m, 3H), 1.40 - 1.18 (m, 12H), 1.10 - 0.85 (m, 3H).
[0343] (9R,llR,12R,13R)-3-(Cyclobutylglycyl)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3- hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15-pentamethyl-17- oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-5-I1-1-1-6) (Compound 17). Prepared according to the methods of S3-5-I1-1-1-1 from S3-1-I1-1-1 and cyclobutylamine to provide the title compound (4.17 mg). Formate salt, mixture of C2 epimers. MS (ESI+) mlz'. 667.40 [M + H]+ 'H NMR (400 MHz, Methanol-d4) 5 8.51 (s, 2H), 4.70 - 4.52 (br m, 1H), 4.51 - 4.38 (m, 1.5H), 4.26 (d, 1H), 4.17 (d, 0.5H), 4.03 - 3.75 (m, 3H), 3.75 - 3.59 (m, 3H), 3.50 - 3.33 (m, 4H), 3.06 (s, 1H), 3.03 (s, 2H), 2.88 - 2.59 (m, 10H), 2.38 - 2.23 (m, 2H), 2.22 - 2.08 (m, 4H), 2.08 - 1.96 (m, 4H), 1.95 - 1.57 (m, 6H), 1.57 - 1.43 (m, 2H), 1.43 - 1.20 (m, 12H), 1.02 (s, 3H).
[0344] (9R,llR,12R,13R)-3-((Cyclopropylmethyl)glycyl)-12-(((2S,3R,4S,6R)-4- (dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-
7,9,11, 13, 15-pentamethyl-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-5-I1-1-1- 7)(Compound 13). Prepared according to the methods of S3-5-I1-1-1-1 from S3-1-I1-1-1 and cyclopropylmethylamine to provide the title compound (11.1 mg). Formate salt, mixture of C2 epimers. MS (ESI+) mlz-. 667.39 [M + H]+. 1 H NMR (400 MHz, Methanol-d4) 6 8.45 (s, 1 ,5H), 4.78 - 4.67 (m, 0.8H), 4.66 - 4.56 (m, 0.2H), 4.56 - 4.40 (m, 2H), 4.27 (d, 0.8H), 4.17 (d, 0.2H), 4.15 - 4.00 (m, 1H), 3.80 - 3.67 (m, 2H), 3.58 - 3.33 (m, 6H), 3.26 - 3.09 (m, 1H), 3.06 (s, 3H), 2.96 - 2.74 (m, 10H), 2,42 (s, 3H), 2.37 - 2.19 (m, 1H), 2.19 - 1.97 (m, 3H), 1.97 - 1.68 (m, 4H), 1.63 - 1.45 (m, 3H), 1.42 (s, 3H), 1.39 - 1.23 (m, 9H), 1.14 - 1.00 (m, 3H), 0.59 - 0.39 (m, 4H).
[0345] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-3-(isopropylglycyl)-ll-methoxy-7,9,ll,13,15- pentamethyl-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-5-Il-l-l-8)(Compound 14). Prepared according to the methods of S3-5-I1-1-1-1 from S3-1-I1-1-1 and isopropylamine to provide the title compound (8.91 mg). Formate salt, mixture of C2 epimers. MS (ESI+) mlz-.
655.41 [M + H]+. LH NMR (400 MHz, Methanol-d4) 5 8.52 (s, 1H), 4.49 (d, 1H), 4.44 (d, 0.5H), 4.26 (d, 1H), 4.21 - 4.06 (m, 1H), 4.05 - 3.92 (m, 1.5H), 3.78 - 3.67 (m, 2H), 3.50 - 3.33 (m, 5H), 3.28 - 3.15 (m, 2H), 3.10 - 2.96 (m, 4H), 2.90 - 2.67 (m, 10H), 2.31 - 2.12 (m, 2H), 2.12 - 1.91 (m, 3H), 1.91 - 1.61 (m, 3H), 1.61 - 1.43 (m, 3H), 1.43 - 1.17 (m, 18H), 1.11 - 0.96 (m, 3H).
[0346] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-3-(N-isopropyl-N-methylglycyl)-ll-methoxy-
7,9,11, 13, 15-pentamethyl-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-5-I1-1-1- 9)(Compound 15). Prepared according to the methods of S3-5-I1-1-1-1 from S3-1-I1-1-1 and N- methylpropan-2-amine to provide the title compound (9.77 mg). Formate salt, mixture of C2 epimers. MS (ESI+) mlz-. 669.40 [M + H]+. 1 H NMR (400 MHz, Methanol-d4) 6 8.53 (s, 2H), 4.49 (d, 1H), 4.26 (d, 1H), 4.13 - 3.85 (m, 3H), 3.78 - 3.65 (m, 2H), 3.53 - 3.33 (m, 5H), 3.10 - 2.94 (m, 3H), 2.89 - 2.56 (m, 14H), 2.30 - 2.14 (m, 1H), 2.14 - 1.89 (m, 3H), 1.88 - 1.57 (m, 3H), 1.57 - 1.43 (m, 2H), 1.43 - 1.18 (m, 22H), 1.11 - 0.95 (m, 3H).
[0347] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-3-((2-methoxyethyl)glycyl)-7,9,ll,13,15- pentamethyl-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-5-Il-l-l-10)(Compound 16). Prepared according to the methods of S3-5-I1-1-1-1 from S3-1-I1-1-1 and 2-methoxyethan- 1-amine to provide the title compound (4.97 mg). Formate salt, mixture of C2 epimers. MS (ESI+) mlz-. 671.42 [M + H]+. 'H NMR (400 MHz, Methanol-d4) 5 8.54 (s, 1H), 4.53 - 4.35 (m, 1H), 4.30 - 4.11 (m, 1H), 3.86 - 3.60 (m, 4H), 3.59 - 3.53 (m, 2H), 3.46 - 3.33 (m, 7H), 3.24 - 3.08 (m, 2H), 3.08 - 2.87 (m, 6H), 2.76 - 2.55 (m, 8H), 2.54 - 2.32 (m, 2H), 2.19 - 1.97 (m, 2H), 1.97 - 1.89 (m, 2H), 1.88 - 1.53 (m, 4H), 1.50 - 1.38 (m, 2H), 1.38 - 1.15 (m, 13H), 1.06 - 0.82 (m, 3H).
[0348] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Z)iW^j;ZawMno)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,H,13,15-pentamethyl-3- (methylglycyl)-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-5-I1-1-1- ll)(Compound 18). Prepared according to the methods of S3-5-I1-1-1-1 from S3-1-I1-1-1 and methylamine to provide the title compound (3.69 mg). Formate salt, mixture of C2 epimers. MS (ESI+) mlz-. 627.38 [M + H]+. 'H NMR (400 MHz, Methanol-d4) 5 8.52 (s, 2H), 4.72 - 4.54 (br s, 1H), 4.53 - 4.38 (m, 1H), 4.30 - 4.14 (m, 1H), 4.14 - 3.89 (m, 2H), 3.84 - 3.55 (m, 2H), 3.52 - 3.33 (m, 6H), 3.06 (s, 1H), 3.03 (s, 2H), 2.89 - 2.47 (m, 14H), 2.28 - 2.13 (m, 1H), 2.12 - 1.89 (m, 4H), 1.88 - 1.56 (m, 4H), 1.57 - 1.43 (m, 2H), 1.43 - 1.19 (m, 13H), 1.12 - 0.88 (m, 3H).
[0349] (9R,llR,12R,13R)-3-(Diethylglycyl)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3- hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15-pentamethyl-17- oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-5-Il-l-l-12)(Compound 28). Prepared according to the methods of S3-5-I1-1-1-1 from S3-1-I1-1-1 and diethylamine to provide the title compound (7.89 mg). Formate salt, mixture of C2 epimers. MS (ESI+) mlz'. 669.46 [M + H]+. rH NMR (400 MHz, Methanol-d4) 8 8.49 (s, 1H), 4.52 - 4.40 (m, 1H), 4.33 - 4.21 (m, 2H), 4.20 - 4.03 (m, 2H), 3.79 - 3.62 (m, 2H), 3.51 - 3.32 (m, 4H), 3.28 - 3.11 (m, 6H), 3.11 - 2.94 (m, 5H), 2.94 - 2.66 (m, 10H), 2.37 - 2.17 (m, 2H), 2.16 - 1.92 (m, 3H), 1.92 - 1.67 (m, 3H), 1.58 - 1.44 (m, 2H), 1.44 - 1.18 (m, 18H), 1.13 - 0.97 (m, 3H).
[0350] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-3-(N-ethyl-N-methylglycyl)-ll-methoxy-7,9,ll,13,15- pentamethyl-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-5-H-l-l-13)(Compound 36). Prepared according to the methods of S3-5-I1 - 1-1- 1 from S3-1-I1-1-1 and N- methylethylamine to provide the title compound (4.79 mg). Formate salt, mixture of C2 epimers. MS (ESI+) m/z: 655.41 [M + H]“. 'H NMR (400 MHz, Methanol-d4) 8 8.54 (s, 2H), 4.52 - 4.42 (m, 1H), 4.25 (d, 1H), 4.03 - 3.92 (m, 1H), 3.71 - 3.58 (m, 2H), 3.57 - 3.37 (m, 4H), 3.23 - 3.10 (m, 1H), 3.08 - 2.91 (m, 4H), 2.79 - 2.50 (m, 10H), 2.48 - 2.29 (m, 6H), 2.22 - 2.08 (m, 2H), 2.07 - 1.97 (m, 2H), 1.96 - 1.84 (m, 2H), 1.83 - 1.52 (m, 2H), 1.51 - 1.20 (m, 16H), 1.19 - 1.07 (m, 4H), 0.96 - 0.80 (m, 3H).
[0351] (9R,llR,12R,13R)-3-(N-(Cyclopropylmethyl)-N-methylglycyl)-12-(((2S,3R,4S,6R)-4- (dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-
7,9,11, 13, 15-pentamethyl-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-5-I1-1-1- 14)(Compound 41). Prepared according to the methods of S3-5-I1-1-1-1 from S3-1-I1-1-1 and (cyclopropylmethyl)methylamine to provide the title compound (5.0 mg). Formate salt, mixture of C2 epimers. MS (ESI+) mlz'. 681.39 [M + H]+. 'H NMR (400 MHz, Methanol-d4) 5 8.52 (s, 2H), 4.70 - 4.52 (br m, 1H), 4.51 - 4.38 (m, 1H), 4.31 - 4.12 (m, 1H), 4.06 - 3.77 (m, 3H), 3.77 - 3.62 (m, 2H), 3.52 - 3.24 (m, 5H), 3.16 - 2.91 (m, 5H), 2.91 - 2.45 (m, 15H), 2.26 - 1.88 (m, 4H), 1.88 - 1.58 (m, 4H), 1.57 - 1.44 (m, 2H), 1.43 - 1.22 (m, 12H), 1.15 - 0.88 (m, 4H), 0.78 - 0.57 (m, 2H), 0.42 - 0.28 (m, 2H).
[0352] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-3-(N-isobutyl-N-methylglycyl)-ll-methoxy-
7,9,11, 13, 15-pentamethyl-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-5-I1-1-1- 15)(Compound 42). Prepared according to the methods of S3-5-I1-1-1-1 from S3-1-I1-1-1 and A-methyl isobutyl amine to provide the title compound (5.03 mg). Formate salt, mixture of C2 epimers. MS (ESI+) mlz'. 683.43 [M + H]+. 1 H NMR (400 MHz, Methanol-d4) 6 8.55 (s, 1H), 4.47 (d, 1H), 4.42 - 4.29 (m, 1H), 4.25 (d, 1H), 3.74 - 3.58 (m, 2H), 3.54 - 3.27 (m, 5H), 3.26 - 3.08 (m, 3H), 3.08 - 2.94 (m, 4H), 2.77 - 2.56 (m, 8H), 2.56 - 2.29 (m, 3H), 2.26 (s, 3H), 2.20 (d, 2H), 2.15 - 2.04 (m, 1H), 2.02 - 1.87 (m, 2H), 1.88 - 1.75 (m, 2H), 1.76 - 1.50 (m, 4H), 1.49 - 1.38 (m, 2H), 1.37 - 1.18 (m, 13H), 1.05 - 0.80 (m, 8H).
[0353] (9R,llR,12R,13R)-3-(N-(tert-Butyl)-N-methylglycyl)-12-(((2S,3R,4S,6R)-4- (dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-
7,9,11, 13, 15-pentamethyl-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-5-I1-1-1- 16)(Compound 43). Prepared according to the methods of S3-5-I1-1-1- 1 from S3- 1-11-1- 1 and N- methyl t-butylamine to provide the title compound (3.71 mg). Formate salt, mixture of C2 epimers. MS (ESI+) m/z: 683.42 [M + H]+. 1 H NMR (400 MHz, Methanol-d4) 6 8.52 (s, 3H), 4.49 (d, 1H), 4.25 (d, 1H), 4.10 - 3.83 (br m, 3H), 3.78 - 3.63 (m, 2H), 3.51 - 3.34 (m, 5H), 3.10 - 2.95 (m, 4H), 2.85 - 2.45 (m, 14H), 2.25 - 2.12 (m, 1H), 2.11 - 1.93 (m, 3H), 1.92 - 1.55 (m, 5H), 1.53 - 1.43 (m, 2H), 1.42 - 1.21 (m, 21H), 1.08 - 0.88 (br m, 3H).
[0354] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-3-(dimethylglycyl)-ll-methoxy-7,9,ll,13,15,15- hexamethyl-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-5-Il-l-2-l)(Compound 61). Prepared according to the methods of S3-5-I1-1-1-1 from S3-1-I1-1-2 and dimethylamine to provide the title compound (5.44 mg). Formate salt. MS (ESI+) m/z: 655.40 [M + H]+. 1 H NMR (400 MHz, Methanol-d4) 8 8.48 (s, 3H), 5.08 - 4.94 (m, 1H), 4.61 (br d, 1H), 4.53 - 4.38 (m, 2H), 4.22 (d, 1H), 3.99 - 3.83 (m, 2H), 3.84 - 3.67 (m, 2H), 3.52 - 3.33 (m, 4H), 3.06 (s, 3H), 2.99 (d, 1H), 2.92 - 2.84 (m, 3H), 2.83 - 2.74 (m, 7H), 2.69 (br d, 6H), 2.36 - 2.19 (m, 2H), 2.18 - 2.07 (m, 1H), 2.06 - 1.96 (m, 2H), 1.91 - 1.73 (m, 2H), 1.58 - 1.44 (m, 5H), 1.44 - 1.27 (m, 13H), 1.08 (br d, 3H).
[0355] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,H,13,15,15-hexamethyl-3-(2- (piperidin-l-yl)acetyl)-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-5-I1-1-2- 2)(Compound 45). Prepared according to the methods of S3-5-I1-1-1-1 from S3-1-I1-1-2 and piperidine to provide the title compound (12.0 mg). Formate salt. MS (ESI+) mlz'. 695.43 [M + H]+. ^NMR (400 MHz, Methanol-d4) 5 8.50 (s, 3H), 5.05 - 4.93 (br s, 1H), 4.61 (d, 1H), 4.54 - 4.38 (m, 2H), 4.22 (d, 1H), 4.01 - 3.87 (m, 2H), 3.86 - 3.78 (m, 1H), 3.79 - 3.67 (m, 1H), 3.60 - 3.33 (m, 4H), 3.25 - 3.14 (br m, 1H), 3.09 - 2.92 (m, 7H), 2.87 (br s, 3H), 2.84 - 2.72 (m, 7H), 2.37 - 2.19 (m, 1H), 2.19 - 2.07 (m, 1H), 2.07 - 1.95 (m, 2H), 1.92 - 1.74 (m, 6H), 1.74 - 1.54 (m, 4H), 1.54 - 1.43 (m, 5H), 1.40 (d, 6H), 1.37 (d, 3H), 1.33 (d, 3H), 1.13 - 0.99 (m, 3H).
[0356] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-3-(N-isopropyl-N-methylglycyl)-ll-methoxy- 7,9,H,13,15,15-hexamethyl-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-5-I1-1-2- 3)(Compound 46). Prepared according to the methods of S3-5-I1- 1-1-1 from S3-1-I1-1-2 and N- methyl-isobutylamine to provide the title compound (13.6 mg). Formate salt. MS (ESI+) ml?.
683.41 [M + H]+. LH NMR (400 MHz, Methanol-d4) 5 8.50 (s, 2H), 5.01 (br s, 1H), 4.62 (d, 1H), 4.58 - 4.41 (m, 2H), 4.27 - 4.13 (m, 2H), 4.07 (d, 1H), 3.98 - 3.82 (m, 1H), 3.80 - 3.68 (m, 1H), 3.62 - 3.50 (m, 1H), 3.50 - 3.33 (m, 4H), 3.28 - 3.15 (m, 1H), 3.12 - 2.94 (m, 4H), 2.90 (br s, 3H), 2.85 - 2.72 (m, 10H), 2.40 - 2.08 (m, 3H), 2.09 - 1.95 (m, 2H), 1,85 (dd, 2H), 1.59 - 1.43 (m, 5H), 1.43 - 1.27 (m, 18H), 1.08 (dd, 3H).
[0357] (9R,llR,12R,13R)-3-(2-(Azetidin-l-yl)acetyl)-12-(((2S,3R,4S,6R)-4-(dimethylamino)- 3-hydroxy-6-methyltetr ahydro-2H-pyran-2-yl)oxy)- 1 l-methoxy-7,9, 11,13,15,15-hexamethyl- 17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-5-Il-l-2-4)(Compound 47). Prepared according to the methods of S3-5-I1-1-1-1 from S3-1-I1-1-2 and azetidine to provide the title compound (3.49 mg). Formate salt. MS (ESI+) mlz'. 667.41 [M + H]+. JH NMR (400 MHz, Methanol-d4) 5 8.50 (s, 3H), 5.11 - 4.91 (br m, 1H), 4.66 - 4.53 (m, 1H), 4.50 (d, 1H), 4.47 - 4.34 (m, 1H), 4.32 - 4.17 (m, 3H), 4.17 - 4.03 (m, 4H), 3.84 - 3.61 (m, 2H), 3.52 - 3.33 (m, 5H), 3.12 - 2.94 (m, 4H), 2.93 - 2.71 (m, 9H), 2.55 - 2.42 (m, 2H), 2.39 - 2.10 (m, 3H), 2.08 - 1.92 (m, 3H), 1.92 - 1.61 (m, 3H), 1.61 - 1.45 (m, 5H), 1.45 - 1.25 (m, 11H), 1.14 - 1.00 (m, 3H).
[0358] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl-3-(2- (pyrrolidin-l-yl)acetyl)-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-5-I1-1-2- 5)(Compound 48). Prepared according to the methods of S3-5-I1-1-1-1 from S3-1-I1-1-2 and pyrrolidine to provide the title compound (5.04 mg). Formate salt. MS (ESI+) m!z\ 681.38 [M + H]+. 'H NMR (400 MHz, Methanol-d4) 5 8.50 (s, 3H), 5.09 - 4.90 (br m, 1H), 4.59 (br d, 1H), 4.52 - 4.35 (m, 2H), 4.32 - 4.04 (m, 4H), 3.90 - 3.64 (m, 3H), 3.51 - 3.33 (m, 5H), 3.19 - 2.93 (m, 4H), 2.92 - 2.70 (m, 10H), 2.34 - 2.14 (m, 2H), 2.15 - 1.93 (m, 9H), 1.93 - 1.66 (m, 3H), 1.60 - 1.43 (m, 5H), 1.43 - 1.26 (m, 12H), 1.13 - 0.97 (m, 3H).
[0359] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-3-(N-ethyl-N-methylglycyl)-ll-methoxy- 7,9,H,13,15,15-hexamethyl-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-5-I1-1-2- 6)(Compound 49). Prepared according to the methods of S3-5-I1-1-1-1 from S3-1-I1-1-2 and methylethylamine to provide the title compound (9.04 mg). Formate salt. MS (ESI+) mlz-. 669.42 [M + H]+. Ti NMR (400 MHz, Methanol-d4) 5 8.47 (s, 2H), 5.03 (br d, 1H), 4.63 (d, 1H), 4.56 -
4.43 (m, 2H), 4.31 - 4.14 (m, 2H), 4.08 (dd, 1H), 3.88 (br d, 1H), 3.80 - 3.68 (m, 1H), 3.52 - 3.33 (m, 4H), 3.27 - 3.09 (m, 3H), 3.07 (s, 3H), 3.03 - 2.95 (m, 1H), 2.95 - 2.87 (m, 3H), 2.86 - 2.74 (m, 10H), 2.38 - 2.15 (m, 2H), 2.08 - 1.97 (m, 3H), 1.93 - 1.77 (m, 2H), 1.59 - 1.44 (m, 5H),
[0360] (9R,llR,12R,13R)-3-(Diethylglycyl)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3- hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl- 17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-5-H-l-2-7)(Compound 50). Prepared according to the methods of S3-5-I1-1-1-1 from S3-1-I1-1-2 and diethylamine to provide the title compound (5.78 mg). Formate salt. MS (ESI+) mlz-. 683.35 [M + H]+. 'H NMR (400 MHz, Methanol-d4) 5 8.50 (s, 3H), 5.10 - 4.91 (br m, 1H), 4.59 (br d, 1H), 4.52 - 4.39 (m, 2H), 4.26 - 4.16 (m, 1H), 4.16 - 4.03 (m, 1H), 4.03 - 3.83 (m, 2H), 3.80 - 3.68 (m, 1H), 3.50 - 3.33 (m, 5H), 3.21 - 2.97 (m, 9H), 2.93 - 2.69 (m, 10H), 2.35 - 2.08 (m, 2H), 2.07 - 1.94 (m, 3H), 1.93 - 1.64 (m, 2H), 1.58 - 1.43 (m, 5H), 1.43 - 1.21 (m, 17H), 1.07 (br d, 3H).
[0361] (9R,llR,12R,13R)-3-(Cyclobutylglycyl)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3- hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl- 17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-5-Il-l-2-8)(Compound 51). Prepared according to the methods of S3-5-I1-1-1-1 from S3-1-I1-1-2 and cyclobutylamine to provide the title compound (5.90 mg). Formate salt. MS (ESI+) mlz'. 681.34 [M + H]+. 'H NMR (400 MHz, Methanol-d4) 5 8.48 (s, 3H), 5.09 - 4.90 (br m, 1H), 4.69 - 4.53 (m, 1H), 4.52 - 4.40 (m, 2H), 4.21 (d, 1H), 4.03 - 3.60 (m, 5H), 3.51 - 3.34 (m, 4H), 3.19 - 2.96 (m, 5H), 2.94 - 2.65 (m, 9H), 2.40 - 2.24 (m, 4H), 2.24 - 2.07 (m, 4H), 2.07 - 1.94 (m, 3H), 1.94 - 1.59 (m, 6H), 1.59 - 1.44 (m, 4H), 1.44 - 1.26 (m, 11H), 1.07 (br d, 3H).
[0362] (9R,llR,12R,13R)-3-(Cyclopropylglycyl)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3- hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl- 17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-5-Il-l-2-9)(Compound 52). Prepared according to the methods of S3-5-I1-1-1-1 from S3-1-I1-1-2 and cyclopropylamine to provide the title compound (4.92 mg). Formate salt. MS (ESI+) mlz'. 667.37 [M + H]+. 'H NMR (400 MHz, Methanol-d4) 8 8.45 (s, 3H), 5.10 - 4.90 (m, 1H), 4.63 (br d, 1H), 4.57 - 4.42 (m, 2H), 4.22 (d, 1H), 3.99 - 3.79 (m, 2H), 3.79 - 3.68 (m, 2H), 3.49 - 3.33 (m, 4H), 3.26 - 3.14 (m, 1H), 3.07 (s, 3H), 3.03 - 2.93 (m, 1H), 2.89 (br s, 3H), 2.84 - 2.74 (m, 7H), 2.50 - 2.38 (m, 1H), 2.38 - 2.19 (m, 2H), 2.19 - 1.93 (m, 4H), 1.93 - 1.72 (m, 3H), 1.58 - 1.45 (m, 5H), 1.44 - 1.26 (m, 11H), 1.08 (d, 3H), 0.66 - 0,53 (m, 3H), 0.53 - 0.39 (m, 1H).
[0363] (9R,llR,12R,13R)-3-((Cyclopropylmethyl)glycyl)-12-(((2S,3R,4S,6R)-4- (dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy- 7,9,H,13,15,15-hexamethyl-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-5-I1-1-2- 10)(Compound 53). Prepared according to the methods of S3-5-I1-1-1-1 from S3-1-I1-1-2 and cyclopropylmethylamine to provide the title compound (5.22 mg). Formate salt. MS (ESI+) mlz'. 681.35 [M + H]+. LH NMR (400 MHz, Methanol-d4) 5 8.51 (s, 3H), 5.09 - 4.91 (m, 1H), 4.69 - 4.51 (m, 1H), 4.52 - 4.37 (m, 2H), 4.26 - 4.15 (m, 1H), 4.15 - 3.92 (m, 2H), 3.91 - 3.66 (m, 3H), 3.45 (dd, 1H), 3.41 - 3.32 (m, 3H), 3.11 (d, 1H), 3.06 (s, 3H), 2.93 - 2.83 (m, 4H), 2.82 - 2.68 (m, 7H), 2.37 - 2.06 (m, 2H), 2.07 - 1.91 (m, 3H), 1.91 - 1.62 (m, 2H), 1.57 - 1.43 (m, 5H), 1.43 - 1.25 (m, 11H), 1.18 - 0.91 (m, 5H), 0.75 - 0.65 (m, 2H), 0.56 - 0.47 (m, 1H), 0.44 - 0.34 (m, 2H), 0.23 (dt, 1H).
[0364] (9R,llR,12R,13R)-3-(N-Cyclopropyl-N-methylglycyl)-12-(((2S,3R,4S,6R)-4- (dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy- 7,9,H,13,15,15-hexamethyl-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-5-I1-1-2- ll)(Compound 54). Prepared according to the methods of S3-5-I1-1-1-1 from S3-1-I1-1-2 and N-methyl cyclopropylamine to provide the title compound (3.16 mg). Formate salt. MS (ESI+) mlz\ 681.34 [M + H]+. 'H NMR (400 MHz, Methanol-d4) 8 8.44 (s, 3H), 5.09 - 4.96 (m, 1H), 4.61 (br d, 1H), 4.56 - 4.38 (m, 2H), 4.22 (d, 1H), 4.17 - 4.03 (m, 1H), 3.80 - 3.67 (m, 1H), 3.51 - 3.32 (m, 7H), 3.27 - 3.14 (m, 1H), 3.06 (s, 3H), 3.02 - 2.73 (m, 11H), 2.40 (s, 3H), 2.35 - 2.23 (m, 1H), 2.12 - 1.93 (m, 4H), 1.93 - 1.75 (m, 3H), 1.59 - 1.44 (m, 5H), 1.44 - 1.27 (m, 11H), 1.08 (d, 3H), 0.50 (d, 2H), 0.44 (d, 2H).
[0365] (9R,llR,12R,13R)-3-(N-(Cyclopropylmethyl)-N-methylglycyl)-12-(((2S,3R,4S,6R)-4- (dimethylamino)-3-hydroxy-6-/we^y/te/ra/tyJra-2H-pyran-2-yl)oxy)-l 1-methoxy- 7,9,H,13,15,15-hexamethyl-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S3-5-I1-1-2- 12)(Compound 55). Prepared according to the methods of S3-5-I1- 1-1-1 from S3-1-I1 -1-2 and N- methylcyclopropylmethylamine to provide the title compound (4.60 mg). Formate salt. MS (ESI+) m/z: 695.37 [M + H]+. WMR ^OO MHz, Methanol -d4) 5 8.51 (s, 3H), 5.16 - 4.92 (m, 1H), 4.69 - 4.55 (m, 1H), 4.56 - 4.37 (m, 2H), 4.21 (d, 1H), 3.95 - 3.79 (m, 1H), 3.79 - 3.64 (m, 2H), 3.50 - 3.32 (m, 5H), 3.10 (d, 2H), 3.06 (s, 3H), 2.94 - 2.74 (m, 9H), 2.74 - 2.54 (m, 6H), 2.36 - 2.18 (m, 1H), 2.14 - 1.92 (m, 3H), 1.91 - 1.71 (m, 2H), 1.58 - 1.44 (m, 4H), 1.44 - 1.27 (m, 11H), 1.14 - 0.90 (m, 5H), 0.74 - 0.57 (m, 2H), 0.55 - 0.46 (m, 1H), 0.31 (s, 1H), 0.28 - 0.18 (m, 2H).
[0366] The following Examples were prepared according to the methods of Scheme 3, substituting the appropriate aminoalcohol (I) from Table 1.
[0367] (2S,3R,4S,6R)-4-(Dimethylamino)-2-(((llR,12R,13R,15R)-13-methoxy-9,ll,I3,15,17- pentamethyl-8,10-dioxo-7-oxa-3,17-diazaspiro[5.12]octadecan-12-yl)oxy)-6- methyltetrahydro-2H-pyran-3-yl benzoate (S3-1-I6-1-1) In a 20 mL vial was a solution of Boc piperidine SI-5-16-1 (105 mg, 0.138 mmol) in 20% trifluoro acetic acid (TFA)-DCM (1 mL) to give a yellow solution which was stirred at rt for 1 h. The reaction mixture was diluted with DCM and quenched with saturated aqueous sodium bicarbonate, the aqueous phase was extracted 3 times w/ DCM, dried over sodium sulfate, filtered and concentrated to give S3-1-I6-1-1 which was used without further purification (94 mg). MS (ESI+) mlz: 330.8 [M + 2H]2+, 660.4 [M + H]+.
[0368] (HR,12R,13R,15R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-9,ll,13,15,17-pentamethyl-7-oxa-3,17- diazaspiro[5.72]octadecane-8, 10-dione (S3-2-I6-l-l-l)(Compound 29). Prepared according to the methods of S3-2-I1-1-1-1 from S3- 1 - 16- 1 - 1 to provide the title compound (9.5 mg). Formate salt, mixture of epimers. MS (ESI+) mfr. 278.9 [M + 2H]2+, 556.4 [M + H]+ ’H NMR (400 MHz, Methanol-^) 5 8.51 (s, 2H), 4.59 (d, 0.55H), 4.54 - 4.31 (m, 2.9H), 4.22 (d, 0.55H), 3.86 - 3.52 (m, 3H), 3.52 - 3.38 (m, 2H), 3.20 - 3.02 (m, 3H), 3.00 (s, 3H), 2.90 - 2.73 (m, 7H), 2.73 - 2.32 (m, 3H), 2.23 - 1.90 (m, 4H), 1.90 - 1.62 (m, 3H), 1.62 - 1.46 (m, 2H), 1.46 - 1.12 (m, 13H), 1.02 (t, 3H), 0.94 - 0.77 (m, 1H).
[0369] (HR,12R,13R,15R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-3,9,77,13,15,17-hexamethyl-7-oxa-3,17- diazaspiro [5.12] octadecane-8, 10-dione (S3-2-I6-l-l-2)(Compound 111). Prepared according to the methods of S3-2-I1-1-1-2 from S3-1-I6-1-1 and formaldehyde to provide the title compound (1.0 mg). Formate salt. MS (ESI+) mfr. 285.8 [M + 2H]2+, 570.3 [M + H]+ JH NMR (400 MHz, Methanol-^) 5 8.36 (s, 8H), 4.49 (d, 1H), 4.24 (d, , 1H), 4.13 (d, 1H), 3.83 - 3.52 (m, 4H), 3.52 - 3.39 (m, 3H), 3.16 - 2.92 (m, 8H), 2.84 (s, 6H), 2.69 - 2.45 (m, 5H), 2.45 - 2.26 (m, 2H), 2.17 (s, 1H), 2.11 - 1.82 (m, 4H), 1.76 (s, 2H), 1.54 (d, 2H), 1.49 - 1.17 (m, 12H), 1.05 (d, 3H).
[0370] (HR,12R,13R,15R)-3-Benzyl-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-9,ll,13,15,17-pentamethyl-7-oxa-3,17- diazaspiro [5.12] octadecane-8, 10-dione (S3-2-I6-l-l-3)(Compound 31). Prepared according to the methods of S3-2-I6-1-1-2 and benzaldehyde to provide the title compound (8.4 mg). Formate salt. MS (ESI+) mlz'. 323.8 [M + 2H]2+, 646.4 [M + H]+ ’H NMR (400 MHz, Methanol-^) 6 8.56 (s, 1H), 7.49 - 7.31 (m, 4H), 7.31 - 7.26 (m, 1H), 4.44 (dd, 1H), 4.17 (dd, 1H), 4.03 - 3.87 (m, 1H), 3.69 (d, 3H), 3.58 (q, 1H), 3.48 - 3.35 (m, 1H), 3.30 - 3.19 (m, 2H), 3.09 - 3.00 (m, 3H), 2.99 (s, 3H), 2.88 - 2.78 (m, 3H), 2.78 - 2.72 (m, 6H), 2.69 (s, 1H), 2.59 (t, 1H), 2.39 (t, 2H), 2.35 - 2.15 (m, 2H), 2.05 - 1.96 (m, 1H), 1.88 - 1.64 (m, 3H), 1.55 - 1.41 (m, 3H), 1.40 - 1.14 (m, 12H), 1.07 - 0.96 (m, 3H), 0.96 - 0.82 (m, 1H).
[0371] (HR,12R,13R,15R)-3-Acetyl-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-9,ll,13,15,17-pentamethyl-7-oxa-3,17- diazaspiro [5.12] octadecane-8, 10-dione (S3-4-WFAl-l)(Compound 30) Prepared according to the methods of S3-4-I1-1-1-1 from S3-1-I6-1-1 and acetic anhydride to provide the title compound (3.1 mg). Formate salt. MS (ESI+) mlz-. 299.7 [M + 2H]2+, 598.4 [M + H]+
(400 MHz, Methanol^) 8 8.56 (s, 2H), 4.61 - 4.32 (m, 2H), 4.32 - 4.10 (m, 1H), 3.99 - 3.50 (m, 4H), 3.46 - 3.34 (m, 1H), 3.25 (d, 1H), 3.15 - 2.89 (m, 1H), 3.02 (s, 6H), 2.84 - 2.50 (m, 6H), 2.50 - 2.19 (m, 4H), 2.17 - 2.07 (m, 3H), 2.05 - 1.52 (m, 4H), 1.52 - 1.14 (m, 16H), 1.14 - 0.77 (m, 5H).
[0372] (HR,12R,13R,15R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-3-(dimethylglycyl)-13-methoxy-9, 11,13, 15,17- pentamethyl-7-oxa-3,l 7-diazaspiro[5.12}octadecane-%, 10-dione (S3-5-I6-l-l-l)(Compound 34). Prepared according to the methods of S3-5-I1-1-1-1 from S3-1-I6-1-1 and dimethylamine to provide the title compound (9.8 mg). Formate salt. MS (ESI+) mlz\ 214.6 321.3 [M + 2H]2+, 641.4 [M + H]+ 'H NMR (400 MHz, Methanol-^) 8 8.52 (s, 3H), 4.53 - 4.39 (m, 2H), 4.24 (d, 1H), 4.09 - 3.88 (m, 2H), 3.76 (dd, 2H), 3.71 - 3.65 (m, 1H), 3.60 (q, 1H), 3.53 - 3.43 (m, 1H), 3.43 - 3.34 (m, 3H), 3.24 (s, 1H), 3.11 - 2.85 (m, 8H), 2.83 (s, 6H), 2.78 (s, 6H), 2.37 (d, 1H), 2.29 (d, 1H), 2.09 - 2.01 (m, 1H), 1.94 - 1.63 (m, 4H), 1.54 (q, 2H), 1.42 (s, 3H), 1.37 - 1.24 (m, 10H), 1.05 (d, 3H).
[0373] (HR,12R,13R,15R)-3-((Cyclopropylmethyl)glycyl)-12-(((2S,3R,4S,6R)-4- (dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oA:v)-13-methoxy- 9,ll,13,15,17-pentamethyl-7-oxa-3,17-diazaspiro[5.12]octadecane-8, 10-dione (S3-5-I6-1-1- 2)(Compound 33). Prepared according to the methods of S3-5-I1-1-1-1 from S3-1-I6-1-1 and cyclopropylmethylamine. Formate salt. MS (ESI+) mlz\ 223.3 [M + 3H]3+, 334.4 [M + 2H]2+, 667.4 [M + H]+ ^NMR (400 MHz, Methanol-^) 8 8.65 (d, 2H), 4.49 (d, 1H), 4.44 (d, 1H), 4.23 (d, 1H), 4.02 (q, 2H), 3.85 - 3.51 (m, 4H), 3.51 - 3.36 (m, 2H), 3.19 - 2.91 (m, 3H), 3.04 (s, 3H), 2.87 (d, 3H), 2.76 (s, 6H), 2.37 (d, 3H), 2.06 - 1.94 (m, 1H), 1.94 - 1.59 (m, 4H), 1.58 - 1.18 (m, 16H), 1.18 - 0.80 (m, 5H), 0.75 - 0.63 (m, 2H), 0.46 - 0.29 (m, 2H).
[0374] (HR,12R,13R,15R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-9, 11, 13,15, 17-pentamethyl-3-(2- (piperidin-l-yl)acetyl)-7-oxa-3,17-diazaspiro[5.12]octadecane-8, 10-dione (S3-5-I6-1-1- 3)(Compound 35). Prepared according to the methods of S3-5-I1-1-1-1 from S3-1-I6-1-1 and piperidine. Formate salt. MS (ESI+) mlz\ 227.9 [M + 3H]3+, 341.4 [M + 2H]2+, 681.4 [M + H]+ 'H NMR (400 MHz, Methanol-^) 5 8.54 (s, 3H), 4.49 (d, 1H), 4.45 (d, 1H), 4.24 (d, 1H), 4.08 - 3.52 (m, 7H), 3.52 - 3.34 (m, 3H), 3.21 - 2.89 (m, 11H), 2.82 (s, 6H), 2.37 (d, 1H), 2.30 (d, , 1H), 2.11 - 1.99 (m, 1H), 1.97 - 1.47 (m, 12H), 1.47 - 1.20 (m, 12H), 1.06 (d, 3H).
[0375] (HR,12R,13R,15R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-3-(N-isopropyl-N-wet/yVg/ycy/)-13-methoxy- 9,ll,13,15,17-pentamethyl-7-oxa-3,17-diazaspiro[5.12]octadecane-8, 10-dione (S3-5-I6-1-1- 4)(Compound 32). Prepared according to the methods of S3-5-I1- 1-1-1 from S3- 1-16- 1-1 and N- methylisopropylamine. Formate salt. MS (ESI+) mlz'. 223.9 [M + 3H]3+, 335.4 [M + 2H]2+, 669.4 [M + H]+ 'H NMR (400 MHz, Methanol-^) 5 8.48 (s, 3H), 4.52 - 4.32 (m, 2H), 4.28 - 3.98 (m, 3H), 3.81 - 3.49 (m, 5H), 3.49 - 3.31 (m, 3H), 3.25 - 3.10 (m, 1H), 3.10 - 2.88 (m, 7H), 2.81 (s, 6H), 2.78 (s, 3H), 2.44 - 2.09 (m, 3H), 2.09 - 1.97 (m, 1H), 1.97 - 1.61 (m, 4H), 1.59 - 1.44 (m, 2H), 1.44 - 1.12 (m, 19H), 1.04 (d, 3H), 0.93 - 0.80 (m, 1H).
Compound 142
[0376] (HR,12R,13R,15R)-3-benzyl-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-9,9,ll,13,15,17-hexamethyl-7-oxa-3,17- diazaspiro [5.12] octadecane-8, 10-dione (Compound 142). Prepared according to Scheme S3 from 16 and benzaldehyde to provide the title compound (20 mg). Formate salt. MS (ESI+) mlz'.
[0377] (HR,12R,13R,15R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-9,9,ll,13,15,17-hexamethyl-3-(pyridin-3- ylmethyl)-7-oxa-3,17-diazaspiro[5.12]octadecane-8, 10-dione (Compound 143). Prepared according to Scheme S3 from 16 and pyridine-3-carboxaldehyde to provide the title compound (23 mg). Formate salt. MS (ESI+) mlz'. 661.5 [M + H]+
Compound 144
[0378] (HR,12R,13R,15R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-3-(3-methoxybenzyl)-9,9,ll,13,15,17-
hexamethyl-7-oxa-3,17-diazaspiro[5.12]octadecane-8, 10-dione (Compound 144). Prepared according to Scheme S3 from 16 and 3 -methoxybenzaldehyde to provide the title compound (11 mg). Formate salt. MS (ESI+) mlz'. 690.5 [M + H]+
Compound 145
[0379] (HR,12R,13R,15R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-3-(4-chlorobenzyl)-9,9,ll,13,15,17- hexamethyl-7-oxa-3,17-diazaspiro[5.12]octadecane-8, 10-dione (Compound 145). Prepared according to Scheme S3 from 16 and 4-chlorobenzaldehyde to provide the title compound (22 mg). Formate salt. MS (ESI+) mlz'. 694.5 [M + H]+
Compound 146
[0380] (HR,12R,13R,15R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-3-(3-chlorobenzyl)-9,9,ll,13,15,17- hexamethyl-7-oxa-3,17-diazaspiro[5.12]octadecane-8, 10-dione (Compound 146). Prepared according to Scheme S3 from 16 and 3-chlorobenzaldehyde to provide the title compound (21 mg). Formate salt. MS (ESI+) mlz'. 694.5 [M + H]+
Compound 147
[0381] (HR,12R,13R,15R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-
methyltetrahydro-2H-pyran-2-yl)oxy)-3-(isoquinolin-6-ylmethyl)-13-methoxy-
9,9,ll,13,15,17-hexamethyl-7-oxa-3,17-diazaspiro[5.12]octadecane-8, 10-dione (Compound
147). Prepared according to Scheme S3 from 16 and isoquinoline-6-carbaldehyde to provide the title compound (20 mg). Formate salt. MS (ESI+) mlz\ 711.5 [M + H]+
Compound 148
[0382] (HR,12R,13R,15R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-9,9,ll,13,15,17-hexamethyl-3-(2-
(pyridin-3-yl)ethyl)-7-oxa-3,17-diazaspiro[5.12]octadecane-8, 10-dione (Compound 148).
Prepared according to Scheme S3 from 16 and 2-(pyri din-3 -yl)acetaldehyde to provide the title compound (11 mg). Formate salt. MS (ESI+) mlz\ 675.5 [M + H]+
Compound 149
[0383] (HR,12R,13R,15R)-3-([l,l'-biphenyl]-3-ylmethyl)-12-(((2S,3R,4S,6R)-4-
(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-
9,9,H,13,15,17-hexamethyl-7-oxa-3,17-diazaspiro[5.12]octadecane-8, 10-dione (Compound
149). Prepared according to Scheme S3 from 16 and [l,l'-biphenyl]-3-carbaldehyde to provide the title compound (11 mg). Formate salt. MS (ESI+) mlz\ 736.5 [M + H]+
Compound 150
[0384] (HR,12R,13R,15R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-3,9,9,H,13,15,17-heptamethyl-7-oxa-
3, 17-diazaspiro[5.12]octadecane-8, 10-dione (Compound 150). Prepared according to Scheme
S3 from 16 and formaldehyde to provide the title compound as the formate salt. MS (ESI+) m/z:
[0385] (HR,12R,13R,15R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-3-(isoquinolin-7-ylmethyl)-13-methoxy- 9,9,H,13,15,17-hexamethyl-7-oxa-3,17-diazaspiro[5.12]octadecane-8, 10-dione (Compound
151). Prepared according to Scheme S3 from 16 and isoquinoline-7-carbaldehyde to provide the title compound (29 mg). Formate salt. MS (ESI+) m/z: 711.5 [M + H]+
Compound 152
[0386] (HR,12R,13R,15R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-3-(4-methoxybenzyl)-9,9,ll,13,15,17- hexamethyl-7-oxa-3,17-diazaspiro[5.12]octadecane-8, 10-dione (Compound 152). Prepared according to Scheme S3 from 16 and 4-methoxybenzaldehyde to provide the title compound (21 mg). Formate salt. MS (ESI+) zw/z: 690.4 [M + H]+
Compound 153
[0387] (HR,12R,13R,15R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-9,9,ll,13,15,17-hexamethyl-3-phenethyl-
7-oxa-3,17-diazaspiro[5.12]octadecane-8, 10-dione (Compound 153). Prepared according to
Scheme S3 from 16 and 2-phenylacetaldehyde to provide the title compound (17.1 mg). Formate salt. MS (ESI+) m!z-. 674.5 [M + H]+
Compound 154
[0388] (HR,12R,13R,15R)-3-([l,l'-biphenyl]-4-ylmethyl)-12-(((2S,3R,4S,6R)-4-
(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-
9,9,H,13,15,17-hexamethyl-7-oxa-3,17-diazaspiro[5.12]octadecane-8, 10-dione (Compound
154). Prepared according to Scheme S3 from 16 and [l,l'-biphenyl]-4-carbaldehyde to provide the title compound (21 mg). Formate salt. MS (ESI+) mlz'. 736.5 [M + H]+
Compound 155
[0389] (HR,12R,13R,15R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-9,9,H,13,15,17-hexamethyl-3-(2-
(pyridin-4-yl)ethyl)-7-oxa-3,17-diazaspiro[5.12]octadecane-8, 10-dione (Compound 155).
Prepared according to Scheme S3 from 16 and 2-(pyridin-4-yl)acetaldehyde to provide the title compound (11 mg). Formate salt. MS (ESI+) mlz\ 675.5 [M + H]+
Compound 156
[0390] (HR,12R,13R,15R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-9,9,ll,13,15,17-hexamethyl-3-(pyridin-4- ylmethyl)-7-oxa-3,17-diazaspiro[5.12]octadecane-8, 10-dione (Compound 156). Prepared according to Scheme S3 from 16 and pyridine-4-carboxaldehyde to provide the title compound (20 mg). Formate salt. MS (ESI+) mlz'. 661.5 [M + H]+
Compound 157
[0391] (HR,12R,13R,15R)-3-acetyl-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-9,9,ll,13,15,17-hexamethyl-7-oxa-3,17- diazaspiro [5.12] octadecane-8, 10-dione (Compound 157). Prepared according to Scheme S3 from 16 and acetyl chloride to provide the title compound as the formate salt. MS (ESI+) m/z:
[0392] (HR,12R,13R,15R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-9,9,ll,13,15,17-hexamethyl-3-(2- phenylacetyl)-7-oxa-3,17-diazaspiro[5.12]octadecane-8, 10-dione (Compound 158). Prepared according to Scheme S3 from 16 and 2-phenylacetyl chloride to provide the title compound (21 mg). Formate salt. MS (ESI+) mlz'. 688.5 [M + H]+
Compound 159
[0393] (HR,12R,13R,15R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-9,9,ll,13,15,17-hexamethyl-3-nicotinoyl- 7-oxa-3,17-diazaspiro[5.12]octadecane-8, 10-dione (Compound 159). Prepared according to Scheme S3 from 16 and nicotinoyl chloride to provide the title compound (25 mg). Formate salt. MS (ESI+) mlz-. 675.5 [M + H]+
Compound 160
[0394] (HR,12R,13R,15R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-3-(4-methoxybenzoyl)-9,9,H,13,15,17- hexamethyl-7-oxa-3,17-diazaspiro[5.12]octadecane-8, 10-dione (Compound 160). Prepared according to Scheme S3 from 16 and 4-methoxybenzoyl chloride to provide the title compound (23 mg). Formate salt. MS (ESI+) mlz-. 704.5 [M + H]+
Compound 161
[0395] (HR,12R,13R,15R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-9,9,H,13,15,17-hexamethyl-3-(2- (pyridin-3-yl)acetyl)-7-oxa-3,17-diazaspiro[5.12]octadecane-8, 10-dione (Compound 161).
Prepared according to Scheme S3 from 16 and 2-(pyri din-3 -yl)acetyl chloride to provide the title compound (7 mg). Formate salt. MS (ESI+) mlz\ 689.5 [M + H]+
Compound 162
[0396] (HR,12R,13R,15R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-3-(3-methoxybenzoyl)-9,9,ll,13,15,17- hexamethyl-7-oxa-3,17-diazaspiro[5.12]octadecane-8, 10-dione (Compound 162). Prepared according to Scheme S3 from 16 and 3 -methoxybenzoyl chloride to provide the title compound (12 mg). Formate salt. MS (ESI+) mlz'. 704.5 [M + H]+
Compound 163
[0397] (HR,12R,13R,15R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-3-(4-chlorobenzoyl)-9,9,ll,13,15,17- hexamethyl-7-oxa-3,17-diazaspiro[5.12]octadecane-8, 10-dione (Compound 163). Prepared according to Scheme S3 from 16 and 4-chlorobenzoyl chloride to provide the title compound (22 mg). Formate salt. MS (ESI+) mlz'. 708.5 [M + H]+
Compound 164
[0398] (HR,12R,13R,15R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-3-isonicotinoyl-13-methoxy-9,9,ll,13,15,17- hexamethyl-7-oxa-3,17-diazaspiro[5.12]octadecane-8, 10-dione (Compound 164). Prepared according to Scheme S3 from 16 and isonicotinoyl chloride to provide the title compound (25 mg). Formate salt. MS (ESI+) mlz'. 675.5 [M + H]+
Compound 165
[0399] (HR,12R,13R,15R)-3-benzoyl-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-9,9,ll,13,15,17-hexamethyl-7-oxa-3,17- diazaspiro [5.12] octadecane-8, 10-dione (Compound 165). Prepared according to Scheme S3 from 16 and benzoyl chloride to provide the title compound (25 mg). Formate salt. MS (ESI+) mlz'. 674.5 [M + H]+
Compound 166
[0400] (HR,12R,13R,15R)-N-benzyl-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-9,9,ll,13,15,17-hexamethyl-8,10-dioxo-7- oxa-3,17-diazaspiro[5.12]octadecane-3-carboxamide (Compound 166). Prepared according to Scheme S3 from 16 and benzyl isocyanate to provide the title compound (14 mg). Formate salt. MS (ESI+) mlz.' 703.5 [M + H]+
[0401] (HR,12R,13R,15R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-N-(4-methoxyphenyl)-9,9,ll,13,15,17- hexamethyl-8,10-dioxo-7-oxa-3,17-diazaspiro[5.12]octadecane-3-carboxamide (Compound
167). Prepared according to Scheme S3 from 16 and 4-methoxyphenyl isocyanate to provide the title compound (30 mg). Formate salt. MS (ESI+) mlz'. 719.5 [M + H]+
Compound 168
[0402] (HR,12R,13R,15R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-9,9,ll,13,15,17-hexamethyl-8,10-dioxo-
N-phenyl-7-oxa-3,17-diazaspiro[5.12]octadecane-3-carboxamide (Compound 168). Prepared according to Scheme S3 from 16 and phenyl isocyanate to provide the title compound (19 mg). Formate salt. MS (ESI+) mlz'. 689.5 [M + H]+
Compound 169
[0403] (HR,12R,13R,15R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-N-(4-chlorophenyl)-9, 9,11,13, 15,17- hexamethyl-8,10-dioxo-7-oxa-3,17-diazaspiro[5.12]octadecane-3-carboxamide (Compound
169). Prepared according to Scheme S3 from 16 and 4-chlorophenyl isocyanate to provide the title compound (23 mg). Formate salt. MS (ESI+) mlz'. 723.4 [M + H]+
Compound 170
[0404] (HR,12R,13R,15R)-3-((4-chlorophenyl)sulfonyl)-12-(((2S,3R,4S,6R)-4-
(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-
9,9,H,13,15,17-hexamethyl-7-oxa-3,17-diazaspiro[5.12]octadecane-8, 10-dione (Compound
170). Prepared according to Scheme S3 from 16 and 4-chlorobenzenesulfonyl chloride to provide the title compound (12 mg). Formate salt. MS (ESI+) m/z: 744.4 [M + H]+
Compound 171
[0405] (HR,12R,13R,15R)-3-((4-methoxyphenyl)sulfonyl)-12-(((2S,3R,4S,6R)-4- (dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-
9,9,H,13,15,17-hexamethyl-7-oxa-3,17-diazaspiro[5.12]octadecane-8, 10-dione (Compound 171). Prepared according to Scheme S3 from 16 and 4-methoxybenzenesulfonyl chloride to provide the title compound (12 mg). Formate salt. MS (ESI+) m/z: 740.4 [M + H]+
Compound 172
[0406] (HR,12R,13R,15R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-9,9,ll,13,15,17-hexamethyl-3- (phenylsulfonyl)-7-oxa-3,17-diazaspiro[5.12]octadecane-8, 10-dione (Compound 172).
Prepared according to Scheme S3 from 16 and benzenesulfonyl chloride to provide the title compound (21 mg). Formate salt. MS (ESI+) mlz\ 710.4 [M + H]+
Compound 173
[0407] (HR,12R,13R,15R)-3-(benzylsulfonyl)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3- hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-9,9,ll,13,15,17-hexamethyl-7- oxa-3,17-diazaspiro[5.12]octadecane-8, 10-dione (Compound 173). Prepared according to Scheme S3 from 16 and benzyl sulfonyl chloride to provide the title compound (24 mg). Formate salt. MS (ESI+) m/z: 724.5 [M + H]+
Compound 174
[0408] (HR,12R,13R,15R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-13-methoxy-9,9,H43,15,17-hexamethyl-3-(pyridin-3- ylsulfonyl)-7-oxa-3,17-diazaspiro[5.12]octadecane-8, 10-dione (Compound 174). Prepared according to Scheme S3 from 16 and pyridine-3-ylsulfonyl chloride to provide the title compound (22.8 mg). Formate salt. MS (ESI+) m/z: 711.5 [M + H]+
Compound 175
[0409] (HR,12R,13R,15R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-3-(N-isopropyl-N-methylglycyl)-13-methoxy- 9,9,lli13,15,17-hexamethyl-7-oxa-3,17-diazaspiro[5.12]octadecane-8, 10-dione (Compound
175). Prepared according to Scheme S3 from 16 and 7V-m ethylisopropylamine to provide the title compound as the formate salt. MS (ESI+) m/z: 683.5 [M + H]+y
[0410] (2S,3R,4S,6R)-4-(Dimethylamino)-2-(((9R,HR,12R,13R)-ll-methoxy-7,9,ll,1^15,15- hexamethyl-14,16-dioxo-17-oxa-2,7-diazadispiro[3.1.126.14]nonadecan-12-yl)oxy)-6- methyltetrahydro-2H-pyran-3-yl benzoate (S3-1-I5-1-2) and (2S,3R,4S,6R)-2- (((7R,9R,10R,llR)-2-(aminomethyl)-2-(chloromethyl)-9-methoxy-5,7,9,ll,13,13- hexamethyl-12,14-dioxo-15-oxa-5-azaspiro[3.12]hexadecan-10-yl)oxy)-4-(dimethylamino)-6- methyltetrahydro-2H-pyran-3-yl benzoate (S3-l-I5b-l-2). S2-2-I5-1 (87 mg, O i l mmol) was dissolved in MeCN (3 mL) and HC1 (4M in dioxane, 0.27 mL, 1.1 mmol) was added at rt and the reaction mixture was allowed to stirred at rt for 10 min. The reaction mixture was concentrated and the crude mixture of S3-1-I5-1-2 and S3-l-I5b-l-2 (83 mg, 95% yield) was used in the next step without further purification. S3-1-I5-1-2: MS (ESI+) mlz'. 229.5 [M + 3H]3+, 343.7 [M + 2H]2+, 686.4 [M + H]+. S3-l-I5b-l-2: MS (ESI+) mlz\ 241.5 [M + 3H]3+, 361.7 [M + 2H]2+, 722.4 [M + H]+.
[0411] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,11513,15,15-hexamethyl-17-oxa-2,7- diazadispiro[3.1.126.14]nonadecane-14, 16-dione (S3-2-I5-l-2-l)(Compound 96). Prepared according to the methods of S3-2-I1-1-1-1 from S3-1-I5-1-2. Formate salt (6.00 mg, 51% yield). MS (ESI+) mlz\ 194.8 [M + 3H]3+, 297.1 [M + 2H]2+, 582.4 [M + H]+; 3H NMR (400 MHz, Methanol-^) 8.54 (s, 3H), 4.45 (dd, 1H), 4.34 - 3.88 (m, 4H), 3.70 (s, 1H), 3.43 (q, 1H), 3.31 (p, 3H), 3.15 (d, 2H), 3.03 (s, 2H), 2.90 - 2.59 (m, 7H), 2.27 (d, 3H), 2.00 (d, 1H), 1.59 - 1.05 (m, 15H), 0.97 (d, 2H).
[0412] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-2,7,9,H913,15,15-heptamethyl-17-oxa- 2, 7-diazadispiro[3.1.126.14]nonadecane-14, 16-dione (S3-2-I5-l-2-2)(Compound 101) and (9R,llR,12R,13R)-12-(((2S,3R?4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro- 2H-pyran-2-yl)oxy)-ll-methoxy-2,2,7,9,H,13,15,15-octamethyl-14,16-dioxo-17-oxa-2,7- (ZiazatZispira[3.1.126.14]nonadecan-2-ium (S3-2-I5-l-2-3)(Compound 107). Prepared according to the methods of S3-2-I1-1-1-2 from S3-1-I5-1-2 and formaldehyde.
[0413] Data for Compound 101 (S3-2-I5-1-2-2): Formate salt (2.83 mg). MS (ESI+) mlz'. 199.5 [M + 3H]3+, 298.7 [M + 2H]2+, 596.4 [M + H]+; 3HNMR (400 MHz, Methanol-^) 5 8.53 (s, 3H), 4.44 (dd, 1H), 4.20 (d, 1H), 4.02 (d, 1H), 3.92 (s, 1H), 3.86 (d, 1H), 3.70 (ddd, 1H), 3.43 (dd, 1H), 3.31 (p, 4H), 3.15 - 3.05 (m, 1H), 3.03 (s, 2H), 2.83 - 2.71 (m, 7H), 2.69 (d, 2H), 2.66 (s, 1H), 2.57 (d, 1H), 2.36 (s, 1H), 2.29 (d, 2H), 1.99 (ddd, 1H), 1.72 (s, 1H), 1.53 (s, 1H), 1.50 (s, 3H), 1.47 (d, 1H), 1.42 (d, 4H), 1.31 (p, 7H), 1.19 (d, 1H), 0.99 (s, 2H).
[0414] Data for Compound 107 (S3-2-I5-1-2-2): Formed during the reaction from S3-l-I5b-l-2. Formate salt (2.13 mg). MS (ESI+) mlz-. 204.1 [M + 3H]3+, 305.7 [M + 2H]2+, 610.4 [M + H]+; 3H NMR (400 MHz, Methanol-^) 6 8.54 (s, 3H), 4.59 (s, 1H), 4.40 (d, 1H), 4.30 - 4.15 (m, 2H), 4.11 (d, 1H), 3.90 - 3.77 (m, 1H), 3.67 (d, 2H), 3.59 - 3.39 (m, 2H), 3.39 - 3.26 (m, 7H), 3.09 (d, 4H), 2.81 (d, 3H), 2.66 (d, 9H), 2.29 (d, 9H), 2.13 (d, 1H), 1.95 (d, 1H), 1.77 - 1.58 (m, 4H), 1.58 - 1.36 (m, 9H), 1.29 (t, 9H), 1.19 (d, 3H).
[0415] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6-
methyltetrahydro-2H-pyran-2-yl)oxy)-2-isopropyl-ll-methoxy-7,9,H,13,15,15-hexamethyl- 17-oxa-2,7-diazadispiro[3.1.126.14]nonadecane-14, 16-dione (S8-7a-2)(Compound 102).
Prepared according to the methods of S3-2-I1-1-1-2 from S3-1-I5-1-2 and acetone. Formate salt (4.70 mg). MS (ESI+) mlz\ 208.3 [M + 3H]3+, 312.7 [M + 2H]2+, 624.5 [M + H]+; 'H NMR (400 MHz, Methanol-^) 8 'H NMR (400 MHz, Chloroform-;/) 8 8.52 (s, 3H), 4.46 (d, 1H), 4.21 (d, 1H), 4.06 (d, 1H), 3.96 (s, 1H), 3.88 (s, 1H), 3.78 - 3.65 (m, 1H), 3.44 (dd, 1H), 3.41 - 3.28 (m, 3H), 3.03 (s, 3H), 2.78 (s, 6H), 2.71 (s, 1H), 2.42 (d, 1H), 2.28 (d, 1H), 2.01 (ddd, 1H), 1.57 - 1.46 (m, 4H), 1.48 - 1.25 (m, 12H), 1.13 (d, 5H), 1.00 (d, 2H).
[0416] (9R,llR,12R,13R)-2-Acetyl-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl-17-oxa-2,7- diazadispiro[3.1.126.14]nonadecane-14, 16-dione (S3-4-I5-l-2-l)(Compound 105) and N- (((7R,9R,10R,llR)-2-(chloromethyl)-10-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-9-methoxy-5,7,9,ll,13,13-hexamethyl-12,14-dioxo-15- oxa-5-azaspiro[3.12]hexadecan-2-yl)methyl)acetamide (S3-4-I5b-l-2-l)(Compound 106). Prepared according to the methods of S3-4-I1-1-1-1 from a mixture of S3-1-I5-1-2 and S3-1-I5b- 1-2 with acetic anhydride.
[0417] Data for Compound 105 (S3-4-I5-1-2-1): Formate salt (5.88 mg). MS (ESH) mlz'. 312.7 [M + 2H]2+, 624.4 [M + H]+; 3H NMR (400 MHz, Methanol-^) 8.53 (s, 3H), 4.45 (d, 1H), 4.31 (d, 1H), 4.22 (d, 2H), 4.09 - 3.97 (m, 3H), 3.70 (dddt, 1H), 3.42 (dd, 1H), 3.34 - 3.25 (m, 3H), 3.04 (s, 3H), 2.74 (s, 7H), 2.04 - 1.90 (m, 2H), 1.85 (d, 3H), 1.45 - 1.38 (m, 4H), 1.39 - 1.27 (m, 9H), 1.02 (d, 2H).
[0418] Data for Compound 106 (S3-4-I5b-l-2-l): Formate salt (3.05 mg). MS (ESH) mlz'. 330.7 [M + 2H]2+, 660.4 [M + H]+; 3H NMR (400 MHz, Methanol-^) 8.55 (s, 3H), 4.56 (d, 1H), 4.20 (s, 2H), 3.83 - 3.57 (m, 2H), 3.51 - 3.22 (m, 4H), 3.07 (d, 3H), 2.56 (d, 5H), 2.22 (d, 3H), 2.04 - 1.79 (m, 5H), 1.38 (s, 7H), 1.33 - 1.17 (m, 6H), 0.94 (s, 2H).
[0419] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Z)i>M^jZawiMo)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-2-(dimethylglycyl)-ll-methoxy-7,9,ll,13,15,15- hexamethyl-17-oxa-2,7-diazadispiro[3.1.126.14]nonadecane-14, 16-dione (S3-5-I5-1-2- l)(Compound 103) and N-(((7R,9R,10R,HR)-2-(chloromethyl)-10-(((2S,3R,4S,6R)-4- (dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-9-methoxy- 5,7,9,H,13,13-hexamethyl-12,14-dioxo-15-oxa-5-azaspiro[3.12]hexadecan-2-yl)methyl)-2- (dimethylamino)acetamide (S3-5-I5b-l-2-l)(Compound 104). Prepared according to the methods of S3-5-I1-1-1-1 from a mixture of S3- 1 - 15- 1 -2 and S3- 1 - 15b- 1 -2 with dimethylamine. [0420] Data for Compound 103 (S3-5-I5-1-2-1): Formate salt (5.32 mg). MS (ESI+) mfr. 223.2 [M + 3H]3+, 334.3 [M + 2H]2+, 667.5 [M + H]+; 3HNMR (400 MHz, Methanol-^) 8.52 (s, 3H), 4.45 (d, 1H), 4.35 (d, 1H), 4.30 - 4.17 (m, 2H), 4.17 - 3.97 (m, 3H), 3.83 - 3.62 (m, 1H), 3.54 - 3.39 (m, 1H), 3.39 - 3.21 (m, 5H), 3.04 (s, 3H), 2.78 (s, 11H), 2.61 - 2.35 (m, 7H), 2.30 (d, 1H), 2.23 - 2.11 (m, 1H), 2.01 (ddd, 1H), 1.59 - 1.45 (m, 4H), 1.40 (d, 5H), 1.33 (dd, 6H), 1.03 (d, 2H).
[0421] Data for Compound 104 (S3-5-I5b-l-2-l): Formate salt (2.82 mg, 18% yield). MS (ESI+) mfr. 235.1 [M + 3H]3’, 352.2 [M + 2H]2+, 703.4 [M + H]+; 'H NMR (400 MHz, Methanol-^) 8.48 (s, 3H), 4.48 (d, 1H), 4.25 (d, 1H), 3.75 (d, 3H), 3.64 - 3.36 (m, 4H), 3.36 - 3.25 (m, 5H), 3.20 (s, 2H), 3,06 (s, 4H), 2.96 (dt, 2H), 2.80 (s, 7H), 2.43 (s, 6H), 2.14 - 1.97 (m, 2H), 1.62 - 1.44 (m, 4H), 1.44 - 1.21 (m, 11H), 1.04 (d, 2H).
[0422] (7R,9R,10R,HR)-10-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6-
methyltetrahydro-2H-pyran-2-yl)oxy)-9-methoxy-7,9,ll913-tetramethyl-15-oxa-2,5- diazaspiro[3.12]hexadecane-12, 14-dione (S3-2-I4-l-l-l)(Compound 20). Prepared according to the methods of S3-1-I6-1-1 (Boc deprotection) and S3-2-I1-1-1-1. Mixture of epimers. Formate salt. MS (ESI+) mlz-. 514.33 [M + H]+; ^NMR (400 MHz, Methanol-^) 5 4.43 (s, 2H), 4.15 - 3.93 (m, 3H), 3.95 - 3.81 (m, 2H), 3.77 - 3.53 (m, 1H), 3.50 - 3.32 (m, 4H), 2.84 (d, 9H), 2.77 (s, 1H), 2.63 (dd, 1H), 2.21 (t, 1H), 2.13 - 1.98 (m, 1H), 1.79 (d, 1H), 1.62 - 1.38 (m, 5H), 1.39 - 1.14 (m, 12H), 1.05 - 0.87 (m, 4H).
[0423] (7R,9R,10R,HR)-10-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-9-methoxy-2,5,7,9,ll,13-hexamethyl-15-oxa-2,5- diazaspiro[3.12]hexadecane-12, 14-dione (S3-2-I4-2-l-l)(Compound 25). Prepared according to the methods of S3-1-I6-1-1 (Boc deprotection) and S3-2-I1-1-1-2 with formaldehyde. Mixture of epimers. Formate salt. MS (ESI+) mlz'. 542.26 [M + H]“; 'H NMR (400 MHz, Methanol-^) 8 4.49 (d, 1H), 4.30-4.40 (m,lH), 4.26 (d, 1H), 3.98 (d, 1H), 3.87 (d, 2H), 3.81 - 3.60 (m, 3H), 3.56 - 3.32 (m, 3H), 2.99 (s, 3H), 2.81 (d, 7H), 2.74 (d, 3H), 2.37 (d, 5H), 2.08 - 1.95 (m, 1H), 1.73 (dd, 1H), 1.61 (s, 1H), 1.50 (q, 1H), 1.42-1.35 (m, lH), 1.34 - 1.24 (m, 13H), 0.97 (d, 3H).
[0424] (7R,9R,10R,llR)-10-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-2-(dimethylglycyl)-9-methoxy-7,9,ll,13-tetramethyl- 15-oxa-2,5-diazaspiro[3.12]hexadecane-12, 14-dione (S3-5-I4-l-l-l)(Compound 24). Prepared according to the methods of S3-1-I6-1-1 (Boc deprotection) and S3-5-I1-1-1-1 from S3-1-I4-1-1 and dimethylamine. Mixture of epimers. Formate salt. MS (ESI+) mlz\ 599.32 [M + H]+; }H NMR (400 MHz, Methanol-^) 84.31 (d, 3H), 4.12-3.82 (m,4H), 3.74 (dd, 3H), 3.67 - 3.61 (m, 1H),
3.58 - 3.33 (m, 6H), 2.79 (d, 7H), 2.70 (d, 1H), 2.61 (s, 5H), 2.50 (s, 4H), 2.39 (s, 1H), 2.01 (d, 1H), 1.80 (d, 2H), 1.62 - 1.35 (m, 3H), 1.35 - 1.16 (m, 10H), 0.97 (t, 3H).
[0425] (7R,9R,10R,llR)-10-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-2-(N-zso/?ropvZ-N-methylglycyl)-9-niethoxy- 5,7,9,H,13-pentamethyl-15-oxa-2,5-diazaspiro[3.12]hexadecane-12,14-dione (S3-5-I4-2-1- l)(Compound 40). Prepared according to the methods of S3-1-I6-1-1 (Boc deprotection) and S3- 5-11-1-1-1 from S3-1-I4-2-1 and N-methylisopropylamine. Mixture of epimers. Formate salt. MS (ESI+) mlz\ 641.42 [M + H]+; NMR (400 MHz, Chloroform-J) 8 4.55 - 4.44 (m, 1H), 4.35 - 4.13 (m, 2H), 4.03 (t, 1H), 3.93 (d, 1H), 3.87 - 3.72 (m, 2H), 3.64 - 3.33 (m, 2H), 3.33 - 3.18 (m, 1H), 3.17 - 3.04 (m, 2H), 3.03 - 2.91 (m, 3H), 2.86 (dp, 2H), 2.54 (s, 4H), 2.33 (d, 4H), 2.23 (d, 3H), 2.19 - 1.97 (m, 1H), 1.79 (d, 11H), 1.37 - 1.19 (m, 11H), 1.01 (t, 6H), 0.91 (dd, 3H).
[0426] (5S,8R,10R,l 1R,12R)-1 l-(((2S,3R,4S,6R)-4-(Z)zzMet/zy/azMzno)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-10-methoxy-6,8,10,12,14-pentamethyl-16-oxa-2,6- diazaspiro [4.12] heptadecane-13, 15-dione (S3-2-I3-l-l-l)(Compound 58). Prepared according to the methods of S3-2-I1-1-1-1 from S3-1-I3-1-1. Separated from diastereomer via prep HPLC to provide the title compound (2.91 mg). MS (ESI+) mlz'. 542.2 [M + H]“.
[0427] (5R,8R,10R,llR,12R)-ll-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-10-methoxy-6,8,10,12,14-pentamethyl-16-oxa-2,6- (Zi'azasp/ro[4.12]heptadecane-13,15-dione (S3-2-I3-l-l-2)(Compound 57). Prepared according to the methods of S3-2-I1-1-1-1 from S3-1-I3-1-1. Separated from diastereomer via prep HPLC to provide the title compound (2.39 mg). MS (ESI+) mlz'. 542.2 [M + H]“.
[0428] (8R,10R,llR,12R,14R)-ll-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-10-methoxy-2,6,8,10,12,14-hexamethyl-16-oxa-2,6- </iazaspira[4.12]heptadecane-13, 15-dione (S3-2-I3-l-l-l)(Compound 72). Prepared according to the methods of S3-2-I1-1-1-1 from S3-1-I3-1-1. Mixture of diastereomers. MS (ESI+) m/z: 279.4 [M + 2H]2+, 556.1 [M + H]+. MS (ESI+) m/z: 271.7 [M + 2H]2+, 542.2 [M + H]+. ’H NMR (400 MHz, Chloroform-d ) 5 4.49 - 4.42 (m, 1H), 4.22 (dd, 1H), 3.98 (q, 1H), 3.73 - 3.65 (m, 1H), 3.51 - 3.32 (m, 1H), 3.08 (d, 3H), 3.03 (s, 3H) 2.73 (s, 6H), 2.48 - 2.22 (m, 6H), 1.97 (d, 1H), 1.53 - 1.06 (m, 15H), 1.11 - 0.98 (m, 2H), 0.96 - 0.82, (m, 4H).
[0429] (8R,10R,llR,12R,14R)-2-Acetyl-ll-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-10-methoxy-6,8,10,12,14-pentamethyl-16-oxa-2,6- diazaspiro [4.12] heptadecane-13, 15-dione (S3-4-I3-l-l-l)(Compound 63). Prepared according to the methods of S3-4-I1-1-1-1 from S3-1-I3-1-1. Mixture of diastereomers. MS (ESI+) m/z: 292.8 [M + 2H]2+, 584.3 [M + H]+. *H NMR (400 MHz, Methanol-d4) 54.58 - 4.38 (m, 3H), 4.29 (dd„ 1H), 4.04 - 3.92 (m, 1H), 3.73 - 3.51 (m, 3H), 3.47 (q, J 1H), 3.45 - 3.32 (m, 2H), 3.01 (d, 3H), 2.81 (s, 6H), 2.66 (s, 2H), 2.53 - 2.09 (m, 4H), 2.04 (d, 3H), 2.00 (d, 1H), 1.51 (q, 2H), 1.36 - 1.18 (m, 12H), 0.93 - 0.84 (m, 3H).
[0430] (8R,10R,llR,12R,14R)-ll-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-2-(dimethylglycyl)-l 0-methoxy-6,8, 10,12, 14- pentamethyl-16-oxa-2,6-diazaspiro[4.12]heptadecane-13, 15-dione (S3-5-I3-1-1- l)(Compound 62). Prepared according to the methods of S3-1-I6-1-1 (Boc deprotection) and S3- 5-11-1-1-1 from S3-1-I3-1-1 and dimethylamine. Mixture of diastereomers. MS (ESI+) m/z: 314.3 [M + 2H]2+, 627.5 [M + H]+.
[0431] (9R,10R,llR,13R)-10-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-2-(2-(3-hydroxyazetidin-l-yl)acetyl)-ll-methoxy- 7,9,11, 13, 15-pentamethyl-5-oxa-2,15-diazaspiro[3.12]hexadecane-6, 8-dione (S3-5-I8-2-1- l)(Compound 38). Prepared according to the methods of S3-1-I6-1-1 (Boc deprotection) and S3- 5-11-1-1-1 from S3-1-I8-2-1 and 3-hydroxyazetidine. Mixture of epimers. Formate salt. MS (ESI+) mlz-. 641.38 [M + H]+; NMR (400 MHz, Methanol-^) 54.50-4.38 (m, 4H), 4.19 (m, 4H), 3.74 (dd, 4H), 3.66 - 3.33 (m, 6H), 3.25 - 3.12 (m, 1H), 2.90 (d, 13H), 2.04 (d, 2H), 1.96 - 1.61 (m, 2H), 1.62 - 1.11 (m, 16H), 1.01 (dq, 4H).
[0432] (9R,10R,llR,13R)-10-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-2-(N-isopropjZ-N-methylglycyl)-ll-methoxy-
7,9,11, 13, 15-pentamethyl-5-oxa-2,15-diazaspiro[3.12]hexadecane-6, 8-dione (S3-5-I8-2-1-
2)(Compound 39). Prepared according to the methods of S3-1-I6-1-1 (Boc deprotection) and S3- 5-11-1-1-1 from S3-1-I8-2-1 and N-methylisopropylamine. Mixture of epimers. Formate salt. MS (ESI+) mlz-. 641.41 [M + H]+; 'H NMR (400 MHz, Methanol-^) 5 4.50-4.38 (m, 2H), 4.19 (s, 2H), 3.99 (s, 1H), 3.87 - 3.53 (m, 4H), 3.55 - 3.31 (m, 6H), 3.06 - 2.51 (m, 15H), 2.03 (q, 2H), 1.71 - 1.41 (m, 2H), 1.40 - 1.07 (m, 23H), 1.06 - 0.76 (m, 3H).
[0433] 3-Benzyl 7-(tert-butyl) (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-3-(benzoyloxy)-4-
(dimethylamino)-6-methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-9, 11,13, 15- tetramethyl-14,16-dioxo-17-oxa-3,7-diazaspiro[5.12]octadecane-3,7-dicarboxylate (S4-1-I1).
SI-4-11 (1.126 g, 1.43 mmol) was dissolved in A. A-di methyl form am ide (7.15 mL), and di-tert- butyl dicarbonate (0.491 mL, 2.14 mmol) and 4-dimethylaminopyridine (17.4 mg, 0.143 mmol) were added. After 1 h, additional di-tert-butyl dicarbonate (0.491 mL, 2.14 mmol) and 4- dimethylaminopyridine (17.4 mg, 0.143 mmol) were added. After an additional 1 h, the reaction mixture was diluted with EtOAc and was washed with NaHCCh (sat, aq, 1 time), water (3 times), and brine (1 time). The EtOAc layer was dried over Na2SO4, was filtered, and was concentrated under reduced pressure. The residue was purified on 80 g of silica gel (elution with 0-10% MeOH-DCM gradient) to give S4-1-I1 (980 mg, 78%) . MS (ESI+) mlz\ 880.33 [M + H]+.
[0434] tert-Butyl (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-3-(benzoyloxy)-4-(dimethylamino)- 6-methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-9,ll,13,15-tetramethyl-14,16-dioxo-17- oxa-3,7-diazaspiro[5.12]octadecane-7-carboxylate (S4-2-I1). S4-1-I1 (820 mg, 0 931 mmol) was dissolved in methanol (1.86 mL) and 1 N aqueous HC1 (0.931 mL, 0.931 mmol), and palladium on carbon (5 wt%, 198 mg, 0.093 mmol) was added. An atmosphere of EL was introduced. After 7 h, the reaction mixture was evacuated and back-filled with N2 (3 times). The reaction mixture was filtered through Celite®, washing with MeOH, and the filtrate was concentrated. This gave the HC1 salt of S4-2-I1 which was used without further purification. MS (ESI+) m/z: 746.23 [M + H]+.
[0435] tert-Butyl (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-3-(rfiwietAy/g/jcj7)-ll-methoxy-9,ll,13,15-
tetramethyl-14,16-dioxo-17-oxa-3,7-diazaspiro[5.12]octadecane-7-carboxylate (S4-3-I1-1).
Prepared according to the methods of S3-5-I1-1-1-1 from S4-2-I1 and dimethylamine to give S4- 3-11-1 , which was used without further purification. MS (ESI+) mlr. 727.34 [M + H]+.
[0436] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-3-(dimethylglycyl)-ll-methoxy-9, 11, 13,15- tetramethyl-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S4-4-Il-l)(Compound 21). S4-3-I1-1 (26.3 mg, 0.0361 mmol) was dissolved in 4M HC1 in 1,4-dioxane (0.4 mL). After 1 h, the reaction mixture was concentrated under reduced pressure. The residue was purified by HPLC (Atlantis T3 column, 5-30% MeCN-water-0.1% HCO2H) to give S4-4-I1-1 (8.55 mg). MS (ESI+) mlz-. 627.37 [M + H]+. ^NMR (400 MHz, Methanol-d4) 8 8.08 (br s, 1H), 5.04 - 4.90 (m, 1H), 4.54 - 4.21 (m, 4H), 4.21 - 4.10 (m, 1H), 4.03 - 3.93 (m, 1H), 3.86 - 3.68 (m, 2H), 3.68 - 3.54 (m, 1H), 3.51 - 3.35 (m, 3H), 3.28 - 3.17 (m, 1H), 3.18 - 3.04 (m, 2H), 3.04 - 2.92 (m, 9H), 2.91 - 2.72 (m, 7H), 2.34 - 2.17 (m, 1H), 2.16 - 1.85 (m, 5H), 1.85 - 1.60 (m, 2H), 1.60 - 1.43 (m, 2H), 1.43 - 1.27 (m, 10H), 1.20 - 1.03 (m, 4H).
[0437] (9R,llR,12R,13R)-3-(Cydopropylglycyl)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3- hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxp)-ll-methoxy-9, 11,13, 15-tetramethyl-17- oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S4-4-Il-2)(Compound 22). Prepared according to the methods of S4-4-I1-1 from S4-1-I1 and cyclopropylamine to provide the title compound (10.2 mg). Formate salt. MS (ESI+) mlz-. 639.35 [M + H]+. 'H NMR (400 MHz, Methanol-d4) 8 8.43 (s, 3H), 4.84 - 4.65 (m, 1H), 4.49 - 4.28 (m, 1H), 4.24 - 3.97 (m, 2H), 3.97 - 3.61 (m, 7H), 3.61 - 3.30 (m, 5H), 3.08 - 2.87 (m, 4H), 2.86 - 2.71 (m, 4H), 2.72 - 2.58 (m,
2H), 2.58 - 2.38 (m, 2H), 2.11 - 1.90 (m, 3H), 1.90 - 1.63 (m, 6H), 1.63 - 1.40 (m, 3H), 1.39 - 1.22 (m, 7H), 1.22 - 1.11 (m, 2H), 1.10 - 0.96 (m, 3H), 0.76 - 0.51 (m, 4H).
[0438] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Diwie/Ay/awzino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-3-(N-isopropyl-N-methylglycyl)-ll-methoxy-
9,11, 13, 15-tetramethyl-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S4-4-I1- 3)(Compound 23). Prepared according to the methods of S4-4-I1-1 from S4-1-I1 and N- methylisopropylamineto provide the title compound (9.88 mg). Formate salt. MS (ESI+) m!z\ 655.33 [M + H]+. LH NMR (400 MHz, Methanol-d4) 5 8.49 (s, 2H), 4.78 (d, 1H), 4.46 (d, 1H), 4.23 - 3.95 (m, 5H), 3.83 - 3.65 (m, 2H), 3.64 - 3.51 (m, 2H), 3.50 - 3.33 (m, 4H), 3.01 - 2.85 (m, 4H), 2.82 (s, 6H), 2.79 (s, 3H), 2.62 (q, 1H), 2.10 - 1.93 (m, 3H), 1.92 - 1.76 (m, 3H), 1.75 - 1.65 (m, 1H), 1.65 - 1.44 (m, 3H), 1.40 - 1.22 (m, 18H), 1.05 (d, 3H).
[0439] Butyl 3-((((2/?.4/?.5/?.6/?)-5-(((2.S'.3/?.4.S.6/?)-3-(Benzoyloxy)-4-(dimethylamino)-6- methyltetrahydro-2//-pyran-2-yl)oxy)-4-methoxy-2,4-diinethyl-6-(2,2,5-trimethyl-4-oxo-4//- l,3-dioxin-6-yl)heptyl)((benzyloxy)carbonyl)amino)methyl)-3-hydroxypyrrolidine-l- carboxylate (S5-1-I7). Ze/V-Butyl 3 -(aminomethyl)-3 -hydroxypyrrolidine- 1 -carboxylate (17, 124 mg, 0.577 mmol) and Sl-1 (310 mg, 0.525 mmol) were dissolved in MeOH (3 mL) and Ti(OEt)4 (0.217 mL, 1.04 mmol) was added. After 30 min, a small aliquot was removed from the reaction mixture and was added to a suspension of a small amount of NaBLL in MeOH. LC/MS analysis showed complete conversion. The reaction mixture was cooled in an ice bath and NaBHi (29.7 mg, 0.787 mmol) was added. When gas evolution ceased, 30% aqueous NH4OH (2mL) was added, and the mixture was filtered through a pad of Celite® with EtOAc. The filtrate was washed with brine, was dried over Na2SO4, was filtered and was concentrated. The residue was dissolved in DCM (3.5 mL), and triethylamine (0.144 mL, 1.04 mmol) followed by Cbz-OSu (130 mg, 0.525 mmol) were added. After 30 mins, solvent was removed and the crude residue was purified on a 12 g SiCh column, eluting with 2-14% MeOH/DCM/0.5% NH4OH, to give the title compound (0.4 g, 0.432 mmol, 83%). MS (ESI+) mfr. 412.92 [M + 2H]2+, 924.38 [M + H]+, 946.42 [M + Na]+; ^NMR (400 MHz, Chloroform-;/) 5 8.04 - 7.94 (m, 2H), 7.54 (t, 1H), 7.41 (t, 2H), 7.33 (q, 5H), 5.19 - 5.00 (m, 3H), 4.65 (d, 1H), 3.81 (d, 1H), 3.64 - 3.27 (m, 8H), 3.27 - 3.04 (m, 2H), 3.04 - 2.75 (m, 5H), 2.28 (s, 5H), 2.04 - 1.84 (m, 2H), 1.84 - 1.73 (m, 6H), 1.69 (s, 3H), 1.65 (d, 3H), 1.43 (s, 11H), 1.29 (dd, 5H), 1.10 (s, 3H), 0.86 (t, 3H), 0.76 (td, 3H).
[0440] Benzyl (101?,lll?,121?,141?)-ll-(((25,31?,45',61?)-3-(Benzoyloxy)-4-(diniethylaniino)-6- methyltetrahydro-2//-pyran-2-yl)oxy)-12-methoxy-8, 10,12, 14-tetramethyl-7, 9-dioxo-6-oxa- 2,16-diazaspiro[4.12]heptadecane-16-carboxylate (S5-3-I7). S5-1-I7 (0.4 g, 0 432 mmol) was concentrated twice from toluene. The material was dissolved in chlorobenzene (120 mL), and a stream of nitrogen was bubbled through the solution for 10 min. The mixture was heated at a bath temperature of 150 °C (approximately 130-135 °C internal temperature) overnight. The reaction was allowed to cool to rt and was concentrated. The residue was purified on 12 g of silica gel (elution with 0-10% MeOH-DCM gradient) to give the title compound (253 mg, 67%). MS (ESI+) m/z: 866.36 [M + H] +, 888.35 [M + Na]+; 'H NMR (400 MHz, Chloroform-^/) 5 8.12 -
7.84 (m, 2H), 7.62 - 7.47 (m, 1H), 7.47 - 7.28 (m, 7H), 5.21 - 4.93 (m, 3H), 4.55 (dt, 1H), 4.09 - 3.94 (m, 1H), 3.93 - 3.67 (m, 2H), 3.67 - 3.39 (m, 5H), 3.39 - 3.02 (m, 3H), 2.98 (t, 2H), 2.94 -
2.84 (m, 1H), 2.83 - 2.71 (m, 1.5H), 2.70 - 2.45 (m, 0.5H), 2.32 - 2.23 (m, 6H), 2.09 - 1.98 (m, 1H), 1.98 - 1.71 (m, 3H), 1.53 - 1.35 (m, 11H), 1.33 - 1.06 (m, 11H), 1.06 - 0.81 (m, 6H). A solution of this material (253 mg, 0.29 mmol) in acetonitrile was added with hydrochloric acid (4M in dioxane, 0.22 mL, 0.88 mmol). The reaction mixture was stirred at room temperature for 1 h and concentrated. The residue was suspended in ethyl acetate and washed with sat. aq. NaHCCh (2 times), the washed solution was dried over sodium sulfate, filtered and concentrated to give the title compound as a white foam (210 mg, 0.27 mmol, 94%). MS (ESI+) m/z: 383.86 [M + 2H]2+, 766.32 [M + H]+, 788.30 [M + Na]+.
[0441] (10/?,ll^,121?,141?)-ll-(((25,31?,45,61?)-4-(Diniethylaniino)-3-hydroxy-6- methyltetrahydro-2/Z-pyran-2-yl)oxy)-12-methoxy-8,10,12,14-tetramethyl-6-oxa-2,16- diazaspiro [4.12] heptadecane-7, 9-dione (S5-5-I7)(Compound 65). S5-2-I7 (50 mg, 0 0652 mmol) was dissolved in methanol (1.5 mL), and the reaction mixture was heated to 60 °C external temperature. After 5 h, the reaction was allowed to cool to rt, hydrochloric acid (0.005 mL) and Pd/C (5 wt%, 13.8 mg, 0.0065 mmol) was added. A balloon of hydrogen was bubbling through the reaction mixture. After 30 min, it was filtered through Celite® with ethyl acetate, and the
filtrate was concentrated in vacuo. The residue was purified by HPLC (Atlantis T3 column, 5- 50% MeCN-water-0.1% HCO2H) to give the title compound as a formate salt (18.2 mg). MS (ESI+) m!z: 264.76 [M + 2H]2+, 528.26 [M + H]+.
[0442] (10^,ll^,12/?,141f)-ll-(((25,3/f,45,6/f)-4-(Dimethylainino)-3-hydroxy-6- methyltetrahydro-2//-pyran-2-yl)oxy)-12-methoxy-2,8,10,12,14-pentamethyl-6-oxa-2,16- diazaspiro [4.12] heptadecane-7, 9-dione (S5-4-I7-l)(Compound 64). To a solution of S5-2-I7 (25 mg, 0.0326 mmol) in DCM (1 mL) was added Na(OAc)3BH (10.3 mg, 0.049 mmol) followed by formaldehyde (37 wt% aqueous solution, 0.0261 mL, 0.326 mmol) was added. After 15 min, the reaction mixture was quenched with sat., aq. NaHCOs and extracted with DCM (3 times). The combined extracts were concentrated in vacuo. The residue was dissolved in methanol (1.5 mL), and the reaction mixture was heated to 60 °C external temperature. After 5 h, the reaction was allowed to cool to rt, hydrochloric acid (0.005 mL) and Pd/C (5 wt%, 6.79 mg, 0.0032 mmol) was added. A balloon of hydrogen was bubbling through the reaction mixture. After 30 min, it was filtered through Celite® with ethyl acetate, and the filtrate was concentrated in vacuo. The residue was purified by HPLC (Atlantis T3 column, 5-50% MeCN-water-0.1% HCO2H) to give the title compound as a diformate salt (9.78 mg). MS (ESI+) m/z'. 271.74 [M + 2H]2+, 542.28 [M + H]+; JH NMR (400 MHz, Methanol-^) 5 8.39 (s, 2H), 4.45 (dd, 1H), 4.20 (dd, 0.5H), 4.04 - 3.85 (m, 0.5 H), 3.83 - 3.58 (m, 3H), 3.54 (tdd, 2H), 3.48 - 3.34 (m, 3H), 3.28 - 3.08 (m, 3H), 3.05 - 2.90 (m, 5H), 2.84 (s, 7H), 2.73 - 2.63 (m, 1H), 2.63 - 2.53 (m, 2H), 2.53 - 2.20 (m, 2H), 2.11 - 1.91 (m, 2H), 1.81 - 1.67 (m, 1H), 1.66 - 1.44 (m, 3H), 1.38 (d, 3H), 1.35 - 1.20 (m, 9H), 1.11 - 0.98 (m, 3H).
[0443] (101?,117?,121?,141?)-ll-(((25,31?,45,61?)-4-(Diniethylamino)-3-hydroxy-6- methyltetrahydro-2//-pyran-2-yl)oxy)-12-methoxy-2,8,10,12,14,16-hexamethyl-6-oxa-2,16- diazaspiro [4.12] heptadecane-7, 9-dione (S5-6-I7-l)(Compound 66). To a solution of S5-5-I7 (17 mg, 0.032 mmol) in DCM (1 mL) was added Na(OAc)3BH (10.2 mg, 0.048 mmol) followed by formaldehyde (37 wt% aqueous solution, 0.0261 mL, 0.322 mmol) was added. After 15 min, the reaction mixture was quenched with sat., aq. NaHCOs and extracted with DCM (3 times). The combined extracts were concentrated in vacuo and the residue was purified by HPLC (Atlantis T3 column, 5-50% MeCN-water-0.1% HCO2H) to give the title compound (2.2 mg). MS (ESI+) mlz: 338.76 [M + 2H]2+, 556.23 [M + H]“.
[0444] (10/?J l/?J2/?.14/?)-l l-(((2.S.3/?.4.S.6/?)-4-(l)iinethylaniino)-3-hydroxy-6- methyltetrahydro-2Z/-pyran-2-yl)oxy)-2-(dimethylglycyl)-12-methoxy-8, 10, 12,14- tetramethyl-6-oxa-2,16-rfiazas/nro[4.12]heptadecane-7, 9-dione (S5-3-I7-l)(Compound 67).
S5-2-I7 (110 mg, 0.143 mmol) was dissolved in DCM (1 mL) and chloroacetyl chloride (0.0017 mL, 0.021 mmol) was added. After 1 hr, the reaction mixture was diluted with DCM and washed with sat. NaHCCh. The wash solution was dried over sodium sulfate, fdtered and concentrated. The acyl product (29 mg, 0.034 mmol) was dissolved in tetrahydrofuran (0.5 mL) and dimethylamine (2 M solution in tetrahydrofuran, 0.172 mL, 0.344 mmol) was added. After 15 min, the reaction mixture was heated to 70 °C. After 4 h, the reaction mixture was allowed to cool to rt and excess solvent and reagent removed under vacuum. The crude material was dissolved in methanol (1 mL), and the reaction mixture was heated to 60 °C external temperature. After 5 h, the reaction was allowed to cool to rt, hydrochloric acid (0.005 mL) and Pd/C (5 wt%, 7.22 mg, 0.0034 mmol) was added. A balloon of hydrogen was bubbling through the reaction mixture. After 30 min, it was fdtered through Celite® with ethyl acetate, and the fdtrate was concentrated in vacuo. The residue was purified by HPLC (Atlantis T3 column, 5-30% MeCN-water-0.1% HCO2H) to give the title compound as a formate salt (3.69 mg). MS (ESI+) m/z: 205.22 [M + 3H]3+, 307.19 [M + 2H]2+, 613.19 [M + H]+; ^NMR (400 MHz, Methanol-^) 8 8.47 (s, 3H),
4.45 (d, 1H), 4.19 (dd, 1H), 4.14 - 3.99 (m, 1H), 3.83 - 3.49 (m, 8H), 3.49 - 3.34 (m, 4H), 3.26 (p, 1H), 3.08 (dd, 1H), 3.01 - 2.97 (m, 1H), 2.97 - 2.90 (m, 2H), 2.86 (s, 1H), 2.81 (s, 6H), 2.78 - 2.70 (m, 2H), 2.67 (d, 4H), 2.55 - 2.40 (m, 1H), 2.05 - 1.87 (m, 2H), 1.77 - 1.61 (m, 1H), 1.60 - 1.40 (m, 3H), 1.40 - 1.24 (m, 9H), 1.24 - 1.09 (m, 3H), 1.09 - 0.95 (m, 3H).
[0445] (10/?J l/?.12/?.14/?)-l l-(((2.S.3/?.4.S.6/?)-4-(l)iinethylaniino)-3-hydroxy-6- niethyltetrahydro-2//-pyran-2-yl)oxy)-2-( \-isopropyl- \-niethylglycyl)-12-methoxy- 8,10,12,14-tetramethyl-6-oxa-2,l 6-diazaspiro[4.12] heptadecane-7, 9-dione (S5-3-I7- 2)(Compound 68). Prepared according to the methods of S5-3-I7-1, substituting N- isopropylmethylamine. Formate salt (3.47 mg). MS (ESI+) mlz\ 214.55 [M + 3H]3+, 321.27 [M + 2H]2+, 641.42 [M + H]+; 3HNMR (400 MHz, Methanol-^) 5 8.47 (s, 2.5H), 4.49 - 4.35 (m, 1H), 4.14 - 3.95 (m, 0.5H), 4.13 - 3.94 (td, 2H), 3.95 - 3.80 (m, 1.5H), 3.73 (dq, 3H), 3.57 (dq, 2H), 3.51 - 3.36 (m, 3H), 3.35 (s, 1H), 3.21 - 3.07 (m, 1H), 3.03 - 2.97 (m, 1H), 2.97 - 2.94 (m, 1H), 2.93 (s, 0.5H), 2.87 (s, 0.5H), 2.82 (s, 6H), 2.77 (q, 2H), 2.64 - 2.42 (m, 1H), 2.42 - 2.18 (m, 1H), 2.07 - 1.88 (m, 2H), 1.73 (dt, 1H), 1.65 - 1.41 (m, 2H), 1.41 - 1.24 (m, 14H), 1.24 - 1.12 (m, 3H), 1.10 - 0.88 (m, 3H).
[0446] (10/?,ll^,12/?,147?)-ll-(((25,3/?,45,6/?)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2//-pyran-2-yl)oxy)-2-(isopropylglycyl)-12-methoxy-8, 10, 12,14- tetramethyl-6-oxa-2,16-diazaspiro[4.12]heptadecane-7, 9-dione (S5-3-I7-3)(Compound 69). Prepared according to the methods of S5-3-I7-1, substituting isopropyl amine. Formate salt (5.83 mg). MS (ESI+) m/z: 209.89 [M + 3H]3’, 314.30 [M + 2H]2+, 627.25 [M + H]“; LH NMR (400 MHz, Methanol-^) 5 8.46 (s, 2H), 4.45 (d, 1H), 4.18 (dd, 0.5H), 4.14 - 3.98 (m, 0.5H), 3.99 -
3.89 (m, 2H), 3.88 - 3.50 (m, 6H), 3.50 - 3.34 (m, 5H), 3.29 - 3.16 (m, 1H), 3.15 - 3.01 (m, 1H), 3.01 - 2.92 (m, 2H), 2.91 (s, 0.5H), 2.87 (s, 0.5H), 2.78 - 2.66 (m, 1H), 2.51 - 2.31 (m, 1H), 2.06 - 1.90 (m, 2H), 1.76 - 1.65 (m, 1H), 1.60 - 1.45 (m, 2H), 1.39 - 1.31 (m, 12H), 1.29 (d, 3H), 1.25 - 1.15 (m, 3H), 1.03 (d, 2H).
[0447] (101?,lll?,121?,141?)-2-(Cyclopropylglycyl)-ll-(((25',31?,45,61?)-4-(dimethylaniino)-3- hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-12-methoxy-8,10,12,14-tetramethyl-6-oxa- 2, 16-diazaspiro[4.12]heptadecane-7, 9-dione (S5-3-I7-4)(Compound 70). Prepared according to the methods of S5-3-I7-1, substituting cyclopropylamine. Formate salt (7.57 mg). MS (ESI+) mlz'.
209.24 [M + 3H]3+, 313.24 [M + 2H]2+, 625.36 [M + H]+; ’H NMR (400 MHz, Methanol-^) 8 8.47 (s, 3H), 4.45 (d, 1H), 4.22 - 4.04 (m, 1H), 3.98 - 3.81 (m, 1H), 3.80 - 3.64 (m, 5H), 3.63 - 3.35 (m, 6H), 3.17 - 3.09 (m, 1H), 2.99 - 2.94 (m, 1H), 2.92 (s, 1H), 2.87 (s, 1H), 2.79 - 2.71 (m, 0.5H), 2.71 - 2.49 (m, 1.5H), 2.49 - 2.39 (m, 0.5H), 2.39 - 2.28 (m, 0.5H), 2.28 - 2.15 (m, 1H), 2.15 - 1.90 (m, 3H), 1.86 - 1.68 (m, 1H), 1.68 - 1.41 (m, 3H), 1.37 (t, 2H), 1.36 - 1.24 (m, 7H),
1.24 - 1.11 (m, 3H), 1.03 (t, 3H), 0.94 - 0.77 (m, 1H), 0.70 (p, 1H), 0.67 - 0.50 (m, 3H), 0.47 (dt, 1H).
[0448] The following Examples were prepared according to the methods of Scheme 5, substituting SI -2-18.
[0449] (9R,10R,llR,13R)-10-(((2S,3R,4S,6R)-4-(Z)M«ef/iy/awM7io)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-2-(dimethylglycyl)-ll-methoxy-7,9,ll,13-tetramethyl-
5-oxa-2,15-diazaspiro[3.12]hexadecane-6, 8-dione. (S5-3-I8-l)(Compound 19). Prepared according to the methods of S5-3-I7-1 from SI-2-18 with dimethylamine. Mixture of epimers.
Formate salt. MS (ESI+) w/z: 599.18 [M + H]+; ’H NMR (400 MHz, Methanol-^) 5 4.43 (d, 2H), 4.18 (d, 3H), 3.73 (dq, 3H), 3.45 (td, 4H), 3.15 - 2.42 (m, 21H), 2.22 - 1.88 (m, 2H), 1.74 - 1.43 (m, 4H), 1.32 (m, 12H), 1.04 (s, 3H).
[0450] (9R,10R,llR,13R)-2-(cyclopropylglycyl)-10-(((2S,3R,4S,6R)-4-(Dimethylamino)-3- hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13-tetramethyl-5-oxa- 2, 15-diazaspiro[3.12]hexadecane-6, 8-dione (S5-3-I8-2)(Compound 26). Prepared according to the methods of S5-3-I7-1 from SI-2-18 with cyclopropylamine. Mixture of epimers, formate salt. MS (ESI+) m/z: 611.02 [M + H]“; 1 H NMR (400 MHz, Methanol-^) 54.42 (d, 2H), 4.16 (d, 2H), 3.90 - 3.66 (m, 2H), 3.58-3.5 (m,2H), 3.49 - 3.36 (m, 4H), 3.09 - 2.84 (m, 4H), 2.80 (s, 4H), 2.63 (tt, 1H), 2.53 (dt, 1H), 2.45 - 2.26 (m, 1H), 2.27 - 2.14 (m, 2H), 2.07 - 1.90 (m, 2H), 1.89 (s, 1H), 1.79 (dq, 2H), 1.68 - 1.41 (m, 4H), 1.30 (td, 9H), 1.08 - 0.95 (m, 3H), 0.94 - 0.76 (m, 2H), 0.75 - 0.63 (m, 2H), 0.52 (dd, 1H), 0.47 (dq, 3H).
[0451] (9R,10R,llR,13R)-10-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13-tetramethyl-2-(2-(piperazin-l- yl)acetyl)-5-oxa-2,15-diazaspiro[3.12]hexadecane-6, 8-dione (S5-3-I8-3)(Compound 27).
Prepared according to the methods of S5-3-I7-1 from SI-2-18 with piperazine. Mixture of epimers, formate salt. MS (ESI+) m/z: 640.32 [M + H]+; 'H NMR (400 MHz, Methanol-6/4) 5 4.49 - 4.38 (m, 3H), 4.22 - 4.01 (m, 2H), 3.83 - 3.63 (m, 1H), 3.62 - 3.34 (m, 5H), 3.23 (q, 7H), 3.04 - 2.89 (m, 2H), 2.88 - 2.70 (m, 14H), 2.69 - 2.45 (m, 1H), 2.16 - 1.86 (m, 2H), 1.72 - 1.42 (m, 3H), 1.40 - 1.20 (m, 13H), 1.02 (dd, 4H).
Scheme S6.
S6-1-I2-1
[0452] tert-Butyl (9R,llR,12R,13R,15S)-15-allyl-12-(((2S,3R,4S,6R)-3-(Benzoyloxy)-4- (dimethylamino)-6-methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15- pentamethyl-14,16-dioxo-17-oxa-3,7-diazaspiro[5.12]octadecane-3-carboxylate (S6-1-I2-1).
SI-5-12-1 (58 mg, 0.076 mmol) was dissolved in THF (2 mL). Allyl tert-butyl carbonate (18 pL. 0.11 mmol) and Pd(PPh3)4 (4.4 mg, 0.0038 mmol) were added at rt. The reaction mixture was degassed with N2 and heated at 60 °C for 16h. LC/MS indicated complete consumption of starting
material. The reaction mixture was cooled and concentrated. The residue was purified on 4 g of silica gel (elution with 0-10% MeOH-DCM + 0.5% of 30% aq NH4OH) to give the title compound (47 mg, 79%). MS (ESI+) m/z: 400.8 [M + 2H]2+, 800.5 [M + H]+.
[0453] (9R,llR,12R,13R,15S)-15-Allyl-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-3-(dimethylglycyl)-ll-methoxy-7,9,H,13,15- pentamethyl-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S14-3)(Compound 73). Prepared according to the methods of S3-1-I6-1-1 (Boc deprotection) and S3-5-I1-1-1-1. Formate salt (8.75 mg). MS (ESI+) m/z: 227.8 [M + 3H]3+, 341.3 [M + 2H]2+, 681.5 [M + H]+; 3HNMR (400 MHz, Methanol^) 8 8.52 (s, 3H), 5.62 (ddt, 1H), 5.23 - 5.10 (m, 2H), 4.52 (dd, 2H), 4.18 (d, 1H), 3.91 (s, 1H), 3.84 - 3.68 (m, 3H), 3.50 - 3.32 (m, 4H), 3.04 (s, 4H), 2.94 (dt, 2H), 2.84 (s, 2H), 2.79 (s, 7H), 2.74 (d, 1H), 2.63 (d, 6H), 2.44 (td, 1H), 2.14 - 1.97 (m, 3H), 1.83 (d, 1H), 1.57 - 1.44 (m, 3H), 1.44 - 1.26 (m, 13H), 1.06 (d, 3H).
[0454] (2S,3R,4S,6R)-4-(Dimethylamino)-2-(((9R,llR,12R,13R)-ll-methoxy-7,9,ll,13,15,15- hexamethyl-14,16-dioxo-3-(vinylsulfonyl)-17-oxa-3,7-diazaspiro[5.12]octadecan-12-yl)oxy)- 6-methyltetrahydro-2H-pyran-3-yl benzoate (S7-1-I1). S3-1-I1-2 (62 mg, 0 080 mmol) was dissolved in DCM (1 mL). EtsN (44.2 pL, 0.32 mmol) and ethenesulfonyl chloride (20 mg, 0.16 mmol) were added at rt. The reaction mixture was allowed to stir at it for 1 h. The reaction was quenched by adding saturated NaHCCh (2 mL), and the aqueous layer was extracted with methylene chloride three times (2 mL). The combined organic layers were dried over MgSCh, filtered and concentrated. The residue was used in the next step without further purification. MSI
(ESI+) mlz'. 382.7 [M + 2H]2+, 764.4 [M + H]+.
[0455] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Z)i>M^jZawiMo)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-3-((2-(dimethylamino)ethyl)sulfonyl)-ll-methoxy- 7,9,H,13,15,15-hexamethyl-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S7-2-I1- l)(Compound 81). The crude S7-1-I1 (8 mg, 0.010 mmol) was dissolved in THF (1 mL) and dimethylamine (2M in THF, 0.016 mL, 0.031 mmol) was added at rt. The reaction mixture was allowed to stirred rt for 2 h. LC/MS shows full conversion. The reaction was quenched by adding saturated NaHCCh (2 mL) and the aqueous layer was extracted with methylene chloride three times (2 mL). The combined organic layers were dried over MgSCL, filtered and concentrated. The residue was used in the next step without further purification. MS (ESI+) m!z\ 270.5 [M + 3H]3+, 405.3 [M + 2H]2+, 809.5 [M + H]+. The material was dissolved in MeOH (0.5 mL) and heated at 60 °C until LC/MS indicated complete consumption of starting material (16 hours). The reaction mixture was filtered through a syringe filter with the aid of methanol and concentrated. The residue was purified by HPLC (MeCN-water-0.1% HCChH) to yield the title compound as a formate salt (4.82 mg, 52% yield in three steps). MS (ESI+) mlz\ 235.8 [M + 3H]3+, 353.2 [M + 2H]2+, 705.4 [M + H]+; 'H NMR (400 MHz, Methanol-^) 5 8.52 (s, 3H), 4.62 (s, 1H), 4.48 (d, 1H), 4.21 (d, 1H), 3.82 (s, 2H), 3.74 (dtd, 1H), 3.44 (dd, 1H), 3.40 - 3.24 (m, 15H), 3.19 - 3.08 (m, 2H), 3.06 (s, 3H), 2.83 (dd, 3H), 2.77 (s, 6H), 2.35 (s, 6H), 2.13 (td, 1H), 2.09 - 1.97 (m, 2H), 1.39 (q, 8H), 1.33 (d, 5H), 1.07 (d, 2H).
[0456] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-3-((2-(ethyl(methyl)amino)ethyl)sulfonyl)-ll- methoxy-7,9,ll,13,15,15-hexamethyl-17-oxa-3,7-diazaspiro[5.12]octadecane-14,16-dione (S7- 2-Il-2)(Compound 83). Prepared according to the methods of S7-2-I1-1, substituting N- methylethanamine. Formate salt (2.42 mg). MS (ESI+) m/z: 240.5 [M + 3H]3+, 360.3 [M + 2H]2+, 719.5 [M + H]+; 3H NMR (400 MHz, Methanol-^) 8 8.55 (s, 3H), 4.48 (d, 1H), 4.20 (s, 1H), 4.01 - 3.64 (m, 2H), 3.47 - 3.36 (m, 1H), 3.29 - 3.15 (m, 5H), 3.06 (s, 3H), 2.95 - 2.83 (m, 3H), 2.71 (s, 6H), 2.56 (q, 2H), 2.32 (s, 3H), 2.12 (s, 1H), 1.98 (d, 1H), 1.47 (d, 4H), 1.43 - 1.25 (m, 12H), 1.18 - 0.98 (m, 6H).
[0457] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-3-((2-(ethyl(methyl)amino)ethyl)sulfonyl)-ll- methoxy-7, 9, 11, 13,15, 15-hexamethyl-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S7- 2-Il-3)(Compound 84). Prepared according to the methods of S7-2-I1-1, substituting N- methylisopropylamine. Formate salt (1.31 mg). MS (ESI+) m/z: 245.2 [M + 3H]3+, 367.3 [M + 2H]2+, 733.5 [M + H]+; 'H NMR (400 MHz, Methanol-^) 8 8.53 (s, 3H), 4.49 (d, 1H), 4.21 (d, 1H), 3.92 - 3.66 (m, 3H), 3.53 - 3.38 (m, 2H), 3.23 - 3.09 (m, 2H), 3.09 - 2.90 (m, 6H), 2.75 (s, 7H), 2.34 (s, 4H), 2.25 - 1.92 (m, 4H), 1.52 (s, 5H), 1.47 - 1.23 (m, 13H), 1.11 (d, 8H).
[0458] (9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-3-((2-(isopropylamino)ethyl)sulfonyl)-ll-methoxy-
7,9,ll,13,15,15-hexamethyl-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S7-2-I1- 4)(Compound 85). Prepared according to the methods of S7-2-I1-1, substituting isopropyl amine. Formate salt (1.85 mg). MS (ESI+) m/z: 240.5 [M + 3H]3+, 360.3 [M + 2H]2+, 719.5 [M + H]+; 3H NMR (400 MHz, Methanol-^) 5 8.52 (s, 3H), 4.60 (s, 1H), 4.49 (d, 1H), 4.20 (d, 1H), 3.84 (s, 1H), 3.73 (dd, 2H), 3.53 - 3.36 (m, 2H), 3.20 (q, 5H), 3.06 (s, 4H), 2.75 (s, 9H), 2.07 (dd, 5H), 1.58 - 1.45 (m, 4H), 1.45 - 1.25 (m, 14H), 1.21 (d, 6H), 1.06 (s, 4H).
[0459] (2S,3R,4S,6R)-4-(dimethylamino)-2-(((9R,llR,12R,13R)-ll-Methoxy-7,9,ll,13,15,15- hexamethyl-3,14,16-trioxo-17-oxa-7-azaspiro[5.12]octadecan-12-yl)oxy)-6- methyltetrahydro-2H-pyran-3-yl benzoate (S8-1-I10-1-2). S2-2-I10-1 (320 mg) was stirred with 50% TFA/DCM (3mL) for 2 h. The solvent was removed under reduced pressure, and the residue was dissolved in DCM. This was washed with NaHCCF (saturated, aqueous), and the DCM layer was dried over TsfeSCh, was concentrated, and was dried under vacuum to give the title compound (296 mg, 97%). MS (ESI+) m/z'. 687.41 [M + H]+.
[0460] (9R,llR,12R,13R)-3-(Dimethylamino)-12-(((2S,3R,4S,6R)-4-(dimethylaniino)-3- hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7, 9,11, 13,15, 15-hexamethyl- 17-oxa-7-azaspiro[5.12]octadecane-14, 16-dione (S8-3-I10-l-2-l)(Compound 93). Prepared according to the methods of S3-2-I1-1-1-2 from S8-1-I10-1-2 and dimethylamine to provide the title compound (7.05 mg). MS (ESI+) mlr. 612.4 [M + H]“, Formate salt. 'H NMR (400 MHz, Chloroform- 54.62 - 4.36 (m, 1H), 4.28 - 4.11 (m, 1H), 3.84 - 3.60 (m, 2H), 3.52 (s, 1H), 3.49 - 3.27 (m, 4H), 3.26 - 3.10 (m, 2H), 3.05 (d, 3H), 2.95 - 2.71 (m, 12H), 2.69 (s, 2H), 2.53 (s, 2H), 2.34 - 1.92 (m, 7H), 1.90 - 1.60 (m, 5H), 1.60 - 1.44 (m, 5H), 1.44 - 1.16 (m, 11H), 1.16 - 0.87 (m, 3H).
[0461] (9R,llR,12R,13R)-3-(Dimethylamino)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3- hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15-pentamethyl-17- oxa-7-azaspiro[5.12]octadecane-14, 16-dione (S8-3-I10-l-l-l)(Compound 87). Prepared according to the methods of S3-2-I1-1-1-2 from S8-1-I10-1-1 and dimethylamine. MS (ESI+) mlz: 598.4 [M + H]+, Formate salt. ^NMR (400 MHz, Chloroform-^/) 84.67 - 4.32 (m, 2H), 4.33 - 4.05 (m, 2H), 3.89 - 3.48 (m, 2H), 3.46 - 3.24 (m, 3H), 3.18 - 2.87 (m, 5H), 2.83 - 2.20 (m, 18H), 2.19 - 1.60 (m, 8H), 1.60 - 1.15 (m, 16H), 1.01 (m, 3H).
[0462] (2S,3R,4S,6R)-4-(Dimethylamino)-2-(((9R,llR,12R,13R)-ll-methoxy-7,9,ll,13,15,15- hexamethyl-3-(methylamino)-14,16-dioxo-17-oxa-7-azaspiro[5.12]octadecan-12-yl)oxy)-6- methyltetrahydro-2H-pyran-3-yl benzoate (S8-2-I10-1-2-2). S8-1-I10-1-2 (130 mg, 0.189 mmol) in DCM (4mL) and methylamine in THF (2M, 0.47mL, 0.944mmol, 5eq) were combined and stirred for 15min. NaBH(OAc)3 (80 mg, 0.378 mmol) was added, and the mixture was stirred for 30 min. The mixture was dilute with DCM and washed with water (2 times). The DCM layer was separated, was dried over NazSCU, and was concentrated under reduced pressure. The residue was dried under vacuum to give the crude product (125mg, 95%). MS (ESI+) mlz'. 702.43 [M + H]+.
[0463] 2-(Dimethylamino)-N-((9R,HR,12R,13R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3- hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl-
14,16-dioxo-17-oxa-7-azaspiro[5.12]octadecan-3-yl)-N-methylacetamide (S8-4-I10-1-2-2- l)(Compound 92). Prepared according to the methods of S3-5-I1-1-1-1 from S8-2-I10-1-2-2 and dimethylamine to provide the title compound. MS (ESI+) mlz: 683.48 [M + H]+, Formate salt. 'H
NMR (400 MHz, Chloroform-t/) 84.64 - 4.28 (m, 2H), 4.27 - 3.85 (m, 4H), 3.72 (d, 2H), 3.43 (d,
4H), 3.26 (d, 1H), 3.07 (d, 3H), 2.99 - 2.55 (m, 18H), 2.36 (d, 3H), 2.16 - 1.66 (m, 9H), 1.64 - 1.18 (m, 17H), 1.08 (d, 3H).
[0464] N-((9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl-14,16-dioxo- 17-oxa-7-azaspiro[5.12]octadecan-3-yl)-2-(isopropyl(methyl)amino)-N-methylacetamide (S8- 4-I10-l-2-2-2)(Compound 109). Prepared according to the methods of S3-5-I1-1-1-1 from S8-2- 110-1-2-2 and N-methylisopropylamine to provide the title compound. MS (ESI+) mtz'. 711.43 [M + H]+, Formate salt. ^NMR (400 MHz, Chloroform^/) 84.60 (d, 1H), 4.47 (d, 1H), 4.36 (s, 1H), 4.22 (d, 1H), 3.99 (dd, 3H), 3.78 - 3.64 (m, 2H), 3.55 - 3.40 (m, 3H), 3.25 (s, 1H), 3.07 (d, 3H), 2.90 (d, 4H), 2.82 - 2.66 (m, 9H), 2.37 (d, 3H), 2.09 - 1.83 (m, 7H), 1.67 (s, 2H), 1.54 - 1.26 (m, 25H), 1.10 (t, 2H), 0.98 (s, 2H).
[0465] 2-(Cyclopropyl(methyl)amino)-N-((9R,HR,12R,13R)-12-(((2S,3R,4S,6R)-4-
(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-
7,9,lli13,15,15-hexamethyl-14,16-dioxo-17-oxa-7-azaspiro[5.12]octadecan-3-yl)-N- methylacetamide (S8-4-I10-l-2-2-3)(Compound 94). Prepared according to the methods of S3- 5-11-1-1-1 from S8-2-I10-1-2-2 and N-methylcyclopropylamine to provide the title compound.
MS (ESI+) mlz-. 695.47 [M + H]“, Formate salt. XH NMR (400 MHz, Chloroform-;/) 8 4.67 - 4.43
(m, 1H), 4.40 - 4.15 (m, 2H), 4.09 (d, 1H), 3.86 - 3.64 (m, 4H), 3.41 (ddd, 3H), 3.21 (t, 1H), 3.16
- 3.03 (m, 4H), 2.97 - 2.76 (m, 11H), 2.39 (dt, 4H), 2.18 - 1.89 (m, 5H), 1.90 - 1.75 (m, 3H),
[0466] N-((9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl-14,16-dioxo- 17-oxa-7-azaspiro[5.12]octadecan-3-yl)-2-(3-hydroxyazetidin-l-yl)-N-methylacetamide (S8- 4-I10-l-2-2-4)(Compound 98). Prepared according to the methods of S3-5-I1-1-1-1 from S8-2- 110-1-2-2 and 4-hydroxyazetidine to provide the title compound. MS (ESI+) mlz\ 711.42 [M + H]+, Formate salt. Ti NMR (400 MHz, Chloroform-;/) 54.69 (dt, 2H), 4.60 - 4.46 (m, 3H), 4.40 - 4.14 (m, 6H), 4.03 - 3.85 (m, 3H), 3.77 (d, 2H), 3.55 - 3.41 (m, 3H), 3.28 - 3.19 (m, 2H), 3.09 (d, 4H), 3.00 - 2.85 (m, 8H), 2.80 (s, 3H), 2.34 (s, 3H), 2.10 - 1.80 (m, 8H), 1.56 - 1.32 (m, 16H), 1.11 (d, 3H).
[0467] N-((9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl-14,16-dioxo- 17-oxa-7-azaspiro[5.12]octadecan-3-yl)-N-methyl-2-(4-methylpiperazin-l-yl)acetaimde (S8- 4-I10-l-2-2-5)(Compound 99). Prepared according to the methods of S3-5-I1-1-1-1 from S8-2- 110-1-2-2 and 1 -methylpiperazine to provide the title compound. MS (ESI+) mlz\ 738.4 [M + H]+, Formate salt. XHNMR (400 MHz, Methanol-d4) 8 8.52 (s, 2H), 4.58 (d, 1H), 4.47 (d, 1H), 4.22 (d, 1H), 4.08 (d, 1H), 4.01 - 3.81 (m, 1H), 3.77 - 3.61 (m, 2H), 3.57 - 3.37 (m, 3H), 3.35 (s, 1H), 3.17 - 2.89 (m, 7H), 2.89 - 2.50 (m, 16H), 2.50 - 2.20 (m, 7H), 2.20 - 1.17 (m, 28H), 1.17 - 0.88 (m, 3H).
[0468] N-((9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl-14,16-dioxo- 17-oxa-7-azaspiro[5.12]octadecan-3-yl)-N-methyl-2-morpholinoacetamide (S8-4-110- 1-2-2- 6)(Compound 95). Prepared according to the methods of S3-5-I1-1-1-1 from S8-2-I10-1-2-2 and morpholine to provide the title compound. MS (ESI+) mlz\ 725.4 [M + H]+, Formate salt.
[0470] N-((9R,llR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl-14,16-dioxo- 17-oxa-7-azaspiro[5.12]octadecan-3-yl)-2-((2-(dimethylamino)ethyl)amino)-N- methylacetamide (S8-4-I10-l-2-2-7)(Compound 100). Prepared according to the methods of S3-5-I1-1-1-1 from S8-2-I10-1-2-2 and 2-(dimethylamino)ethylamine to provide the title compound. MS (ESI+) mlz\ 726.5 [M + H]+, Formate salt.
[0471] 2-(cyclopropylamino)-N-((9R,l lR,12R,13R)-12-(((2S,3R,4S,6R)-4-(dimethylamino)-3- hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)- 11 -m ethoxy-7, 9, 11,13,15,15-hexam ethyl- 14, 16- dioxo-17-oxa-7-azaspiro[5.12]octadecan-3-yl)-N-methylacetamide (S8-4-I10-l-2-2-8)(Compound 141) Prepared according to the methods of S3-5-I1 - 1 -1 -1 from S8-2-I10-1-2-2 and cyclopropylamine. 3.4 mg Formate salt. MS (ESI+) mlz'. 695.5 [M + H]+, LH NMR (400 MHz, Methanol </) 8 8.47 (d, 2H), 4.67 - 4.44 (m, 1H), 4.22 (d, 1H), 4.09 (d, 1H), 3.90 - 3.57 (m, 4H), 3.57 - 3.41 (m, 2H), 3.41 - 3.35 (m, 1H), 3.27 - 3.15 (m, 1H), 3.15 - 3.02 (m, 3H), 3.02 - 2.85 (m, 5H), 2.80 (d, 6H), 2.52 - 2.24 (m, 4H), 2.18 - 1.72 (m, 8H), 1.72 - 1.60 (m, 2H), 1.52 (s, 4H), 1.46 - 1.36 (m, 6H), 1.33 (d, 6H), 1.18 - 0.88 (m, 3H), 0.72 - 0.50 (m, 4H).
Scheme S9
[0472] 2-((9R,HR,12R,13R)-12-(((2S,3R,4S,6R)-3-(benzoyloxy)-4-(Dimethylamino)-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,ll,13,15,15-hexamethyl-14,16-dioxo- 17-oxa-3,7-diazaspiro[5.12]octadecan-3-yl)acetic acid (S9-1-I1-1-2). S3-1-I1-1-2 (56 2 mg, 71.7 mmol) was dissolved in DCM (358 mL) and Et;N (0.0298 mL, 0.215 mmol), and glyoxylic acid monohydrate (19.7 mg, 0.215 mmol) and Na(OAc)3BH (30.3 mg, 0.143 mmol) were added. After stirring overnight, the reaction mixture was quenched with NH4CI (sat, aq) and was extracted with DCM (3 times). The combined extracts were dried over Na2SO4, were filtered, and were concentrated under reduced pressure. LC/MS analysis indicated only trace product. The aqueous layer was adjusted to pH 7-8 with NaHCCh (sat, aq) and was extracted with DCM (4x). The combined extracts were dried over NazSCh, were filtered, and were concentrated under reduced pressure to give the crude title compound (85.4 mg). The material was used without further purification. MS (ESI+) mlz'. 732.35 [M + H]+.
[0473] 2-((9R,HR,12R,13R)-12-(((2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)-ll-methoxy-7,9,1143,15,15-hexamethyl-14,16-dioxo- 17-oxa-3,7-diazaspiro[5.12]octadecan-3-yl)-N,N-dimethylacetamide (S9-2-I1-1-2- l)(Compound 71). S9-1-I1-1-2 (52.4 mg, 0.0715 mmol) was dissolved in DCM (0.357 mL) and A. A-di isopropyl ethylamine (0.0132 mL, 0.0858 mmol) and 1 -hydroxybenzotriazole (12.5 mg, 0.0929 mmol), dimethylamine(l M in THF, 0.143 mL, 0.143 mmol), and A,A- diispropylcarbodiimide (0.0132 mL, 0.0858 mmol) were added sequentially. After stirring overnight, the reaction mixture was diluted with EtOAc and was washed with NaHCCL (sat, aq, 2 times) and brine (1 time). The organic layer was dried over NazSCh, was filtered, and was concentrated under reduced pressure. The material was purified by ISCO (24 g column, 4-20% MeOH/DCM/0.5% NH4OH gradient), yielding the benzoate intermediate (21.2 mg, 39%, 2 steps). MS (ESI+) mlz\ 759.37 [M + H]+. The material was dissolved in MeOH (1 mL), and the reaction mixture was heated to 65 °C. After 3 h, the reaction mixture was concentrated under reduced pressure and the material was purified by HPLC (MeCN-water-0.1% HCO2H) to yield the title compound (14.2 mg, 78%). Formate salt. MS (ESI+) mlz\ 655.41 [M + H]+. 'H NMR (400 MHz, Methanol-d4) 5 8.38 (s, 2H), 4.59 (d, 1H), 4.48 (d, 1H), 4.22 (d, 1H), 3.74 (ddt, 1H), 3.50 - 3.40 (m, 2H), 3.40 - 3.33 (m, 3H), 3.21 (t, 1H), 3.09 - 2.96 (m, 9H), 2.94 (s, 3H), 2.91 (s, 3H), 2.86 - 2.77 (m, 7H), 2.49 (q, 2H), 2.39 - 2.24 (m, 2H), 2.15 (td, 1H), 2.09 - 2.01 (m, 1H), 1.99 - 1.89 (m, 1H), 1.89 - 1.73 (m, 2H), 1.59 - 1.44 (m, 5H), 1.44 - 1.30 (m, 13H), 1.08 (d, 3H).
[0474] (9R, HR, 12R,13R)-3-(Dimethylglycyl)-12-hydroxy-ll-methoxy-7, 9, 11,13, 15,15- hexamethyl-17-oxa-3,7-diazaspiro[5.12]octadecane-14, 16-dione (S10-l-Il-l-2-l)(Compound 97). S3-5-I1-1-2-1 was dissolved in 1 N aqueous HC1, and the solution was freeze-dried. HPLC indicated significant hydrolysis of the desosamine sugar. The residue was purified by HPLC (Atlantis T3 column, 5-50% MeCN-water-0.1% HCO2H) to yield the title compound as a formate salt (29.7 mg). MS (ESI+) mlz\ 498.18 [M + H]+. ^NMR (400 MHz, Methanol-d4) 6 8.46 (s, 1H), 5.10 (d, 1H), 4.66 - 4.45 (m, 2H), 4.29 (dd, 1H), 4.16 - 4.04 (m, 1H), 3.93 (d, 1H), 3.84 (d, 1H), 3.47 - 3.14 (m, 2H), 3.13 - 2.99 (m, 4H), 2.99 - 2.75 (m, 11H), 2.41 - 2.18 (m, 2H), 2.10 - 1.98 (m, 2H), 1.94 - 1.77 (m, 2H), 1.50 (s, 3H), 1.37 (d, 6H), 1.29 (dd, 1H), 1.22 (d, 3H), 1.15 - 1.03 (m, 3H).
[0475] Compound 113 was prepared as provided in Scheme SI 1.
Compound A
[0476] Compound A was prepared according to the methods of SI-2-11 from II and replacing Sl-
[0477] Benzyl (9R,1 lR,12R,13R,15R)-12-(((2S,3R,4S,6R)-3-(benzoyloxy)-4-(dimethylamino)-
6-methyltetrahydro-2H-pyran-2-yl)oxy)- 11 -(2-hydroxyethoxy)-7,9, 11,13,15 -pentamethyl- 14,16- dioxo-17-oxa-3,7-diazaspiro[5.12]octadecane-3-carboxylate (Compound B). Compound A (461 mg, 0.562 mmol) was dissolved in DCM (20 mL) and TFA (0.214 mL, 2.81 mmol) was added. The reaction mixture was cooled to -78 °C. A stream of ozone (7 PSI, 2 LPM) was bubbled through the reaction mixture until a blue color persisted (approximately 1 min). The ozone stream was removed, and nitrogen was then bubbled through the solution for 5 min (blue color disappeared). Ph3P (737 mg, 2.81 mmol) was added, and the reaction mixture was removed from the bath and allowed to warm to it After 45 min, the reaction mixture was diluted with NaHCOs (sat, aq) and was extracted with DCM (3x). The combined extracts were dried over NazSCh, were filtered, and were concentrated under reduced pressure. The crude material was dissolved in MeOH (3 mL) and was cooled to 0 °C. NaBEL (42.3 mg, 1.12 mmol) was added. After 15 min, the reaction mixture was quenched with NaHCCh (sat, aq) and was extracted with DCM (3x). The combined extracts were dried over NazSCU, were filtered, and were concentrated under reduced pressure. The material was purified by column chromatography (ISCO 40 g column, 2 to 15% MeOH/DCM/O.5% NH4OH gradient), yielding 174.5 mg (38%) of Compound B. MS (ESI) m/z 824.38 (M+H).
Compound C
[0478] Benzyl (lR,8R,10R,15R,16R)-16-(((2S,3R,4S,6R)-3-(benzoyloxy)-4-(dimethylamino)-6- methyltetrahydro-2H-pyran-2-yl)oxy)- 1,6,8,10,15 -pentamethyl -2, 14-dioxo-3 , 11 -dioxa-6- azaspiro[bicyclo[8.3.3]hexadecane-5,4'-piperidine]-l'-carboxylate (Compound C). p- toluenesulfonyl chloride (28.9 mg, 0.152 mmol) was added to a solution of Compound B (115.7 mg, 0.139 mmol) and triethylamine (0.0578 mL, 0.416 mmol) in toluene (0.694 mL) at rt. After 1.5 h, N, A-di methyl ami nopyridine (5 mg) and additional p-toluenesulfonyl chloride (15 mg, 0.0787 mmol) were added. After an additional 1.5 h, additional A,A-dimethylaminopyridine (15 mg) was added, resulting in formation of a precipitate. Acetonitrile was added. After 3 h, additional p-toluenesulfonyl chloride (15 mg, 0.0787 mmol) was added and the mixture was stirred overnight. The reaction mixture was diluted with EtOAc and was washed with NaHCCh
(sat, aq, 2 x), water (3x), and brine (lx). The EtOAc layer was dried over NazSCU, was filtered, and was concentrated under reduced pressure. The crude material was dissolved in acetone (1 mL) and sodium iodide (208 mg, 1.39 mmol) was added. The reaction mixture was heated to 60 °C. After 4 h, the reaction mixture was cooled to rt, was diluted with EtOAc, and was washed with water (2x). The EtOAc layer was dried over Na2SO4, was filtered, and was concentrated under reduced pressure. The crude product was dissolved in DMF (1.38 mL) and CS2CO3 (224 mg, 0.690 mmol) was added. After stirring at rt overnight, the reaction mixture was diluted with EtOAc and was washed with water (3x) and brine (lx). The EtOAc layer was dried over Na2SO4, was filtered, and was concentrated under reduced pressure. The material was purified by column chromatography (ISCO 24 g column, 2 to 10% MeOH/DCM/0.5% NH4OH gradient), yielding 31.6 mg (28%, 3 steps) of Compound C. MS (ESI) m/z 806.32 (M+H).
Compound D
[0479] Benzyl (lR,8R,10R,15R,16R)-16-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)- 1,6,8,10,15 -pentamethyl -2, 14-dioxo-3 , 11 -dioxa-6- azaspiro[bicyclo[8.3.3]hexadecane-5,4'-piperidine]-l'-carboxylate (Compound D). Compound C (4.7 mg, 0.0058 mmol) was dissolved in MeOH (1 mL) and was heated to 65 °C. After 3 h 20 min, the reaction mixture was cooled to rt and was concentrated under reduced pressure. The material was purified by HPLC (Atlantis T3 column, 5 to 50 to 90% gradient of Acetonitrile/0.1% formic acid and Water/0.1% formic acid). Fractions with the desired mass were collected and freeze-dried, yielding 3.00 mg (73%) of the title compound. Formate salt. JH NMR (400 MHz, Methanol-^) 6 8.55 (s, 1H), 7.42 - 7.23 (m, 6H), 5.20 - 5.01 (m, 3H), 4.38 (d, 1H), 4.21 - 4.00 (m, 2H), 4.00 - 3.79 (m, 2H), 3.79 - 3.67 (m, 2H), 3.67 - 3.53 (m, 2H), 3.21 - 2.80 (m, 5H), 2.79 - 2.62 (m, 2H), 2.62 - 2.44 (m, 7H), 2.37 (s, 3H), 2.16 (d, 1H), 2.05 - 1.91 (m, 1H), 1.91 - 1.76 (m, 3H), 1.49 - 1.30 (m, 5H), 1.30 - 1.02 (m, 11H), 0.89 - 0.69 (m, 3H); MS (ESI) m/z 702.32 (M+H).
Compound E
[0480] (2S,3R,4S,6R)-4-(dimethylamino)-6-methyl-2-(((lR,8R,10R,15R,16R)-l,6,8,10,15- pentamethyl-2,14-dioxo-3,l l-dioxa-6-azaspiro[bicyclo[8.3.3]hexadecane-5,4'-piperidin]-16- yl)oxy)tetrahydro-2H-pyran-3-yl benzoate (Compound E). Compound C (26.8 mg, 0.0332 mmol) was dissolved in MeOH (1 mL) and IN aqueous HC1 (0.0996 mL). 5% Pd on carbon (14 mg) was added and an atmosphere of hydrogen was introduced (balloon). After 1.5 h, the reaction mixture was evacuated and back-filled with N2 (3x), and the solution was filtered through a 0.2 pM syringe filter. The filtrate was concentrated under reduced pressure and was used without further purification. MS (ESI) m/z 6T1A (M+H).
Compound 113
[0481] (2S,3R,4S,6R)-4-(dimethylamino)-2-(((lR,8R,10R,15R,16R)-T-(dimethylglycyl)- l,6,8,10,15-pentamethyl-2,14-dioxo-3,l l-dioxa-6-azaspiro[bicyclo[8.3.3]hexadecane-5,4'- piperidin]-16-yl)oxy)-6-methyltetrahydro-2H-pyran-3-yl benzoate (Compound 113).
Chloroacetyl chloride (0.0032 mL, 0.040 mmol) was added to a solution of Compound E (25.9 mg, 0.0331 mmol) and trimethylamine (0.0137 mL, 0.0993 mmol) in dichloromethane (2 mL). After Ih and 10 min, the reaction mixture was concentrated under reduced pressure. The crude material was dissolved in dimethylamine solution (2.0 M in THF, 1.23 mL, 2.47 mmol), and the mixture was heated to 65 °C. After 40 min, the reaction mixture was concentrated under reduced pressure. The crude material was dissolved in MeOH (2 mL) and was heated to 50 °C overnight. The reaction mixture was cooled to rt and was concentrated under reduced pressure. The material was purified by HPLC (Atlantis T3 column, 5 to 50 to 90% gradient of Acetonitrile/0.1% formic
acid and Water/0.1% formic acid). Fractions with the desired mass were collected and freeze- dried, yielding 6.23 mg (29%) of Compound F. Formate salt. 'H NMR (400 MHz, Methanol-c/v) 5 8.50 (s, 2H, formic acid), 5.19 (d, 1H), 4.50 (dd, 2H), 4.31 (bs, 1H), 4.05 - 3.60 (m, 7H), 3.50 - 3.30 (m, 4H), 2.84 - 2.56 (m, 18H), 2.19 (d, 1H), 2.15 - 1.70 (m, 8H), 1.51 (q, 2H), 1.44 (s, 3H), 1.37 (d, 3H), 1.28 (dd, 7H), 0.98 (s, 3H).; MS (ESI) m/z 653.38 (M+H).
Compound 113
[0482] (lR,8R,10R,15R,16R)-16-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6- methyltetrahydro-2H-pyran-2-yl)oxy)- 1,6,8,10,15 -pentamethyl -3,11 -dioxa-6- azaspiro[bicyclo[8.3.3]hexadecane-5,4'-piperidine]-2, 14-dione (Compound G). Material was isolated during purification of Compound F, having been formed from unreacted Compound E. 2.29 mg (12%, 4 steps). Formate salt. XH NMR (400 MHz, Methanol-^) 8 8.44 (s, 3H), 5.21 (d, 1H), 4.45 (d, 1H), 4.22 - 3.52 (m, 5H), 3.50 - 3.32 (m, 4H), 3.25 - 2.97 (m, 3H), 2.92 - 2.62 (m, 9H), 2.64 - 2.42 (m, 2H), 2.35 (d, 1H), 2.16 - 1.75 (m, 6H), 1.58 - 1.44 (m, 2H), 1.39 (s, 3H), 1.35 - 1.05 (m, 9H), 0.98 - 0.75 (m, 2H); MS (ESI) m/z 568.35 (M+H).
Biological Activity
A novel class of Ribosome Modulating Agents (RMAs) targets ribosome heterogeneity in a subset of colorectal cancers
[0483] Background: Aberrant protein translation is a key driver in cancer downstream of pro- oncogenic stimuli. The aberrant protein translation is frequently carried out by ribosomes that have cancer specific alterations providing an opportunity to selectively target “oncoribosomes”. Our unique synthetic chemistry generates novel macrolides that are Ribosome Modulating Agents (RMAs) capable of selectively targeting oncoribosomes. Wnt-pathway activated colorectal cancers (CRC) tend to be highly dependent on elevated protein translation capacity. These types of cancers maybe vulnerable to RMAs that selectively inhibit oncoribosomes dependent protein translation.
[0484] Material and methods: Cell proliferation was assessed using Cell Titer Gio assay. New
protein synthesis was evaluated by metabolic labelling using L-Azidohomoalanine (AHA) followed by biotinylation and detection by Western Blot as provided below. Quantitative Mass spectrometric analysis of proteins was conducted using pulsed Stable Isotope Labeling with Amino acids in Cell culture (pSILAC) proteomics method. Cell cycle arrest and apoptosis were assessed using flow cytometry.
[0485] Results: We evaluated a representative RMA, across a panel of 34 CRC cell lines. The representative compound inhibited of proliferation of 24% of cell lines. Genomic analysis showed that all cell lines sensitive to the compound belonged to the Consensus Molecular Subgroup 2 (CMS2) sub-type. The anti-proliferative effect of the representative compound was confirmed in a panel of CMS2 patient derived organoids while sparing normal colon organoids. Metabolic labelling showed that the representative compound inhibited protein translation in SW 1417 (CMS2) cells but had no impact on protein translation in COLO-320DM (CMS4). Consistent with this, treatment of SW 1417 with the representative compound triggered nucleolar stress response resulting in cell cycle arrest and apoptosis. pSILAC proteomics showed that the compound selectively inhibited translation of a subset of proteins. The impacted proteins were enriched for proteins containing positively charged regions, particularly those involved in ribogenesis and protein translation. Finally, we show that the representative compound causes synthetic lethality with DNA intercalating agents, a class of chemotherapeutics that are known to inhibit ribogenesis. [0486] Conclusions: We have identified a new class of molecules that selectively inhibit protein translation in CMS2 subtype of CRC which is characterized as MicroSatellite Stable (MSS) and tends to harbor high activity of Wnt/Myc pathway. The selectivity of protein translation inhibition is further characterized by preferential effect on positively charged proteins including those involved in ribogenesis and protein translation. This novel mechanism shows synergy with traditional cytotoxic therapy to generate potential new cancer therapeutics.
Proliferation Assay Protocol:
[0487] The anti-proliferative effect of compounds was tested on colorectal (CRC)-derived SW1417 (ATCC, catalog number: CCL-238) and small cell lung cancer (SCLC)-derived NCIH446 (ATCC, catalog number: HTB-171) cell lines using an opaque- walled, clear-bottom, 384-well plate format. Cells were counted with a Vi-cell XR cell counter and subsequently seeded in their corresponding complete medium: DMEM medium (Invitrogen, catalog number: 11995- 040) supplemented with 10% fetal bovine serum (FBS) for SW1417 cells; RPMI-1640
(Invitrogen, catalog number: 11875-093) supplemented with 10% FBS for NCIH446 cells at a density of 600 (SW1417) and 1,200 (NCIH446) cells/well in a final volume of 40ul. Seeded plates were incubated overnight at 37 °C and 5% CO2.
[0488] Plates were prepared from 60mM DMSO compound stocks with intermediate doses in medium using an automated liquid handler, to achieve the following conditions: 60uM as top concentration, 4 doses, 3-fold dilutions all at 0.1% final volume/volume of DMSO/well. 2ul of diluted compounds, from plates where doses were prepared, were added to 40ul of medium with cells already attached. Staurosporine was used as a reference compound at a starting concentration of 2uM, 7 doses, and 3 -fold dilutions for every plate with test compounds.
[0489] Plates seeded with NCIH446 and SW1417 cells were treated for 96 and 144 hours, respectively. The experiment included a time zero (tO) plate for each cell line. All plates were incubated at 37 °C and 5% CO2 for the duration of their corresponding treatments.
[0490] CellTiterGlo Luminescence kit (Coming, catalog number: G7573) was used to measure ATP levels as a readout for cell viability. CellTiterGlo reagents were equilibrated at room temperature prior to use. Plates seeded with cells were also equilibrated at room temperature for approximately 30 minutes. 25ul of CellTiterGlo reagent/well were added to cells. Plates were gently mixed for 10 minutes at room temperature and protected from light. Luminescence was recorded with an EnVision plate reader and measurements were performed with 0.1s iterations. [0491] Data analysis was performed to calculate Minimum Response Percentage values with XLFit curve fitting software using (IF) logical test: =IF(T greater than T0,100*(T-T0)/(C- T0),100*(T-T0)/T0), where T = Luminescence of compound treatment; TO = Luminescence of compound treatment at time zero; C = Luminescence of vehicle treatment.
Results
[0492] Data for individual compounds is presented in the following Table as the Minimum Response Percentage for each cell line tested. ++++ = less than -50% (cytotoxic); +++ = less than 0 to -50% (moderately cytotoxic); ++ = less than 50 to 0% (growth inhibition); + = less than 100 to 50% (moderate growth inhibition); - = greater than 100% (no growth inhibition).
[0493] FRT cells expressing CFTR P-globin fusion proteins (W134X) are cultured in Coon’s F- 12 Medium supplemented with 5% fetal bovine serum and 100 units/mL penicillin-streptomycin. Cells are kept in a humidified, 5% CO2 atmosphere at 37°C. Cells are transfected with 0.5 pg/mL of the described construct, and 48 hours later, the levels of luciferase are measured with the luciferase assay lit (Promega, USA), according to the manufacturer’s instructions.
[0494] A NanoLuc luciferase reporter plasmid was developed to target the identification of both readthrough and NMD modulators by using the addition of a nonsense mutation (W134X) in the Nanoluc region to test for readthrough as well as upstream of a P-globin intron to test for NMD attenuation. The G418 used in experiments was commercial G418-sulfate (Gibco, # 10131-027). Following normalization, the differences in luciferase activities reflect the frequency of stop codon readthrough.
[0495] Panel 1: Readthrough was observed when cells were treated with various amounts of Compound 40 alone or in combination with 100 uM G418.
[0496] Panel 2: Readthrough was observed when cells were treated with various amounts Compound 40 alone or in combination with 100 uM G418 alone or in combination with 50 uM G418.
Full method
Cell Culture
[0497] FRT cells expressing CFTR P-globin fusion proteins (W134X) are cultured at 37°C and 5% CO2 in BioChrom Coon’s F-12 Medium (Cedar Lane Labs, #F0855) with 5% fetal bovine serum (Gibco, #26140-079), 1% penicillin-streptomycin (Gibco, #15140-122), L-glutamine (Gibco, #25030) and 200 pg/mL Zeocin (Life Technology, #R25005).
HTS
[0498] Cells are removed from -80 °C freezers, thawed, and pelleted at 1000 rpm for 5 min at room temperature. The cells are resuspended in FRT growth media. A multidrop reagent dispenser (Thermo Fisher Scientific, #22-387-053) is used to plate cells (25,000 cells/well, 50 pL/well) into 384-well assay plates (Coming, #3570BC). The plates are centrifuged at 500 rpm for 2 min at room temperature and incubated for 48 h at 37°C and 5% CO2. before compound
administration of 5 pL/well, to yield a final assay volume of 55 pL/well. The cells are incubated for 48 h at 37°C and 5% CO2.
[0499] For the W134X screening, the medium is aspirated and replaced with 16 pL of Opti-MEM medium (Life Technology, #11058), without FBS, buffered with HEPES (Gibco, #15630-080). 4 pL of Nano-Gio Live Cell Reagent (Promega, #N2013) is added and luminescence was read using an integration time of 0.1-2 seconds.
RDEB Assay Rational, Methodology and Results Example 1. Collagen Type VII Immunoblotting Assay [0500] Rationale
[0501] To assess the ability of compounds in inducing the expression of full-length Collagen VII protein in two RDEB patient Fibroblasts (R578X/R578X or R613X/R1683X) or keratinocytes (R2814X/R2814X, R2610X/R2610X or Q251X/Q251X) after 48 hours of treatment.
[0502] Methodology
[0503] This method has been described in detail by Cogan and colleagues (Cogan et al., Molecular therapy, vol. 22,10 (2014): 1741-52). Cells were plated at 70-80% confluency on 6- well plates. On the following day, media were replaced with fresh media and cells were untreated or treated with test compounds (tested range: 10-60 pM, see table 3 for details) or gentamicin (positive control; 200 pg/ml or 400 pg/ml). At 24 hours, the media was replaced with fresh media and compound. After 48 hours of treatment, cells were lysed and subjected to immunoblot analysis using a polyclonal antibody to type VII collagen and a monoclonal antibody to P- Actin (loading control). ImageJ was used to quantify the intensity of the specific bands and all samples were normalized to 0-Actin. Resultant densitometry values were expressed relative to 0-Actin and then expressed as a percentage relative to non-treated cells.
[0504] The ability of the test compounds in inducing readthrough of Collagen VII protein was assessed in 4 different RDEB derived patient cells using two different cell types (fibroblasts and keratinocytes). The average readthrough activity is expressed as a percentage of activity relative to gentamicin: + = 0-33% of gentamicin, ++ = 34-66% of gentamicin, and +++ = greater than 66% of gentamicin.
Example 2. Fibroblast Migration Assay
Rationale
[0505] RDEB patient fibroblasts have a hypermotility phenotype relative to fibroblasts derived from normal subjects. This cellular phenotype is thought to be linked to the inability of RDEB fibroblasts to attach to the growth substrate due to a lack of Collagen VII (Chen et al., Nature genetics vol. 32,4 (2002): 670-5; Cogan et al., 2014). We therefore test the effect of test compounds in reducing/ rescuing the hypermotility phenotype by induction of Collagen VII nonsense mutation readthrough.
Methodology
[0506] This method has been described in detail by Cogan and colleagues (Woodley et al., Journal of cellular physiology vol. 136,1 (1988): 140-6; Chen et al., 2002; and Cogan et al., 2014). Briefly, R578X/R578X, R613X/R1683X and normal human dermal fibroblasts were plated at a density of 300,000 cells per well of a 6-well plates. On the following day, cells were untreated or treated with test compounds for 24 hours (tested range: 10-60 pM, see table 4 for details). Media and compound were then replaced with fresh media containing indicated doses of compounds. After 48 hours of treatment, cells were sub-cultured onto coverslips and subjected to a well-established fibroblast migration assay as follows: Colloidal gold salts were immobilized on coverslips and covered with type I collagen (15 mg/ml). Fibroblast cultures were suspended, plated on the coverslips, and allowed to migrate for 16-20 hours. The cells were fixed in 0.1% formaldehyde in phosphate-buffered saline and examined under dark field optics. 15-20 non- overlapping fields in each experimental condition were analyzed with NIH Image 1.6 and the percentage area of each field consumed by cell migration tracks was determined (termed Migration Index, MI). In this assay migration indexes of treated and untreated RDEB cells were compared to normal human fibroblast (NHF) cells as well as RDEB cells treated with gentamicin (previously shown to rescue hypermotility phenotype by Cogan et al., 2014; positive control).
[0507] The ability of the test compounds in inducing the expression of full-length Collagen VII protein in two RDEB patient fibroblast cell lines with R578X/R578X and R613X/R1683X
mutations was assessed after 48 hours of treatment. Compounds were ranked by considering the MI of compound treated fibroblasts relative to untreated and NHF cells. In this assay untreated cells are most motile, (with little/ no readthrough; marked as +) while NHFs are least motile. Compounds that induce a high level of readthrough have a similar motility level (and therefore MI) to NHFs (marked as +++).
Example: CF Assay Rational, Methodology and Results
Automated Equivalent Current (IEQ) Assay
Rationale
[0508] The efficacy of compounds in increasing chloride ion transport by inducing readthrough of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) nonsense mutation was assessed in primary CF human Bronchial Epithelial (hBE) cultures after 96 hours of treatment using a TECC24 assay setup.
Methodology
[0509] This method has previously been described in detail (Vu et al., Journal of medicinal chemistry vol. 60,1 (2017): 458-473). Cell culture: primary CF hBE cells from a donor with the G542X/F508del-CFTR mutation (patient code KK34J) were cultured as monolayers on Transwell 24-well filter plates at an Air Liquid Interface (ALI) for 4-6 weeks until fully differentiated. Treatment procedure: cultures were basolaterally treated with media containing test compounds (diluted in DMSO) at a final concentration of 20 pM and 60 pM. After 2 days of incubation, basolateral media was replaced with fresh media containing test compounds and the apical mucus was washed with media for at least 30 minutes and incubated for a further 2 days (total of 96 hours). 125 pg/mL ELX-02 was used as a positive control and a CFTR activity standard for readthrough ranking. IEQ measurements: custom software was used to measure transepithelial voltage (VT) and conductance (GT) with a 24-channel current clamp circuit and electrode manifold (TECC24; EP Design BVBA, Bertem, Belgium) coupled to a cartesian robot.
Measurements were made every approximately 5 minutes. Electrodes were washed between each plate read cycle. Baseline reads were measured for approximately 20 minutes. After this period
for each epithelium, 25 pL of 100 pM benzamil (10 pM final concentration) was added apically to block ENaC currents, and readings were taken for an additional 20 minutes. After this period, forskolin (10 pM final concentration) and the potentiator VX-770 (100 nM final concentration) were added apically (27.8 pL of combined 100 pM forskolin, 1 pM VX-770 stock). After an additional approximately 20 minutes, 30.9 pL of 200 pM CFTRinh-172 (20 pM final concentration) was added to the apical solution to terminate the run by inhibiting the CFTR- dependent current. Data analysis: The Ohm’s law equation IEQ= VTGT was used to calculate current using Microsoft Excel software. IEQ responses to the above experimental reagents were calculated at each step. The change in current from the baseline that is resultant from the simultaneous addition of forskolin and VX-770 is termed activation current and was used to determine the level of CFTR activity (and hence readthrough) in these studies.
[0510] Activity data is expressed as the percent activation relative to vehicle treated (0%) and ELX-02 (100%) treated cells: + = less than or equal to 10%, ++ = 11-50%, +++ = 51-100%, ++++ = greater than 100%.
In vivo APCmin Study
[0511] ApcMin mice (C57BL/6J-ApcMin/J)JAX, Jackson laboratory, Bar Harbor ME) harboring the L850X mutation are randomized and dosed with either test agent or vehicle control starting at 10 weeks of age. The mice are dosed daily for a period of 8 weeks at which time the mice are sacrificed, and small intestine, large intestine and spleen are harvested. Spleen weights are measured and recorded. Photographs of the whole small intestine and partial large intestine (approximately 300-400mm) are captured. The middle section of each small intestine is fixed in 10% neutral buffered formalin (NBF, RT) for 24-36h and transferred to ethanol. Subsequently, all
samples are processed to FFPE blocks for histology analysis.
[0512] During the dosing phase of the study animal body weights are measured and recorded daily. During the dosing phase, any mice showing anemia, greater than 20% body weight loss or clinical signs of pain are euthanized, and small intestine, large intestine and spleen are harvested. Efficacy of test agent is assessed by comparing Polyp counts, spleen weights and histopathology assessments between the vehicle treat mice and the test agent treated mice.
Identification, validation and initial SAR exploration of oncoribosome targeting macrolides [0513] The transformation of normal cells into cancerous cells is associated with changes in the structure and function of ribosomes. This includes an increase in biogenesis, development of mutations, and alterations in post-translational modifications of ribosomal proteins. Sulima, S. 0.; Hofman I. J. F.; De Keersmaecker, K.; Dinman, J. D. “How Ribosomes Translate Cancer.” Cancer Discov. 2017, 7, 1069. These “oncoribosomes” show shifts in the pattern of mRNA translation compared to normal ribosome, which can lead to the genesis or sustainment of tumors. Kampen, K. R.; Sulima, S. O.; De Keersmaecker, K. “Rise of the specialized onco- ribosomes.” Oncotarget. 2018, 9, 35205. Genuth, N. R.; Barna, M. “The discovery of ribosome heterogeneity and its implications for gene regulation and organismal life.” Mol. Cell, 2018, 71, 364. Therefore, we believe that selectively targeting oncogenic ribosome forms is a potential anti-tumor therapy. To achieve this, we are leveraging our knowledge on the synthesis of ribosomal modulating agents (RMAs) and their unique interactions. Clark, R. B.; Myers, A. G. “Discovery of Macrolide Antibiotics Effective against Multi-Drug Resistant Gram-Negative Pathogens.” Acc. Chem. Res. 2021, 54, 1635. 4Van Rechem, C.; Black, J. C.; Boukhali, M.; Aryee, M. J.; Graslund, S.; Haas, W.; et al. “Lysine demethylase KDM4A associates with translation machinery and regulates protein synthesis.” Cancer Discov. 2015, 5, 255.
[0514] We prepared a library of more than 1000 RMAs and screened this library against several cancerous cell lines as well as non-cancerous controls. We found that the phenotypic screen of our library of more than 1000 RMAs identified hits selective for cancer cell lines over non- cancerous cell lines, and demonstrated responsive SAR. The lead compound identified by this screen showed selective inhibition of total protein synthesis in colorectal cancer cell lines and induced increased expression of p21 , a cell cycle regulator that is indicative of ribosomal stress. The compound selectively inhibited the growth of CRC organoids in vitro, and 50 mpk dosing
resulted in an 40% inhibition of xenograft tumor growth in mice. As a result of this data, this series of RMAs deserves further exploration and development as a potential anti -tumor therapy.
Assay Methods
[0515] Cell Culture: HEK293 (human embryonic kidney) cells used as counter-screen. SW1417 and SW948 are colorectal cancer derived cell lines. All cell lines grown as recommended by ATCC.
[0516] Screen: HEK293 and SW1417 cell lines were treated with compounds for 72 and 144 hours, respectively. Cell viability was quantitated by assessing ATP levels at the end of the assay. [0517] Protein translation detection: SW1417 cells were seeded for 48 hours and subsequently treated with compounds 9 and 11 for 48 hours for both assays.
[0518] 1. Nascent protein translation was assessed using a metabolic labeling assay that incorporates a methionine analog, which was fluorescently labeled on a 96-well plate and quantitated.4
[0519] 2. p21 protein expression was assessed via Western Blot assay. Protein lysates from treated cells were loaded on 4-12% acrylamide gels. Anti-p21 antibody was used to detect protein on gel.4 Image studio 5.2 software was used to acquire images and quantitate intensities from both protein translation detection assays. GraphPad Prism 9 software was used to calculate tumor volume, IC50 (uM), and relative protein expression. Spotfire (TIBCO) 12.0.0.223 was used to plot bar graph for organoid response.
[0520] FIG.l provides a chart showing that compounds selective for cancerous cells were present in the library.
[0521] FIG.2 indicates that aryl and lipophilic compounds were found to be more potent..
[0522] In-cell Metabolic labeling (AHA) Assay: Cells were seeded at a density of 30xl04 cells in a 96-well black clear-bottom plates (Sigma) in triplicate for 48 hours. Cells were treated with DMSO and specified concentrations of test compounds for 24 hours, and 50ug/mL of CHX (Sigma) for 2 hours prior to incubation in methionine free (-Met) media. Cells were washed once with warm -Met media and incubated in -Met media with treatments for 30 minutes. 50uM of AHA (L- Azidohomoalanine) reagent was added to the -Met media for each condition and incubated for 1 hour. Cells were washed with PBS and fixed using 3.7% formaldehyde in PBS followed by permeabilization using 0.5% Triton X-100. The click reaction and detection were performed using the Click-iT™ AHA Alexa Fluor™ 488 Protein Synthesis HCS Assay kit
(Invitrogen). Plates were read on Biotek Cytation 5 plate-reader (Agilent) and data was analyzed using GraphPad Prism software.
[0523] FIGS. 3A and 3B provide an SAR examination of the series.
[0524] Western Blotting Assay: Cells were plated at a density of 0.75xl06 cells/60mm dish. After 48 hours, cells were treated with either DMSO or test compounds at specified concentrations for 48 hours. Following treatment, cells were lysed with 250mL of RIP A buffer (RIPA lysis and Extraction Buffer, Thermo Scientific) supplemented with IX protease and phosphatase inhibitors (Halt™ Protease and Phosphatase Inhibitor Cocktail (I00X), Thermo Scientific) and nuclease (1 :1000, Universal Nuclease, Thermo Scientific). Proteins were separated on 4-12% gradient gels (NuPAGE Bis-Tris protein gels, Invitrogen) using SDS running buffer (NuPAGE MES SDS Running Buffer, Invitrogen). Primary antibodies: p21 Wafl/Cipl (2947, Cell Signaling Technology, 1: 1000) and PSMD14 (4197, Cell Signaling Technology, 1:5000). [0525] FIGS. 4A and 4B indicate that Compound 9 inhibited protein translation in the CRC cell lines that were tested.
[0526] Organoid Culture: Fourteen colorectal cancer-derived (CMS2) organoids and 1 normal organoid from the Hubrecht Organoid Technology (HUB) were thawed, expanded, and screened following HUB’s guidelines and using established formulated media. For cell viability screening assay, organoids were passaged and seeded at high density. After one day of expansion, organoids were harvested by adding Dispase at a final concentration of 1 mg/mL to the culture medium and incubating at 37°C to digest Matrigel (MG)/Basement Membrane Extract (BME). Then, organoids were collected and size-selected between 40 and 100pm using cell strainers. 250 organoids were dispensed/well in a total volume of 40pL of organoid culture medium (with 5% extracellular matrix) in triplicates for all test conditions in ultra-low attachment (ULA) 384-well plates. Two plates were simultaneously seeded from the same organoid suspension, one for CellTiter-Glo measurement directly after plating (“Day 0”) and one to be measured 7 days after incubation with 9 doses in 3 -fold dilutions of compound 9 with 60uM as top concentration with normalization to 0.3% vehicle in all test wells. Immediately after plating, all compounds were dispensed on the “Day 7” assay plate using the Tecan D300. Staurosporine was used at 2pM as a positive control for cell death in all “Day 7” assay plates. After 7 days of exposure to compound 9, luminescence was measured using Cell Titer-Gio 3D on a Tecan Spark 10M plate reader. IC50 values were calculated using the GRmetrics package.
[0527] FIGS. 5A and 5B show that Compound 9 (as provided in the figure) selectively inhibited CRC organoids and causes tumor growth inhibition.
Example
A novel class of Ribosome Modulating Agents (RMAs) exploits cancer ribosome heterogeneity to selectively target CMS2 subtype of colorectal cancer
Abstract
[0528] Ribosomes in cancer cells accumulate numerous patient-specific structural and functional modifications with disease progression. These changes facilitate tumor progression by modifying protein translation. However, prior ribosome inhibitors have had limited success in the clinic because they target universally conserved catalytic steps and lack selectivity for cancer cells. To selectively target cancer subtypes, we have taken an orthogonal approach by synthetic chemistry to generate novel macrolides, Ribosome Modulating Agents (RMAs), that act distal to catalytic sites and exploit cancer ribosome heterogeneity. By allosterically targeting ribosomes, an RMA compound of the invention as disclosed herein shows for the first time two levels of selectivity: 1) selective translation inhibition of a subset of proteins enriched for components of the ribosome and protein translation machinery that are upregulated by MYC; and 2) selective inhibition of proliferation of a subset of colorectal cancer (CRC) cell lines. Mechanistically, the selective ribosome targeting in sensitive cells triggered a nucleolar stress response resulting in cell cycle arrest and apoptosis; Consequently, in CRC, sensitivity to the RMA compound of the invention in cell lines and patient derived organoids was restricted to the Consensus Molecular Subtype 2 (CMS2) subtype that is distinguished by high MYC and WNT pathway activity. Not only did the RMA compound of the invention show potential for efficacy as single agent, the potency and efficacy of the RMA compound of the invention synergizes with clinically approved chemotherapeutics known to inhibit ribogenesis. In conclusion, the RMA compound of the invention represents a new class of allosteric ribosome inhibitors that display cancer selectivity through specific ribosome inhibition in the CMS2 subtype of CRC potentially targeting MYC- driven addiction to high protein translation. Moreover, this study demonstrates that ribosome heterogeneity in cancer can be exploited to develop selective ribogenesis inhibitors. The CRC CMS2 subtype, with a high unmet need for therapeutics, shows vulnerability to our novel selective ribosome mdulator. The mechanism suggests that other cancer subtypes with high MYC activation could also be targeted.
Introduction
[0529] Over the last 20 years, a growing body of evidence indicates that ribosome abundance, composition, stoichiometry, and function can vary significantly between developmental states, tissues, cell types and even at different subcellular locations in the same cell (1,2). Tissue- or disease-specific expression of Ribosomal Protein Genes (RPGs), rRNA variants, as well as differential chemical modification of rRNA bases contribute to ribosome heterogeneity. This ribosome heterogeneity can alter the structure, processivity, and transcript selectivity of ribosomes and provides one mechanism for selectively regulating protein expression in response to various stimuli or cell states (1,2).
[0530] In cancer, mutations and copy number alterations in RPGs, dysregulated expression of snoRNAs that control chemical modification of specific rRNA residues, and dysregulation of various steps involved in ribogenesis has been shown to facilitate oncogenesis (3-6). These cancer-specific alterations in ribosomes leading to addiction of cancer cells to altered protein translation patterns provide an opportunity to selectively target cancer ribosomes while potentially sparing other cell types.
[0531] Due to the critical function played by ribosomes in oncogenesis, targeting the cancer ribosome has been a focus of earlier drug development efforts (7). Many molecules have been identified that target the different catalytic steps occurring in the ribosome during protein synthesis (8). However, these steps are not just required for oncogenesis, but also required for normal protein synthesis leading to poor selectivity of these agents and resultant narrow therapeutic window.
[0532] Traditional macrolide antibiotics target the bacterial ribosome at the nascent peptide exit tunnel (NPET) to selectively inhibit translation of proteins enriched for positively charged amino acids resulting in a bacteriostatic effect (9). While the macrolide binding site between prokaryotes and eukaryotes is generally conserved, macrolide antibiotics do not bind or modulate eukaryotic ribosome function nor are used in cancer therapy. This is because of a small difference, the adenosine at position 2058 of the 23 S rRNA (Escherichia coli numbering), which in eukaryotes is replaced with guanine (9,10) and consequently precludes binding of macrolide antibiotics to eukaryotic ribosomes. Since small changes in rRNA sequence can drive large differences in selectivity of macrolides for the eukaryotic ribosome, we have synthesized novel macrolides called Ribosome Modulating Agents (RMAs) using our unique chemistry (11) that can explore an
alternative chemical space with potential to target the eukaryotic ribosome. These new RMAs can potentially leverage cancer ribosomal heterogeneity and selectively inhibit activity of ribosomes in some cancer subtypes but not others.
[0533] We present data demonstrating that the RMA compound of the invention, a representative RMA, selectively inhibits protein translation in a subset of cancer cell lines. Consequently, treatment of sensitive cells lines with the RMA compound of the invention triggered nucleolar stress, resulting in cell cycle arrest and apoptosis. We identified that the proteins impacted by the RMA compound of the invention in sensitive cancer cells are enriched for proteins containing high density of positively charged regions. This pattern of protein translation inhibition by protein charge characteristics also enriched for MYC regulated components of the ribosome and protein translation machinery. Further evaluation of the RMA compound of the invention across a panel of CRC-derived cell lines and patient derived organoids identified that the Consensus Molecular Subtype 2 (CMS2) (12,13) of CRC characterized by high MYC and Wnt pathway activation is particularly sensitive to the RMA compound of the invention. Finally, we show that the potency and efficacy of the RMA compound of the invention synergizes with chemotherapeutics that are known to inhibit ribogenesis (14). In conclusion, we have invented a new class of molecules that target a critical pathway in cancer to selectively induce cell cycle arrest and apoptosis in cancer cells. This novel mechanism can be used as monotherapy or combined with approved chemotherapeutics in a rational manner to generate potential new cancer therapeutics.
Materials and Methods
Cell Culture
[0534] Cell lines were acquired from ATCC: SW1417, CCL-238, RRID: CVCL 1717; COLO320DM, CCL-220, RRID: CVCL 0219; SW403, CCL-320, RRID:CVCL_0545; and SW948, CCL-237, RRID:CVCL_0632. COLO320DM were cultured in RPMI Media (ATCC 30- 2001). SW1417, SW403 and SW948 were cultured in DMEM (GIBCO 10569010). Cell lines were maintained in humidified 37°C incubators with 5% CO2. All media were formulated using 10% FBS and 1% penicillin/streptomycin. Assay-specific media formulations are described in their corresponding sections. All cell lines were tested for Mycoplasma contamination using the Myco Alert Assay Control Set (Lonza LT07-518) following the manufacturer’s instructions and used only if results were negative. SW1417, COLO320DM, and SW403 cell lines were authenticated by LabcorpBurlington, NC, USA). For all experiments in this study, all cell lines
were grown and expanded for a maximum of 15 passages from their thawing.
Proliferation Assay
[0535] Cells were resuspended in 40ul of medium, seeded in 384-well flat transparent bottom tissue culture treated plates (Greiner 781098) at the following densities: COLO320DM (400/well), SW1417, SW403 (600/well) and 1000/well (SW948) and incubated for 24 hours. All treatments were performed using the D300e digital liquid dispenser (TEC AN). A compound of the invention was dosed as a single agent starting at 60uM in both an 8-point three-fold serial dilution, or a 10-point two-fold serial dilution (combinatorial treatments). Mitoxantrone (Selleckchem S2485), Doxorubicin (Selleckchem S1208) or Actinomycin-D (Sigma Aldrich SBR00013) were dosed in a 10-point three-fold dilution series. DMSO’s limit for all treatments was 0.2%. Treatment timepoints for COLO320DM (48 hours) and for SW1417, SW403 and SW948 (144 hours) were selected to span at least two cell doublings. ATP levels were measured as readout for cell viability using CellTiter-Glo 2.0 reagent (Promega G9243) for all timepoints, including day 0 (untreated cells). Luminescence reading was performed using Cytation5 Multi- Mode plate reader (Agilent). Minimum Response Percentage values were calculated using (IF) logical test: =IF(Tgreater than T0,100*(T-T0)/(C-T0),100*(T-T0)/T0). Key: T: Drug Treatment; TO: Drug treatment at time zero; C: Vehicle treatment. To ensure that GI50 in each cell line is measured at the same number of cell doublings (in this case 2 cell doublings), the GI50 for all cell lines were evaluated at timepoints based on their specific doubling time. This is the recommended protocol from the National Cancer Institute (NCI) (dtp.cancer.gov/discovery_development/nci- 60/methodology.htm).
[0536] Drug synergy was analyzed using the Bliss Independence (BI) Principle. BI scores were calculated from averaged values (2 replicates/plate/tested dose as single agent or in combination) using the following formula: Observed - Expected = BI Score. BI scores were defined as follows: antagonistic less than -0.14; -0.14 less than additive less than 0.14; and synergistic greater than 0.14. The first column (Compound of the invention) and bottom row (Actinomycin D, Doxorubicin, or Mitoxantrone) of each matrix were used for single agent treatments.
Metabolic labeling
[0537] Cells were seeded at a density of 7xl05 (SW1417) and 5xl05 (COLO320DM) in a 6-well plate for 48 and 24 hours, respectively. Cells were treated with DMSO and 40uM of the compound of the invention for 24 hours and 50ug/mL of CHX (Sigma) for 2 hours prior to
incubation in methionine free (-Met) media. L- Azidohomoalanine (AHA) incorporation and Click-iT reaction were performed as in (15). Specific modifications are detailed in the supplementary section. pSILAC
[0538] DMEM for SILAC (Gibco) was supplemented with dialyzed Fetal Bovine Serum (FBS) (Gibco). The light media was supplemented with L-Lysine-2HC1 for SILAC (Thermo) and L- Arginine-HCl for SILAC (Gibco). The heavy media was supplemented with L-Lysine-2HC1, 13C6, 15N2 for SILAC (Thermo) and L-Arginine-HCl, 13C6, 15N4 for SILAC (Thermo). SW1417 cells were seeded at a density of 2xl06 cells per 60mm dish in light media (+Light Arg/Lys) for 24 hours. Cells were treated with DMSO and the compound of the invention (20uM) for 1 hour in DMEM for SILAC with dialyzed FBS (-Arg/Lys), followed by a wash with warm heavy media (+Heavy Arg/Lys). Cells in both conditions were incubated in +Heavy Arg/Lys media for a total of 6 and 24 hours. Subsequently, cells were scrapped off, collected in a 1.5mL tube, and centrifuged at 500g for 5 minutes. Cell pellets were washed twice with PBS, centrifuged at 500g for 5 minutes, and stored at - 20C until ready to be processed for Mass Spectrometry.
Mass Spectrometry
[0539] Cell pellets were lysed in 5% SDS, 50 mM tri ethylammonium bicarbonate (TEAB) pH 8.5, and protein concentration was determined using the BCA protein assay. Samples were reduced in 10 mM dithiothreitol for 30 min at 37°C followed by alkylation in 20 mM iodoacetamide for 20 min at room temperature. Samples were acidified and digested on an S- Trap™ spin column (Profiti) by addition of trypsin at 1 :20 for 3 h at 47°C. Peptides were eluted in 50 mM TEAB pH 8.0, 0.2% formic acid and 50% acetonitrile, respectively.
2ug of protein per sample were used for LC-MS/MS analysis. The raw mass spectrometric data were processed in MaxQuant (version 2.0.3.0) for peptide and protein identification. More detailed protocol in the supplementary section.
Immunoblotting
[0540] Assay performed as in (15). Specific modifications are detailed in the supplementary section.
Cell cycle analysis
[0541] SW1417 cells were plated at a density of O. lxlO6 cells/well in a 12-well plate, and COLO320DM cells were plated at a density of IxlO6 cells/well in a 6-well plate. After 24 hours, cells were treated with DMSO or the compound of the invention at various concentrations for 48 hours. Following treatment, cell pellets were washed twice with IX PBS, and then fixed with Fixation buffer (BioLegend) for 15 minutes at room temperature. The pellets were then washed with Staining buffer (BioLegend) and then permeabilized with IX Click-iTTM permeabilization and wash reagent (ThermoFisher) for 15 minutes at room temperature. The cells were then stained with DNA-specific dye FxCycleTM Violet Stain (Invitrogen) for 30 minutes and analyzed using the BD FACSCelestaTM Cell Analyzer (flow cytometer).
Organoid Culture
[0542] CRC-derived (CMS2) organoids (14) and a normal organoid from the Hubrecht Organoid Technology (HUB) were thawed, expanded, and screened following HUB’s guidelines and using formulated media internally established. CRC-derived organoid cultures and the normal organoid culture were propagated and screened in colon tumor medium (CTM) and colon surrogate medium (CSM), respectively. CTM medium is routinely used for the culture and screening of colon cancer organoids. CSM contains NGS-Wnt and is routinely used for the culture and screening of colon organoids derived from healthy tissue. Organoid culture composition table, organoid handling, and treatment conditions are detailed in the supplementary section.
[0543] Characterization data for Compound of the invention Citric Acid Salt. 'l l NMR (400 MHz, CD3OD) <57.24 (t, J= 7.8 Hz, 1H) 6.88 - 6.96 (m, 2H) 6.85 (dd, J= 8.2, 2.0 Hz, 1H) 4.56 (br d, 13.6 Hz, 1H) 4.46 (d, J= 7.2 Hz, 1H) 4.2O (d, J = 10.0 Hz, 1H) 3.79 (s, 3H) 3.67 - 3.75 (m, lH) 3.62 (br s, 2H) 3.43 (dd, J= 10.4, 7.2 Hz, 1 H) 3.33 (br s, 1H) 3.23 - 3.29 (m, 1H) 3.11 - 3.20 (m, 1H) 2.94 - 3.07 (m, 5H) 2.87 (br s, 3H) 2.69 - 2.82 (m, 11H) 2.19 - 2.47 (m, 4H) 2.13 (br dd, J= 12.8, 8.0 Hz, 1H) 2.01 (dt, J= 10.6, 2.0 Hz, 1H) 1.90 - 1.97 (m, 1H) 1.80 (br d, J= 13.2 Hz, 2H) 1.28 - 1.56 (m, 17 H) 1.06 (br d, J= 6.6 Hz, 3H). MS (ESI) m/z 690.5 (M+H). 99.7% purity by HPLC (UV @ 220 nM). Yellow solid.
[0544] Quality control HNMR, LCMS, and HPLC data for the Compound of the Invention are provided as a supplementary document.
Software Analysis
[0545] GraphPad Prism 9 (RRID:SCR_002798) was used to plot percent response dose curves
and bar graphs, calculate GI50 and LD50 values, and plot bar graphs for protein intensities. Image Studio 5.2 (LI-COR, RRID:SCR_015795) was used to acquire images and quantitate intensities from Smear and Western blot membranes. Spotfire TIBCO 12.0.0.223 (RRID:SCR_008858) was used to plot volcano plots, bar graphs, pie chart, and scatter plot. Fiji 2.6.0 (RRID:SCR_002285) image processing package software was used to analyze in-cell metabolic labeling (AHA) assay.
Data Availability Statement
[0546] The data generated in this study are available within the article and its Supplementary Data files.
Results
[0547] The RMA compound of the invention selectively inhibits protein translation in a sensitive but not insensitive CRC cell line
[0548] We evaluated the impact of the RMA compound of the invention on proliferation of two CRC cell lines (SW 1417 and COLO320DM). Treatment with the RMA compound of the invention shows a robust growth inhibitory effect on SW1417 cells while displaying a minimal anti-proliferative activity in COLO320DM cells (FIG. 6.1A). To determine if the anti- proliferative activity of the RMA compound of the invention is due to impact on protein translation, we conducted a metabolic labeling study using L- Azidohomoalanine (AHA), which is incorporated into newly synthesized proteins in place of methionine (Met) (FIG. 6.1B). L- AHA incorporated into newly synthesized proteins was biotinylated and detected by Western blot. Treatment of SW 1417 with the RMA compound of the invention for 24 hours resulted in a 27% decrease in AHA incorporation into newly synthesized proteins. In contrast, the RMA compound of the invention treatment had no significant impact on AHA incorporation in COLO320DM cells (FIG. 6.1C). These results contrast with the global effect observed after cycloheximide (CHX) treatment, which completely inhibited new protein synthesis in both cell lines. This decrease in new protein synthesis was confirmed in a plate reader assay that uses fluorescence to quantitate AHA incorporation into newly synthesized proteins. In SW1417 cells, the RMA compound of the invention inhibited new protein synthesis in a dose-dependent manner (Supplementary FIG. 6.1S1A and B). Taken together, these data indicate that the RMA compound of the invention selectively inhibited protein translation in SW 1417 cells and that this partial inhibition of protein translation is associated with growth inhibition.
[0549] The RMA compound of the invention selectively inhibits translation of a subset of proteins
[0550] To further characterize the impact of the RMA compound of the invention on protein translation, we conducted a pSILAC proteomics study in SW1417 cells. We treated cells with either the RMA compound of the invention (20uM) or DMSO and concomitantly exposed them to heavy isotope-labelled forms of arginine and lysine (heavy medium) (FIG. 6.2 and Supplementary FIG. 6.2S2A). Mass Spectrometric quantitation of heavy and light isotope labelled peptides was used to assess the impact of the RMA compound of the invention on translation rate and abundance of newly synthesized proteins. At the 6-hour time-point, no significant change in global abundance of proteins was observed, but the significant decrease in the heavy-to-light isotope ratio (H/L ratio) of 129 out of 1188 proteins evaluated (Supplementary FIG. 6.2S2B) was indicative of a decrease in protein translation rate. Gene Ontology (GO) analysis (15) indicated that a third of these 129 proteins were nucleic acid binding proteins, 60% of which are known to be involved in protein translation including ribosomal proteins, rRNA maturation factors, and translation factors (Supplementary FIG. 6.2S2C). At the 24-hour time- point, we observed a significant decrease in the abundance of newly synthesized molecules for a large subset (1482 out of 2867) of the detected proteins (FIG. 6.2A). Since macrolide antibiotics selectively inhibit protein translation at peptide motifs enriched for positively charged amino acids (9), analysis of the positive charge density of all detected proteins performed. We observed that, as the density of positively charged regions increased, a larger fraction of proteins was sensitive to translation inhibition (FIG. 6.2B). Gene overrepresentation analysis (16) indicated that proteins sensitive to the RMA compound of the invention mediated translation inhibition were highly enriched for MYC target genes (FIG. 6.2C). A deeper dive into overrepresentation analysis showed that the top gene sets were highly overlapping with MYC targets, with 16 of the top 20 significant gene sets containing protein translation related proteins including ribosomal proteins, translation initiation and elongation factors as the key representative genes (FIG. 6.2C). Since ribosomal proteins have been reported to be highly enriched for positively charged regions (17), it was striking that 68 out of 73 of the detected ribosomal proteins showed a significant decrease in protein synthesis in response to the RMA compound of the invention treatment (FIG. 6.2D) This impact of the RMA compound of the invention on ribosomal protein synthesis was confirmed by Western Blot analysis of a subset of ribosomal proteins (Supplementary FIG.
6.2S2D). These data demonstrate that the RMA compound of the invention selectively inhibited the synthesis of a subset of proteins that are components of the cellular protein translation machinery and map to the MYC pathway. Specifically, the decrease in translation of almost all ribosomal proteins indicated that the RMA compound of the invention selectively inhibited ribogenesis in these sensitive cancer cells.
[0551] The RMA compound inhibits ribogenesis
[0552] Perturbations that disrupt ribogenesis have been reported to trigger nucleolar stress leading to cell cycle arrest or apoptosis (18,19). To characterize the cellular response to the RMA compound of the invention treatment, we assessed the impact of the RMA compound of the invention on the cell cycle. As seen in FIG. 6.3A, a 48-hour treatment with the RMA compound of the invention leads to an increase in p21 protein levels. FACS analysis assessing DNA content showed that the RMA compound of the invention treatment triggered a strong G1 arrest in SW1417 cells. A significant and dose-dependent increase in subGO content, indicative of apoptotic cells, was also observed (FIG. 6.3B). These responses were not observed in the refractory cell line COLO320DM (Supplementary FIG. 6.3S3A and B). These data demonstrate that the RMA compound of the invention inhibits ribogenesis, leading to induction of p21 , and resulting in cell cycle arrest and apoptosis.
[0553] The CMS2 subtype of CRC is highly sensitive to the RMA compound of the invention
[0554] To further characterize the response to the RMA compound of the invention we profiled its activity across a panel of 34 CRC cell lines. We observed that 8 cell lines were highly sensitive to the RMA compound of the invention while 12 cell lines were completely refractory (FIG. 6.4A). The remaining lines showed an intermediate level of sensitivity to the RMA compound of the invention. These CRC lines have been well characterized in the literature and genomic data associated with these lines are publicly available. We leveraged these data sources to characterize the clinical and molecular features associated with sensitivity to the RMA compound of the invention. Our analysis identified that all 8 cell lines sensitive to the RMA compound of the invention belong to the CMS2 subtype of CRC which is characterized by high MYC and WNT pathway activity, whereas the insensitive and intermediate cell lines distributed across all 4 CMS subtypes. Another molecular feature shared by all CMS2 cell lines sensitive to the RMA compound of the invention is the Microsatellite-stable status (MSS), which is known to
harbor significantly more copy number variations (CNV) than those of the Microsatellite- instable status (MSI). Interestingly, our analysis also identified copy number gains of Chr20ql 1 as a novel genomic feature present in all CMS2 cell lines sensitive to the RMA compound of the invention (FIG. 6.4B and C). To further validate the sensitivity associated with the CMS2 subtype, we evaluated the RMA compound of the invention across a panel of CMS2, patient- derived CRC organoids, the RMA compound of the invention inhibited proliferation of most of the CMS2, patient-derived organoids without affecting growth of a model organoid derived from normal colon (FIG. 6.4D). These data demonstrate that the RMA compound of the invention selectively targets colon cancer cells of the CMS2 subtype characterized by high MYC and WNT pathway activity.
[0555] DNA intercalating agents demonstrate robust combination synergy with the RMA compound of the invention
[0556] Development of novel cancer therapies not only requires single agent activity, but also requires combinations with existing agents to achieve maximal clinical efficacy. While additivity between two cancer agents can be sufficient, synergy is highly desired to maximize the anti- cancer effect. To identify the therapeutics that could synergize with the RMA compound of the invention, we screened a panel of 14 approved drugs that are Standard-of-Care chemotherapeutics or targeted therapies used to treat CRC. The potential for combination synergy was evaluated in SW403 (CMS2 line) using the Bliss Independence Model (20). A majority of the drugs tested were classified as having an additive effect in combination with the RMA compound of the invention (FIG. 6.5A), but interestingly, the three DNA intercalating agents consistently showed synergistic effects in combination with the RMA compound of the invention in two CMS2 CRC cell lines (FIG. 6.5A-C). In the two CMS2 lines, cytostatic concentrations of single agents, when combined, generated a robust cytotoxic response, demonstrating the combination synergy of DNA intercalating agents with the RMA compound of the invention. (FIG. 6.5D and E)
[0557] Discussion
[0558] Ribosome production in a rapidly dividing cell requires immense cellular resources (21), and thus targeting ribosomes in cancer represents an attractive approach to treatment. As with targeting universal cellular processes to treat cancer through chemotherapy or anti-metabolite therapy where the therapeutic window becomes limiting, targeting catalytic ribosome steps
suffers from the same drawback. We have taken an orthogonal approach by leveraging rapid advances in chemistry coupled with detailed understanding of ribosome biology. First, we have used our advanced chemistry platform to create a library of novel macrolides (11) which occupy a new chemical space with increased potential to target the human ribosome due to the high degree of conservation of the macrolide binding site across species (10). Macrolides bind to the nascent peptide exit tunnel, and thus act as allosteric modulators of the ribosome, overcoming issues with inhibiting the highly conserved catalytic steps involved in protein synthesis. Second, we have identified a subset of molecules, including the RMA compound of the invention, which exploit cancer ribosome heterogeneity to selectively target a subset of cancer cell lines.
[0559] The RMA compound of the invention demonstrates two levels of selectivity. First, protein translation inhibition only occurs in some cell types and not others, exemplified by SW1417 vs. COLO320DM. While previously theorized (22), this selectivity ribosome inhibition in one cell line versus one is the first demonstration of differential ribosome targeting. A second level is the propensity of the RMA compound of the invention to selectively inhibit translation of proteins with a high density of positively charged regions. This activity was less surprising given that the mechanism of protein translation inhibition by macrolide antibiotics is well described, and the process of ribosome mediated protein synthesis is conserved across prokaryotes and eukaryotes. It is hypothesized that the positively charged amino acids interact with the negatively charged rRNA lining the NPET which slows down the passage of the nascent peptide through the NPET (17). We observed that as the density of positively charged regions increased, a larger fraction of proteins was sensitive to translation inhibition by the RMA compound of the invention (FIG. 6.2B). The slow translation of sequences enriched for positively charged amino acids is likely further exacerbated by the presence of the RMA compound of the invention in the NPET, resulting in ribosome stalling and translation inhibition. Published reports indicated that nucleic acid binding proteins and ribosomal proteins in particular are highly enriched for positively charged regions (17). Additional classes of proteins enriched for positively charged regions include chromosomal and nucleolar proteins as well as proteins localized to the mitochondria. Consistent with these reports, all these classes of proteins are enriched among the proteins impacted by the RMA compound of the invention. This finding is also a first - all known human ribosome inhibitors target catalytic steps and do not show selectivity for specific protein sequences.
[0560] The RMA compound of the invention also sheds new light on mechanisms used by cancer to co-opt normal cellular processes for disease progression. It was unexpected that the RMA compound of the invention-induced protein translation inhibition significantly impacted proteins that map to the MYC pathway. Hence it was not surprising that cell line profiling across 34 CRC lines identified 8 that were sensitive to the RMA compound of the invention belong to the CMS2 subtype of CRC (12). The CMS2 subtype accounts for 37% of CRC and is characterized by activated WNT pathway and high MYC activation (12). Sensitivity of CMS2 subtype was confirmed in a panel of CMS2 patient derived organoids, highlighting the potential for clinical translation of this novel mechanism (7). The spectrum of MYC targets whose protein synthesis was affected were predominantly those that contain high density of positively charged regions and are involved in protein translation either directly, i.e., eukaryotic initiation factors, or indirectly, i.e., ribosomal proteins that are components of ribosomes.
[0561] The nucleolus, the site of ribogenesis, plays a critical role in regulating cell cycle progression, senescence, and apoptosis (19). Perturbations that interfere with ribogenesis trigger a nucleolar stress response that leads to cell cycle arrest and apoptosis via p53-dependent and p53 -independent mechanisms (23). The CRC cell line profiling data indicate that sensitivity to the RMA compound of the invention does not require wild type p53 (data not shown). Consistent with this, inhibition of ribogenesis by the RMA compound of the invention led to a robust G1 arrest and induction of apoptosis.
[0562] Cancer therapy is rarely based on single agents. However, most combinations used in cancer therapy show additivity. We observed that combining the RMA compound of the invention with DNA intercalating agents, that are known to inhibit rRNA expression (14), resulted in a robust synergistic, anti-proliferative effect. Among the various therapeutics tested, only DNA intercalating agents demonstrated synergy with the RMA compound of the invention. [0563] Combining cytostatic concentrations of the RMA compound of the invention and DNA intercalating agents generated a robust cytotoxic response in two CMS2 lines. These data highlight the potential to design mechanism-based combinations that target vulnerability of CMS2 subtype of CRC to ribogenesis inhibition and thereby provide opportunities to optimize therapy with the RMA compound of the invention.
[0564] Many small molecule anticancer agents, especially kinase inhibitors, demonstrate the ability to inhibit targets at a cellular level at sub-micromolar concentrations. However, the RMA
compound of the invention requires tens of micromolar concentrations to show effect on protein synthesis. An assessment of target protein abundance showed that while kinases are present at approiximately 103 copy numbers of protein per cell, ribosomes have 106-l 07 copy numbers per cell (24), and it is likely higher in cancer cells. Based on average cytoplasmic volume of 1 picoliter (25), the estimated ribosomal concentration ranges from 1 mM to 10 mM, which is aprroximately 1000-fold greater than the concentration of typical kinase drug targets. The potency of the RMA compound of the invention in sensitive lines is consistent with this high concentration of ribosomes in cells.
[0565] Fortuitously, RMAs retain the excellent drug-like properties and high tissue exposure that is inherent to the macrolide class of antibiotics (26). In a single-dose mouse PK study, the RMA compound of the invention dosed PO at 50 mg/kg achieved a terminal skin tissue concentration of 7uM (data not shown). The long half-life and high tissue exposure of macrolides enables coverage of high abundance of ribosomes.
[0566] The activity and selectivity of the RMA compound of the invention exploits two factors: 1) addiction of CMS2 subtype to high protein translation capacity; and 2) ribosome heterogeneity, that enables selective targeting of ribosomes in this subtype of cancers. Mutations and copy number alterations in RPGs, dysregulated expression of snoRNAs that regulate chemical modification of specific rRNA residues, and dysregulation of various steps involved in ribogenesis prevalent in sensitive CMS2 subtype likely enables the RMA compound of the invention to selectively target ribosomes in this subtype of cancer. Additional studies will be needed to further characterize the specific binding interactions resulting from ribosome alterations associated with sensitivity to the RMA compound of the invention. In conclusion, our initial studies demonstrating the novel mechanism of action of the RMA compound of the invention provide evidence that ribosome heterogeneity in cancer can be exploited by this novel class of allosteric ribosome inhibitors to develop selective ribogenesis inhibitors for CMS2 subtype and potentially other cancer subtypes that show high MYC activation and thus potential addiction to high protein translation capacity.
[0567] FIGURES
[0568] FIG. 6.1.
[0569] The RMA compound of the invention is selectively active in a sensitive CRC cell line. A, % Response curves of the RMA compound of the invention treatment in COLO320DM and
SW1417 cells. Representative of 3 independent experiments. Error bars are standard deviations of two technical replicates. Table shows GI50 and LD50 values B, Metabolic labeling assay’s workflow. C, Representative Western blot membranes of 2 independent experiments: -AHA (no AHA reagent added to lysate); Cycloheximide (CHX) (positive control for translation inhibition); DMSO (negative control); and the RMA compound of the invention treatment (40uM). Equal protein amount for all samples used for click chemistry reaction. Samples resuspended in equal volume were loaded on gel. Intensity from densitometry of the RMA compound of the invention-treated samples were normalized to those of DMSO samples to calculate relative protein translation. Bar graph shows normalized values from two independent experiments. Error bars are standard deviations.
[0570] FIG. 6.1 SI A
[0571] Panels showing representative immunofluorescence images of SW1417 cells stained for DNA (Hoechst, blue) and AHA incorporated into newly synthesized proteins (Alexa 488, green) after 24hr treatment. -AHA (no AHA reagent added to medium); Cycloheximide (CHX) (positive control for translation inhibition); DMSO (negative control); and Compound of the invention treatment (60uM). Sale bar = lOOum.
[0572] FIG. 6.1 SIB
[0573] Bar graph from representative experiment plotting relative Alexa 488 signal from SW1417 cells treated with DMSO and 5 doses of Compound of the invention for 24 hr. Error bars are standard deviations. Two independent experiments were conducted.
[0574] FIG. 6.2
[0575] The RMA compound of the invention inhibits nascent protein translation in a sensitive CRC cell line. A, Volcano plot showing heavy-isotope intensities (newly synthesized protein abundance) for 2867 proteins detected at 24-hour time point. Protein fraction classification: Decreased (log2FC less than -0.4, adjusted p-value less than 0.05, red); Downward Trend (log2FC less than -0.4, adjusted p-value greater than 0.05, pink); Increased (log2FC greater than 0.4, adjusted p-value less than 0.05, dark green); Upward Trend (log2FC greater than 0.4, adjusted p-value greater than 0.05, light green); Unchanged (-0.4 less than log2FC less than 0.4, adjusted p-value greater than 0.05, dark gray). Dotted lines indicate -0.5 and 0.5 log2FC values. B, Bar graph plotting percent protein fraction of heavy-isotope intensity (categorized as in A) at 24-hour time point versus positively charged regions. Positive charge windows were generated
by assigning K and R residues a positive 1 charge and all other amino acid residues a charge of 0. Average charge values were then calculated along a sliding window 10 amino acids long for each protein amino acid sequence (starting at the first residue and ending at the last complete set of 10 residues) C, Overrepresentation analysis and pathway enrichment in significantly downregulated proteins from A. Count refers to the number of genes found in each pathway while Gene ratio refers to the count divided by all genes in the pathway. D, Bar graph showing nascent protein abundance for 68 Ribosomal proteins from heavy-isotope intensity analysis at 24-hour time point (categorized as in A). Dotted line indicates -0.4 log2FC value.
[0576] FIG. 6.2S2A
[0577] pSILAC assay’s workflow.
[0578] FIG. 6.2S2B
[0579] Volcano plot showing heavy-to-light (H/L) ratios for 1188 proteins detected at 6-hour time point. Proteins displaying significantly decreased (adjusted p-value less than 0.05) H/L ratios (129) are depicted in red circles. Detected proteins not significantly affected by the compound of the invention are depicted in black circles.
[0580] FIG. 6.2S2C
[0581] Pie chart of 129 significantly decreased detected proteins grouped in classes curated from Gene Ontology (GO) classification. Bar graph shows 5 subclasses within the Nucleic acid binding class.
[0582] FIG. 6.2S2D, Immunoblots for RPL11, RPS11, RPS29, and RPS21 showing samples from SW 1417 cells treated with DMSO or the compound of the invention (20uM) for 72 hours. Bar graph showing quantitated intensities normalized to PSMD14 (loading control).
[0583] FIG. 6.3.
[0584] The RMA compound of the invention alters cell cycle in a sensitive CRC cell line. A, Immunoblots for p21 following 24-hour treatments with DMSO or the RMA compound of the invention (40uM). Bar graphs show quantitated intensities normalized to B2M (loading control). B, Bar graph plotting percentage of SW1417 cells from cell cycle phases.
[0585] FIG. 6.3S3A and B
[0586] FIG. 6.S3A, Bar graph plotting percentage of COLO320DM cells from cell cycle phases: [0587] FIG. 6.S3B, DNA content analysis by flow cytometry for control (OuM) and 48-hour the compound of the invention treatment (20, 40, and 60uM) conditions from SW147 and
COLO320DM cell lines.
[0588] FIG. 6.4.
[0589] CMS2 cell lines display high sensitivity to the RMA compound of the invention and distinct molecular signatures. A, Scatter plot displays drug sensitivity metrics for the RMA compound of the invention across 37 CRC cell lines with colors indicating sensitive, intermediate and insensitive cell lines. B, Heat map of gene expression data for CMS subtype genes across CRC cell lines shows an enrichment of sensitive cell lines in the CMS2 subtype. Row annotations show drug sensitivity, MSI/MSS status, CMS subtypes and average CNV ratios for Chr20ql 1-13. C, Bar graph plotting Chr20 CNV ratios for CRC cell lines, split by CMS2 subtype shows a further enrichment of sensitive cell lines in the CMS2 subtype with Chr20ql 1- 13 CNV gain. D, Bar graph plotting IC50 values for the RMA compound of the invention across CRC-derived CMS2 (light blue bars) and normal (black bar) organoids. Dotted line indicates IC50 30uM.
[0590] FIG. 6.5.
[0591] The RMA compound of the invention is synergistic with DNA intercalating agents on selected CRC cell lines. A, List of 14 inhibitors combined with the RMA compound of the invention. Color coded according to results from BLISS Independence (BI) analysis blue (synergism) or orange (antagonism). B, Matrices with BI scores for combinations of the RMA compound of the invention with Actinomycin D and Doxorubicin on SW948 cells. C, Matrices with BI scores for combinations of the RMA compound of the invention with Mitoxantrone on 2 cell lines: SW948 and SW403. Single agent concentrations in all first columns and bottom rows for all matrices. D, % Response bar graphs showing the RMA compound of the invention’s efficacy enhanced in combination with Actinomycin D (Act-D) and Doxorubicin (Doxo) in SW948 cells. DMSO (black), the RMA compound of the invention (30uM, red), Act-D (lOnM, blue), Doxo (330nM, blue), the RMA compound of the invention+Act-D and the RMA compound of the invention+Doxo (purple). E, % Response bar graphs showing the RMA compound of the invention’s efficacy enhanced in combination with Mitoxantrone (Mitox) in SW948 and SW403 cells. DMSO (black), the RMA compound of the invention (30uM, red), Mitox (6nM, blue) (SW948), Mitox (5.56nM, blue) (SW403), and the RMA compound of the invention+Mitox (purple).
Materials and Methods
Cell Culture
[0592] All cell lines (SW1417, COLO320DM, SW403 and SW948) acquired from ATCC. COLO320DM were cultured in RPMI Media (ATCC 30-2001). SW1417, SW403 and SW948 were cultured in DMEM (GIBCO 10569-010). All cell lines were maintained in a humidified 37C incubator with 5% CO2. All media were formulated using 10% FBS and 1% penicillin/streptomycin. Assay-specific media formulations are described in their corresponding sections.
Proliferation Assay
[0593] Cells were resuspended in 40ul of medium, seeded in 384-well flat transparent bottom tissue culture treated plates (Greiner 781098) at the following densities: COLO320DM (400/well), SW1417, SW403 (600/well) and 1000/well (SW948) and incubated for 24 hours. All treatments were performed using the D300e digital liquid dispenser (TECAN). the RMA compound of the invention was dosed as a single agent starting at 60uM in both an 8-point three- fold serial dilution, or a 10-point two-fold serial dilution (combinatorial treatments).
Mitoxantrone (Selleckchem S2485), Doxorubicin (Selleckchem S1208) or Actinomycin-D (Sigma Aldrich SBR00013) were dosed in a 10-point three-fold dilution series. DMSO’s limit for all treatments was 0.2%. Treatment timepoints for COLO320DM (48 hours) and for SW1417, SW403 and SW948 (144 hours) were selected to span at least two cell doublings. ATP levels were measured as readout for cell viability using CellTiter-Glo 2.0 reagent (Promega G9243) for all timepoints, including day 0 (untreated cells). Luminescence reading was performed using Cytation 5 Multi-Mode plate reader (Agilent). Minimum Response Percentage values were calculated using (IF) logical test: =IF(T greater than T0,100*(T-T0)/(C-T0),100*(T- T0)/T0). Key: T: Drug Treatment; TO: Drug treatment at time zero; C: Vehicle treatment.
[0594] Drug synergy was analyzed using the Bliss Independence (BI) Principle. BI scores were calculated from averaged values (2 replicates/plate/tested dose as single agent or in combination) using the following formula: Observed - Expected = BI Score. BI scores were defined as follows: antagonistic: less than -0.14; -0.14 less than additive is less than 0.14; and synergistic: greater than 0.14. First column (the RMA compound of the invention) and bottom row (Actinomycin D, Doxorubicin, or Mitoxantrone) of each matrix were used for single agent treatments.
Metabolic labeling
[0595] Cells were seeded at a density of 7x105 (SW1417) and 5xl05 (COLO320DM) in a 6-well plate for 48 and 24 hours, respectively. Cells were treated with DMSO and 40uM of the RMA compound of the invention for 24 hours and 50ug/mL of CHX (Sigma) for 2 hours prior to incubation in methionine free (-Met) media. L- Azidohomoalanine (AHA) incorporation and Click-iT reaction were performed as in (27).
Metabolic labeling - Supplementary
[0596] Cells were washed once with warm -Met media and incubated in -Met media with DMSO, 40uM the RMA compound of the invention, or 50ug/mL CHX for 30 minutes. 50uM of AHA (L- Azidohomoalanine) reagent was added to the -Met media for each condition and incubated for 1 hour. Cells for each condition were washed once with complete media (culturing media) and incubated for 1 hour in complete media. Cells were washed with PBS and 200uL lysis buffer containing 50mM Tris HC1 at pH 8.0 (Thermo), 1%SDS (Fisher Chemicals), 1: 100 of 100X protease and phosphatase inhibitor (Pierce Biotech) and 1 : 1000 of 20X Universal Nuclease for cell lysis (Invitrogen) were added per well to the plate for SW1417. For COLO320DM, the cells were collected in a 15mL tube and centrifuged at 1200rpm for 5 minutes, washed with PBS once and centrifuged again; 200uL of lysis buffer were added to each tube. For SW 1417, the cells were scraped and transferred to 1 ,5mL tube. The samples were kept on ice for 15 minutes, followed by vortexing for 5 minutes and spinning at 15000g for 10 minutes at 4C. The supernatant was transferred into a new 1.5mL tube. Protein concentration was determined using BCA assay (Pierce Biotech). 200ug of protein from all cell lysates were prepared in 50uL and then brought up to final volume (60uL) with deionized water. For click chemistry, the Click-iT Protein Reaction Buffer Kit (Invitrogen) was used. All reagents in the kit were reconstituted and click reaction was completed following manufacturer's instructions. The dried samples were reconstituted in 25uL of IX LDS sample loading buffer (Invitrogen) and resolved by SDS-PAGE. The Gel was transferred and blocked for Ih in 1 :20000 of IRDye® 800CW Streptavidin (LiCor). The membrane was washed 3 times with IX TBST (Thermo) for 5 minutes.
In-cell Metabolic labeling - Supplementary
[0597] Cells were seeded at a density of 30xl04 cells in a 96-well black clear-bottom plates (Sigma) in triplicate for 48 hours. Cells were treated with DMSO or the RMA compound of the invention at various concentrations for 24 hours, and 50ug/mL of CHX (Sigma) for 2 hours prior
to incubation in methionine free (-Met) media. Cells were washed once with warm -Met media and incubated in -Met media with treatments for 30 minutes. 50uM of AHA (L- Azidohomoalanine) reagent was added to the -Met media for each condition and incubated for 3 hour. Cells were washed with PBS and fixed using 3.7% formaldehyde in PBS followed by permeabilization using 0.5% Triton X-100. The click reaction and detection were performed using the Click-iT™ AHA Alexa Fluor™ 488 Protein Synthesis HCS Assay kit (Invitrogen). Plates were read on Biotek Cytation 5 plate-reader (Agilent) and data was analyzed using GraphPad Prism software. Images were acquired on the EVOS™ M5000 Imaging System (Invitrogen) with 20X objective lenses. pSILAC
[0598] DMEM for SILAC (Gibco) was supplemented with dialyzed Fetal Bovine Serum (FBS) (Gibco). The light media was supplemented with L-Lysine-2HC1 for SILAC (Thermo) and L- Arginine-HCl for SILAC (Gibco). The heavy media was supplemented with L-Lysine-2HC1, for SILAC (Thermo) and L-Arginine-HCl, 13C6, 15N4 for SILAC (Thermo). SW1417 cells were seeded at a density of 2xl06 cells per 60mm dish in light media (+Light Arg/Lys) for 24 hours. Cells were treated with DMSO and the RMA compound of the invention (20uM) for 1 hour in DMEM for SILAC with dialyzed FBS (-Arg/Lys), followed by a wash with warm heavy media (+Heavy Arg/Lys). Cells in both conditions were incubated in +Heavy Arg/Lys media for a total of 6 and 24 hours. Subsequently, cells were scrapped off, collected in a 1.5mL tube, and centrifuged at 500g for 5 minutes. Cell pellets were washed twice with PBS, centrifuged at 500g for 5 minutes, and stored at -20C until ready to be processed for Mass Spectrometry.
[0599] Mass Spectrometry
[0600] Cell pellets were lysed in 5% SDS, 50 mM tri ethyl ammonium bicarbonate (TEAB) pH 8.5, and protein concentration was determined using the BCA protein assay. Samples were reduced in 10 mM dithiothreitol for 30 min at 37°C followed by alkylation in 20 mM iodoacetamide for 20 min at room temperature. Samples were acidified and digested on an S- Trap™ spin column (Profiti) by addition of trypsin at 1 :20 for 3 h at 47°C. Peptides were eluted in 50 mM TEAB pH 8.0, 0.2% formic acid and 50% acetonitrile, respectively.
2ug of protein per sample were used for LC-MS/MS analysis. The raw mass spectrometric data were processed in MaxQuant (version 2.0.3.0) for peptide and protein identification. More detailed protocol in the supplementary section.
[0601] Mass Spectrometry - Supplementary
[0602] LC-MS/MS Analysis: Dried peptides were resuspended in 0.1% formic acid and then analysed by online nanoflow LC-MS/MS using an Orbitrap Exploris 240 mass spectrometer (Thermo Scientific) coupled to an Ultimate 3000 RSLCnano (Thermo Scientific). Peptides (equivalent to 2pg protein) were injected on an Acclaim PepMap 100 C18 LC trap column (100 pm ID x20 mm, 5 pm, 100 A) followed by separation on an EASY-Spray nanoLC C18 column (75 pm ID ><500 mm, 2 pm, 100 A) at a flow rate of 250nl/min. Buffer A contained 0.1% formic acid in water and Buffer B contained 0.1% formic acid in acetonitrile. Peptides were separated with a linear gradient of 2-37% Buffer B over 213 min followed by a step from 37 to 80% Buffer B in 1 min; then, the column was washed with 80% Buffer B and re-equilibrated to 2% Buffer B to complete the 240 min run. The Orbitrap Exploris 240 was operated in positive-ion data-dependent mode. Precursor ion (MSI) scans were performed in the Orbitrap mass analyzer in the range of 350-1,400 m/z, with a resolution of 120,000 (at 200 m/z). Precursor ions were isolated using a quadrupole mass filter with an isolation width of 1.6 m/z and fragmented using higher energy collision dissociation (HCD) with a collision energy of 30%. MS/MS fragment ions were analysed in the Orbitrap mass analyser with a resolution of 15,000 (at 200 m/z). The database search was performed using the Homo sapiens reference proteome from UniProtKB. Oxidation of methionine and acetylation of protein N-terminus were allowed as variable modifications, while carbamidomethylation of cysteine was allowed as a fixed modification. The estimated false discovery rate was set to 1% at the peptide and protein levels. A maximum of two missed cleavages were allowed. Reverse hits, contaminants, and proteins only identified by site were removed before further analysis. Protein groups were further filtered to contain at least two unique peptides. Hypothesis testing was performed in R (version 4.1.0) using the Limma package available in the R/Bioconductor repository and p-values were corrected for multiple hypothesis testing using the Benjamini -Hochberg method. Proteins with a corrected p-value less than 0.05 were considered significantly differential.
Immunoblotting
[0603] Assay performed as in (27). Specific modifications are detailed in the supplementary section.
Immunoblotting - Supplementary
[0604] Cells were plated at a density of 0.75xl06 cells/60mm dish. After 48 hours, cells were
treated with either DMSO or the RMA compound of the invention at specified concentrations for specified time periods. Following treatment, cells were lysed with 250mL of RIP A buffer (RIPA lysis and Extraction Buffer, Thermo Scientific) supplemented with IX protease and phosphatase inhibitors (Halt™ Protease and Phosphatase Inhibitor Cocktail (100X), Thermo Scientific) and nuclease (1 : 1000, Universal Nuclease, Thermo Scientific). Proteins were separated on 4-12% gradient gels (NuPAGE Bis-Tris protein gels, Invitrogen) using SDS running buffer (NuPAGE MES SDS Running Buffer, Invitrogen). Primary antibodies: RPL11 (18163, Cell Signaling Technology, 1: 1000), RPS11 (ab 175213, Abeam, 1 :1000), RPS21 (PA5-51914, Invitrogen, 1: 1000), RPS29 (PA5-41744, Invitrogen, 1: 1000), Fibrillarin (2639, Cell Signaling Technology, 1: 1000), p21 Wafl/Cipl (2947, Cell Signaling Technology, 1: 1000), p2-microglobulin (12851, Cell Signaling Technology, 1 :5000), and PSMD14 (4197, Cell Signaling Technology, 1 :5000).
Cell cycle analysis
[0605] SW1417 cells were plated at a density of O. lxlO6 cells/well in a 12-well plate, and COLO320DM cells were plated at a density of IxlO6 cells/well in a 6-well plate. After 24 hours, cells were treated with DMSO or the RMA compound of the invention at various concentrations for 48 hours. Following treatment, cell pellets were washed twice with IX PBS, and then fixed with Fixation buffer (BioLegend) for 15 minutes at room temperature. The pellets were then washed with Staining buffer (BioLegend) and then permeabilized with IX Click-iT™ permeabilization and wash reagent (ThermoFisher) for 15 minutes at room temperature. The cells were then stained with DNA-specific dye FxCycle™ Violet Stain (Invitrogen) for 30 minutes and analyzed using the BD FACSCelesta™ Cell Analyzer (flow cytometer).
Organoid Culture
[0606] 14 CRC-derived (CMS2) organoids and 1 normal organoid from the Hubrecht Organoid Technology (HUB) were thawed, expanded, and screened following HUB’s guidelines and using established formulated media. For cell viability screening assay, organoids were passaged and seeded at high density. Cell handling and treatment conditions are detailed in the supplementary section.
Organoid Culture - Supplementary
[0607] After one day of expansion, organoids were harvested by adding Dispase at a final concentration of 1 mg/mL to the culture medium and incubating at 37°C to digest Matrigel (MG)/Basement Membrane Extract (BME). Then, organoids were collected and size-selected
between 40 and 100pm using cell strainers. 250 organoids were dispensed/well in a total volume of 40pL of organoid culture medium (with 5% extracellular matrix) in triplicates for all test conditions in ultra-low attachment (ULA) 384-well plates. Two plates were simultaneously seeded from the same organoid suspension, one for CellTiter-Glo measurement directly after plating (“Day 0”) and one to be measured 7 days after incubation with 9 doses in 3-fold dilutions of the RMA compound of the invention with 60uM as top concentration with normalization to 0.3% vehicle in all test wells. Immediately after plating, all compounds were dispensed on the “Day 7” assay plate using the Tecan D300. Staurosporine was used at 2pM as a positive control for cell death in all “Day 7” assay plates. After 7 days of exposure to the RMA compound of the invention, luminescence was measured using Cell Titer-Gio 3D on a Tecan Spark 10M plate reader. IC50 values were calculated using the GRmetrics package.
Bioinformatic analysis - Supplementary
[0608] Amino Acid Residue Charge Analysis: Protein amino acid sequences were downloaded from Uniprot (Homo sapiens & reviewed_yes) and were cross referenced with mass spectrometry data using the uniport protein ID. Proteins from differential expression analysis with adjusted p value less than 0.05 were analyzed for amino acid sequence charge distributions and gene set enrichment. To investigate consecutive positively charged amino acid sequences effect on ribosomal translation, we focused on positively charged amino acids only, assigning lysine (K) and arginine (R) a positive 1 charge and all other amino acid residues a charge of 0. Average charge values were then calculated along a sliding window 10 amino acids long for each protein amino acid sequence (starting at the first residue and ending at the last complete set of 10 residues). The distribution of average charge windows for all proteins were binned into groups of X<=1, 1<X<=2, 2<X<=3, and 3<X. Geneset enrichment analysis was conducted using the over representation analysis method and an unranked list of significantly downregulated genes from the mass spectrometry experiment. Genesets were obtained from MsigDB using the clusterProfiler package in R. For each geneset and subcategory (Hallmark, CP, GO, CGP, C6, and Cl), over representation analysis was run and results pooled for visualization.
[0609] The ClusterProfiler that was used can be found in: ClusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters. Guangchuang Yu, Li-Gen Wang, Yanyan Han, and Qing-Yu He. OMICS: A Journal of Integrative Biology 2012 16:5, 284-287. (dx.doi.org/10.1089/omi.2011.0118 (last visited 6/14/2023).
[0610] ORA: GO::TermFinder — open source software for accessing Gene Ontology information and finding significantly enriched Gene Ontology terms associated with a list of genes. Elizabeth I. Boyle, Shuai Weng, Jeremy Gollub, Heng Jin, David Botstein, J. Michael Cherry, Gavin Sherlock. Bioinformatics, Volume 20, Issue 18, December 2004, Pages 3710— 3715. (doi.org/10.1093/bioinformatics/bth456).
[0611] Drug sensitivity cutoffs: Cell lines were grouped into sensitive, intermediate, and resistant groups using empirically derived cutoffs on GI50 and Amax drug response metrics. Expression and CNV data for CRC cell lines were downloaded from the CCLE (DepMap 22Q1; https://depmap.org/). Consensus molecular subtypes (CMS) for colorectal cancer cell lines were computed using the genes associated with each of the subtypes from Guinney et al (Reference). Gene signature scores were computed for each subtype by taking the average z-scaled gene expression for the genes associated with those subtypes. Subtypes were assigned to cell lines based on the highest gene signature score. Chr20ql 1-13 CNV ratios were computed by taking the average of the CNV ratios for genes in this chromosomal segment. Genes were mapped to their chromosomal segments using the latest stable ensemble genome release containing chromosomal band annotations (GRCh37). Chromosomal segment scores were generated for each cell line by taking the average CNV ratios across genes mapping to chromosomal segments Chr20ql l, Chr20ql2, and Chr20ql3. Cell lines having high chromosomal segment scores are indicative of amplified segments while low scores represent segment deletions. Visualizations and statistical analyses were performed using R 4.1.2 version. Packages used: tidyverse 1.3.1, data.table 1.14.2, ComplexHeatmap 2.10.0, dittoSeq 1.6.0.
Software Analysis
[0612] GraphPad Prism 9 was used to plot percent response dose curves and bar graphs, calculate GI50 and LD50 values, and plot bar graphs for protein intensities.
[0613] Image Studio 5.2 was used to acquire images and quantitate intensities for from Smear and Western blot membranes.
[0614] Spotfire (TIBCO) 12.0.0.223 was used to plot volcano plots, bar graphs, pie chart, and scatter plot.
[0615] Fiji 2.6.0 image processing package software was used to analyze in-cell metabolic labeling (AHA) assay.
References
1. Genuth NR, Barna M. The Discovery of Ribosome Heterogeneity and Its Implications for Gene Regulation and Organismal Life. Mol Cell 2018;71(3):364-74 doi 10.1016/j.molcel.2018.07.018.
2. Genuth NR, Barna M. Heterogeneity and specialized functions of translation machinery: from genes to organisms. Nat Rev Genet 2018; 19(7):431-52 doi 10.1038/s41576-018-0008-z.
3. Bastide A, David A. The ribosome, (slow) beating heart of cancer (stem) cell. Oncogenesis 2018;7(4):34 doi 10.1038/s41389-018-0044-8.
4. Guimaraes JC, Zavolan M. Patterns of ribosomal protein expression specify normal and malignant human cells. Genome Biol 2016; 17(1):236 doi 10.1186/sl3059-016-l 104-z.
5. Janin M, Coll-SanMartin L, Esteller M. Disruption of the RNA modifications that target the ribosome translation machinery in human cancer. Mol Cancer 2020; 19(l):70 doi
10.1186/S12943-020-01192-8.
6. Liang J, Wen J, Huang Z, Chen XP, Zhang BX, Chu L. Small Nucleolar RNAs: Insight Into Their Function in Cancer. Front Oncol 2019;9:587 doi 10.3389/fonc.2019.00587.
7. Zisi A, Bartek J, Lindstrom MS. Targeting Ribosome Biogenesis in Cancer: Lessons Learned and Way Forward. Cancers (Basel) 2022;14(9) doi 10.3390/cancersl4092126.
8. Garreau de Loubresse N, Prokhorova I, Holtkamp W, Rodnina MV, Yusupova G, Yusupov M. Structural basis for the inhibition of the eukaryotic ribosome. Nature 2014;513(7519):517-22 doi 10.1038/naturel3737.
9. Vazquez-Laslop N, Mankin AS. How Macrolide Antibiotics Work. Trends Biochem Sci 2018;43(9):668-84 doi 10.1016/j .tibs.2018.06.011.
10. Svetlov MS, Koller TO, Meydan S, Shankar V, Klepacki D, Polacek N, et al. Context- specific action of macrolide antibiotics on the eukaryotic ribosome. Nat Commun
2021; 12(l):2803 doi 10.1038/s41467-021-23068-l .
11. Seiple IB, Zhang Z, Jakubec P, Langlois-Mercier A, Wright PM, Hog DT, et al. A platform for the discovery of new macrolide antibiotics. Nature 2016;533(7603):338-45 doi 10.1038/naturel7967.
12. Guinney J, Dienstmann R, Wang X, de Reynies A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med 2015;21(l 1): 1350-6 doi 10.1038/nm.3967.
13. Linnekamp JF, Hooff SRV, Prasetyanti PR, Kandimalla R, Buikhuisen JY, Fessler E, et
al. Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models. Cell Death Differ 2018;25(3):616-33 doi 10.1038/s41418-017-0011-5.
14. Burger K, Muhl B, Harasim T, Rohrmoser M, Malamoussi A, Orban M, et al. Chemotherapeutic drugs inhibit ribosome biogenesis at various levels. J Biol Chem 2010;285(16): 12416-25 doi 10.1074/jbc.M109.074211.
15. Ashbumer M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000;25(l ):25-9 doi 10.1038/75556.
16. Boyle El, Weng S, Gollub J, Jin H, Botstein D, Cherry JM, et al. GO: :TermFinder— open source software for accessing Gene Ontology information and finding significantly enriched Gene Ontology terms associated with a list of genes. Bioinformatics 2004;20(l 8) 3710-5 doi 10.1093/bioinformatics/bth456.
17. Requiao RD, Fernandes L, de Souza HJA, Rossetto S, Domitrovic T, Palhano FL. Protein charge distribution in proteomes and its impact on translation. PLoS Comput Biol
2017; 13(5):el005549 doi 10.1371/journal.pcbi.1005549.
18. Yang K, Yang J, Yi J. Nucleolar Stress: hallmarks, sensing mechanism and diseases. Cell Stress 2018;2(6): 125-40 doi 10.15698/cst2018.06.139.
19. Weeks SE, Metge BJ, Samant RS. The nucleolus: a central response hub for the stressors that drive cancer progression. Cell Mol Life Sci 2019;76(22):4511-24 doi 10.1007/s00018-019- 03231-0.
20. Bliss CI. The calculation of microbial assays. Bacteriol Rev 1956;20(4):243-58 doi 10.1128/br.20.4.243-258.1956.
21. Warner JR. The economics of ribosome biosynthesis in yeast. Trends Biochem Sci 1999;24(l l):437-40 doi 10.1016/s0968-0004(99)01460-7.
22. Almutairi MM, Svetlov MS, Hansen DA, Khabibullina NF, Klepacki D, Kang HY, et al. Co-produced natural ketolides methymycin and pikromycin inhibit bacterial growth by preventing synthesis of a limited number of proteins. Nucleic Acids Res 2017;45(l 6): 9573-82 doi 10.1093/nar/gkx673.
23. James A, Wang Y, Raj e H, Rosby R, DiMario P. Nucleolar stress with and without p53. Nucleus 2014;5(5):402-26 doi 10.4161/nucl.32235.
24. Beck M, Schmidt A, Malmstroem J, Claassen M, Ori A, Szymborska A, et al. The
quantitative proteome of a human cell line. Mol Syst Biol 2011;7:549 doi 10.1038/msb.2011.82.
25. Tzur A, Kafri R, LeBleu VS, Lahav G, Kirschner MW. Cell growth and size homeostasis in proliferating animal cells. Science 2009;325(5937): 167-71 doi 10.1126/science.1174294.
26. Fohner AE, Sparreboom A, Altman RB, Klein TE. PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics. Pharmacogenet Genomics 2017;27(4): 164-7 doi 10.1097/FPC.0000000000000270.
27. Van Rechem C, Black JC, Boukhali M, Aryee MJ, Graslund S, Haas W, et al. Lysine demethylase KDM4A associates with translation machinery and regulates protein synthesis. Cancer Discov 2015;5(3):255-63 doi 10.1158/2159-8290.CD-14-1326.
Example
A novel class of Ribosome Modulating Agents (RMAs) targets ribosome heterogeneity in a subset of Small Cell Lung Cancers
[0616] Small cell lung cancer (SCLC) has a very poor prognosis and limited treatment options. Genomic studies in SCLC show that MYC isoforms are key oncogenic drivers in most of SCLC tumors. As a result, these tumors tend to have high proliferation and protein translation rates. We synthesized ribosome modulating agents (RMAs), a novel class of macrolides, capable of selectively inhibiting translation of a subset of molecules enriched for ribogenesis and translation-related proteins in sensitive SCLC cell lines. A second RMA representative compound of the invention which is disclosed herein selectively inhibits growth and induces apoptosis in a subset of SCLC cell lines characterized by high MYC activity and high ribogenesis rates. Furthermore, the second representative RMA compound is synergistic with current SCLC standard of care DNA intercalating drugs. The dependency of MYC-driven cancers on abnormally high protein translation rates can therefore be exploited by our RMAs presenting a novel therapeutic opportunity for this recalcitrant disease with high unmet needs. [0617] FIG.7.1 summarizes the approach we employed in identifying RMAs.
[0618] FIGS. 7.2A and B summarize clinical subtypes in solid and hematological cancers that are highly sensitive to the second representative RMA of the invention.
[0619] According to FIGS. 7.3, forty five percent of small cell lung cancer cell lines are highly sensitive to the second representative RMA compound of the invention.
[0620] According to FIGS. 7.4A-C, this sensitivity is associated with high expression of
ribogenesis, protein translation, and MYC pathway genes.
[0621] FIGS. 7.5A-C indicate that the anti -proliferative effect of RMAs is driven by selective inhibition of new protein synthesis
[0622] FIGS. 7.6A-B show that proteins with higher positively charged regions are more sensitive to translation inhibition by RMAs.
[0623] FIGS. 7.7 indicates that decreased proteins show a large impact on ribogenesis and protein translation machinery.
[0624] FIG.7.8 indicates that the second representative compound of the invention induces apoptosis in sensitive cells.
[0625] FIG.7.9 shows that the second representative compound of the invention selectively inhibits SCLC-patient derived organoids (PDOs).
[0626] FIG.7.10 shows that the second representative compound of the invention demonstrates combination synergy with DNA targeting chemotherapeutics known to inhibit tRNA synthesis.
[0627] FIG.7.11 summarizes the multiple levels of selectivity of allosteric inhibition by the RMAs of the invention.
Conclusion.
[0628] Several lung cancer subtypes are sensitive to novel allosteric ribosome modulators.
Sensitivity in small cell lung cancer (SCLC) is associated with high expression of MYC target genes involved in Ribogenesis and protein translation. The anti-proliferative effect is driven by selective inhibition of ribogenesis and new protein synthesis. We have found that RMAs show additive and synergistic effects with major chemotherapy backbone agents.
Equivalents and Scope
[0629] Furthermore, the invention encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms from one or more of the listed claims is introduced into one claim. For example, any claim that is dependent on one claim can be modified to include one or more limitations found in any other claim that is dependent on the same base claim. Where elements are presented as lists, e.g, in Markush group format, each subgroup of the elements is also disclosed, and any element(s) can be removed from the group. It should it be understood that, in general, where the invention, or aspects of the invention, is/are referred to as comprising particular elements and/or features, certain embodiments of the
invention or aspects of the invention consist, or consist essentially of, such elements and/or features. For purposes of simplicity, those embodiments have not been specifically set in verbatim herein. It is also noted that the terms “comprising” and “containing” are intended to be open and permits the inclusion of additional elements or steps. Where ranges are given, endpoints are included. Furthermore, unless otherwise indicated or otherwise evident from the context and understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value or sub-range within the stated ranges in different embodiments of the invention, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise.
[0630] This application refers to various issued patents, published patent applications, journal articles, and other publications, all of which are incorporated herein by reference. If there is a conflict between any of the incorporated references and the instant specification, the specification shall control. In addition, any particular embodiment of the present invention that falls within the prior art may be explicitly excluded from any one or more of the claims. Because such embodiments are deemed to be known to one of ordinary skill in the art, they may be excluded even if the exclusion is not set forth explicitly herein. Any particular embodiment of the invention can be excluded from any claim, for any reason, whether or not related to the existence of prior art.
[0631] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation many equivalents to the specific embodiments described herein. The scope of the present embodiments described herein is not intended to be limited to the above Description, but rather is as set forth in the appended claims. Those of ordinary skill in the art will appreciate that various changes and modifications to this description may be made without departing from the spirit or scope of the present invention, as defined in the following claims.
Claims
Claims
I or a pharmaceutically acceptable salt thereof, wherein:
R2a is selected from the group consisting of H, halo, optionally substituted C1-10 alkyl, optionally substituted C1-10 alkoxy, and optionally substituted C1-10 alkenyl, wherein C1-10 alkyl, C1-10 alkoxy, and C1-10 alkenyl are optionally substituted with one or more groups selected from the group consisting of halo, aryl, amino, alkyl, heteroalkyl, heteroalkenyl, heterocycloalkyl, and heteroaryl; and
R2b is selected from the group consisting of halo, optionally substituted C1-10 alkyl, optionally substituted C1-10 alkoxy, and optionally substituted C1-10 alkenyl, wherein C1-10 alkyl, C1-10 alkoxy, and C1-10 alkenyl are optionally substituted with one or more groups selected from the group consisting of halo, aryl, amino, alkyl, heteroalkyl, heteroalkenyl, heterocycloalkyl, and heteroaryl;
R4a and R4b are each independently selected from the group consisting of -H, and optionally substituted C1-10 alkyl, wherein C1-10 alkyl, is optionally substituted with one or more groups selected from the group consisting of halo, aryl, amino, alkyl, heteroalkyl, heteroalkenyl, heterocycloalkyl, and heteroaryl;
Rs is selected from the group consisting of H, an oxygen protecting group, and
, wherein “ ” indicates the point of attachment;
Rea is optionally substituted C1-10 alkyl, wherein C1-10 alkyl, is optionally substituted with one or more groups selected from the group consisting of halo, aryl, amino, alkyl, heteroalkyl, heteroalkenyl, heterocycloalkyl, and heteroaryl;
Reb is -H, optionally substituted C1-10 alkyl, optionally substituted C1-10 hydroxyalkyl, and optionally substituted allyl, wherein C1-10 alkyl, C1-10 hydroxyalkyl, and allyl are optionally substituted with one or more groups selected from the group consisting of halo, aryl, amino, alkyl, heteroalkyl, heteroalkenyl, heterocycloalkyl, and heteroaryl;
Rsa and Rsb are each independently selected from the group consisting of -H and optionally substituted C1-10 alkyl, wherein C1-10 alkyl, is optionally substituted with one or more groups selected from the group consisting of halo, aryl, amino, alkyl, heteroalkyl, heteroalkenyl, heterocycloalkyl, and heteroaryl;
Rba is selected from the group consisting of -H, -C(=N)-NH2, -C(=O)-C1-6 alkyl , -C(=O)- C1-6 alkylene-NR9a’R9a”, C1-10 alkyl and C1-10 alkenyl, wherein C1-10 alkyl and C1-10 alkenyl are optionally substituted with 1, 2, or 3 groups independently selected from the group consisting of amino, heterocycloalkyl, halo, hydroxy, alkoxy, aryl, heteroaryl, and heteroarylene-heteroaryl, wherein aryl, heteroaryl, and heteroarylene-heteroaryl, are optionally substituted with halo, alkoxy, and -NH2; wherein Rba’ and Rba” are selected from the group consisting of H, C1-6 alkyl, cycloalkyl, C1.4 alkyl ene-cycloalkyl, or Rba’ and Rba” together with the atom to which there are attached from a 3-, 4-, 5-, or 6-membered ring optionally containing an additional heteroatom selected from 0, S, SO, SO2, NH, and N-C1.4 alkyl;
Rioa and Riob are taken together with the carbon atom to which they are attached to form
, wherein Q is a 3-, 4-, 5-, or 6-membered cycloalkyl or heterocyclic ring, wherein “ j'nn' ” indicates points of attachment and Rna and Rub are each independently selected from the group consisting of H, halo, and optionally substituted C1-10 alkyl; or
Riia and Rub are taken together with the carbon atom to which they are attached to form
, wherein Q is a 3-, 4-, 5-, or 6-membered cycloalkyl or heterocyclic ring, wherein “ ” indicates points of attachment and Rioa and Riob are each independently selected from the group consisting of H, halo, and optionally substituted C1-10 alkyl;
Rq at each occurrence is independently selected from the group consisting of H, halo, - NRxRx”, C1-6 alkyl, C1-6 haloalkyl, OH, C1-6 alkoxy, -C(=O)-C1-6 alkyl, -C(=O)O-C1-6 alkylene- aryl, -C(=O)-C1-6 alkylene-C1-6 alkyl, -C(=O)-C1-6 alkylene-OC1-6 alkyl, -C(=O)-C1-6 alkylene- aryl, -C(=O)O-C1-6 alkyl ene-heteroaryl, -C(=O)-C1-6 alkyl ene-heteroaryl, -C1-6 alkylene- cycloalkyl, -C1-6 alkylene-aryl, -C1-6 alkylene-heterocycloalkyl, -C1-6 alkylene-heteroaryl, -C1-6 alkylene-C(=O)-NRX’Rx”, -C(=O)-C1-6 alkylene-cycloalkyl, -C(=O)-C1-6 alkylene- heterocycloalkyl, -C(=O)-C1-6 alkylene-NRx’Rx”, -C(=0)-CHCH20H-alkylene-NRx Rx”, -SO2-C1. 6 alkyl, -SO2-C1.6 alkylene-NRx’Rx”, -NRZC(=0)-C1-6 alkyl, -NRZC(=0)0-C1-6 alkylene-aryl, - NRZC(=0)-C1-6 alkylene-aryl, -NRZC(=0)0-C1-6 alkylene-heteroaryl, -NRZC(=0)-C1-6 alkylene- heteroaryl, -C1-6 alkylene-cycloalkyl, -C1-6 alkylene-heterocycloalkyl, -Ci-e alkylene-aryl, -C1-6 alkylene-heteroaryl, -NRX””C(=0)-C1-6 alkylene-cycloalkyl, -NRX ’C(=O)-C1-6 alkylene- heterocycloalkyl, -NRZC(=0)-C1-6 alkylene-NRx’Rx”, -NRzC(=0)-CHCH20H-alkylene-NRx’Rx”, -NRx ” ’ SO2-C1.6 alkyl, -NRX””SO2-CI.6 alkyl ene-NRX’RX”, -C(=O)-heterocycloalkyl, -C(=O)-C1-6 alkylene-heterocycloalkyl, -C1-6 alkyl ene-NRzC(=0)-C1-6 alkyl, -C(=O)-C1-6 alkylene- NRx””cycloalkyl, -C(=O)-C1-6 alkylene-NRx””-C1-6 alkylene-cycloalkyl, -NRX””-C(=0)-C1-6 alkylene-heterocycloalkyl, -C(=O)-C1-6 alkylene-NRX””-Ci^ alkylene-cycloalkyl, -C(=O)-C1-6 alkylene-NRx””-C1-6 alkylene- C1-6 alkoxy, -C1-6 alkylene-NRx””-C(=0)-C1-6 alkylene-NRx’Rx”, - NRX””-C(=O)-C1-6alkylene -NRX” ”-C1-6 alkylene-NRx’Rx”, -C(=O)-cycloalkyl, -C(=O)-aryl, - C(=O)-heterocycloalkyl, C(=O)-heteroaryl, -C1-6 alkylene-arylene-aryl, -C(=O)-cycloalkyl, - C(=O)-heterocycloalkyl, -C(=O)-NRzaryl, -C(=0)NRZ-C1-6 alkylene-aryl, -SO2-C1.6 alkyl, -SO2- aryl, -SO2-heteroaryl, -SO2-C1.6 alkylene-NRx’Rx”, and -SO2- C1-6 alkylene-aryl; or or two Rq together with the atom to which they are attached form oxo, or an oxo protecting group, or a 3, 4, 5, or 6-membered cycloalkyl or heterocycle optionally substituted with one or more substituents selected from the group consisting of OH, halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkylene-NHz, C1-6 alkylene-NH(C1-6 alkyl), C1-6 alkyl ene-N(C1-6 alkyl)2, C1-6 alkylene-NH-C(=O)-C1-6 alkyl, C1-6 alkyl ene-N(C1-6 alkyl)-C(=O)-C1-6 alkyl, C1-6 alkylene-NH-
C(=0)-C1-6 alkylene-NH2, C1-6 alkylene-NH-C(=0)-C1-6 alkyl ene-NH(C1-6 alkyl), -C(=0)-C1-6 alkyl, -C(=0)-C1-6 alkylene-N(C1-6 alkyl)z, and C1-6 alkyl ene-NH-C(=0)-C1-6 alkyl ene-N(C1-6 alkyl)2;
Rx’ and Rx” are each independently selected from the group consisting of H, C1-6 alkyl, cycloalkyl, C1-6 alkylene-cycloalkyl, C1-6 alkylene-heterocycloalkyl, C1-6 alkylene-aryl, C1-6 alkylene-heteroaryl, C1-6 alkylene-N-RzRx ” C1-6 alkylene-OH, C1-6 alkylene-O-C1-6 alkyl, cycloalkyl, heterocycloalkyl, or Rx’ and R.< are joined together with the atom to which they are attached to form a 3-, 4-, 5-, 6-, or 7-membered ring optionally containing an additional heteroatom selected from 0, S, SO, SO2, N-Rx ”, wherein said ring is further optionally substituted with halo, OH, C1-6 alkyl, -O-C1-6 alkyl; wherein Rx ” is H, C1-6 alkyl, -C(=0)-C1-6 alkyl, -C(=0)0-C1-6 alkylene-aryl, -C(=0)-C1-6 alkylene-aryl, -C(=0)0-C1-6 alkylene-heteroaryl, -C(=0)-C1-6 alkylene-heteroaryl, -C1-6 alkylene-aryl, -C1-6 alkylene-heteroaryl, -C(=0)-C1-6 alkylene-cycloalkyl, -C(=0)-C1-6 alkylene- heterocycloalkyl; each Rx”” and Rz is independently H or C1-6 alkyl; or are joined together with the atom to which they are attached form a 3, 4, 5, or 6-membered cycloalkyl or heterocycle optionally substituted with one or more substituents selected from the group consisting of OH, halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkylene-NH2, C1-6 alkyl ene-NH(C1-6 alkyl), C1-6 alkylene-N(C1-6 alkyl)2, C1-6 alkylene-NH-C(=0)-C1-6 alkyl, C1-6 alkyl ene-N(C 1-6 alkyl)-C(=0)-C1-6 alkyl, C1-6 alkylene-NH-C(=0)-C1-6 alkylene-NH2, C1-6 alkylene-NH-C(=0)-C1-6 alkylene-NH(C1-6 alkyl), - C(=0)-C1-6 alkyl, -C(=0)-C1-6 alkyl ene-N(C1-6 alkyl)2, and C1-6 alkylene-NH-C(=0)-C1-6 alkylene-N(C1-6 alkyl)i; and wherein unless otherwise specified, each occurrence of alkylene, alkyl, alkenyl, alkoxy, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl is independently and optionally substituted with halo, OH, C1-6 alkyl, alkoxy, or oxo.
2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, which is a compound of formula IA:
3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, which is a compound of formula IB:
4. The compound of any of claims 1-3, or a pharmaceutically acceptable salt thereof, which is a compound of formula IC:
5. The compound of any of claims 1-4, or a pharmaceutically acceptable salt thereof, which is a compound of formula ID:
6. The compound of claim 5, or a pharmaceutically acceptable salt thereof, wherein Reb is selected from the group consisting of -H, optionally substituted C1-C10 alkyl, optionally substituted C1-C10 hydroxyalkyl, and optionally substituted allyl.
7. The compound of claim 6, or a pharmaceutically acceptable salt thereof, wherein Reb is
selected from the group consisting of methyl, hydroxymethyl hydroxy ethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, -CH2CHOHCH2OH, and allyl.
8. The compound of any of claims 1-7, or a pharmaceutically acceptable salt thereof, which is a compound of formula IE:
9. The compound of any of claims 1-8, or a pharmaceutically acceptable salt thereof, which is a compound of formula IF:
10. The compound of any of claims 1-9, or a pharmaceutically acceptable salt thereof, which is a compound of formula IG:
11. The compound of any of claims 1-10, or a pharmaceutically acceptable salt thereof, wherein one of Ri;i and Rib is optionally substituted C1-10 alkyl.
12. The compound of any of claims 1-10, or a pharmaceutically acceptable salt thereof, wherein one of Ri;i and Rib is methyl and the other of Ria and Rib is H, or both of Ri;i and Rib are methyl.
13. The compound of any of claims 1-10, or a pharmaceutically acceptable salt thereof, wherein one of Ria and Rib is methyl and the other is halo.
14. The compound of any of claims 1-10, or a pharmaceutically acceptable salt thereof, wherein one of Ria and Rib is methyl and the other is optionally substituted C1-10 alkyl.
15. The compound of any of claims 1-10, or a pharmaceutically acceptable salt thereof,
wherein one of R.2a and R2b is methyl and the other of R.2a and R2b is selected from the group consisting of optionally substituted C1-10 alkyl, optionally substituted C1-10 alkoxy, and optionally substituted C1-10 alkenyl, wherein optionally substituted C1-10 alkyl, optionally substituted C1-10 alkoxy, and optionally substituted C1-10 alkenyl are optionally substituted with one or more selected from the group consisting of halo, aryl, and heteroaryl.
16. The compound of claims 1-15 or a pharmaceutically acceptable salt thereof, wherein R<)a is selected from the group consisting of -H and optionally substituted C1-10 alkyl; and either Rioa and Riob or Rna and Riib are taken together to form
wherein Q is a 3-, 4-, 5-, or 6-membered cycloalkyl or heterocyclic ring, wherein “ ” indicates points of attachment.
17. The compound of claim 16 or a pharmaceutically acceptable salt thereof, wherein Rq at each occurrence is independently selected from the group consisting of halo, -NRx’Rx”, Ci-e alkyl, C1-6 haloalkyl, OH, C1-6 alkoxy, -C(=O)-C1-6 alkyl, -C(=O)O-C1-6 alkylene-phenyl, -C1-6 alkylene-phenyl, -C1-6 alkylene-(5-10 membered heteroaryl), -C1-6 alkylene-C(=O)-NRX’Rx”, - C(=O)-C1-6 alkylene-(3-6 membered heterocycloalkyl), -C(=O)-C1-6 alkylene-NRx’Rx”, -SO2-C1.6 alkyl, -SO2-C1-6 alkylene-NRx’Rx”, -NRX ” ”C(=O)-C1-6 alkylene-(3-6 membered heterocycloalkyl), -NRZC(=0)-C1-6 alkylene-NRx’Rx”, -C(=O)-(3-6 membered heterocycloalkyl), -C1-6 alkyl ene-NRzC(=O)-C 1-6 alkyl, -C1-6 alkylene-NRx””-C(=O)-C1-6 alkylene-NRx’Rx”, - NRX’ ” -C(=O)-C1-6 alkylene-NRx” ”-C1-6 alkylene-NRx’Rx”, -C(=O)-phenyl, -C(=O)-(5-10 membered heteroaryl), -C1-6 alkylene-biphenyl, -C(=O)-(3-6 membered cycloalkyl), -C(=O)- NRz-phenyl, -C(=0)NRZ-CI.6 alkylene-phenyl, -SO2-phenyl, -SO2-(5-10 membered heteroaryl), and -SO2-C1.6 alkylene-phenyl; wherein Rx and Rx” are each independently selected from the group consisting of H, C1-6 alkyl, C1-6 alkylene-(3-6 membered cycloalkyl), C1-6 alkylene-(3-6 membered heterocycloalkyl), C1-6 alkyl ene-O-C i-6 alkyl, 3-6 membered cycloalkyl, and 3-6 membered heterocycloalkyl; each Rx”” and Rz is independently H or C1-6 alkyl; or two Rq together with the atom to which they are attached form oxo, or an oxo
protecting group, or a 5 or 6-membered heterocycle optionally substituted with one or more substituents selected from the group consisting of OH, halo, C1-6 alkyl, -C(=O)-C1-6 alkyl, and - C(=O)-C1-6 alkyl ene-N(C i-6 alkyl )2; wherein each occurrence of alkylene, alkyl, phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl is independently and optionally substituted with halo, OH, C1-6 alkoxy, or C1-6 alkyl.
18. The compound of claim 16 or a pharmaceutically acceptable salt thereof, wherein Rq at each occurrence is independently selected from the group consisting of H, -NRx’Rx”, C1-6 alkyl, C1-6 haloalkyl, -C(=O)-C1-6 alkyl, -C(=O)O-C1-6 alkyl ene-phenyl, -C1-6 alkylene-phenyl, -C1-6 alkylene-(5-10 membered heteroaryl), -C1-6 alkylene-C(=O)-NRx’Rx’’, -C(=O)-C1-6 alkylene-(3-6 membered heterocycloalkyl), -C(=O)-C1-6 alkyl ene-NRx’Rx”, -SO2-C1.6 alkyl, -SO2-C1.6 alkylene- NRx’Rx”, -NRX” ”C(=O)-C1-6 alkylene-(3-6 membered heterocycloalkyl), -NRZC(=0)-C1-6 alkylene-NRx’Rx”, -C(=O)-(3-6 membered heterocycloalkyl), -C1-6 alkyl ene-NRzC(=0)-C1-6 alkyl, -NRX””-C(=0)-C1-6 alkylene-NRX””-Ci.6 alkylene-NRxRx”, -C(=O)-phenyl, -C(=O)-(5-10 membered heteroaryl), -C1-6 alkylene-biphenyl, -C(=O)-(3-6 membered cycloalkyl), -C(=O)- NRz-phenyl, -C(=0)NRZ-C1-6 alkylene-phenyl, -SO2-phenyl, -SO2-(5-10 membered heteroaryl), and -SO2-C1.6 alkylene-phenyl; wherein Rx’ and Rx” are each independently selected from the group consisting of H, C1-6 alkyl, C1-6 alkylene-(3-6 membered cycloalkyl), C1-6 alkyl ene-O-C1-6 alkyl, and 3-6 membered cycloalkyl; each RX”” and Rz is independently H or C1-6 alkyl; or two Rq together with the atom to which they are attached form oxo, or a 5 or 6- membered heterocycle optionally substituted with one or more substituents selected from the group consisting of C1-6 alkyl, -C(=O)-C1-6 alkyl, and -C(=O)-C1-6 alkylene-N(C1-6 alkyl)i; wherein each occurrence of alkylene, alkyl, phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl is independently and optionally substituted with OH, C1-6 alkoxy, or C1-6 alkyl.
19. The compound of claim 16 or a pharmaceutically acceptable salt thereof, wherein Rq is selected from the group consisting of H, -CH2CI, carboxybenzyl, acetyl, methyl, isopropyl,
20. The compound of claims 1-19 or a pharmaceutically acceptable salt thereof, which is a compound of formula Cl, or a pharmaceutically acceptable salt thereof:
wherein R.9a is selected from the group consisting of -H and optionally substituted C1-10 alkyl;
A is
wherein Q is a 3-, 4-, 5-, or 6-membered cycloalkyl or heterocyclic ring, wherein each “ ” indicates a point of attachment and B is is CR’R”, wherein R’ and R” are each independently optionally substituted alkyl; or
B is
wherein Q is a 3-, 4-, 5-, or 6-membered cycloalkyl or heterocyclic ring, wherein each “ ” indicates a point of attachment and A is is CR’R”, wherein R’ and R” are each independently optionally substituted alkyl.
21. The compound of claim 20 or a pharmaceutically acceptable salt thereof, wherein R9a is - H or Ci-4 alkyl.
22. The compound of claim 21 or a pharmaceutically acceptable salt thereof , wherein A is
and Q is a 3-, 4-, 5-, or 6-membered optionally substituted cycloalkyl or a 3-, 4-, 5-, or 6-membered optionally substituted heterocycloalkyl and B is CR’R”, wherein R’ and R” are H.
23. The compound of claim 21 or a pharmaceutically acceptable salt thereof, wherein B is
and Q is a 3-, 4-, 5-, or 6-membered optionally substituted cycloalkyl or is a 3-, 4-, 5-, or 6-membered optionally substituted heterocycloalkyl and A is CR’R”, wherein R’ and R” are H.
24. The compound of claim 21 or a pharmaceutically acceptable salt thereof, which is a compound of formula C-2 or C-3, or a pharmaceutically acceptable salt thereof:
25. The compound of claim 21 or a pharmaceutically acceptable salt thereof, which is a compound of formula C-4, C-5, C-6, or C-7, C-8, C-9, C-10, or C-l 1, or a pharmaceutically acceptable salt thereof, wherein Rq is as defined in claims claims 17-19:
m 21, or a pharmaceutically acceptable salt thereof:
C-15
C-18
wherein Rna and Rub are as defined for R’ and R”; each Rt is independently selected from the group consisting of H, halo, -NRXRX”, C1-6 alkyl, C1-6 haloalkyl, OH, C1-6 alkoxy, -C(=O)-C1-6 alkyl, -C(=O)O-C1-6 alkylene-aryl, -C(=O)- C1-6 alkylene-aryl, -C(=O)O-C1-6 alkylene-heteroaryl, -C(=O)-C1-6 alkylene-heteroaryl, -C1-6 alkylene-aryl, -C1-6 alkylene-heteroaryl, -C1-6 alkylene-C(=O)-NRX’Rx”, -C(=O)-C1-6 alkylene- cycloalkyl, -C(=O)-C1-6 alkylene-heterocycloalkyl, -C(=O)-C1-6 alkylene-NRx’Rx”, -C(=O)- CHCH2OH-alkylene-NRx’Rx”, -SO2-C1.6 alkyl, -SO2-C1.6 alkylene-NRx Rx”, -NRZC(=0)-C1-6 alkyl, -NRZC(=0)0-C1-6 alkylene-aryl, -NRZC(=0)-C1-6 alkylene-aryl, -NRZC(=0)0-C1-6 alkylene-heteroaryl, -NRZC(=0)-C1-6 alkylene-heteroaryl, -C1-6 alkylene-aryl, -C1-6 alkylene- heteroaryl, -NRX””C(=0)-C1-6 alkylene-cycloalkyl, -NRX’ C(=O)-C1-6 alkylene-heterocycloalkyl, -NRZC(=0)-C1-6 alkylene-NRx’Rx”, -NRzC(=O)-CHCH2OH-alkylene-NRxRx”, -NRX’ ’SO2-C1.6 alkyl, -NRX’ ’SO2-C1.6 alkylene-NRx’Rx”, -C(=O)-heterocycloalkyl, -C(=O)-C1-6 alkylene- heterocycloalkyl, -C1-6 alkylene-NRzC(=O)-C1-6 alkyl, -C(=O)-C1-6 alkylene-NRx ””cycloalkyl, - C(=O)-C1-6 alkylene-NRx” ”-C1-6 alkylene-cycloalkyl, -NRX ” ”-C(=O)-C1-6 alkylene- heterocycloalkyl, -C(=O)-C1-6 alkylene-NRX””-C1-6 alkylene-cycloalkyl, -C(=O)-C1-6 alkylene- NRX””-C1-6 alkylene- C1-6 alkoxy, -C1-6 alkylene-NRx””-C(=O)-C1-6 alkylene-NRx’Rx”, -NRX ’ ”- C(=O)-C1-6 alkylene -NRX””-C1-6 alkylene-NRX’RX’, -C(=O)-aryl, -C(=O)-heteroaryl, -C1-6 alkylene-arylene-aryl, -C(=O)-cycloalkyl, -C(=O)-NRzaryl, -C(=0)NRZ-C1-6 alkylene-aryl, -SO2- aryl, -SO2-heteroaryl, and -SO2- C1-6 alkylene-aryl;
wherein Rx’ and Rx” are each independently selected from the group consisting of H, C1-6 alkyl, C1-6 alkylene-cycloalkyl, C1-6 alkylene-heterocycloalkyl, C1-6 alkylene-O-C1-6 alkyl, cycloalkyl, heterocycloalkyl, or Rx’ and Rx are joined together with the atom to which they are attached to form a 3-, 4-, 5-, 6-, or 7-membered optionally substituted ring optionally containing an additional heteroatom selected from 0, S, SO, SO2, N-RX ”, wherein RX ” is H, C1-6 alkyl, - C(=O)-Ci-6 alkyl, -C(=O)O-Ci-6 alkylene-aryl, -C(=O)-Ci-6 alkylene-aryl, -C(=O)O-Ci-6 alkylene-heteroaryl, -C(=O)-C1-6 alkylene-heteroaryl, -C1-6 alkylene-aryl, -C1-6 alkylene- heteroaryl, -C(=O)-C1-6 alkylene-cycloalkyl, -C(=O)-C1-6 alkylene-heterocycloalkyl; and each Rx ” ” and Rz is independently H or C1-6 alkyl, wherein each occurrence of alkylene, alkyl, phenyl, heteroaryl, cycloalkyl, and heterocycloalkyl is independently and optionally substituted with halo, OH, C1-6 alkoxy, or C1-6 alyl.
27. The compound of claim 26, wherein Rt is selected from the group consisting of H, carboxybenzyl, acetyl, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertbutyl, benzyl, -
28. A compound which is selected from Table A of Table B, or a pharmaceutically acceptable salt thereof.
29. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof of any of claims 1-28, and a pharmaceutically acceptable excipient.
30. A kit comprising the compound or pharmaceutically acceptable salt thereof of any of claims 1-28, or a pharmaceutical composition of claim 29, and instructions for administering to a subject in need thereof.
31. A method for treating a subject having a proliferative disease or disorder, comprising: administering a therapeutically effective amount of the compound or pharmaceutically acceptable salt thereof of any of claims 1-28, or a pharmaceutical composition of claim 29, to the subject in need thereof.
32. A method for treating a subject having a genetic disease comprising: administering a therapeutically effective amount of the compound or pharmaceutically acceptable salt thereof of any of claims 1-28, or a pharmaceutical composition of claim 29, to the subject in need thereof.
33. A method for treating a subject having a proliferative disease or disorder, comprising: administering a therapeutically effective amount of the compound or pharmaceutically acceptable salt thereof of any of claims 1-28, or a pharmaceutical composition of claim 29, in combination with at least one other agent to the subject in need thereof
34. A method for treating a subject having a genetic disease associated with a premature termination codon mutation, the method comprising: administering an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof as recited in claims 1-28 or a pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof as recited in claim 29.
35. The method of claim 34, wherein the compound of formula I or a pharmaceutically acceptable salt thereof as recited in claims 1-28, or a pharmaceutical composition of claim 29 is administered to the subject alone or in any combination with an agent selected from the group
consisting of aminoglycoside, potentiator, corrector, amplifier, and any combinations thereof.
36. The compound of formula P-3 or a salt thereof:
wherein Rioa, Riob, Riia, and Rub are as defined in Claim 1.
37. A process for preparing a compound of formula I as defined in claims 1-28, comprising:
(a) coupling a compound of formula P-1 with a compound of formula P-4 to provide a compound of formula P-5:
(b) cyclizing a compound of formula P-5 and subsequently deprotecting to provide a compound of formula I or a salt thereof:
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263355302P | 2022-06-24 | 2022-06-24 | |
US63/355,302 | 2022-06-24 | ||
US202263402790P | 2022-08-31 | 2022-08-31 | |
US63/402,790 | 2022-08-31 | ||
US202263416288P | 2022-10-14 | 2022-10-14 | |
US63/416,288 | 2022-10-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023250513A1 true WO2023250513A1 (en) | 2023-12-28 |
Family
ID=87378100
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/069034 WO2023250513A1 (en) | 2022-06-24 | 2023-06-24 | 13-membered macrolide compounds for treating diseases mediated by abnormal protein translation |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023250513A1 (en) |
Citations (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4886499A (en) | 1986-12-18 | 1989-12-12 | Hoffmann-La Roche Inc. | Portable injection appliance |
US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US5015235A (en) | 1987-02-20 | 1991-05-14 | National Carpet Equipment, Inc. | Syringe needle combination |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5141496A (en) | 1988-11-03 | 1992-08-25 | Tino Dalto | Spring impelled syringe guide with skin penetration depth adjustment |
US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5417662A (en) | 1991-09-13 | 1995-05-23 | Pharmacia Ab | Injection needle arrangement |
US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
US5480381A (en) | 1991-08-23 | 1996-01-02 | Weston Medical Limited | Needle-less injector |
US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
WO1997013537A1 (en) | 1995-10-10 | 1997-04-17 | Visionary Medical Products Corporation | Gas pressured needle-less injection device |
US5649912A (en) | 1994-03-07 | 1997-07-22 | Bioject, Inc. | Ampule filling device |
WO1997037705A1 (en) | 1996-04-11 | 1997-10-16 | Weston Medical Limited | Spring-powered dispensing device for medical purposes |
US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
US5780045A (en) | 1992-05-18 | 1998-07-14 | Minnesota Mining And Manufacturing Company | Transmucosal drug delivery device |
US5804212A (en) | 1989-11-04 | 1998-09-08 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
WO1999034850A1 (en) | 1998-01-08 | 1999-07-15 | Fiderm S.R.L. | Device for controlling the penetration depth of a needle, for application to an injection syringe |
US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
US20130090326A1 (en) | 2009-10-16 | 2013-04-11 | Rib-X Pharmaceuticals, Inc. | Antimicrobial Compounds and Methods of Making and Using the Same |
WO2020106636A1 (en) * | 2018-11-19 | 2020-05-28 | Zikani Therapeutics, Inc. | C11-cyclic substituted 13-membered macrolides and uses thereof |
WO2020106627A1 (en) * | 2018-11-19 | 2020-05-28 | Zikani Therapeutics, Inc. | C10-alkylene substituted 13-membered macrolides and uses thereof |
WO2022251730A1 (en) * | 2021-05-28 | 2022-12-01 | Zikani Therapeutics, Inc. | Compounds for treating genetic diseases |
-
2023
- 2023-06-24 WO PCT/US2023/069034 patent/WO2023250513A1/en unknown
Patent Citations (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US4886499A (en) | 1986-12-18 | 1989-12-12 | Hoffmann-La Roche Inc. | Portable injection appliance |
US5015235A (en) | 1987-02-20 | 1991-05-14 | National Carpet Equipment, Inc. | Syringe needle combination |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
US5141496A (en) | 1988-11-03 | 1992-08-25 | Tino Dalto | Spring impelled syringe guide with skin penetration depth adjustment |
US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
US5804212A (en) | 1989-11-04 | 1998-09-08 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
US5503627A (en) | 1989-11-09 | 1996-04-02 | Bioject, Inc. | Ampule for needleless injection |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
US5480381A (en) | 1991-08-23 | 1996-01-02 | Weston Medical Limited | Needle-less injector |
US5417662A (en) | 1991-09-13 | 1995-05-23 | Pharmacia Ab | Injection needle arrangement |
US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
US5780045A (en) | 1992-05-18 | 1998-07-14 | Minnesota Mining And Manufacturing Company | Transmucosal drug delivery device |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5520639A (en) | 1992-07-24 | 1996-05-28 | Bioject, Inc. | Needleless hypodermic injection methods and device |
US5704911A (en) | 1992-09-28 | 1998-01-06 | Equidyne Systems, Inc. | Needleless hypodermic jet injector |
US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
US5649912A (en) | 1994-03-07 | 1997-07-22 | Bioject, Inc. | Ampule filling device |
US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
WO1997013537A1 (en) | 1995-10-10 | 1997-04-17 | Visionary Medical Products Corporation | Gas pressured needle-less injection device |
US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
WO1997037705A1 (en) | 1996-04-11 | 1997-10-16 | Weston Medical Limited | Spring-powered dispensing device for medical purposes |
US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
WO1999034850A1 (en) | 1998-01-08 | 1999-07-15 | Fiderm S.R.L. | Device for controlling the penetration depth of a needle, for application to an injection syringe |
US20130090326A1 (en) | 2009-10-16 | 2013-04-11 | Rib-X Pharmaceuticals, Inc. | Antimicrobial Compounds and Methods of Making and Using the Same |
WO2020106636A1 (en) * | 2018-11-19 | 2020-05-28 | Zikani Therapeutics, Inc. | C11-cyclic substituted 13-membered macrolides and uses thereof |
WO2020106627A1 (en) * | 2018-11-19 | 2020-05-28 | Zikani Therapeutics, Inc. | C10-alkylene substituted 13-membered macrolides and uses thereof |
WO2022251730A1 (en) * | 2021-05-28 | 2022-12-01 | Zikani Therapeutics, Inc. | Compounds for treating genetic diseases |
Non-Patent Citations (54)
Title |
---|
"Remington: The Science and Practice of Pharmacy", 2005, LIPPINCOTT WILLIAMS & WILKINS |
ALMUTAIRI MMSVETLOV MSHANSEN DAKHABIBULLINA NFKLEPACKI DKANG HY ET AL.: "Co-produced natural ketolides methymycin and pikromycin inhibit bacterial growth by preventing synthesis of a limited number of proteins", NUCLEIC ACIDS RES, vol. 45, no. 16, 2017, pages 9573 - 82 |
ASHBURNER MBALL CABLAKE JABOTSTEIN DBUTLER HCHERRY JM ET AL.: "Gene ontology: tool for the unification of biology", THE GENE ONTOLOGY CONSORTIUM. NAT GENET, vol. 25, no. 1, 2000, pages 25 - 9 |
BASTIDE ADAVID A: "The ribosome, (slow) beating heart of cancer (stem) cell", ONCOGENESIS, vol. 7, no. 4, 2018, pages 34 |
BECK MSCHMIDT AMALMSTROEM JCLAASSEN MORI ASZYMBORSKA A ET AL.: "The quantitative proteome of a human cell line", MOL SYST BIOL, vol. 7, 2011, pages 549 |
BLISS CI: "The calculation of microbial assays", BACTERIOL REV, vol. 20, no. 4, 1956, pages 243 - 58 |
BORDEIRA-CARRICO, R. ET AL., TRENDS IN MOLECULAR MEDICINE, vol. 18, no. 11, 2012, pages 667 - 678 |
BOYLE EIWENG SGOLLUB JJIN HBOTSTEIN DCHERRY JM ET AL.: "GO::TermFinder--open source software for accessing Gene Ontology information and finding significantly enriched Gene Ontology terms associated with a list of genes", BIOINFORMATICS, vol. 20, no. 18, 2004, pages 3710 - 5 |
BOYLESHUAI WENGJEREMY GOLLUBHENG JINDAVID BOTSTEINJ. MICHAEL CHERRYGAVIN SHERLOCK, BIOINFORMATICS, vol. 20, 18 December 2004 (2004-12-18), pages 3710 - 3715 |
BURGER KMUHL BHARASIM TROHRMOSER MMALAMOUSSI AORBAN M ET AL.: "Chemotherapeutic drugs inhibit ribosome biogenesis at various levels.", J BIOL CHEM, vol. 285, no. 16, 2010, pages 12416 - 25 |
CASPI MICHAL ET AL: "A flow cytometry-based reporter assay identifies macrolide antibiotics as nonsense mutation read-through agents", JOURNAL OF MOLECULAR MEDICINE, SPRINGER BERLIN HEIDELBERG, BERLIN/HEIDELBERG, vol. 94, no. 4, 1 December 2015 (2015-12-01), pages 469 - 482, XP035801357, ISSN: 0946-2716, [retrieved on 20151201], DOI: 10.1007/S00109-015-1364-1 * |
CHEN ET AL., NATURE GENETICS, vol. 32, no. 4, 2002, pages 670 - 5 |
CHEN MEI ET AL: "Use of Zikani's Ribosome Modulating Agents for Treating Recessive Dystrophic & Junctional Epidermolysis Bullosa with Nonsense Mutations", ICRDOD 2020 : INTERNATIONAL CONFERENCE ON RARE DISEASES AND ORPHAN DRUGS, vol. 14, 24 December 2020 (2020-12-24), pages 2020 - 1, XP055955199, Retrieved from the Internet <URL:https://publications.waset.org/abstracts/129833/pdf> * |
CLARK, R. B.MYERS, A. G.: "Discovery of Macrolide Antibiotics Effective against Multi-Drug Resistant Gram-Negative Pathogens.", ACC. CHEM. RES, vol. 54, 2021, pages 1635 |
COGAN ET AL., MOLECULAR THERAPY, vol. 22, no. 10, 2014, pages 1741 - 52 |
DABROWSKI MACIEJ ET AL: "Advances in therapeutic use of a drug-stimulated translational readthrough of premature termination codons", MOLECULAR MEDICINE, vol. 24, no. 1, 1 December 2018 (2018-12-01), Washington , DC, XP055954670, ISSN: 1076-1551, Retrieved from the Internet <URL:https://molmed.biomedcentral.com/track/pdf/10.1186/s10020-018-0024-7.pdf> DOI: 10.1186/s10020-018-0024-7 * |
E. W. MARTIN: "Remington's Pharmaceutical Sciences", 1980, MACK PUBLISHING COMPANY |
ELOXX PHARMACEUTICALS: "RARE Thinking for RARE Solutions - Leader in Ribosome Targeted Genetic Therapies", 1 July 2021 (2021-07-01), XP093097917, Retrieved from the Internet <URL:https://investors.eloxxpharma.com/static-files/ff2bf135-4d87-4cf2-9871-db58f0e70d41> [retrieved on 20231103] * |
FOHNER AESPARREBOOM AALTMAN RBKLEIN TE: "PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics", PHARMACOGENET GENOMICS, vol. 27, no. 4, 2017, pages 164 - 7, XP055848633, DOI: 10.1097/FPC.0000000000000270 |
GARREAU DE LOUBRESSE NPROKHOROVA 1HOLTKAMP WRODNINA MVYUSUPOVA GYUSUPOV M: "Structural basis for the inhibition of the eukaryotic ribosome", NATURE, vol. 513, no. 7519, 2014, pages 517 - 22 |
GENUTH NRBARNA M: "Heterogeneity and specialized functions of translation machinery: from genes to organisms", NAT REV GENET, vol. 19, no. 7, 2018, pages 431 - 52, XP036524924, DOI: 10.1038/s41576-018-0008-z |
GENUTH NRBARNA M: "The Discovery of Ribosome Heterogeneity and Its Implications for Gene Regulation and Organismal Life", MOL CELL, vol. 71, no. 3, 2018, pages 364 - 74 |
GENUTH, N. R.BARNA, M.: "The discovery of ribosome heterogeneity and its implications for gene regulation and organismal life.", MOL. CELL, vol. 77, 2018, pages 364 |
GRAF MARTIN R. ET AL: "Novel read through agent: ZKN-0013 demonstrates efficacy in APCmin model of familial adenomatous polyposis", JOURNAL OF MOLECULAR MEDICINE, vol. 101, no. 4, 20 February 2023 (2023-02-20), Berlin/Heidelberg, pages 375 - 385, XP093098350, ISSN: 0946-2716, Retrieved from the Internet <URL:https://link.springer.com/article/10.1007/s00109-023-02291-x/fulltext.html> DOI: 10.1007/s00109-023-02291-x * |
GUANGCHUANG YULI-GEN WANGYANYAN HANQING-YU HE, OMICS: A JOURNAL OF INTEGRATIVE BIOLOGY, vol. 16, no. 5, 2012, pages 284 - 287 |
GUIMARAES JCZAVOLAN M: "Patterns of ribosomal protein expression specify normal and malignant human cells", GENOME BIOL, vol. 17, no. 1, 2016, pages 236, XP055566778, DOI: 10.1186/s13059-016-1104-z |
GUINNEY JDIENSTMANN RWANG XDE REYNIES ASCHLICKER ASONESON C ET AL.: "The consensus molecular subtypes of colorectal cancer", NAT MED, vol. 21, no. 11, 2015, pages 1350 - 6, XP055360839, DOI: 10.1038/nm.3967 |
JAMES AWANG YRAJE HROSBY RDIMARIO P: "Nucleolar stress with and without p53", NUCLEUS, vol. 5, no. 5, 2014, pages 402 - 26 |
JANIN MCOLL-SANMARTIN LESTELLER M: "Disruption of the RNA modifications that target the ribosome translation machinery in human cancer", MOL CANCER, vol. 19, no. 1, 2020, pages 70 |
KAMPEN, K. R.SULIMA, S. O.DE KEERSMAECKER, K.: "Rise of the specialized oncoribosomes", ONCOTARGET., vol. 9, 2018, pages 35205 |
KARIV R. ET AL: "128P - Erythromycin readthrough of APC nonsense stop codon mutation in Familial adenomatous polyposis", ANNALS OF ONCOLOGY, 1 March 2018 (2018-03-01), pages iii29, XP093097927, Retrieved from the Internet <URL:https://www.annalsofoncology.org/action/showPdf?pii=S0923-7534%2819%2932613-4> [retrieved on 20231103], DOI: 10.1093/annonc/mdy047 * |
KIM M. KEELINGK. M BEDWELL, D.M., WILEY INTERDISCIPLINARY REVIEWS: RNA, vol. 2, no. 6, 2011, pages 837 - 852 |
KNICKER, PHARMACOLOGICAL REVIEWS OCTOBER, vol. 73, no. 4, 2021, pages 1404 - 1433 |
KRAWCZAK M ET AL., HUM MUTAT., vol. 15, 2000, pages 45 - 51 |
LIANG JWEN JHUANG ZCHEN XPZHANG BXCHU L: "Small Nucleolar RNAs: Insight Into Their Function in Cancer", FRONT ONCOL, vol. 9, 2019, pages 587 |
LINNEKAMP JFHOOFF SRVPRASETYANTI PRKANDIMALLA RBUIKHUISEN JYFESSLER E ET AL.: "Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models", CELL DEATH DIFFER, vol. 25, no. 3, 2018, pages 616 - 33, XP036444064, DOI: 10.1038/s41418-017-0011-5 |
MORT ET AL., M. HUM. MUTAT., vol. 29, 2008, pages 1037 - 47 |
REQUIAO RDFERNANDES LDE SOUZA HJAROSSETTO SDOMITROVIC TPALHANO FL: "Protein charge distribution in proteomes and its impact on translation", PLOS COMPUT BIOL, vol. 13, no. 5, 2017, pages 005549 |
S. M. BERGE ET AL.: "Pharmaceutical Salts", J. PHARM. SCI, vol. 66, 1977, pages 1 - 19, XP002675560, DOI: 10.1002/jps.2600660104 |
SEIPLE IBZHANG ZJAKUBEC PLANGLOIS-MERCIER AWRIGHT PMHOG DT ET AL.: "A platform for the discovery of new macrolide antibiotics", NATURE, vol. 533, no. 7603, 2016, pages 338 - 345, XP055380898, DOI: 10.1038/nature17967 |
SONG, P.YANG, F.JIN, H. ET AL.: "The regulation of protein translation and its implications for cancer", SIG TRANSDUCT TARGET THER BE, 2021, pages 68, Retrieved from the Internet <URL:https://doi.org/10.1038/s41392-020-00444-9> |
SULIMA, S. O.HOFMAN I. J. F.DE KEERSMAECKER, K.DINMAN, J. D.: "How Ribosomes Translate Cancer.", CANCER DISCOV, vol. 7, 2017, pages 1069 |
SVETLOV MSKOLLER TOMEYDAN SSHANKAR VKLEPACKI DPOLACEK N ET AL.: "Context-specific action of macrolide antibiotics on the eukaryotic ribosome", NAT COMMUN, vol. 12, no. 1, 2021, pages 2803 |
TERZO ESTEBAN ET AL: "A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer", CANCER RESEARCH COMMUNICATIONS, vol. 3, no. 6, 5 June 2023 (2023-06-05), pages 969 - 979, XP093097915, DOI: 10.1158/2767-9764.CRC-22-0469 * |
TZUR AKAFRI RLEBLEU VSLAHAV GKIRSCHNER MW: "Cell growth and size homeostasis in proliferating animal cells", SCIENCE, vol. 325, no. 5937, 2009, pages 167 - 71 |
VAN RECHEM, C.BLACK, J. C.BOUKHALI, M.ARYEE, M. J.GRASLUND, S.HAAS, W. ET AL.: "Lysine demethylase KDM4A associates with translation machinery and regulates protein synthesis", CANCER DISCOV, vol. 5, no. 3, 2015, pages 255 - 63, XP055528737, DOI: 10.1158/2159-8290.CD-14-1326 |
VAZQUEZ-LASLOP NMANKIN AS: "How Macrolide Antibiotics Work", TRENDS BIOCHEM SCI, vol. 43, no. 9, 2018, pages 668 - 84, XP085447985, DOI: 10.1016/j.tibs.2018.06.011 |
VU ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 60, no. 1, 2017, pages 458 - 473 |
WALKER: "Cambridge Dictionary of Biology", 1990, CAMBRIDGE UNIVERSITY PRESS |
WARNER JR: "The economics of ribosome biosynthesis in yeast", TRENDS BIOCHEM SCI, vol. 24, no. 11, 1999, pages 437 - 40 |
WEEKS SEMETGE BJSAMANT RS: "The nucleolus: a central response hub for the stressors that drive cancer progression", CELL MOL LIFE SCI, vol. 76, no. 22, 2019, pages 4511 - 24, XP036930713, DOI: 10.1007/s00018-019-03231-0 |
WOODLEY ET AL., JOURNAL OF CELLULAR PHYSIOLOGY, vol. 136, no. 1, 1988, pages 140 - 6 |
YANG KYANG JYI J: "Nucleolar Stress: hallmarks, sensing mechanism and diseases", CELL STRESS, vol. 2, no. 6, 2018, pages 125 - 40 |
ZISI ABARTEK JLINDSTROM MS: "Targeting Ribosome Biogenesis in Cancer: Lessons Learned and Way Forward", CANCERS (BASEL, no. 9, 2022, pages 14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200392142A1 (en) | CDK2/4/6 Inhibitors | |
US9969732B2 (en) | Tetrahydroisoquinoline estrogen receptor modulators and uses thereof | |
EP2989101B1 (en) | 3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1h-pyrrolo[2,3-c]pyridine derivatives as nik inhibitors for the treatment of cancer | |
KR102559719B1 (en) | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | |
US9782386B2 (en) | CDC7 kinase inhibitors and uses thereof | |
WO2018226542A1 (en) | Modulators of proteolysis and associated methods of use | |
US20190152970A1 (en) | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | |
EP3209662B1 (en) | New compounds as nik inhibitors | |
EP3752144B1 (en) | Tricyclic heterocycle compounds useful as hiv integrase inhibitors | |
BR112016006232B1 (en) | 3-(1H-PIRAZOL-4-IL)-1H-PYROLO[2,3-C]PYRIDINE DERIVATIVES AS NIK INHIBITORS AND THE PHARMACEUTICAL COMPOSITION INCLUDING THEM | |
US20230065740A1 (en) | Cyclin-dependent kinase inhibitors | |
US20220153766A1 (en) | Condensed tricyclic compound used as kinase inhibitor | |
US10654867B2 (en) | Heteroaryl estrogen receptor modulators and uses thereof | |
CA3124574A1 (en) | Cyclin-dependent kinase inhibitors | |
WO2023250513A1 (en) | 13-membered macrolide compounds for treating diseases mediated by abnormal protein translation | |
CA3119882A1 (en) | Heterocyclic spiro-compounds as am2 receptor inhibitors | |
EP4353724A1 (en) | Compound as cdk kinase inhibitor and use thereof | |
CA3174972A1 (en) | Co-treatment with cdk4/6 and cdk2 inhibitors to suppress tumor adaptation to cdk2 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23742605 Country of ref document: EP Kind code of ref document: A1 |